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Abstract 
The chromosomal translocation, t(12;21)(p13;q22), resulting in ETV6-RUNX1 fusion 
gene, is the most common chromosomal abnormality in childhood B-cell precursor 
acute lymphoblastic leukaemia (BCP-ALL). It acts as an initiating factor which arises in 
utero but is unable to generate clinical leukaemia. Hence considerable research has 
been devoted to characterising the additional abnormalities that are acquired 
postnatally for the leukaemogenic transformation. This project investigated the 
spectrum of secondary abnormalities and clonal evolution in ETV6-RUNX1 ALL using 
fluorescence in situ hybridization, multiplex ligation- dependent probe amplification, 
single nucleotide polymorphism arrays and copy number real time polymerase chain 
reaction. Abnormalities affecting transcriptional co-regulators (ETV6, TBL1XR1 and BTG1) 
were much more common in ETV6-RUNX1 ALL compared to other ALL cases (52% v 10%; 
13% v 0.69%; 15% v 3%, respectively); while alterations affecting the IKZF1 gene, which 
is involved in B-cell lymphocyte development pathway, were less prevalent (3% v 18%).  
Interestingly, we have identified and characterised two new abnormalities which both 
target the der(12)t(12;21) chromosome and the RUNX1-ETV6 fusion gene in 12% of 
ETV6-RUNX1 cases. The first abnormality was a deletion of der(12)t(12;21) (8%) 
occurring on either sides of the translocation breakpoint, but never both sides 
simultaneously, and occurred in 100% of ETV6-RUNX1 positive cells. The second 
abnormality was the duplication of RUNX1-ETV6 fusion gene (4%) and occurred in an 
average of 55% of ETV6-RUNX1 positive cells as a result of the formation of der(12) 
[der(12)(21qter → 21q22.12::12p13.2-12p12.3::12p12.3 → 12qter). Detailed 
investigation of these abnormalities identified potential tumor suppressor genes (LRP6 
and BCL2L14) and a role for the RUNX1-ETV6 fusion protein. 
Although ETV6-RUNX1 patients respond well to current therapy, some relapses do occur 
and the identification of prognostic biomarkers is required. No potential relapse driving 
genes were defined; however, CDKN2A/B losses showed around three fold increase in 
the relapse cases as compared to non-relapse cases.  Analysis of 9 matched diagnostic-
relapse samples revealed a high degree of clonal relatedness between the two points 
but also evidence of low level sub-clones at diagnosis emerging as the major clone at 
relapse. 
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Finally, the spectrum of secondary abnormalities in atypical ETV6-RUNX1 cases (i.e. 
younger/older patients and Down syndrome) was different with respect to the genetic 
diversity, nature and frequencies of alterations targeting the following genes – BTG1, 
RB1 and CDKN2A/B. Hence, considering the eight MLPA genes including ETV6, 
CDKN2A/B, PAX5, BTG1, RB1, EBF1, IKZF1 and PAR1, infant cases showed fewer 
alterations compared to non-infant cases (0.67 v 1.3 alterations per case) and CDKN2A/B 
seemed not to be contributing in their leukaemogenic development. Both BTG1 and RB1 
losses are commoner in adolescents and young adults (AYA) group as compared to those 
under the age of 10 years (33% and 14% v 21% and 7%, respectively).    
In conclusion, this study has catalogued the frequency of key secondary abnormalities 
in ETV6-RUNX1 ALL and identified a number of genes whose role in the pathogenesis of 
this subtype warrants further investigation. 
  
vi 
 
List of abbreviations 
 
ABL1 The tyrosine kinase Abelson       
aCGH Array comparative genomic hybridisation    
ALL  Acute lymphoblastic leukaemia 
BAC Bacterial artificial chromosomes   
BCP-ALL        Precursor B-cell ALL                      
BM    Bone marrow      
bp Base pairs 
CNAs    Copy number alterations      
CNN-LOH Copy number neutral loss of heterozygosity   
CNS    Central nervous system       
CR  Complete remission    
CRD      Common region of deletion              
CT Cycle threshold   
der(12)t(12;21) Derived chromosome 12    
der(21)t(12;21)   Derived chromosome 21     
DGV Database of Genomic Variants   
DMC       Differentially methylated CpG     
DS                    Down syndrome                     
dup(Xq)                                Duplicated Xq                                
EFS   Event-free survival      
  
vii 
 
ETS E-26 transforming specific      
ETV6 The ETS- type variant 6 
FISH Fluorescent in situ hybridization     
GC Glucocorticoids     
HD      Heterodimerization domain          
HeH  High hyperdiploidy    
HLH Helix–loop–helix domain      
HR High-risk              
HSC   Haematopoietic stem cells       
IGH The immunoglobulin heavy chain    
IR Intermediate risk      
MLL Mixed lineage leukaemia        
MLPA Multiplex ligation dependent probe amplification      
MRD Minimal residual disease    
O/N Overnight 
PAR1                The pseudo-autosomal region                  
PCR    Polymerase chain reaction                   
Ph Philadelphia chromosome       
RT Room temperature   
RUNX1 Runt- related transcription factor 1    
SNP     Single Nucleotide Polymorphism         
SR Standard risk   
  
viii 
 
T-ALL T cell acute lymphoblatic leukaemia  
TSG                          Tumour suppressor genes                       
ΔCT CT difference  
ΔΔCT Comparative CT 
 
  
  
ix 
 
Table of Contents 
Chapter 1. Introduction ............................................................................................ 1 
1.1 Cancer ................................................................................................................. 2 
1.1.1 Overview ..................................................................................................... 2 
1.1.2 Incidence ..................................................................................................... 2 
1.1.3 Multistep development of cancer............................................................... 2 
1.1.4 Genetic determinants of cancer ................................................................. 3 
1.2 Leukaemia development .................................................................................... 4 
1.2.1 Epidemiology ............................................................................................... 6 
1.2.2 Classification and Diagnosis ........................................................................ 7 
1.2.3 Clinical overview ......................................................................................... 8 
1.3 Acute lymphoblastic leukaemia ......................................................................... 8 
1.3.1 Aetiology ..................................................................................................... 9 
1.3.2 Natural history of leukaemia .................................................................... 11 
1.3.3 Classification and Diagnosis ...................................................................... 12 
1.3.4 Clinical presentation ................................................................................. 15 
1.3.5 Treatment.................................................................................................. 15 
1.3.6 Outcome .................................................................................................... 18 
1.4 Genetics of acute lymphoblastic leukaemia .................................................... 22 
1.4.1 B-cell acute lymphoblastic leukaemia ....................................................... 22 
1.4.1.1 Numerical chromosomal abnormalities ............................................ 24 
1.4.1.2 Chromosomal translocations/rearrangements ................................. 25 
1.4.1.3 Secondary copy number alterations .................................................. 28 
1.4.1.4 Sequence mutations .......................................................................... 32 
1.4.1.5 DNA methylation ............................................................................... 34 
1.4.2 T-cell acute lymphoblastic leukaemia ....................................................... 35 
1.4.3 The prognostic effect of different genetic alterations .............................. 37 
1.5 t(12;21)(p13;q22)/ETV6-RUNX1 ....................................................................... 43 
1.5.1 Overview ................................................................................................... 43 
1.5.2 Epidemiology/ Clinical characteristics ...................................................... 44 
1.5.3 Structure and function of ETV6 and RUNX1 genes ................................... 44 
1.5.4 Structure and mechanism of pathogenesis of the fusion gene ................ 46 
1.5.5 Secondary genetic abnormalities .............................................................. 50 
1.5.5.1 Copy number alterations (CNAs) ....................................................... 51 
1.5.5.2 Sequence mutations .......................................................................... 54 
1.5.5.3 Epigenetics ......................................................................................... 55 
  
x 
 
1.5.6 Clonal heterogeneity ................................................................................. 56 
1.5.7 Prognostic impact of ETV6-RUNX1 and its associated genetic alteration 57 
1.6 Summary and aims ........................................................................................... 59 
Chapter 2. Materials and Methods .......................................................................... 61 
2.1 General chemicals and Equipment ................................................................... 62 
2.2 Patient Cohorts and Material ........................................................................... 62 
2.3 Cytogenetic analysis ......................................................................................... 62 
2.4 Cell lines ............................................................................................................ 63 
2.5 Harvesting cells for FISH ................................................................................... 63 
2.6 DNA extraction ................................................................................................. 64 
2.7 DNA quantification using the NanoDrop-1000 ................................................ 64 
2.8 Fluorescence in situ hybridisation (FISH) ......................................................... 64 
2.8.1 Bacterial artificial chromosome (BAC) clones selection ........................... 66 
2.8.2 Culturing BAC clones ................................................................................. 66 
2.8.3 DNA extraction .......................................................................................... 67 
2.8.4 Nick Translation (probe labelling) ............................................................. 67 
2.8.5 Slide Preparation/ Hybridisation ............................................................... 67 
2.8.6 Post-hybridisation washes/ Counterstaining ............................................ 68 
2.8.7 Analysis ...................................................................................................... 68 
2.8.8 Establishment of the cut-off values and algorithm strategy for FISH 
review 68 
2.9 Multiplex Ligation- Dependent Probe Amplification (MLPA) ........................... 69 
2.9.1 Overview ................................................................................................... 69 
2.9.2 Experimental set-up .................................................................................. 69 
2.9.3 Analysis ...................................................................................................... 71 
2.10 Single nucleotide polymorphism (SNP) genotyping ......................................... 71 
2.10.1 Overview ................................................................................................... 71 
2.10.2 Principles of the technique ....................................................................... 72 
2.10.3 Analysis ...................................................................................................... 73 
2.11 Real-time polymerase chain reaction (qPCR) using TaqMan Copy Number 
Assays 73 
2.11.1 Overview ................................................................................................... 74 
2.11.2 Experiment set-up ..................................................................................... 74 
2.11.3 Principles of the technique ....................................................................... 75 
2.11.4 Analysis ...................................................................................................... 76 
2.12 Statistical Analyses ........................................................................................... 79 
Chapter 3. Spectrum of key secondary abnormalities in ETV6-RUNX1 positive BCP-ALL
  
xi 
 
............................................................................................................................... 80 
3.1 Introduction ...................................................................................................... 81 
3.2 Aims and Objectives ......................................................................................... 81 
3.3 Patients and Methods ...................................................................................... 82 
3.4 Results .............................................................................................................. 82 
3.4.1 Cohort Description .................................................................................... 82 
3.4.2 Cytogenetic abnormalities ........................................................................ 83 
3.4.3 Copy number alterations/Rearrangements in ETV6-RUNX1 BCP-ALL ...... 84 
3.4.3.1 Copy number alterations in B- cell differentiation genes ................. 89 
3.4.3.2 Copy number alterations in cell cycle control genes ......................... 94 
3.4.3.3 Copy number alterations in transcription regulating genes .............. 95 
3.4.3.4 Rearrangements of Pseudoautosomal region 1 (PAR1) .................... 98 
3.4.4 Comparison between ETV6-RUNX1 positive and other BCP-ALL subtypes.
 98 
3.5 Discussion ....................................................................................................... 104 
Chapter 4. Secondary abnormalities involving the der(12)t(12;21) in ETV6-RUNX1 
positive BCP-ALL ................................................................................................... 110 
4.1 Introduction .................................................................................................... 111 
4.2 Aims and Objectives ....................................................................................... 112 
4.3 Patients and Methods .................................................................................... 113 
4.3.1 Patient cohort ......................................................................................... 113 
4.3.2 Methods .................................................................................................. 113 
4.3.2.1 FISH .................................................................................................. 113 
4.3.2.2 MLPA ................................................................................................ 119 
4.3.2.3 SNP6 ................................................................................................. 120 
4.4 Results ............................................................................................................ 120 
4.4.1 Characterisation of the deletion of der(12)t(12;21) ............................... 120 
4.4.1.1 Deleted 3’ETV6 sequences from der(12)t(12;21) ............................ 120 
4.4.1.2 Deleted 5’RUNX1 sequences of der(12)t(12;21) ............................. 125 
4.4.2 Gain of RUNX1-ETV6 fusion gene on a 
der(12)(21qter→21q22.12::12p13.2-12p12.3::12p12.3→12qter) ........................ 125 
4.4.3 Detection of additional cases with either deletion or gain of the 
der(12)t(12;21) based on their MLPA ETV6 profile ................................................ 129 
4.4.3.1 MLPA ETV6 profile of 3’ETV6 sequences deletions of der(12)t(12;21)
 130 
4.4.3.2 MLPA ETV6 profile of Gain of RUNX1-ETV6 fusion gene ................. 133 
  
xii 
 
4.5 Discussion ....................................................................................................... 133 
Chapter 5. Investigations of relapse related genes in ETV6-RUNX1 positive BCP-ALL
............................................................................................................................. 138 
5.1 Introduction .................................................................................................... 139 
5.2 Aims and Objectives ....................................................................................... 142 
5.3 Patients and Methods .................................................................................... 143 
5.3.1 Patient cohort ......................................................................................... 143 
5.3.2 Real-time polymerase chain reaction (PCR) using TaqMan Copy Number 
Assays 143 
5.3.2.1 Selection of the positive gene deletion controls ............................. 144 
5.3.2.2 Sensitivity assay of the Real-time polymerase chain reaction (PCR) 
using TaqMan Copy Number Assays .................................................................. 144 
5.3.2.3 Cohort screening .............................................................................. 144 
5.3.3 Fluorescence in situ hybridisation (FISH) ................................................ 145 
5.3.4 Multiplex ligation dependent probe amplification (MLPA) .................... 147 
5.4 Results ............................................................................................................ 147 
5.4.1 Cohort Description .................................................................................. 147 
5.4.1.1 Cytogenetic abnormalities ............................................................... 148 
5.4.2 Real-time polymerase chain reaction (PCR) using TaqMan Copy Number 
Assays 149 
5.4.2.1 Sensitivity assay of the Real-time polymerase chain reaction (PCR) 
using TaqMan Copy Number Assays .................................................................. 149 
5.4.2.2 Cohort screening .............................................................................. 151 
5.4.3 Fluorescence in situ hybridisation (FISH) ................................................ 155 
5.4.4 Consistency between qPCR and FISH data ............................................. 155 
5.4.5 Multiplex ligation dependent probe amplification (MLPA) .................... 156 
5.4.6 Comparisons between the relapse and non-relapse cohorts ................. 156 
5.4.7 The clonal evolution of the relapsed clones ........................................... 158 
5.5 Discussion ....................................................................................................... 162 
Chapter 6. The genetic landscape of patients with ETV6-RUNX1 positive BCP-ALL and 
an atypical demographic and clinical profile .......................................................... 167 
6.1 Introduction .................................................................................................... 168 
6.2 Aims ................................................................................................................ 169 
6.3 Patients and Methods .................................................................................... 169 
6.3.1 Patient cohort ......................................................................................... 169 
6.3.2 Methods .................................................................................................. 171 
6.4 Results ............................................................................................................ 171 
  
xiii 
 
6.4.1 Infant group............................................................................................. 171 
6.4.1.1 Cohort Description ........................................................................... 171 
6.4.1.2 The genetic comparison between the infants and non-infant 
subgroups 172 
6.4.2 Adolescents and young adults (AYA) group ............................................ 175 
6.4.2.1 Cohort Description ........................................................................... 175 
6.4.2.2 The genetic comparison between the AYA and non-AYA subgroups
 175 
6.4.3 Down syndrome group............................................................................ 178 
6.4.3.1 Cohort Description ........................................................................... 178 
6.4.3.2 The genetic comparison between DS and non-DS subgroups ........ 178 
6.4.3.3 The genomic profile of Down syndrome ETV6-RUNX1 cases .......... 180 
6.5 Discussion ....................................................................................................... 185 
Chapter 7. Summary and Discussion...................................................................... 190 
7.1 Overview ......................................................................................................... 191 
7.2 What is the overall spectrum of secondary abnormalities in ETV6-RUNX1 
positive cases and is it the same as other subtypes of ALL? ..................................... 193 
7.2.1 ETV6-RUNX1 inherently favours a higher degree of genetic diversity ... 193 
7.2.2 The characteristic genetic alterations associated with ETV6-RUNX1 ..... 194 
7.2.3 Aberrant RAG activity drives the most frequent focal deletions in ETV6-
RUNX1 positive cases ............................................................................................. 194 
7.2.4 The proposed functional effect of ETV6 losses and gain of der(12)t(12;21)
 195 
7.2.5 Possible contribution of BTG1 losses on the outcome of NCI high risk 
patients 195 
7.2.6 PAX5 deletions have different breakpoints in ETV6-RUNX1 and other BCP-
ALL 196 
7.2.7 Lack of the classic IKZF1 exons 4-7 deletions among ETV6-RUNX1 positive 
cases 197 
7.3 Methodologies for detecting secondary abnormalities ................................. 197 
7.3.1 Cytogenetics versus FISH ........................................................................ 197 
7.3.2 FISH versus MLPA .................................................................................... 198 
7.3.3 SNP arrays versus other methods (MLPA, FISH, qPCR) ........................... 199 
7.3.4 Detection of sequence mutations ........................................................... 199 
7.4 Does RUNX1-ETV6 play a role in the development of ETV6-RUNX1 ALL? ..... 200 
7.4.1 Abnormalities of RUNX1/ETV6 fusion gene ............................................ 200 
7.4.2 Pathogenesis of deleted der(12)t(12;21) ................................................ 200 
  
xiv 
 
7.4.3 Previously reported similar deletions in ETV6-RUNX1 ........................... 201 
7.4.4 Previously reported related deletions in other BCP-ALL subtypes ......... 202 
7.4.5 Pathogenesis of the complex der(12) [der(12)(21qter 
→21q22.12::12p13.2-12p12.3::12p12.3→12qter)] ............................................... 202 
7.4.6 Importance of the reciprocal products of different translocations in BCP-
ALL 203 
7.5 What are the mechanisms of relapse in ETV6-RUNX1 ALL? .......................... 204 
7.5.1 What are the key genetic drivers? .......................................................... 205 
7.5.2 Possible mechanisms behind reduction in relapse rate ......................... 207 
7.5.3 Possible targeted therapy to avoid toxicity-related chemotherapy ....... 207 
7.6 Is there anything to be learnt from studying outliers with ETV6-RUNX1 ALL?
 208 
7.6.1 The demographic features of ETV6-RUNX1 ALL are very tight ............... 208 
7.6.2 What happens outside this scenario - is it clinically relevant? ............... 209 
7.6.2.1 Age ................................................................................................... 209 
7.6.2.2 DS ALL............................................................................................... 211 
7.7 Overall summary of thesis .............................................................................. 214 
7.8 Future publications ......................................................................................... 215 
Chapter 8. References ........................................................................................... 216 
Chapter 9. Appendices .......................................................................................... 253 
Chapter 10. Publications ....................................................................................... 306 
 
  
  
xv 
 
List of Figures 
Figure 1.1 Diagrammatic representation of haematopoiesis. ..................................... 5 
Figure 1.2 Graph showing leukaemia incidence rates in relation to sex and age per 
100,000 population in UK in 2010. ............................................................................ 7 
Figure 1.3 A two-step model for the natural history of acute lymphoblastic 
leukaemia. .............................................................................................................. 10 
Figure 1.4 Survival and relapse rates of the overall trial of UKALL2003 of children and 
young adults ALL..................................................................................................... 19 
Figure 1.5 Overall survival rates at 4 years of the overall trial of UKALL XII/ECOG 2993 
in Ph- negative and Ph- positive adult ALL (no imatinib treatment. .......................... 19 
Figure 1.6 The estimated prevalence of different selected chromosomal 
abnormalities according to the age at diagnosis. ..................................................... 23 
Figure 1.7 Diagrammatic representation of the role of the genetic alterations in the 
leukaemic development and progression. ............................................................... 30 
Figure 1.8 Diagrammatic representation of T-cell ALL distinct subgroups 
(frequency %) in relation to their T-cell developmental stage (based on EGIL or TCR 
classification systems). ........................................................................................... 36 
Figure 1.9 Event free survival of childhood BCP-ALL in relation to the primary genetic 
subgroups. .............................................................................................................. 38 
Figure 1.10 Overall survival of adult BCP-ALL by primary genetic subtypes. ............. 38 
Figure 1.11 Diagrammatic representation of the t(12;21)(p13;q22. .......................... 44 
Figure 1.12 Diagrammatic representation of the structures of ETV6, RUNX1 and ETV6-
RUNX1 proteins ...................................................................................................... 47 
Figure 1.13 Diagrammatic representation of the hypothesized molecular mechanism 
of ETV6-RUNX1 protein. .......................................................................................... 50 
Figure 1.14 Clonal origins of relapsed acute lymphoblastic leukaemia. .................... 57 
Figure 2.1 Principles of Fluorescence in situ hybridisation (FISH). ............................. 66 
Figure 2.2 Principles of MLPA techniques. ............................................................... 70 
Figure 2.3 Overview on the SNP 6 array processing which involved mainly the 
following steps ....................................................................................................... 73 
Figure 2.4 Principles of qPCR techniques for the detection of target (left) and 
reference (right) DNA sequences in a duplex reaction ............................................. 76 
Figure 2.5 Representative plot of real time quantitative polymerase chain reaction. 78 
Figure 2.6 Flow chart describing the comparative cycle threshold (ΔΔCT) method 
calculation of the target copy number in a test sample. .......................................... 79 
Figure 3.1 Comparison of PAX5 deletion breakpoints between ETV6-RUNX1 and other 
BCP-ALL cases. ........................................................................................................ 90 
Figure 3.2 Comparison of IKZF1 deletion breakpoints between ETV6-RUNX1 and 
other BCP-ALL cases. ............................................................................................... 93 
Figure 3.3 Comparison of ETV6 deletion breakpoints between ETV6-RUNX1 and other 
  
xvi 
 
BCP-ALL cases. ........................................................................................................ 96 
Figure 3.4 Bar chart showing the percentage of patients with increasing numbers of 
CNA within ETV6-RUNX1 and other BCP ALL subtypes. .......................................... 103 
Figure 3.5 Bar chart showing the percentage of patients with increasing numbers of 
CNA within ETV6-RUNX1 and other BCP ALL subtypes based on National Cancer 
Institute categories (High and Standard risk). ........................................................ 103 
Figure 4.1 Idiogram show the different signal patterns given by ETV6 (left) and 
RUNX1 (right) dual color (DC) breakapart (BA) probes ........................................... 112 
Figure 4.2 Idiograms show the signal patterns generated from the mapping deletion 
probes targeting either 3’ETV6 or 5’RUNX1 sequences of der(12)t(12;21) .............. 115 
Figure 4.3 Idiograms of the home grown probes used in the three colour FISH ...... 116 
Figure 4.4 The expected signal pattern of the suggested duplicated RUNX1-ETV6 
fusion gene using 5’RUNX1 (labelled red)/3’ETV6 (labelled green) DS SF probe set 117 
Figure 4.5 The locations of ETV6 exon 8 [3’ ETV6] probes with either 5’ETV6 or 
5’RUNX1 probes. .................................................................................................. 119 
Figure 4.6 Deletion mapping of der(12)t(12;21) cases within ETV6-RUNX1 positive 
BCP-ALL. ............................................................................................................... 121 
Figure 4.7 Confirmation of the origin of the der(12)t(12;21) deletion using three 
colour FISH ........................................................................................................... 122 
Figure 4.8 SNP6 based genomic profile of chromosome 12 in patient 3189. ........... 124 
Figure 4.9 The observed signal pattern of 1R 0G 2F in patient no. 3726 with suggested 
duplicated RUNX1-ETV6 fusion gene using the DC SF probe ................................... 126 
Figure 4.10 SNP6 based genomic profile of chromosome 12 in two patients with 
duplicated RUNX1-ETV6 fusion gene. .................................................................... 128 
Figure 4.11 Identification and proposed mechanism of the duplicated RUNX1-ETV6 
reciprocal fusion gene formation .......................................................................... 129 
Figure 4.12 Different resultant signal patterns obtained from the application of ETV6 
DC BA probe in 20 ETV6-RUNX1 patients with isolated ETV6 exon 8 deletions. ...... 132 
Figure 5.1 The location of both the different target probe assays and the FISH probes 
in relation to different genes investigated in this study. ........................................ 146 
Figure 5.2 Histogram showing the decrease in the copy number with increasing 
proportion of cell line DNA. .................................................................................. 150 
Figure 5.3 Different TBL1XR1 breakpoints in the relapse and non-relapse cases. .... 158 
Figure 6.1 Idiogram represent the alterations detected by SNP6 arrays in the four 
Down syndrome cases. ......................................................................................... 182 
Figure 6.2 Log2 ratio and copy number plots of focal deletions detected by SNP6 
arrays in the four Down syndrome cases ............................................................... 183 
Figure 6.3 SNP 6.0 profile for chromosome 18 from patient no. 3472 (blue) and 3428 
(green) ................................................................................................................. 184 
 
 
  
xvii 
 
List of Tables 
Table 1.1 The 2008 WHO classification of acute lymphoblastic leukaemia. .............. 14 
Table 1.2 Generic estimates of acute lymphoblastic leukaemia risk based on several 
risk factors. ............................................................................................................. 20 
Table 1.3 Event rates at 5 years (95% CI) within MRD risk groups treated on 
UKALL2003 trial. ..................................................................................................... 21 
Table 1.4 Generic estimates of survival after first relapse ........................................ 22 
Table 1.5 Frequencies of the recurrent gene deletions in BCP-ALL cases with their 
cytogenetic subgroups’ associations. ...................................................................... 31 
Table 1.6 Recurrent mutations of genes/ pathways in BCP-ALL cases. ...................... 33 
Table 1.7 Clinically relevant genetic aberration subgroups in B-cell precursor acute 
lymphoblastic leukaemia patients. .......................................................................... 40 
Table 1.8 Common recurrent copy number alterations in ETV6-RUNX1 patients. ..... 53 
Table 1.9 Survival rates of ETV6-RUNX1 patients from selected modern clinical trials.
............................................................................................................................... 58 
Table 1.10 Conflicting results of the prognostic effect of the abnormalities involving 
ETV6 or RUNX1 genes from selected study groups................................................... 59 
Table 2.1 Different stages of the MLPA procedure. .................................................. 71 
Table 2.2 Stages of qPCR using TaqMan Copy Number Assays. ................................ 75 
Table 3.1 Cytogenetic abnormalities and their frequencies in ETV6-RUNX1 cohort. . 84 
Table 3.2 Number and percentages (%) of ETV6-RUNX1 BCP-ALL patients with 
different gene deletions stratified by sex, age and white cell count and NCI risk 
status. .................................................................................................................... 86 
Table 3.3 Correlation between different gene deletions and types of relapses in 
ETV6-RUNX1 patients treated on ALL97/99 and ALL2003. ........................................ 87 
Table 3.4 Correlation among different gene deletions within ETV6-RUNX1 BCP ALL. 88 
Table 3.5 Comparison of the demographics and clinical features between ETV6-
RUNX1 positive and other BCP ALL patients. ........................................................... 99 
Table 3.6  Comparison of the incidences and type of relapses between ETV6-RUNX1 
positive and other BCP ALL patients in UKALL97/99 and UKALL2003. ..................... 100 
Table 3.7 Comparison of the incidences of different genetic alterations between 
ETV6-RUNX1 positive and other BCP ALL patients. ................................................ 102 
Table 4.1 Detailed FISH studies of ETV6-RUNX1- Positive BCP- ALL Patients with 
duplicated RUNX1-ETV6 fusion gene. .................................................................... 126 
Table 5.1 Literature search of other important gene deletions in ETV6-RUNX1 cases.
............................................................................................................................. 141 
Table 5.2 Genes tested and the positive controls used. ......................................... 144 
Table 5.3 FISH review algorithm. ........................................................................... 147 
Table 5.4 The demographic and clinical features of the relapse and the non-relapse 
groups within ETV6-RUNX1 BCP-ALL. .................................................................... 148 
  
xviii 
 
Table 5.5 The first sensitivity detection test of monoallelic deletion of NR3C2 gene in 
KG1 cell line. ......................................................................................................... 150 
Table 5.6 The second sensitivity assay for the detection of the monoallelic deletion of 
NR3C2 gene in KG1 cell line. .................................................................................. 151 
Table 5-7 FISH and q PCR data of the relapse and the non-relapse cases . .............. 154 
Table 5-8 The genetic landscape of the diagnostic samples of the relapse and non-
relapse cases. ....................................................................................................... 157 
Table 5-9 Cytogenetics, FISH and Molecular data of the nine matched 
diagnosis/relapse cases. ....................................................................................... 161 
Table 6.1 Different atypical subgroups of patients included in this study with the 
number of cases investigated in each based on the availability of material. ........... 170 
Table 6.2 Comparison between the infant and non-infant cases within ETV6-RUNX1 
cases in terms of sex and WCC. ............................................................................. 172 
Table 6.3 Genetic comparison between the infant and non-infant cases within ETV6-
RUNX1 cases. ........................................................................................................ 174 
Table 6.4 Comparison between the AYA and non-AYA cases within ETV6-RUNX1 
cases in terms of sex and WCC. ............................................................................. 175 
Table 6.5 Genetic comparison between the AYA and non-AYA cases within ETV6-
RUNX1 cases ......................................................................................................... 177 
Table 6.6 Comparison between DS and non-DS cases within ETV6-RUNX1 cases in 
terms of sex and WCC ........................................................................................... 178 
Table 6.7 Genetic comparison between the DS and non-DS cases within ETV6-RUNX1 
cases. ................................................................................................................... 180 
 
 
  
1 
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1.1 Cancer 
1.1.1 Overview 
Cancer is a heterogeneous collection of diseases that result from uncontrolled growth 
and invasion of cells owing to the presence of aberrant genes involved in various cellular 
processes including proliferation and apoptosis. Although germline genetics plays an 
important role in driving this abnormal growth and its spread either locally or to distant 
organs, environmental factors are considered as the mainstay of this genetic 
deregulation. More than 200 different types of cancer have been described and they 
differed in their genetic complexities and clinical pictures. Thus, cancer is one of the 
biggest fears in the worldwide public (CRUK, 2011). 
1.1.2 Incidence 
Cancer incidence in the developed countries has continued to increase. More than 1 in 
3 people will develop cancer in the UK during their life; in spite of an increase awareness 
of the determinants of cancer and the reduction of the risky lifestyle factors (CRUK, 
2011). A plausible explanation for this increase might be due to the increase in lifespan 
which increases the risk of exposure to environmental factors resulting in accumulating 
genetic aberrations responsible for developing cancer. Generally, males are at a higher 
risk of developing cancer as compared to females. Both sexes display different 
incidences and mortality rates of different types of cancer that also vary across the world. 
Males tend to develop prostate, lung and colorectal cancers, while breast, cervical, lung, 
colorectal cancers are the most common types in females. It is worth noting that cancer 
can develop at any age with higher risk in older age compared to children, adolescent 
and young adults (up to the age of 24 years) who make up less than 1% of cancers (CRUK, 
2011). 
1.1.3 Multistep development of cancer  
The normal biological cell cycle is tightly controlled to ensure the homeostasis of cell 
numbers and the maintenance of tissue architecture. Transformation of normal cells to 
malignant cells is a multistep process in which these normal cells acquire certain 
characteristics including both genetic instability and inflammation that give them 
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specific capabilities which facilitate neoplastic formation (Hanahan and Weinberg, 
2011). Thus the genome instability generates random genetic errors/ mutations, while 
the inflammation results from the innate immune cells that are normally responsible for 
fighting infections and healing wounds and released different growth/ survival factors. 
There are eight acquired capabilities constituting the hallmarks of cancer development 
namely: 1) production of their own extracellular growth factors (sustainability of the 
proliferative signalling), 2) insensitivity to anti-growth signals (uncontrolled division of 
cells), 3) resistance to apoptosis (further proliferation of cells), 4) limitless replicative 
potential (uncontrolled cell division by maintaining the telomere length), 5) sustained 
angiogenesis (source of required oxygen and nutrients), 6) tissue invasion and 
metastasis (abnormal interaction of cancer cells to the adjacent cells and extracellular 
matrix), 7) deregulation of cellular energetics (reprogramming of cellular metabolism) 
and 8) avoidance of immune destruction (invasion of the immune system). It is worth 
noting that these hallmarks are common for all different types of malignancies, but the 
acquisitioned distinct mechanisms and timing, within the cancer type itself and across 
all types of cancer, are crucial in the diversification of these neoplasms (Hanahan and 
Weinberg, 2011). 
Understanding the principles of the different hallmarks of cancer sheds light on the 
development of new targeted therapy (Hanahan and Weinberg, 2011). Thus, each drug 
is specific to a particular molecular target that is involved in one way or another in the 
activation of certain capabilities, which are important for the biology of tumours, and 
accordingly, less non-specific toxicity would result. However, owing to the presence of 
other parallel pathways regulating that specific capability, these drugs were observed to 
have transient clinical response ending with relapses due to the partial shut down of 
that hallmark capability.  
1.1.4 Genetic determinants of cancer 
There are two classes of genes that are fundamental in cancer development when they 
are altered: oncogenes and tumour suppressor genes (TSG). Multiple environmental 
exposures to mutagenic factors (ultraviolet light, ionizing radiation and other chemical 
mutagens) and inherited cancer syndromes with heterozygous mutation of one allele 
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(vulnerable for further mutations in the other allele) are predisposing factors resulting 
in various genetic alterations.   
Oncogenes are genes that activate cell transformation. They arise from proto-
oncogenes, whose normal function is to regulate cell growth and differentiation, via 
activating mutations and/or increased expression. Examples of these genes are RAS, c-
MYC or other chimeric genes BCR-ABL1 whose activations promote tumourgenesis 
(Meyer and Penn, 2008; Goldman, 2010; Pylayeva-Gupta et al., 2011). On the other 
hand, TSG encode for proteins that prevent a cell from progressing towards cancer in 
response to cellular stresses or DNA damage (Sherr, 2004).  These genes can be altered 
by either inactivating mutations (recessive in nature) or deletions resulting in the 
deregulation of the cell growth. The two-hit hypothesis of TSG inactivation was 
proposed by Knudsen that arose of out his interest in retinoblastoma. He hypothesized 
that in order for the cell to become malignant, both alleles of the TSG must be mutated 
(Knudson, 1971). This hypothesis sheds light on one of the most important genetic 
determinants of cancer and helped in the identification of other several TSG. However, 
not all TSG follow the two hit hypothesis. In some cases loss of only a single copy of TSG 
results in haplo-insufficiency which can promote cancer as seen in CDKN1B gene  (Le 
Toriellec et al., 2008).  
Other genetic alterations which inactivate DNA repair mechanisms are also important in 
neoplastic transformation. Inability to repair damaged DNA will lead to the generation 
of various mutations that resulted from errors in the base excision repair, homologous 
recombination and mismatch repair. In addition, gene expression can be affected by 
epigenetic alterations without any alterations in its genetic sequence and this can be 
achieved by different mechanisms including: DNA methylation and post translational 
histone modification.  There is a growing body of literature that indicates the importance 
of epigenetic mechanisms as critical events in tumorigenesis (Jones and Laird, 1999; 
Jones and Baylin, 2002; Baylin and Jones, 2011). 
1.2 Leukaemia development 
Haematopoiesis is a highly complex process that is characterised by a hierarchical, 
stepwise development, which results in the ongoing generation of the cellular 
constituents of the blood and lymphoid organs. This process provides all blood cell types 
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which originate from haematopoietic stem cells (HSCs) that can proliferate and maintain 
the stem cell pool. There are two main subgroups of blood cells: the myeloid 
compartment, which comprises the macrophages, monocytes, granulocytes, mast cells, 
erythrocytes and thrombocytes, and the lymphoid compartment, which comprises 
natural killer cells, T-lymphocytes and B- lymphocytes (Figure 1.1).  
 
Figure 1.1 Diagrammatic representation of haematopoiesis. Pluripotent stem cell in the bone 
marrow gives rise via cell division and differentiation to circulating peripheral blood cells. Figure 
was taken from http://www.bdbiosciences.com/documents/cd_marker_handbook.pdf.  
These cell types are responsible for different vital functions including gaseous exchange, 
clotting and the immune system. Specifically, lymphocytes are responsible for the 
adaptive immunity, whereas, the myelocytes are involved in diverse roles such as innate 
and adaptive immunity as well as blood coagulation. Different surface expression 
markers aid in the specification of different cell types at different stages of 
differentiation (McKenzie, 1996). This developmental process is tightly regulated by 
cellular interaction, the micro-environment of the bone marrow (BM), several 
regulatory glycoproteins and haematopoietic growth factors. Thus, when deregulated, 
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this process ultimately can result in one of a variety of haematological neoplasms: 
leukaemia, lymphomas, myeloproliferative and myelodysplastic disorders originating 
from lymphoid or myeloid compartments. This project will focus on the leukaemia 
derived from the lymphoid component and accordingly, understanding the regulatory 
networks, required for maintenance of normal haematopoiesis, is critically needed to 
uncover their implications for the leukaemic transformation. Leukaemia is a term 
constituted of the two Greek words; leukos for “white” and haima for “blood”. In 
leukaemia, uncontrolled proliferation of leukaemic blasts that accumulate in BM and 
peripheral blood (PB) leading to a decrease in normal blood cell production. It is 
important to note that the precise molecular mechanisms required for the sustainability 
of normal haematopoiesis remain to be fully elucidated, although some of them have 
already been defined including numerous genes and cellular networks (cell cycle 
regulators and the PI3-kinase signalling pathway, transforming growth factor-β, Wnt, 
Hedgehog, and Notch) (Warr et al., 2011). Recently, the vital role of epigenetic histone 
modifications has been recognised in the maintenance of HSCs (Wang et al., 2013). This 
will yield significant insight into the systems biology that will differentiate between the 
normal HSCs and the leukaemic stem cells enabling the design of targeted therapy that 
overcome the aberrant function of these regulators. 
1.2.1 Epidemiology 
Leukaemia is the 12th most commonly diagnosed cancer in UK, representing around 3% 
of all new cases. It is more common in males than in females, giving incidence rates of 
16 males or 11 females per 100,000 per year in 2010. In addition, it is strongly correlated 
with age with an average of 62% of the diagnosed cases occurring in those aged 65 years 
and above (Figure 1.2) (CRUK, 2011). 
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Figure 1.2 Graph showing leukaemia incidence rates in relation to sex and age per 100,000 
population in UK in 2010. Figure was taken from (CRUK, 2011). 
1.2.2 Classification and Diagnosis 
Leukaemia is classified into four major categories depending on the particular cell type 
affected (myeloid or lymphoid) as well as the rate of cell growth (acute or chronic). They 
are acute lymphoblastic leukaemia, chronic lymphoblastic leukaemia, acute myeloid 
leukaemia and chronic myeloid leukaemia. These specific subgroups differ substantially 
in terms of morphology, cytogenetics features and the characteristic cell surface 
markers including the cluster differentiation (CD) antigen system, indicating diverse 
underlying aetiologies. There is evidence that understanding the genetic mutations 
associated with individual subtypes might uncover the responsible causal mechanisms 
for the leukaemic transformation.  
The complete medical history and physical examination are pivotal in establishing the 
differential diagnosis. Essential diagnostic investigations include complete blood count, 
BM aspiration/biopsy, cerebral spinal fluid analysis, lymph nodes biopsy, imaging 
procedures and other complementary tests related to liver/ kidney/genetics.  
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Although molecular genetic tests are vital tools in refining the diagnosis, 
immunophenotyping is considered important to provide a prompt diagnosis. The 
immunophenotyping involves either flow cytometry or immunohistochemistry 
techniques.   
1.2.3 Clinical overview 
Acute leukaemia is characterised by a fast progression in which the immature leukaemic 
cells accumulate resulting in low levels of mature blood cell types. Early initiation of 
treatment is critically required due to the fast progression of the disease resulting in the 
extreme enrichment of malignant cells leading to infiltration into the blood and other 
organs including liver, spleen and lymph nodes. There are variations in the clinical 
picture of this disease in each individual but generally the symptoms and signs may 
include: recurrent infections, anaemia, bleeding, bruising, loss of appetite, loss of weight 
and enlarged lymph nodes/liver/spleen. In addition, they may include headaches, 
vomiting, confusion, seizures related to the meningeal spread, sores in the eye or skin 
or bone and swollen testicles owing to neoplastic infiltrations.  
However, in the chronic type, mainly found in older patients, the leukaemic cells 
accumulate over a long period that usually takes months to years and patients are often 
monitored for evidence of substantial disease progression before being treated. They 
are usually asymptomatic or show non- specific signs/ symptoms such as anorexia, 
weight loss and fatigue. 
This Chapter focuses on a subtype of acute lymphoblastic leukaemia (ALL) and the 
following section will further elaborate on this entity of leukaemia. 
1.3 Acute lymphoblastic leukaemia 
Acute lymphoblastic leukaemia (ALL) is a heterogeneous disease entity with a variety of 
genetic aberrations in the leukaemic blasts impeding important functions in cellular 
growth, differentiation, and death (apoptosis), thus contributing to a wide range of 
clinical presentations and outcomes. ALL is the most common type of leukaemia in 
children representing around four-fifths of all diagnosed childhood leukaemia in United 
Kingdom (CRUK, 2011). Generally, the incidence peaks between the ages of (2-5) years, 
decreasing to become a much rarer disease of adulthood, with 5 per million cases per 
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year in ages 20 to 59 years with a two fold increase in ages 60 to 79 years (Juliusson et 
al., 2010).   
1.3.1 Aetiology 
The exact cause of ALL remains unresolved in the majority of cases. However, 
combinations of genetic and environmental factors required for malignant 
transformation are well established in a small proportion of cases. Patients with Down 
syndrome (DS) and disorders with excessive chromosomal fragility (Bloom’s syndrome, 
ataxia-telangiectasia, Nijmegen breakage syndrome and Fanconi anemia) are at higher 
risk of developing ALL compared with the general population, however, they contribute 
to less than 5% of total ALL cases (Pui et al., 2008; Reaman and Smith, 2011). DS is the 
most frequent genetic syndrome encountered in childhood ALL with 1 out of 100 DS 
cases developing ALL and this corresponds to a 10-20 fold increase in risk compared to 
non-DS cases. In addition, ionizing radiation, prior chemotherapy, high birth weight (> 
4,000 g), parental occupation, maternal reproductive history (maternal age more than 
35 years), parental tobacco or alcohol use and maternal diet are considered to be risk 
factors for childhood ALL.  
Furthermore, infection was found to play a role in the observed worldwide variation of 
childhood leukaemia incidences. British investigators have postulated two parallel 
infection-based hypotheses: Kinlen’s population-mixing hypothesis (Kinlen, 1988) and 
Greaves’ delayed-infection hypothesis (Greaves, 2005; Greaves, 2006). These 
hypotheses originated from the observations of a peak age of development of childhood 
ALL of 2–5 years, an increased prevalence of the disease with industrialisation, and the 
occasional clustering of childhood leukaemia cases. Kinlen predicted that low immunity 
individuals exposed to a common but unidentified infection were at increased risk of 
developing ALL. Hence, this can give rise to localized epidemics and so-called leukaemia 
clusters. Greaves’ hypothesis is based on a minimal two-hit model and suggests that 
delayed exposure to common infections predisposes the immune system of these 
individuals to aberrant or pathological responses resulting in increased lymphoid-cell 
proliferation (Figure 1.3). The delayed exposure is considered as a second hit that would 
require prior existence of pre-leukaemic clone (first hit) for the leukaemic 
transformation. 
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Figure 1.3 A two-step model for the natural history of acute lymphoblastic leukaemia.  Figure 
adapted from (Greaves, 2005). 
Interestingly, previous studies examining the contribution of single nucleotide 
polymorphisms (SNPs) to childhood leukaemia development reported possible role of 
SNPs targeting genes involved in the folate metabolism and xenobiotic 
transport/metabolism in increasing the leukaemia risk (Chokkalingam and Buffler, 2008; 
Koppen et al., 2010). However, recent genome- wide association studies of large 
populations of leukaemic and non-leukaemic individuals through analysis of SNPs 
identified other SNPs, known to be important in lymphoid development/differentiation, 
targeting IKZF1 (7p12.2) (odds ratio (OR) = 1.69, P = 1.20 x 10-19), ARID5B (10q21.2) (OR 
= 1.65, P = 6.69 x 10-19),  and CEBPE (14q11.2) (OR = 1.34, P = 2.88 x 10-7) (Papaemmanuil 
et al., 2009; Trevino et al., 2009). These SNPs were found to be positively correlated with 
the development of leukaemia, while those SNPs involved in folate and xenobiotic 
metabolism were not reported to have a significant difference between the cases and 
controls in one of these studies (Trevino et al., 2009). Furthermore, the SNP targeting 
ARID5B was found to be a characteristic feature distinguishing BCP-ALL high 
hyperdiploid from other subtypes (p= 3.84 X 10–6). Recently, an additional 
comprehensive association study, which combined both the local study with other 
published genome-wide association studies, provided an evidence of additional novel 
loci located at both 10p12.2 (PIP4K2A) (OR = 1.23; P = 2.30 × 10-9) and 10p14 (GATA3) 
(OR = 1.31; P = 8.62 × 10-12) with the SNP affecting PIP4K2A was specifically associated 
with high hyperdiploid BCP-ALL (p= 2.60 x 10-7). Interestingly, the SNP located within 
GATA3 was found to be associated with a specific subtype of ALL known ‘’Philadelphia 
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like’’ (P = 1.05 × 10-8). This subtype is enriched for CRLF2 rearrangements, IKZF1 
deletions and JAK mutations (Perez-Andreu et al., 2013).  
1.3.2 Natural history of leukaemia  
Molecular studies have contributed to identify the prenatal origin of some 
translocations and hyperdiploid event in some childhood leukaemic cases and these 
abnormalities were considered as initiating events (first hits) owing to the variable 
latency period before the overt leukaemia. The identical (monozygotic monochorionic) 
twin studies were the most important evidence of in utero initiation of leukaemia. There 
were several twin studies which confirmed the presence of identical primary 
rearrangement breakpoints (e.g. MLL rearrangements, t(12;21)) in both twins in several 
twin pairs, even those with different timing of leukaemia development. The plausible 
explanation is that the initiating events arose from a single clone in one twin and was 
transferred via shared placenta to the other twin (Ford et al., 1993; Greaves et al., 2003; 
Greaves and Wiemels, 2003; Reaman and Smith, 2011). Recently, comprehensive whole 
genome sequencing was performed on two pairs of monozygotic monochorionic twins, 
one with ETV6-RUNX1 positive and one ETV6-RUNX1 negative BCP-ALL, respectively, to 
further elucidate the developmental timing of different somatic alterations. This study 
focused on twins with ETV6-RUNX1 fusion gene and showed conclusively that this was 
the only lesion common to both individuals and therefore must have been the initiating 
event (Ma et al., 2013). 
Furthermore, additional studies utilising the Guthrie cards or neonatal blood spots, 
which were collected at birth, confirmed the prenatal origin of some childhood 
leukaemia-specific fusion genes (e.g. ETV6-RUNX1, RUNX1-RUNX1T1) and hyperdiploidy 
(Gale et al., 1997; Maia et al., 2004; Greaves, 2005). In addition, some T-cell ALL 
associated abnormalities targeting T-cell-receptor loci and NOTCH1 were also identified 
in both archived neonatal blood spots (Guthrie cards) and the monozygotic 
monochorionic twin studies with identical breakpoints presented at overt leukaemia 
(Ford et al., 1997; Fasching et al., 2000; Fischer et al., 2007; Eguchi-Ishimae et al., 2008).  
The ETV6-RUNX1 fusion gene was detected in 1% of the healthy newborn babies, a 
frequency 100 times greater than the incidence of ETV6-RUNX1 positive BCP-ALL 
indicating (a) the requirement of the acquisition of additional abnormalities for the 
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leukaemogenic transformation; and (b) that most patients do not acquire these 
additional hits and therefore they do not develop ALL (Mori et al., 2002; Zuna et al., 
2011). It is worth noting that the oldest case reported previously with positive Guthrie 
card test for ETV6-RUNX1 fusion gene was aged 14 years at the time of clinical leukaemia 
indicating prolonged latency period (Wiemels et al., 1999). Although researchers have 
reported an equal prevalence of ETV6-RUNX1–positive cells in both healthy newborn 
and adults (Olsen et al., 2006), the observed cell level of 10-3 to 10-4 in neonatal blood 
does not persist throughout adult life. Instead it has been found to be much lower 
reaching a cell level of 10-5 to 10-6 which may explain the lower incidence of this 
abnormality in adult ALL compared to childhood ALL. 
1.3.3 Classification and Diagnosis 
The classification and accurate diagnosis of ALL involves a stepwise process, which has 
improved over the past 20 years with the development of new techniques. It is classified 
according to morphologic, immunologic and cytogenetic features of leukaemic 
lymphoblast derived from PB smear, BM aspirate or tissue biopsy specimens. It was 
initially classified solely using the French-American-British morphological classification 
system that is important in distinguishing between ALL and the leukaemic phase arising 
from Burkitt lymphoma and this contributes to major therapeutic implications (Bennett 
et al., 1976; Bennett et al., 1981; Bennett et al., 1985). Later, subsequent immunological 
classification followed and it was useful to some extent in risk stratification (Kersey et 
al., 1975; Bene et al., 1995). 
The most recent classification system is the 2008 World health organization (WHO) that 
uses morphologic, immunophenotypic, genetic, and clinical features to define distinct 
diagnoses within ALL (Table 1-1) (Vardiman et al., 2009). Thus, ALL is classified into three 
major subgroups: acute leukaemias of ambiguous lineage (rare, do not fit into a defined 
entity), B lymphoblastic leukaemia/lymphoma and T lymphoblastic 
leukaemia/lymphoma with the vast majority of ALL cases in children is of B cell type, 
comprising nearly 85%. To note, lymphoblastic lymphoma can be differentiated from 
leukaemia when a mass is present based on the percentage of lymphoblast in BM (< 
25%). B lymphoblastic leukaemia is further sub-classified based on the recurrent genetic 
abnormalities. Although several specific recurrent chromosome aberrations and gene 
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mutations also occur in T cell- ALL, at present they are not used to delineate separate 
entities within this ALL lineage in this current classification system (Swerdlow, 2008; 
Vardiman et al., 2009). This approach has been adapted to improve the accurate 
assessment of patient outcome.  
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Acute leukaemias of ambiguous lineage 
Acute undifferentiated leukaemia 
Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1 
Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged 
Mixed phenotype acute leukaemia, B-myeloid, NOS 
Mixed phenotype acute leukaemia, T-myeloid, NOS 
Provisional entity natural killer cell lymphoblastic leukaemia/lymphoma 
B lymphoblastic leukaemia/lymphoma 
B lymphoblastic leukaemia/lymphoma, NOS 
B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities: 
B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities with 
t(9;22)(q34;q11.2); BCR-ABL 1 
B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities with t(v;11q23); 
MLL rearranged 
B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities with 
t(12;21)(p13;q22); ETV6-RUNX1 
B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities with 
hyperdiploidy 
B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities with hypodiploidy 
B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities with 
t(5;14)(q31;q32); IL3-IGH 
B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities with 
t(1;19)(q23;p13.3); TCF3-PBX1 
T lymphoblastic leukaemia/lymphoma 
Table 1-1 The 2008 WHO classification of acute lymphoblastic leukaemia.  NOS: not 
otherwise specified. Information was extracted from (Vardiman et al., 2009). 
  
There are different diagnostic investigations that are required to precisely refine the 
evolving diagnosis (Crisan, 2010). The BM aspiration and biopsy evaluations, which 
provide the morphological appearance, are useful in identification of the working 
differential diagnosis. More detailed phenotypic characterisation of cells is obtained by 
the flow cytometry and/or immunohistochemistry analysis to determine the specific 
lineage involved. The cytogenetic/molecular cytogenetic tests are widely used as 
important tools to further refine the final diagnosis. Thus, karyotype analysis provides 
information about gross chromosomal abnormalities, while molecular cytogenetic 
techniques including fluorescence in situ hybridisation (FISH) are important to give 
information about the presence or absence of specific lesions e.g. deletions, 
duplications, translocations and inversions. In addition, other molecular tests including 
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polymerase chain reaction (PCR) are used to detect specific abnormalities e.g. gene 
fusions.  
1.3.4 Clinical presentation 
ALL is thought to originate as a result of various important somatic genetic lesions in the 
differentiating progenitor cells that are committed to either the T-cell or B-cell pathway, 
giving rise to the different subtypes of ALL. These mutations impart the capacity for 
clonal expansion of a transformed haematopoietic cell or arrest the differentiation at an 
early stage in lymphoid cell development.  
The clinical presentation of this disease results from the leukaemic blasts replacing 
normal marrow cells which in turn causes a marked decrease in the production of 
normal blood cells. This eventually leads to varying degrees of anaemia, 
thrombocytopenia, neutropenia and suppression of normal residual haematopoiesis 
which results in fatigue, bleeding, fever and infections. Concomitantly, these blasts can 
also infiltrate extramedullary tissues such as, e.g., liver, spleen, lymph nodes and the 
central nervous system (CNS) resulting in painful enlargement which may compromise 
normal organ function; hepato- and splenomegaly. These symptoms and signs are 
considered to be common in ALL patients in general.  
In addition, bone pains and arthritis may be presenting features of B- cell type of ALL, 
while T cell-ALL may present with respiratory distress owing to the possible presence of 
a mediastinal mass. There are other rare symptoms involving the CNS including 
headache, vomiting, altered mental status which are more common in T-cell ALL than B-
cell type. Painless testicular enlargement, usually unilateral, may be presenting feature 
but it is rare.   
1.3.5 Treatment 
There are four available standard modalities of treatment for ALL including: 
chemotherapy, radiation therapy, stem cell transplant and targeted therapy. Treatment 
typically consists of three phases: remission-induction, intensification and maintenance 
treatments along with CNS prophylaxis. Patients with mature B cell ALL (Burkitt 
leukaemia) are usually treated with short-term intensive chemotherapy like other 
lymphomas. Firstly, remission-induction treatment aims to kill more than 99% of the 
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initial burden of leukaemic cells and to restore rapidly normal haematopoiesis with 
associated normal performance status. This phase of treatment typically includes a 
glucocorticoid agent (preferably dexamethasone) as a choice of treatment along with 
other agents including vincristine and L- asparaginase drugs. Secondly, intensification 
treatment is used to eradicate drug- resistant residual leukaemic cells, thus reduces the 
risk of relapse. Basically, it resembles the induction phase but with augmented doses of 
different combinations of drugs such as glucocorticoid, L- asparaginase, vincristine and 
6-mercaptopurine drugs. Various clinical trials follow different intensification regimens 
to assess their effectiveness on certain subtypes of leukaemia. Lastly, maintenance 
treatment is less intensive regimen which is applied to ALL patients except those with 
mature B- ALL. Some clinical trials such as Medical Research Council ALL97/99 (Mitchell 
et al., 2010) or United Kingdom (UK) ALL2003 (Qureshi et al., 2010) extended this phase 
of treatment to 3 years in boys owing to the increase risk of testicular relapses. However, 
most current protocols apply same duration of therapy in both genders because the 
gender seems not to be a prognostic factor with improved therapy. In this phase of 
treatment, drugs such as glucocorticoid, methotrexate and 6-mercaptopurine may be 
administered in different combinations and timing intervals.  
Furthermore, CNS infiltration is a feature of ALL and can be present at diagnosis or cause 
relapse. Thus, CNS- directed treatment is important in order to control the CNS disease 
especially in those with high risk features including a T-cell immunophenotype, 
hyperleucocytosis, high-risk genetic abnormalities and presence of leukaemic cells in 
cerebrospinal fluid. There are different CNS-directed therapy options including 
intrathecal chemotherapy, systemic chemotherapy and cranial irradiation. The 
intrathecal chemotherapy consists of different combinations of methotrexate, 
cytarabine and glucocorticoid drugs, whereas the systemically administered drugs 
include methotrexate, L-asparaginase and glucocorticoid drugs.   The combination of 
intrathecal and systemic chemotherapy is needed for controlling the CNS disease along 
with decreasing the risk of BM or other extramedullary  relapses, respectively (Richards 
et al., 2013). However, the cranial irradiation may be reserved only for patients with 
refractory CNS disease or as salvage therapy for patients with CNS relapse in some 
current clinical trials owing to its adverse side effects.  
  
17 
 
Risk assessment is based on different factors generated by the clinical and laboratory 
features at diagnosis including: age, WCC, early response to treatment (ER), minimal 
residual disease (MRD) at the end of induction and genetics (Pui, 2012; Moorman et al., 
2013). Currently, most studies stratify patients into three risk groups with similar but 
not identical risk criteria. For instance, ALL97/99 or UKALL2003 trials divided patients 
based on a combination of National Cancer Institute (NCI) criteria, cytogenetic and early 
response to induction therapy. Firstly, patients were classified based on age and WCC 
following NCI criteria: thus patients aged 1-9 years with a WCC < 50 x109/L at initial 
presentation are stratified as standard NCI risk, whereas those with ≥ 10 years or a WCC 
≥ 50 x109/L were considered as high NCI risk category. Genetic abnormalities play an 
important role in the risk stratification; hence those with high risk cytogenetic (see 
section 1.4) are treated on the most intensive regimen irrespective of the NCI risk. The 
identification of those with high or low MRD levels is crucial in the treatment 
stratification. Hence those with high MRD level get more intensive therapy, while those 
with low MRD gets less therapy. Accordingly, risk stratification will spare low risk 
patients from unneeded toxicity. It is noteworthy that risk stratification is still not 
sufficient to identify all patients destined to relapse; hence most relapses arise in those 
with low or intermediate risk group (Moricke et al., 2008; Mitchell et al., 2009; Pui, 
2012). However, the level of MRD seems to be a promising risk factor for which it is 
incorporated in the current risk stratification systems (Pui, 2012; Vora et al., 2013).  
In addition, haematopoietic stem-cell transplantation is one of the treatment modality 
that is reserved for high risk patients who have refractory leukaemia (especially T-cell 
ALL), high MRD level and early haematological relapses. There are two types of grafts 
including autologous (from the patient) and allogeneic (from matched related or 
unrelated) transplants. The autologous type carries less risk of infection and graft- 
versus- host disease owing to the rapid recovery of the immune function and the cells 
originated from the same individual, respectively. The allogeneic matched related donor 
is recommended over unrelated one in order to decrease the risk of developing graft- 
versus- host disease that adversely impacts on the transplant outcome. However, the 
matched unrelated transplant may be reserved for those with no available matched 
related donor. In general, the outcome of children with high risk BCP-ALL can be 
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improved by the application of the allogeneic transplant from either matched related or 
unrelated donor (Fagioli et al., 2013).  
All these modalities cause late effects/ complications which result in increased rates of 
morbidity and mortality. There are several adverse effects including: secondary 
neoplasms, many endocrine diseases, growth impairment, neurocognitive dysfunction 
and neurotoxic effects. In addition, development of chronic medical conditions like 
cardiac, musculoskeletal, gastrointestinal disorders and other chronic illnesses can arise 
from such treatment. These therapies have the potential to disrupt the social 
development in survivors, thus lower rates of marriages and achievement at 
schools/colleges were recorded. 
Recently, new drugs targeting specific genetic alterations/ pathways have been 
developed and they often have lesser side effects as compared to the conventional 
therapy. In the USA, clinicians and researchers are collaborating in a project known as 
TARGET (Therapeutically Applicable Research to Generate Effective Treatments; 
www.target.gov) which aims to identify alterations in genes/ pathways related to high 
risk ALL using advancing technologies (e.g. high-throughput genomics and sequencing). 
Accordingly, these alterations may act as novel targets for therapy. An example of 
successful targeted therapy is tyrosine kinase inhibitors including imatinib and its 
analogues which target the BCR-ABL1 fusion gene. This fusion gene is generated as a 
primary product of the translocation t(9;22)(q34;q11) in both acute lymphoblastic/ 
chronic myeloid leukaemia and is responsible for the tyrosine kinase pathway activation 
(see section 1.4.1.2) (Druker et al., 2006). In addition, the tyrosine kinase inhibitors may 
be beneficial in treating patients with activated kinase signatures among the newly 
identified BCR-ABL1-like group especially those with ABL1 translocations (e.g. the 
NUP214-ABL1 fusion) (see section 1.4.1.2) (Harrison, 2013).  
1.3.6 Outcome 
The treatment advances in ALL have resulted in dramatic improvement of the survival 
rates in children with 5- year event free survival (EFS) and overall survival (OS) of 87·2% 
and 91·5% with 8.8% 5- year cumulative risk of relapse (Figure 1.4) (Vora et al., 2013). 
However, adult ALL showed lower survival rates with OS of approximately 40% and two 
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fold increase in the survival of those with Ph- negative ALL patients (Figure 1.5) 
(Goldstone et al., 2008).      
 
Figure 1.4 Survival and relapse rates of the overall trial of UKALL2003 of children and young 
adults ALL. Overall survival and event free survival: time from diagnosis to death/ last contact 
follow up or adverse events, respectively. Figure was taken from (Vora et al., 2013). 
 
Figure 1.5 Overall survival rates at 4 years of the overall trial of UKALL XII/ECOG 2993 in Ph- 
negative and Ph- positive adult ALL (no imatinib treatment. The OS rate at 4 years of Ph- 
positive adult ALL (with imatinib treatment) is 38% as compared to 22% in those who did not 
receive imatinib (Ph- positive adult ALL (no imatinib treatment) (Fielding et al., 2014).  Figure 
was taken from (Goldstone et al., 2008).    
Both age and WCC are important risk factors in the determination of NCI risk groups (see 
section 1.3.5). Furthermore, cytogenetic plays an important role in the risk stratification 
of ALL patients (see section 1.4.3). There are other factors that may affect the outcome 
including: early treatment response, MRD level, immunophenotype, sex, CNS disease 
and obesity (Table 1-2). 
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Risk factors Estimate of risk 
Age >10 years do worse than <10 years 
WCC >50 ×10⁹/L do worse than <50 ×10⁹/L 
MRD risk  Positive MRD do worse than negative MRD 
Immunophenotype  T-cell do worse than B-cell 
Table 1-2 Generic estimates of acute lymphoblastic leukaemia risk based on several risk 
factors. WCC white cell count, MRD minimal residual disease. 
Early treatment response is considered as an important measure to stratify patients into 
appropriate treatment allocations based on the percentage of blasts during the 
induction period at specific days that varied between different protocols. Thus, patients 
with > 25% blasts are classified as slow early treatment responders who constitute a 
high risk group. However, this factor lacks the prognostic value, hence 12% (35/285) of 
those patients with remission-induction failure (the persistence of the leukaemic blasts 
in BM or an extramedullary site at the end of the induction therapy) had rapid clearance 
of leukaemic blasts at around day 15 from the treatment initiation (Schrappe et al., 
2012).     
Importantly, monitoring of MRD is an essential factor in the determination of the relapse 
risk and its predictive value is dependent on the measuring technique used, time point 
at measurement and therapy applied before and after the measurement (Vora et al., 
2013). MRD level can be obtained using either PCR detection of immunoglobulin and T-
cell receptor gene rearrangements or flow cytometry of aberrant immunophenotypes. 
Although the PCR techniques are highly sensitive, combination of both techniques may 
be useful in order to reduce the false negative results in either technique. Patients with 
MRD negative have a favourable outcome compared to those who fail to achieve this 
immunologic/ molecular remission (Table 1-3) (Stow et al., 2010; Vora et al., 2013).  
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MRD risk Relapse % Death in remission %  Event free survival % 
Low 4.0 (2.4-5.6) 1.5 (0.7-2.3) 94.2 (92.4-96.0) 
High 15.0 (12.3-17.7) 4.5 (3.1-5.9) 79.8 (76.9-82.7) 
Table 1-3 Event rates at 5 years (95% CI) within MRD risk groups treated on UKALL2003 trial. 
Data was extracted from (Vora et al., 2013). 
Almost half of the non-relapsed death cases in induction/ remission, for instance in 
UKALL2003, were pertaining to the therapy related toxicity (Vora et al., 2013). 
Dexamethasone might be the contributor for this toxicity owing to increased 
susceptibility of patients to infections and osteonecrosis with associated negative 
impact on the quality of life (Hurwitz et al., 2000; McNeer and Nachman, 2010; Vora et 
al., 2013). In addition, L- asparaginase has potential toxic effects including pancreatitis, 
hypersensitivity reactions, thrombosis/ haemorrhage and hepatic injury. Hence, the 
identification of patients with low relapse risk is a pivotal management plan in order to 
reduce their exposure to the toxic effects of intensive therapy without compromising 
the survival rates and has been accomplished in some studies (Seibel et al., 2008; 
Matloub et al., 2011; Vora et al., 2013). In addition, targeted therapy might contribute 
further to decrease the toxicity by replacing some toxic drugs in conventional 
chemotherapy. 
The outcome of the patients with first relapse ALL is heterogeneous based on the 
received treatment protocols (Roy et al., 2005; Parker et al., 2010; Eckert et al., 2013; 
Kako et al., 2013). There are several factors contributing to the prediction of survival 
after first relapse including: duration of the first complete remission and 
immunophenotype (Table 1-4). The site of first relapse has also been associated with 
survival rates after relapse but not consistently.    
Furthermore, the interventions received by patients with first relapse are contributing 
factors in the prediction of second relapse, thus those who are treated by salvage 
chemotherapy alone, high risk patients in particular, have increasing susceptibility for 
second relapses with resultant lower survival rates. In addition, matched allogeneic stem 
cell transplant was found to improve the outcome of patients, adults in particular, when 
offered in second complete remission (Kako et al., 2013).  
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Risk factors Estimate of survival after 1st relapse 
Duration of CR1 Shorter CR has lower survival rates 
Immunophenotype  T-cell has lower survival rates than B- cell 
Table 1-4 Generic estimates of survival after first relapse. 
1.4 Genetics of acute lymphoblastic leukaemia  
The genetic changes found in haematopoietic malignancies serve as hallmarks for the 
leukaemic subtypes and provide important diagnostic and prognostic information. 
Genetic changes in ALL may be of numerical or structural type such as translocations, 
inversions and deletions. In addition, sequence mutations and methylation alterations 
occur. Here in this section, an overview will be given around the most prominent 
alterations found in both B and T cell ALL.  
1.4.1 B-cell acute lymphoblastic leukaemia 
The genetic subtypes in BCP-ALL can be divided into five main groups: (1) aneuploidy 
subgroups characterised by the gain or loss of multiple non-random chromosomes; (2) 
chromosomal translocations which result in the formation of fusion genes that disrupt 
transcription factors or activate oncogenes; (3) copy number alterations; (4) sequence 
mutations and (5) methylation alterations. Although these genetic subtypes can be seen 
in all age groups, the overall distribution of these alterations differs and the structural 
rearrangements/ aneuploidy subgroups are clear examples (Figure 1.6). In addition, 
these alterations affect different genes at variable stages of cell development (Figure 
1.7). The majority of the chromosomal abnormalities including t(12;21)(p13;q22), 
t(9;22)(q34.1;q11.2), MLL rearrangements, t(1;19)(q23;p13.3), High hyperdiploidy and 
Hypodiploidy are primary, while the remaining aberrations are secondary abnormalities.  
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Figure 1.6 The estimated prevalence of different selected chromosomal abnormalities 
according to the age at diagnosis.  Figure was taken from (Moorman, 2012). 
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1.4.1.1 Numerical chromosomal abnormalities 
High hyperdiploidy (HeH) is defined as having a total modal number of 51-65 
chromosomes present in the leukaemic cells (Paulsson and Johansson, 2009) with a 
variable definition of the upper limit as 61 (Forestier et al., 2008a), 65 (Moorman et al., 
2003; Sharathkumar et al., 2008), and 67 (Raimondi et al., 1996; Heerema et al., 2007). 
HeH BCP-ALL is the most common genetic abnormality that is characterised 
cytogenetically by a non-random gain of eight chromosomes (X, 4, 6, 10, 14, 17, 18, and 
21) (Moorman, 2012). Interestingly, around 33% of HeH cases have several mutations 
affecting FLT3, NRAS, KRAS and PTPN11 genes and thus in turn implies the possible 
development of novel therapies targeting the RTK-RAS signalling pathway (Case et al., 
2008; Paulsson et al., 2008).  
Hypodiploidy is characterised by a modal number of ≤ 45 chromosomes. It is subdivided 
into three distinct subgroups based on chromosome number, other cytogenetic features 
and clinical parameters: near-haploidy (<30 chromosomes), low hypodiploidy (30-39 
chromosomes) and high hypodiploidy (40-45 chromosomes) (Harrison et al., 2004; 
Moorman, 2012). To note, these subgroups have variable distributions among different 
age groups, thus near-haploidy is more common in younger children as compared to low 
hypodiploidy subtype that occurs in older children, adolescents and adults. In addition, 
the pattern of the chromosome loss is non-random but it varies between near-haploidy 
and low hypodiploidy. Near-haploidy is characterised by the frequent retention of few 
chromosomes including: sex chromosomes and chromosomes 10, 14, 18 and 21, while 
low hypodiploidy typically exhibits loss of chromosomes 3, 7, 15, 16 and 17 with 
associated retention of chromosomes 1, 6, 11 and 18. Whole genome and exome 
sequencing studies found that near haploidy group is characterised by an increase 
number of alterations activating RAS signalling pathways (e.g. NF1, NRAS and KRAS) 
(71%) and the lymphoid transcription factor gene IKZF3 (13%), while the low 
hypodiploidy group harbours alterations affecting TP53 (~90%), that are commonly 
germline in almost half of children, IKZF2 (53%) and RB1 (41%) genes (Holmfeldt et al., 
2013). Both subgroups have a shared characteristic of activating Ras and 
phosphoinositide 3-kinase (PI3K) signalling pathways for which further research is 
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required to assess the efficacy of PI3K inhibitors as targeted therapy. Interestingly, both 
near-haploidy and low hypodiploidy subgroups showed a phenomenon of doubling-up 
of the existing clone, that arises from clonal evolution, and resulted in a modal 
chromosome number of high hyperdiploid (50-56) or high hyperdiploid (60-65) and near 
triploid (66-78) ranges, respectively, based upon the pre-existing number of 
chromosomes (Charrin et al., 2004; Moorman, 2012). It is worth noting that all disomic 
or trisomic chromosomes in the apparent high hyperdiploid or near triploid, respectively, 
are of uniparental origin unlike the true high hyperdiploid or near triploid which proves 
the origin of the doubled up clone. Hence, the misclassification of these cases is an 
important clinical issue that required adhered caution because they differ in terms of 
outcome and treatment allocation (see section 1.4.3), thus the identification of the 
uniparental isodisomy using high- resolution genomic profiling techniques can be used 
to reliably distinguish these subgroups.  
1.4.1.2 Chromosomal translocations/rearrangements 
The translocation t(12;21)(p13;q22) is the most common translocation in childhood BCP-
ALL and results in the formation of the chimeric fusion gene ETV6-RUNX1 (see section 
1.5).  
The translocation t(9;22)(q34.1;q11.2) produces the functional fusion gene BCR-ABL1, 
by fusing the 3’ segment of the tyrosine kinase Abelson (ABL1) oncogene at 9q34 to the 
5’ segment of the breakpoint cluster region (BCR) gene at 22q11. This reciprocal 
translocation results in the formation of the derived chromosome 22, known as the 
Philadelphia chromosome (Ph) and was first identified in CML (Rowley, 1973). There are 
three differently sized transcripts encoding: p190, p210 and p230 (rare) owing to the 
heterogeneous breakpoints at the BCR locus and all these protein products result in 
activation of the tyrosine kinase.  
Translocations involving the mixed lineage leukaemia gene (MLL; known as KMT2A), 
which is located at 11q23, create fusion genes with different partner genes (Szczepanski 
et al., 2010; Meyer et al., 2013). MLL rearrangements are also frequently seen in AML, 
in particular therapy- related AML (Slany, 2009) as well as in some T-ALL cases. The 
5’portion of the MLL gene fuses to the 3’ portion of the partner gene on the derivative 
chromosome 11 which is thought to exert the leukaemogenic effect. By far the most 
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common MLL translocations in ALL are t(4;11)(q21;q23)/MLL-AFF1 (MLL-AF4), that 
frequently occurs in infants/ adults and is characterised by CD10 negative cells (very 
early immunophenotype) and t(11;19)(q23;p13.3)/ MLL-MLLT1 (MLL-ENL), which is 
common in infants (Moorman, 2012). There are other well defined chromosomal 
translocations involving MLL that are found in all age groups but at lower incidence rates 
including: t(9;11)(p21;q23), t(6;11)(q27;q23) and t(10;11)(p12;q23). The fusion partners 
in these translocations are MLLT3 (AF9), MLLT4 (AF6) and MLLT10 (AF10), respectively 
(Secker-Walker et al., 1998). The MLL protein is responsible for the regulation of the 
HOX genes and contains several functional domains including the SET domain. The SET 
domain enhances the methylation of lysine 4 of histone 3 (H3K4) which mediates 
chromatin modification involved in epigenetic transcriptional activity (Milne et al., 2002; 
Nakamura et al., 2002). MLL rearranged proteins lose the SET domain (Hess, 2004) and 
hence recruit another histone methyltransferase, namely DOT1L. DOT1L aberrantly 
methylates histone 3 lysine 79 (H3K79) (Feng et al., 2002; Steger et al., 2008) which 
results in overexpression of the HOX genes which, in turn, drives leukaemogenesis 
(Okada et al., 2005) .    
The translocation t(1;19)(q23;p13.3) juxtaposes the trans-activation domain of the 
transcription factor 3 gene TCF3 (E2A), located at chromosomal band (19p13), with the 
majority of the PBX1 gene (homeobox HOX), positioned at 1q23, to form the TCF3-PBX1 
fusion gene (Hunger et al., 1991). It is worth noting that some cases (5%) showed 
different gene fusions (Privitera et al., 1992; Barber et al., 2007). The t(1;19) occurs 
either as a balanced translocation t(1;19) or unbalanced form where only 
der(19)t(1;19)(q23;p13.3) is present. A variant of the t(1;19) translocation exists at an 
estimated rate of 0.1% and results in the fusion of the HLF gene, located at 17q22, to 
TCF3 as a consequence of t(17;19)(q23;p13) translocation.  
Chromosomal translocations involving the immunoglobulin heavy chain (IGH) locus 
(Table 1-7), at 14q32 chromosomal region, define common subgroups of B-cell mature 
leukaemia and lymphoma but also occur in BCP-ALL (Moorman et al., 2012; Russell et 
al., 2014). IGH translocations result in deregulation of oncogene expression because of 
their juxtaposition to IGH transcriptional enhancers (Chapiro et al., 2013). Recent 
advanced molecular studies have identified several novel IGH translocations involving 
important genes involved in cytokine receptors, transcription factors, apoptosis, cell 
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cycle progression and signalling adapter molecules/ miRNAs. The most common partner 
genes are CRLF2 and the CEBP family members; however other recurrent genes were 
reported including MYC, BCL2, ID4, EPOR and CCND1 and ongoing research studies are 
still uncovering new partners. Thus identification of these oncogenic genes will shed 
light on the pathogenic mechanisms and may result in the development and rational use 
of targeted therapies.   
Deregulated expression of CRLF2 (Table 1-7) is driven by juxtaposition to the IGH@ 
enhancer or P2RY8 promoter which arise from either a cryptic chromosomal 
translocation: t(X;14)(p22;q32)/ t(Y;14)(p11;q32), or a cryptic interstitial deletion within 
the pseudo-autosomal region (PAR1): del(X)(p22.33p22.33)/del(Y)(p11.32p11.32), 
respectively (Russell et al., 2009). In addition, rare activating mutations have also been 
reported (Russell et al., 2009; Chapiro et al., 2010; Hertzberg et al., 2010). Interestingly, 
CRLF2 overexpression was found to arise in the absence of these rearrangements or the 
rare activating mutations (Russell et al., 2009; Chapiro et al., 2010; Hertzberg et al., 
2010). The resulting CRLF2 overexpression activates the JAK-STAT pathway that is 
responsible for the sustained proliferation and transformation of the primary B-cell 
progenitors. Aberrant CRLF2 expression in children results from a 5:1 relative proportion 
of P2RY8-CRLF2:IGH@-CRLF2 cases, while a 1:2 relative proportion of P2RY8-
CRLF2:IGH@-CRLF2 cases has been reported among adults. The prevalence of 
deregulated CRLF2 expression among DS ALL patients is much higher, occurring in more 
than 50% cases with a predominant P2RY8-CRLF2 type of deregulation (Kearney et al., 
2009; Mullighan et al., 2009a; Hertzberg et al., 2010; Moorman et al., 2012).   
Intrachromosomal amplification of chromosome 21 (iAMP21) (Table 1-7) is 
characterised by multiple regions of inversion, deletion, duplication and amplification 
affecting the whole long arm of chromosome 21 resulting in 3 or more extra copies of 
the RUNX1 gene, however, the target gene in iAMP21 pathogenesis has not yet been 
determined (Harrison et al., 2013; Li et al., 2014). Although the amplicon size and degree 
of amplification varied considerably between patients, a common 5.1 Mb region of 
amplification (CRA) was identified spanning the chromosomal regions 21q22.11 to 
21q22.12, which encompasses the RUNX1 gene. This was accompanied by a <1 Mb 
common region of deletion (CRD) close to the telomere in 80% of patients.  
  
28 
 
A newly identified genetic subgroup namely BCR-ABL1- like constitutes up to 10%-15% 
of childhood BCP-ALL cases. This novel subgroup displays a gene expression signature 
similar to that seen in BCR-ABL positive cases and it often has IKZF1 alterations (either 
deletion/ sequence mutations) (Den Boer et al., 2009; Roberts et al., 2012). Half of the 
BCR-ABL1- like cases exhibit CRLF2 rearrangements and 50% of those rearranged CRLF2 
cases have concomitant JAK1/2 mutations which are responsible for the activation of 
the tyrosine kinase pathway. The remaining half of the non-CRLF2 rearranged cases 
harboured a wide range of rearrangements which generate fusion genes capable of 
activating cytokine receptor/ tyrosine kinases signalling pathways. These 
rearrangements include NUP214-ABL1, ETV6-ABL1, EBF1-PDGFRB and IGH-EPOR (Den 
Boer et al., 2009; Roberts et al., 2012).  
1.4.1.3 Secondary copy number alterations  
Generally, CNAs can be classified into potential drivers, potential neutral/non-functional 
passengers, and physiological CNAs (Bateman et al., 2010). Neutral passengers are 
defined as non-recurrent lesions in gene poor regions or are targeting genes with no 
functional relation to lymphocyte biology or leukaemia (Lilljebjorn et al., 2007; 
Mullighan et al., 2007; Strefford et al., 2007; Tsuzuki et al., 2007; Bateman et al., 2010). 
Examples of physiological CNAs include gene deletions in IGH or TCR loci which are 
associated with the developmental rearrangements of these loci and resulted in the 
diversification of antigen receptors in the lymphoid lineages (Mullighan et al., 2007). The 
vast majority of genomic studies have focussed on the recurrent potential drivers which 
are observed in previous genomic screens or in close proximity to functional genes 
involved in leukaemogenesis or B-cell regulation (Lilljebjorn et al., 2007; Mullighan et al., 
2007; Strefford et al., 2007; Tsuzuki et al., 2007). There are more than 50 recurrent CNAs 
which target a single gene or few genes involved in various cellular processes and 
responsible for the leukaemic transformation/ progression (Figure 1.7) (Mullighan, 
2012). In normal haematopoiesis, multiple transcription factors are tightly regulating the 
development of the B-lymphoid lineage from haematopoietic stem cells. Thus, 
alterations affecting PAX5, EBF1 and IKZF1 transcription factor genes can result in direct 
B-cell developmental arrest at pro- to pre-B stage of maturation which is an essential 
component of BCP-ALL. These alterations can occur as CNA, sequence mutations and 
rearrangements and are present in over 60% of BCP-ALL cases. Subsequently, other co-
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operating events are needed for further progression of the disease targeting various key 
pathways (Figure 1.7). Generally, the number of gene losses exceeds the number of copy 
number gains by almost 2:1 with a mean of 6.46 alterations per case (Mullighan et al., 
2007). The genetic diversity level varies between BCP-ALL subtypes, with MLL 
translocations tending to have a stable genome with an estimated mean of less than 1 
CNA per case (Mullighan, 2009). However, the translocations t(12;21) and t(9;22) have 
an increased number of alterations with over 6 alterations per patient. Furthermore, the 
distribution of individual genetic lesions and their associations to different cytogenetic 
subtypes differ (Table 1-5). 
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Figure 1.7 Diagrammatic representation of the role of the genetic alterations in the leukaemic 
development and progression. Acquisition of the primary genetic lesions occurs early leading 
to aberrant self-renewal. Block in maturation at pro- to pre-B cell stage of maturation as a result 
of aberrations of B cell transcription genes. Subsequent cooperating genetic alterations 
responsible for various cellular processes will be acquired by these cells, resulting in leukaemic 
transformation. Figure adapted from (Mullighan, 2012). 
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Abnormality  
Frequency 
(total)%* 
Cytogenetic subgroup association 
Frequency in 
subgroup% 
CDKN2A/B  34 Common 34 
PAX5 30 Common 30 
ETV6  27 ETV6-RUNX1 70 
IKZF1 9 BCR-ABL1 85 
CD200/BTLA 7 ETV6-RUNX1 15 
BTG1 7 ETV6-RUNX1 13 
RB1 5 iAMP21  
Low hypodiploidy 
39‡ 
41¥ 
NR3C1 5 ETV6-RUNX1 6 
EBF1 4 BCR-ABL1 like 38
# 
NR3C2 3 ETV6-RUNX1 9 
TBL1XR1 3 ETV6-RUNX1 13 
RAG1/2 2 ETV6-RUNX1 14 
Table 1-5 Frequencies of the recurrent gene deletions in BCP-ALL cases with their cytogenetic 
subgroups’ associations. *percentages calculated out of the total number of BCP-ALL cases, all 
percentages were extracted from (Mullighan et al., 2007) apart from ‡, ¥ and # which were taken from 
(Schwab et al., 2013), (Holmfeldt et al., 2013) and (Tijchon et al., 2013), respectively.  
Most of deletions (44%) are focal (sized less than 1 Mb) encompassing a single gene and 
specific losses including IKZF1, CDKN2A/B, RAG1/2 and BTG1 are postulated to be driven 
from the aberrant activity of the RAG recombinase which is encoded by recombination- 
activating genes 1 and 2 (RAG1 and RAG2) (Mullighan and Downing, 2009a; Kuiper and 
Waanders, 2014; Papaemmanuil et al., 2014). The normal RAG recombinase activity is 
tightly controlled and responsible for the wide diversity in the antigen receptors during 
the early stages of lymphocyte development. It is worth noting that the aberrant RAG 
mediated recombination constitutes a driving mechanism in ETV6-RUNX1 positive BCP-
ALL, in particular, owing to its enrichment of RAG1/2 alterations as compared to other 
ALL subtypes (14% v 0.69%) (Mullighan et al., 2007). This RAG activity can be evidenced 
by the presence of the recombination signal sequences (RSSs) (which bind the RAG 
complex) and RSS- like motifs (small but highly conserved segments) which were 
determined in 12% and 40% of the alterations in ETV6-RUNX1 cases, respectively (Kuiper 
and Waanders, 2014; Papaemmanuil et al., 2014). In addition, the non-templated 
sequences were one of the features of RAG mediated mechanism presenting at 70% of 
the breakpoints in ETV6-RUNX1 and resulted from terminal deoxynucleotidyl 
transferase (TdT) activity. Furthermore, these RAG mediated rearrangements are 
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enriched in active promoters/ enhancers especially those with RSS- like motifs and are 
repetitive in space/ time. 
1.4.1.4 Sequence mutations  
Although sequence mutations play an important role in leukaemogenesis, they are less 
frequent than CNAs with a mean of 1 sequence mutation (range 0-4) per case versus 
8.36 CNA alterations (range 0-86) per patient (Zhang et al., 2011; Mullighan, 2012; 
Mullighan, 2013). These mutations target different genes which are involved in different 
signalling pathways including B- cell development/ differentiation, Ras signalling, 
cytokine receptor/ kinase (JAK/STAT), TP53/RB1 tumour suppression and epigenetic 
regulators. The identification of these mutations sheds light on the mechanism of 
leukaemic transformation and progression that arise from the possible interactions 
between different pathways/ genes alterations. Alterations in the transcription factor 
genes implicated in lymphoid differentiation (e.g. PAX5, IKZF1 and EBF1) are coupled 
with other mutations involved in cell survival and proliferation (Ras, cytokine and kinase 
signalling pathways). Alterations in these two common pathways are subsequently 
followed by further acquisition of genetic defects targeting transcriptional co-regulators 
and tumor suppressor genes (TBL1XR1, BTG1 and CREBBP, CDKN2A/B, RB1 and TP53). 
These mutations can be either activating or inactivating type and their frequencies differ 
among different ALL subtypes (Table 1-6). For instance, the activating JAK mutations 
involving JAK1 and JAK2 are associated with CRLF2 rearranged cases and mediate the 
activation of JAK/STAT pathway and are important alterations in almost half of CRLF2 
rearranged BCR-ABL1-like cases (see section 1.4.1.2). In addition, IKZF1 mutations which 
directly impair the B-cell lymphoid development are often seen in one third of BCR-
ABL1- like cases.  
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Signalling Pathway Genes  Type of mutations %* Cytogenetic subtype association %* 
Ras NRAS, KRAS, PTPN11 and NF1 Activating 35 
Near haploidy 
High hyperdiploidy  
71 
33 
Transcriptional regulation of  
B-cell development/differentiation 
PAX5  
Inactivating 
10¶ Common  NA 
IKZF1 10¶ BCR-ABL 1 positive 85¥ 
JAK/STAT  
JAK1 and JAK2 
Activating 11¶ 
CRLF2 rearranged BCR-ABL 1 like cases   57 
ABL1, PDGFRB and EPOR BCR-ABL 1 like 50 
TP53/RB1 tumour suppression TP53 Inactivating 4¶ Low hypodiploid 90 
Table 1-6 Recurrent mutations of genes/ pathways in BCP-ALL cases. * frequencies obtained from (Case et al., 2008), (Zhang et al., 2011), (Mullighan, 2012), (Paulsson et 
al., 2008) and (Holmfeldt et al., 2013), NA: not available, ¥ includes deletions, ¶ frequencies estimated in a biased cohort of high risk BCP-ALL. 
 
                    
               
  
34 
 
At relapse, somatic mutations may be acquired as new lesions or lost similar to CNAs 
(Mullighan, 2012). RAS signalling pathway (NRAS, KRAS, PTPN11 and NF1) and B cell 
development (PAX5) mutations are found to be lost at relapse in spite of their initial 
detection at presentation. However, some other mutations affecting CREBBP and CREB 
binding protein are found at a low level or absent at diagnosis but are enriched at relapse 
(20%) especially those with high hyperdiploid relapses. CREBBP mutations are related to 
drug resistance owing to the disruption of the normal transcription response to 
glucocorticoids (Inthal et al., 2012). Given the fact that enriched histone 
acetyltransferase (HAT) domains are responsible for these mutations, introduction of 
histone deacetylase inhibitors as a targeted therapy might be of an option. In addition, 
inactivating TP53 mutations are enriched in the relapsed cases with 54% of these 
mutations are acquired at relapse and carry independent poor prognostic factors (Hof 
et al., 2011).    
1.4.1.5 DNA methylation 
Epigenetics has emerged as a critical regulator of cell function that is responsible for 
leukaemogenic progression. This can be achieved by different mechanisms including: 
DNA methylation and post translational histone modification. The former mechanism 
targets the cytosine preceding guanine (CpG) nucleotides that are located in regions rich 
in CG known as CpG islands (CGI) and which normally have a lower rate of methylated 
CpG sites compared to the whole genome (Nordlund et al., 2013). Overall, differentially 
methylated CpG (DMC) sites across all genetic subtypes were not shown to target 
cellular pathways, instead all DMC signatures were enriched for important genes 
involved in various biological functions in cancer development and progression. 
Furthermore, approximately 15% of DMC signatures were correlated with expression of 
the involved genes (Nordlund et al., 2013); hypermethylation of CpG promoters resulted 
in gene silencing and subsequent neoplastic transformation (tumour suppressor genes). 
The global decrease in methylation (hypomethylation) that occurs in gene body regions 
is associated with genomic instability and chromosomal rearrangements. 
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1.4.2 T-cell acute lymphoblastic leukaemia 
T-cell acute lymphoblastic leukaemia constitutes 15 and 25% of total cases of childhood 
and adult ALL, respectively, and it is more common in older age (Pui, 2004). It is a 
heterogeneous disease with up to 50% of these cases having an abnormal karyotype 
with associated frequent translocations (Meijerink, 2010). In general, there are two 
types of mutations: type A which defines four distinct genetic subgroups and type B 
mutations which are common and can occur in any subgroup. Type A mutations are 
characterised by the mutual exclusive rearrangements including TLX3 (HOX11L2), TLX1 
(HOX11), TAL/LMO complex and HOXA abnormalities which have distinct gene 
expression signatures corresponding to a specific level of T cell development in each 
subgroup. On the other hand, type B mutations target different cellular processes 
resulting in cell cycle defects and activation of multiple pathways and they include 
CDKN2A/B, NOTCH1, FLT3, BCL11B, PTPN2, BHF6, NRAS and WT1 alterations. 
Interestingly, a fifth distinct subgroup was unmasked by the gene expression profiles 
namely: an early T-cell precursor that is characterised by immature T cells with no 
characteristic chromosomal abnormality (Figure 1.8). Generally, both TAL/LMO and 
TLX1 subgroups are characterised by a good outcome, while those patients in TLX3, 
HOXA or ETP-ALL have an adverse outcome (Meijerink, 2010). 
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Figure 1.8 Diagrammatic representation of T-cell ALL distinct subgroups (frequency %) in 
relation to their T-cell developmental stage (based on EGIL or TCR classification systems). Five 
subgroups: ETP-ALL (early T-cell precursors ALL), HOXA, TLX3, TLX1 and TAL/LMO; 
NOTCH1/FBXW7 mutations can present in any subgroup; CDKN2A/B alterations  occurs rarely in 
the immature stage; ETP-ALL is characterised by high expression of LYL1, LMO2 and ERG; the 
less and more mature stage is characterised by high expression of PTCRA (pre T- cell receptor A) 
and TCRA (T-cell receptor A), respectively; * high LMO2 expression can occur in LMO2-
rearranged cases; CD7 occur across the T-cell developmental stages; CD5 is weakly expressed in 
the immature stages; CD33/CD13 (aberrant myeloid markers) occurs in ETP-ALL; CD1/Cytb are 
expressed in the cortical stages; mCD3 is expressed in the mature stages; TCR αβ or TCR γδ are 
expressed in the more mature cells. Information was extracted from (Meijerink, 2010). 
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1.4.3 The prognostic effect of different genetic alterations  
A large and growing body of studies have focussed on the genetic abnormalities that 
constitute the hallmarks of this disease owing to their importance in understanding the 
leukaemogenesis and establishing the diagnosis/ classification (e.g. WHO classification) 
and treatment stratification. This in turn has led to the recognition of their clinical 
significance and as such they are incorporated into routine clinical practice. It is essential 
to identify good and poor risk genetic subtypes that will aid in directing therapy (Table 
1-7). The outcome of those with poor risk cytogenetics can be improved by more 
intensive therapy, while those with good risk cytogenetics can be treated with less 
intensive treatment to enable the reduction in the toxicity related deaths. Although 
these genetic alterations convey similar prognostic relevance in either children or older 
patients (Figure 1.9), however, older patients usually exhibit lower survival rates (Figure 
1.10). 
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Figure 1.9 Event free survival of childhood BCP-ALL in relation to the primary genetic 
subgroups. Percentages are event free survival at 7 years after a median follow up time of 8.2 
years. Figure was taken from (Moorman, 2012). 
 
 
Figure 1.10 Overall survival of adult BCP-ALL by primary genetic subtypes. Percentages are 
overall survival at 7 years after a median follow up time of 8.2 years. Cases were classified as 
follows: high hyperdiploidy , t(9;22)(q34;q11), high risk abnormalities [t(4;11)(q21;q23), IGH@ 
translocations, CRLF2 rearrangements, low hypodiploidy/near-triploidy and complex karyotype], 
standard risk abnormalities [all other karyotypes]. Figure was taken from (Moorman, 2012). 
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Numerical chromosomal 
abnormalities 
Modal chromosome 
number 
Incidence Result of the 
aberration 
Prognostic significance 
children adults children adults 
High hyperdiploidy  51-65/67 chromosomes 35% 10% Poorly understood Excellent  
Significantly improved 
survival 
Low hypodiploidy  30-39 chromosomes 
5–6% 2% Poorly understood Very poor 
Near-haploidy  <30 chromosomes 
Chromosomal 
translocations/rearrangements 
Genes           
t(12;21)(p13;q22) ETV6-RUNX1 15-35% 4% 
Interferes with 
expression of HOX 
genes in lymphopoiesis 
Favourable  Good 
t(9;22)(q34;q11) BCR-ABL1 2–3% 
20-
40% 
Activation of mitogenic 
signalling, attenuation 
of apoptosis, altered 
cell adhesion 
Very poor unless treated with imatinib or 
other tyrosine kinase inhibitor 
11q23 rearrangements 
MLL gene with different 
partner genes 
Infants 70-
80%; 
Children 2-
3% 
6% 
Alter the pattern of 
HOX gene expression 
Very poor 
t(1;19)(q23;p13.3)/ 
der(19)t(1;19)(q23;p13.3) 
TCF3-PBX1 5–6% 4% 
Interferes with 
haematopoietic-
lymphoid 
differentiation 
intermediate/good 
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Numerical chromosomal 
abnormalities 
Modal chromosome 
number 
Incidence Result of the 
aberration 
Prognostic significance 
children adults children adults 
IGH@ translocations 
IGH with different partner 
genes 
5% 
Deregulated oncogene 
expression via its  
juxtaposition to the 
IGH@ enhancer 
Unkown Poor 
CRLF2 overexpression CRLF2 5% 5% 
Activates the JAK-STAT 
pathway  
Intermediate/poor Poor 
iAMP21                       Unidentified  2-3% NA Unknown Unfavourable NA 
 
Table 1-7 Clinically relevant genetic aberration subgroups in B-cell precursor acute lymphoblastic leukaemia patients. NA: no adult cases identified. Data 
extracted from (Moorman et al., 2010a; Szczepanski et al., 2010; Pui et al., 2011; Moorman, 2012). 
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ETV6-RUNX1 (see section 1.5.7) and HeH patients are assigned as good prognostic 
markers. The identification of the risk factors within HeH patients is still to be defined, 
in spite of good outcome, because 15% of patients do relapse. The Children's Oncology 
Group consider the presence of the triple trisomy (simultaneous gain of chromosomes 
4, 10 and 17) to be a favourable factor, while a UK study found that only trisomy 18 
conveys a better indicator of good outcome (Moorman, 2012). Recently, it was reported 
that trisomy 4 was associated with good outcome in Ph- negative HeH patients treated 
on UKALLXII/ECOG2993 trial, while patients with trisomy 20 showed inferior outcome 
(Chilton et al., 2013). However, trisomy 5 had an adverse impact in Ph-positive HeH 
patients.   
The poor risk cytogenetic subgroups constitute the following: t(9;22)/ BCR-ABL1, MLL 
rearrangements, near haploidy (< 30 chromosomes), Low hypodiploidy (30-39 
chromosomes), iAMP21 and t(17;19)/E2A-HLF (Moorman et al., 2010b). 
Patients with BCR-ABL1 fusion gene are assigned to the high risk category and receive 
more intensive therapy. In addition, the use of tyrosine kinase inhibitors (imatinib, 
dasatinib, nilotinib) along with intensive chemotherapy is beginning to show promising 
results in children and adolescents. Thus, paediatric cases that were treated with 
imatinib had a 4 year disease free survival rate of 75·2% (61·0—84·9) versus 55·9% 
(36·1—71·7) in those who received only conventional chemotherapy (p=0.06) in the per-
protocol analysis (adjusted for minimal residual disease) (Biondi et al., 2012). 
Furthermore, the improvement of outcome in the imatinib treated adult patients as 
compared to those who did not receive imatinib was observed with a 4 year OS, EFS and 
RFS rates of 38% v 22% (p=0.0003), 33% v 18% (p=0.0001) and 50% v 33% (p=0.0003), 
respectively (Fielding et al., 2014). 
In one study, 70-80% of infant cases exhibited MLL rearrangements with half of them 
showing t(4;11) that is characterised by poor outcome in all age groups, whereas the 
remaining translocations showed insignificant poor outcome in adults (Moorman, 
2012). The promising results of the in vitro and in vivo effects of DOT1L inhibitors 
(EPZ004777) against MLL rearranged cells have offered the basis of the targeted therapy 
in high risk patients (Daigle et al., 2011). 
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Children with t(1;19) were associated with a poor outcome prior to the intensive 
modern protocols but currently on contemporary protocols this rearrangement was 
shown to have an intermediate/good outcome (Moorman, 2012). On the other hand, 
the prognostic effect of this rearrangement in adults is still debatable which is probably 
due to variations in treatment. 
The prognostic relevance of CRLF2 overexpression in children has conflicting results with 
the disparity was attributed to the different protocols studied. One study reported poor 
outcome (relapse free survival (RFS) at 4 years 35% versus 71%) of high risk patients with 
CRLF2 overexpression treated on COG P9906 trial (Harvey et al., 2010). In addition, non-
high risk patients with P2RY8-CRLF2 treated on AEIOP-BFM-2000 were also shown to 
have an adverse outcome (EFS: 28% versus 83% at 6 years) (Cario et al., 2010). In 
contrast, a similar outcome was found between patients with CRLF2 deregulation and 
patients in the intermediate cytogenetic risk group in children treated on ALL97 (OS at 
5 years 81% versus 85%) (Ensor et al., 2011). To date, there have been few reports on 
the prognostic relevance of CRLF2 deregulation in adults, although one study has 
reported it as being associated with an adverse clinical outcome: EFS <25% at 5 years 
(Moorman et al., 2012).   
iAMP21 was not used previously to guide therapy and patients with this rearrangement 
were treated as standard risk patients. However, the 3-fold increase in the relapse risk  
and the dismal outcome experienced by iAMP21 patients compared to those who did 
not have this abnormality (EFS (29% v 78%), OS (71% v 87%) at 5 years) (Moorman et al., 
2007) warranted recruiting patients to the high risk arm in the following trials. 
Accordingly, marked improvement in outcome was observed as evidenced in 
UKALL2003 treated patients, thus at 5 years the EFS and OS increased to 78% and 89%, 
respectively, with reduction in the relapse risk from 70% to 16% (Moorman et al., 2013). 
In agreement with these findings, iAMP21 patients treated in contemporary Children’s 
Oncology Group also showed inferior outcome (a 4 year EFS and OS of 73% and 88%), 
but with better survival rates than the previous report owing to possible differences in 
the treatment protocols (Heerema et al., 2013). 
BCR-ABL1- like group is a high risk group which confers a dismal outcome and the 
introduction of the tyrosine kinase inhibitors have shown promising results especially 
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those cases with NUP214-ABL1 and EBF1-PDGFRB fusion genes (Roberts et al., 2012; 
Lengline et al., 2013; Weston et al., 2013). 
1.5 t(12;21)(p13;q22)/ETV6-RUNX1  
1.5.1 Overview  
The translocation, t(12;21)(p13;q22), which generates the ETV6–RUNX1 fusion gene, is 
the most common chromosomal translocation in BCP-ALL (Golub et al., 1995; Romana 
et al., 1996; Moorman et al., 2010b). It is invisible by conventional cytogenetic analysis 
as the banding pattern and the size of the translocated regions between chromosomes 
12 and 21 are identical (Heim and Mitelman, 2009). Thus, FISH was responsible for its 
discovery when investigating patients with deletions in the short arm of chromosome 
12 (Romana et al., 1994). The translocation results in the fusion of the ETS- type variant 
6 (ETV6) gene (previously known as TEL-translocated ETS leukaemia gene), located at 
12p13, with the RUNX1 gene (runt- related transcription factor 1, previously known as 
AML1- acute myeloid leukaemia 1), located at 21q22, to create the chimeric fusion gene 
ETV6-RUNX1 on the derived chromosome 21 (der(21)t(12;21)) (Figure 1.11) (Golub et 
al., 1995; Romana et al., 1995a). ETV6-RUNX1 is postulated to be responsible for the 
expansion of a candidate preleukaemic stem cell population that has an early B lineage 
phenotype (CD34+CD38–CD19+) and persists in the bone marrow for several years 
(Hong et al., 2008). Hence, this fusion gene is the first transforming event arising 
prenatally (see section 1.3.2), but it is unable to generate overt disease by itself and 
additional secondary genetic events are required to drive leukaemogenesis (Mori et al., 
2002; Greaves and Wiemels, 2003; Zuna et al., 2011; Ma et al., 2013).  
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Figure 1.11 Diagrammatic representation of the t(12;21)(p13;q22. Locations of the ETV6-
RUNX1 and its reciprocal RUNX1-ETV6 fusion genes on der(21)t(12;21) and der(12)t(12;21), 
respectively. 
1.5.2 Epidemiology/ Clinical characteristics 
ETV6-RUNX1 is found in ~25% of BCP-ALL cases, with a peak incidence between the ages 
of 3–6 years of children with BCP-ALL (Golub et al., 1995; Romana et al., 1996; Moorman 
et al., 2010b). In contrast, this translocation is relatively rare in adults (older than 15 
years) constituting (1-4%) of BCP-ALL cases (Aguiar et al., 1996; Raynaud et al., 1996; 
Kwong and Wong, 1997; Jabber Al-Obaidi et al., 2002). The ETV6-RUNX1 fusion gene 
originates in the prenatal period as evidenced from the neonatal blood spots or Guthrie 
cards (Mori et al., 2002; Greaves and Wiemels, 2003; Zuna et al., 2011; Ma et al., 2013). 
However, the fusion gene is unable to generate clinical leukaemia and additional genetic 
alterations are needed for the leukaemic transformation (see section 1.3.2). ETV6-
RUNX1 patients are usually characterised by younger age, low WCC levels with 
associated immunophenotypic expression of CD10+ and aberrant myeloid markers 
CD13/CD33 (Shurtleff et al., 1995).  
1.5.3 Structure and function of ETV6 and RUNX1 genes 
The ETV6 gene, consists of eight exons, encodes an ETS (E-26 transforming specific) 
family transcription factor and it is located at 11,802,788-12,044,558 bp (according to 
Ensembl version 62) on chromosome 12p13.1. ETV6 gene was first cloned in 1994 as a 
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novel fusion partner to the PDGFRb locus in cases of chronic myelomonocytic leukaemia 
with t(5;12)(q33;p13) (Golub et al., 1994) and has since been found rearranged with a 
number of tyrosine kinase genes, including ABL1 and JAK2 (Papadopoulos et al., 1995; 
Lacronique et al., 1997). 
The encoded protein contains two functional domains: an N-terminal pointed (PNT) 
domain (also known as helix–loop–helix (HLH) domain) that is involved in protein-
protein interactions with itself and other proteins (Golub et al., 1994; McLean et al., 
1996; Jousset et al., 1997), and a C-terminalDNA-binding domain (Ets domain) (Figure 
1.12). The latter domain is homologous to all Ets proteins, recognizes a purine-rich 
GGAA/T core motif within promoters and enhancers of various genes (Golub et al., 1994; 
Graves and Petersen, 1998) and participates in protein–protein interactions (Bassuk and 
Leiden, 1995; Batchelor et al., 1998; Kim et al., 1999).  ETV6 has a role in both 
angiogenesis and hematopoiesis and acts as a transcriptional repressor (Sawinska and 
Ladon, 2004).  
Core binding factor (CBF) is a heterodimeric transcription factor that binds to the core 
element of many enhancers and promoters. RUNX1, located at position 36,160,098-
37,357,047 bp (according to Ensembl v.62) on chromosome 21q22, encodes the alpha 
subunit of CBF that, together with the non-DNA-binding β subunit (CBFβ), forms a 
heterodimeric transcription factor. RUNX1 was first identified through its fusion with the 
ETO gene in t(8;21)(q22;q22)-associated AML (Miyoshi et al., 1991; Erickson et al., 1992; 
Nisson et al., 1992; Miyoshi et al., 1993). RUNX1 proteins contain two functional 
domains: the N-terminal runt homology domain (RHD) and the C terminal transcription 
activation domain (TAD) (Figure 1.12). The former domain is required for binding to DNA 
and to the heterodimerization domain (HD) of CBFβ, whereas, TAD confers both 
increased DNA-binding affinity and stability to RUNX1 (Ogawa et al., 1993; Wang et al., 
1993). 
This gene is thought to be involved in the development of normal haematopoiesis by 
associating with transcriptional cofactors, repressors, and other DNA-binding 
transcription factors in a promoter context-dependent fashion (Licht, 2001; Durst and 
Hiebert, 2004). Chromosomal translocations involving this gene are well-documented 
and have been associated with several types of myeloid and lymphoid leukaemia. 
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1.5.4 Structure and mechanism of pathogenesis of the fusion gene 
The chimeric fusion gene ETV6-RUNX1 consists of the NH2-terminal part of the ETV6 
protein including the dimerization PNT domain and all known functional regions of 
RUNX1, including its RUNT DNA binding domain (Figure 1.12) (Golub et al., 1996; Berger, 
1997; Greaves and Wiemels, 2003). In this respect, ETV6-RUNX1 fusion protein is 
structurally distinct from other RUNX1 fusion proteins, which retain only the 
aminoterminal RUNT domain and not the C-terminal regulatory sequences of RUNX1. 
The chromosomal breakpoints at ETV6 occur almost exclusively within the 15 kb intron 
5, whereas the breakpoint cluster region (BCR) of RUNX1 includes the large 155 kb intron 
1 or the 5.5 kb intron 2 (Greaves and Wiemels, 2003). Hence, variant transcripts of the 
fusion gene have been observed in the same patient on some occasions (Satake et al., 
1997; Codrington et al., 2000; Tiensiwakul, 2004; Kustanovich et al., 2006). However, 
the pathogenic effects of these variants are not yet fully understood. 
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Figure 1.12 Diagrammatic representation of the structures of ETV6, RUNX1 and ETV6-RUNX1 
proteins ETV6 protein composed of: an N-terminal pointed (PD) domain, central repression 
domain (repression) and a C-terminal DNA-binding domain (ETS domain). RUNX1 protein 
contains: the N-terminal runt homology domain (Runt), mSin3A interaction domain (SID) (which 
interacts with the p300 HAT (p300 ID)), the C terminal transcription activation domain 
(Activation) with attached motif namely Carboxy-terminal VWRPY to enable its binding to DNA. 
Arrows indicate the breakpoints in both ETV6 and RUNX1 in t(12;21) to form the ETV6-RUNX1 
fusion protein. Figure was adapted from (Zelent et al., 2004).  
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The HLH and co-repressor domains of ETV6 and the RHD domain of RUNX1 are all 
required by ETV6-RUNX1 to alter haematopoiesis (Morrow et al., 2007). The chimeric 
protein retains both HLH and TA structures which increase its affinity to proteins/co-
repressors such as: N-CoR (component of the nuclear receptor corepressor complex 
with histone deacetylase activity), mSin3 and subsequent complex stability. Accordingly, 
ETV6-RUNX1–N-CoR or–mSin3 complexes influence the transcriptional activity of other 
genes including RUNX1 target genes (Figure 1.13) (Hiebert et al., 1996; Fenrick et al., 
1999; Guidez et al., 2000). Recently, a comprehensive study was carried out to globally 
investigate either direct or indirect impact of this fusion protein in a murine cell line that 
lacks any secondary abnormalities using collective tests of chromatin 
immunoprecipitation, mRNA expression and differential stable isotope labelling of 
proteins (Linka et al., 2013). It has been proposed that the promoter regions of this 
chimeric gene are significantly different than those related to the wild type RUNX1 
proteins, but still mediated by the Runt DNA-binding domain, and concomitant 
suppression of the mRNA transcription results in the downregulation of multiple genes 
targeting several cellular and biological processes, importantly SMAD-dependent TGF-β 
pathway resulting in impairment of the signal transduction. These findings further 
support a previous study (Ford et al., 2009) postulating that the selective expansion of 
these clones expressing ETV6-RUNX1 might be mediated in part by the inhibitory impact 
of ETV6-RUNX1 expression on the response to the transforming growth factor β (TGF-
β). This inhibitory effect is facilitated through the binding of the chimeric gene to a 
principal signalling target of TGF-β (smad3). TGF-β is believed to function as a potent 
tumor suppressor via its Smad dependent inhibitory impact on c-Myc and its activation 
of p15INK4b/p15 and p21/p27KIP1 (Siegel and Massague, 2003; Bierie and Moses, 2006). 
The erythropoietin receptor (EPOR) gene is expressed as a direct function of the ETV6-
RUNX1 fusion protein, thus provides cell survival signals that may also contribute 
critically to persistence of covert pre-malignant clones in children (Inthal et al., 2008; 
Torrano et al., 2011). Furthermore, ETV6-RUNX1 fusion gene has been shown to impair 
apoptosis through down-regulation of the microRNAs: miRNA-494 and miRNA-320a 
which in turn increases survivin expression (Diakos et al., 2010). Downregulation of 
ETV6-RUNX1 expression has led to the inactivation of the phosphoinositide 3-
kinase/AKT/mammalian target of rapamycin (mTOR) pathway (Fuka et al., 2011; Fuka et 
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al., 2012; Tijchon et al., 2013) which endorses the notion of being aberrantly activated 
in ETV6-RUNX1 BCP-ALL as suggested by different gene expression studies (Yeoh et al., 
2002; Ross et al., 2003; Andersson et al., 2005; Gandemer et al., 2007). The mTOR 
pathway is known to be involved in various cellular processes including proliferation, 
protein synthesis and apoptosis.  
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Figure 1.13 Diagrammatic representation of the hypothesized molecular mechanism of ETV6-
RUNX1 protein. A. The activating and repressing function of RUNX1 protein is determined by its 
recruitment to p300 and mSin3A/HDAC, respectively. B. ETV6-RUNX1 fusion protein acts as a 
repressor complex via its interaction with N-CoR/ mSin3A co-repressors and this interaction is 
facilitated by the HLH (PD) structures of ETV6 protein. p300 may be capable to interact with the 
fusion protein but without exerting its activating function as seen in A. Figure was adapted from 
(Zelent et al., 2004).   
 
1.5.5 Secondary genetic abnormalities 
ETV6-RUNX1 requires secondary genetic aberrations to transform a pre-leukaemic clone 
into a clinical leukaemia. The translocation t(12;21) is mutually exclusive with other well-
known BCP-ALL associated genetic abnormalities such as high hyperdiploidy (>50 
chromosomes) and other rearrangements including BCR-ABL1 and TCF3-PBX1 fusions, 
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and MLL rearrangements (Cayuela et al., 1996; Fears et al., 1996; Borkhardt et al., 1997; 
Raimondi et al., 1997; Rubnitz et al., 1997; Eguchi-Ishimae et al., 1998; Raynaud et al., 
1999; Andreasson et al., 2000; Tsang et al., 2001; Uckun et al., 2001; Attarbaschi et al., 
2004). Although co-existence of t(12;21) and high hyperdiploidy has been reported, it is 
extremely rare and it is likely to reflect a ETV6-RUNX1 sub-clone with an unusual number 
of extra chromosomes rather than true coexistence (Moorman et al., 2010b). Two 
groups reported a significant association between near- tetraploidy (80 or more 
chromosomes) and ETV6-RUNX1 which represents the doubling-up of a pseudodiploid 
ETV6-RUNX1 clone (Attarbaschi et al., 2006; Raimondi et al., 2006). There are other 
secondary alterations associated with this ALL subtype including: copy number 
alterations (CNAs), sequence mutations and DNA methylation. 
1.5.5.1 Copy number alterations (CNAs)  
Recurrent CNAs target various pathways such as lymphoid development, tumor 
suppression, cell cycle, apoptosis, lymphoid signalling, nuclear hormone response and 
drug responsiveness (Table 1-8) (Kuiper et al., 2007; Lilljebjorn et al., 2007; Mullighan et 
al., 2007; Tsuzuki et al., 2007; Kawamata et al., 2008; Mullighan et al., 2008a; Parker et 
al., 2008; Lilljebjorn et al., 2010). It is worth noting that alterations affecting nuclear 
hormone response, involved in transcriptional repression or 
glucocorticoid/mineralocorticoid sensitivity, include TBL1XR1 and NR3C1/NR3C2, 
respectively and are characteristic features of ETV6-RUNX1 as compared to other BCP-
ALL subtypes (13% v 0.69%, 6% v 2%, 9% v 0.69%, respectively) (Mullighan et al., 2007; 
Lilljebjorn et al., 2010). They present in 24% of ETV6-RUNX1 cases, thus this pathway is 
targeted equally as the B- cell development pathway which involves lesions in PAX5, 
EBF1 and TCF4.  
Overall, 79% of ETV6-RUNX1 patients exhibit at least one genetic alteration with the 
majority (74%) of them displaying a unique pattern among individual patients with a 
mean of 3.5 CNA per case (range 0-13), emphasising the characteristic genetic diversity 
(Mullighan et al., 2007; Lilljebjorn et al., 2010). The most common abnormalities include 
gene deletions that represent 74-82% of these aberrations, while the remaining lesions 
are gains.  
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Focal deletions (sized less than 1Mb) encompass one or two genes and constitute 40% 
of the total gene deletions. These focal lesions most commonly affect ETV6, CDKN2A/B, 
PAX5, BTG1, BMF, CD200/ BTLA, TBL1XR1, NR3C1, NR3C2 and EBF1 and they differ in 
their frequencies within this ALL subgroup (Table 1-8).  
The remaining (60%) deletion cases compromise large regions (sized more than 1Mb) of 
different chromosomes including 12p, 6q, 9p, 11q and 13q which are present in 39%, 
13%, 10%, 10% and 10% of ETV6-RUNX1 cases, respectively.  
On the other hand, most of the gains (98%) affect larger regions (sized more than 1Mb) 
or the whole chromosome. The most common alterations include duplicated 
chromosome Xq, gain of chromosomes 21, der(21)t(12;21), 10 or 16 (Table 1-8) 
(Lilljebjorn et al., 2010). 
  
 53 
 
Abnormality  Cytoband Function Frequency% 
Deletions 
ETV6 12p13 Transcriptional repressor 59 
CDKN2A/B 9p21 Cell cycle regulator 22 
PAX5 9p13.2 B-cell differentiation  20 
RAG1/2 11p13 
Activation of immunoglobulin V-D-J 
recombination 
14 
CD200/BTLA 3q13.2 Immune system or during B-cell differentiation 13 
TBL1XR1 3q26.32 
Nuclear hormone receptor transcriptional  
repression via the SMRT/N-CoR complex 
13 
BTG1 12q21.33 Co-activator of cell differentiation  13 
NR3C1 5q31.3 
Nuclear hormone receptors binding 
glucocorticoids 
13 
NR3C2 4q31.23 
Nuclear hormone receptors binding 
mineralocorticoid/ glucocorticoids 
11 
EBF1 5q34 Transcriptional activator 11 
FHIT 3p14.2 Induction of apoptosis  8.5 
TOX 8q12.1  T-cell development regulator 8.5 
BMF 15q15.1 Anti- or pro-apoptotic regulators  6 
Abnormality Genes  Pathogenesis Frequency% 
Gains 
dup(Xq)  
SPANXB, 
HMGB3,  
FAM50A, 
HTATSF1  
and 
RAP2C 
Undetermined 16 
der(21)t(12;21) 
Multiple  
Increase potency of ETV6-RUNX1 fusion gene 12 
21 
Undetermined 
12 
10 9 
16 9 
Table 1-8 Common recurrent copy number alterations in ETV6-RUNX1 patients. Gene 
functions were obtained from gene cards, frequencies were extracted from (Mullighan et al., 2007; 
Lilljebjorn et al., 2010).   
The most prevalent alteration is ETV6 deletion which occurs in two thirds of ETV6-
RUNX1 cases. This gene acts as a transcriptional repressor (see section 1.5.3). It has been 
proposed that heterodimerization between ETV6 and ETV6-RUNX1 proteins  hampers 
the function of the fusion protein, thus loss of the non-rearranged ETV6 would increase 
the ratio of ETV6-RUNX1 over normal ETV6 proteins which in turn increases the potency 
of the fusion protein (McLean et al., 1996). 
Duplicated chromosome Xq (dup(Xq)) is predominately found in males and the testis-
specific gene SPANXB was the only gene showing a high and uniform overexpression, 
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irrespective of gender and presence of dup(Xq) in ETV6-RUNX1. Thus, the SPANXB gene 
might be considered as a target of this duplication and it is normally involved in 
spermatogenesis (Lilljebjorn et al., 2007; Lilljebjorn et al., 2010).  
Interestingly, there is a strong associated co-occurrence between trisomy 10 and 
trisomy 16 (p<0.001) which was explained by their tendency to occur in cases with 
acquired random chromosome gains (p<0.001) (Lilljebjorn et al., 2010). The acquisition 
of gained chromosomes may arise sequentially or through a single abnormal mitosis. 
1.5.5.2 Sequence mutations 
Whole genome and exome sequencing have enabled better understanding of 
leukaemogenic pathogenesis by identifying different somatic mutations which might be 
clinically important. Previous sequencing studies have revealed distinct patterns of 
somatic mutations in different signalling pathways including B- cell development/ 
differentiation, Ras signalling, cytokine receptor/ kinase (JAK/STAT), TP53/RB1 tumour 
suppression and epigenetic regulators (see section 1.4.1.4) (Zhang et al., 2011; 
Lilljebjorn et al., 2012; Roberts et al., 2012; Holmfeldt et al., 2013; Mullighan, 2013; 
Papaemmanuil et al., 2014). The frequency and nature of these mutations vary across 
different ALL subtypes. Although previous sequencing studies have focussed on high risk 
ALL groups (Zhang et al., 2011; Roberts et al., 2012; Holmfeldt et al., 2013; Mullighan, 
2013), some other studies were conducted on standard risk groups including ETV6-
RUNX1 subtype (Lilljebjorn et al., 2012; Jaffe et al., 2013; Papaemmanuil et al., 2014). A 
low number of recurrent coding-region and kinase mutations was found in ETV6-RUNX1 
cases, unlike high risk subtypes of ALL.  
Of the commonly deleted genes in ETV6-RUNX1, there are five genes including ETV6, 
BTG1, TBL1XR1, PAX5 and CDKN2A which are targeted by deletions or inactivating 
somatic mutations (Papaemmanuil et al., 2014). Furthermore, ATF7IP, MGA and STAG2 
genes undergo different mutational processes (deletions, inter-chromosomal 
rearrangements and inactivating mutations) which highlight possible roles in 
leukaemogenesis. These genes play important roles in mediating heterochromatin 
formation/ transcriptional repression, regulating the expression of Max network and T-
box family target genes (e.g. MYC) and being a component of the cohesion complex, 
respectively.  
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Interestingly, there are other significant recurrent activating mutations in ETV6-RUNX1 
cases encompassing important genes namely: NRAS, KRAS and SAE1 that each occurs in 
6% of ETV6-RUNX1 cases (Papaemmanuil et al., 2014). In addition, activating mutation 
of WHSC1 (NSD2) was found in ETV6-RUNX1 cases and constituted 14% of cases (Jaffe 
et al., 2013). NSD2 protein acts as histone methyltransferase that is involved in 
transcription regulation. Other mutations target FLT3, MCAM and RUNX1T1 genes at 
lower rates in ETV6-RUNX1 cases and they might be of a particular role owing to their 
occurrence in different types of cancer (Lilljebjorn et al., 2012).  
1.5.5.3 Epigenetics 
Generally, each ALL subtype exhibits one unique methylation signature which 
distinguishes it from other ALL subtypes (Busche et al., 2013; Nordlund et al., 2013). In 
these two studies, there were 2114 differentially methylated CpG sites affecting 156 
genes which are unique to ETV6-RUNX1. Of these genes, several hypomethylated genes 
with consistent upregulation in expression targeting DSC3, EPOR, FUCA1, HLA-DPB1, 
TCFL5, NRN1, IGF2BP1, BEST3, SOX11 and TMED6 are suggested as potential candidate 
targets owing to their roles in leukaemogenesis. In addition, SPSB1 was the only gene 
that was characterised by hypermethylation with concordant downregulation in ETV6-
RUNX1 cases, but it is not known to be related to leukaemia.  
Of these candidate hypomethylated genes, EPOR expression is already described as a 
direct function of ETV6-RUNX1 fusion gene and it is responsible for cell survival (see 
section 1.5.4) (Inthal et al., 2008; Torrano et al., 2011). High expression of IGF2BP1 plays 
a role in elevating MYC expression levels, this in turn resulting in the enhancement of 
tumour proliferation (Kobel et al., 2007). Furthermore, down-regulation of TCFL5 was 
reported to hamper the cell viability of human colorectal cancer cell lines (Sillars-
Hardebol et al., 2012).    
It is worth noting that epigenetic modifications can extend to involve the microRNA 
genes and there are significant hypermethylated miRNA genes including miRNA-320a, 
miRNA-494 and miRNA-200c which are identified in ETV6-RUNX1. Subsequent down-
regulation of both miRNA-320a and miRNA-494 results in enhancement of the 
antiapoptotic signalling pathway via their inhibition of survivin (see section 1.5.4) 
(Diakos et al., 2010). miRNA-200c acts as a strong tumour suppressor gene which 
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modulates the expression of BMI1 (Shimono et al., 2009). BMI1 plays an essential role 
as a regulator of stem cell self-renewal.   
1.5.6 Clonal heterogeneity   
The clonal heterogeneity with a high degree of genetic variability is one of the driving 
mechanisms of tumour development and progression. The resultant genetic 
heterogeneity is a product of the non-linear (branching) evolution of malignant clones, 
driven by the Darwinian natural selection process, that can extend to include the 
epigenetic alterations (Marusyk and Polyak, 2010). This genetic diversity aids further 
proliferation, migration, invasion and metastasis of the malignant cells enabling them to 
adapt to any hostile environment. In spite of the existence of this heterogeneity in many 
cancer types including leukaemia, breast, colon, prostate cancer and other various types 
of malignancies (Maley et al., 2006; Campbell et al., 2010; Park et al., 2010), the exact 
biology of this important genetic entity still to be resolved. ETV6-RUNX1 BCP-ALL 
subtype is one of the clear examples of the presence of the clonal heterogeneity 
(Mullighan et al., 2008b; Lilljebjorn et al., 2010). Furthermore, treatment may influence 
the genetic diversity of subclones owing to their different responses to 
chemotherapeutic agents leading to expansion of resisting clones along with extinction 
of more sensitive clones. The resistant clones acquire further different mutations that 
undergo through selection process, similar to the initial diagnosis, and constitute the 
basis of relapse. In addition, the relapsed leukaemia has been suggested to emerge as 
being unrelated to the initial diagnostic clones in small number of cases (6%) using solely 
the whole genomic studies (Figure 1.14) (Mullighan et al., 2008b). 
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Figure 1.14 Clonal origins of relapsed acute lymphoblastic leukaemia. The majority of relapse 
cases originate either from the diagnosis (42%), acquiring additional genetic lesions or from an 
ancestral clone (52%) in which the relapse clone acquires new lesions while retaining some but 
not all of the lesions found in the diagnostic sample. In only a minority of ALL cases (6%), the 
relapse clone represents the emergence of a genetically distinct and thus unrelated second 
leukaemia. Figure was taken from (Mullighan et al., 2008b). 
 
1.5.7 Prognostic impact of ETV6-RUNX1 and its associated genetic alteration 
Soon after the identification of ETV6-RUNX1 fusion gene, it was reported that 
patients with this fusion had an excellent prognosis (Shurtleff et al., 1995). Since then, 
numerous studies have investigated several risk factors in this ALL subtype 
generating inconsistent outcome data owing to different initial risk stratification 
criteria with subsequent dose intensity treatment. Thus, a high incidence rate of 
relapses (20%) was initially reported and almost half of ALL relapse cases which 
occurred ≥ 5 years from diagnosis (late relapses) harboured ETV6-RUNX1 (Harbott et 
al., 1997; Forestier et al., 2008a). However, another childhood trial namely UKALLXI 
indicated that ETV6-RUNX1 had no effect on outcome (Hann et al., 2001). On modern 
protocols, the presence of the ETV6-RUNX1 gene fusion correlates with an excellent 
outcome that can be explained by the introduction of higher doses of asparaginase 
in their treatment protocols (Table 1-9) (Loh et al., 2006; Rubnitz et al., 2008; Pui et 
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al., 2009; Conter et al., 2010; Moorman et al., 2010b). ETV6-RUNX1 positive 
lymphoblasts are highly sensitive to asparaginase in vitro (Ramakers-van Woerden et 
al., 2000). A Lower rate of relapses (13%) was recorded in ETV6-RUNX1 patients who 
were treated on UKALL97/99 after a median follow-up time of 8.2 years (Moorman 
et al., 2010b). ETV6-RUNX1 relapses occurred mostly late (> 6 months after end of 
treatment) (Harbott et al., 1997; Forestier et al., 2008a) 
Study Years 
No. 
cases 
Age 
EFS at 5 
years 
Survival at 5 
years 
Total Therapy 
XV study (Pui et al., 2009) 
2000-
2007 
96 1-18 98% 99% 
AIEOP-BFM ALL 2000 (Conter et 
al., 2010)  
2000-
2006 
762 1-18 95%* NA 
UKALL97/99 (Moorman et al., 
2010b) 
1997-
2002 
368 1-18 89% 96% 
DFCI ALL Consortium 
Protocol 95-01 (Loh et al., 2006) 
1996- 
2000 
77 1-18 89% 97% 
POG ALinC 16 (Rubnitz et al., 
2008) 
1995-
1998 
244 
1.4- 
19.7 
86% NA 
Table 1-9 Survival rates of ETV6-RUNX1 patients from selected modern clinical trials. EFS 
event free survival rate, OS overall survival rate, * EFS was estimated for those with MRD standard risk 
(n=440), while those with MRD intermediate (n=312) or high risk (n=10), EFS was estimated to be 82% or 
55%, respectively.  
Turning to the secondary abnormalities that usually accompanied this ALL subtype; it is 
worth noting that the prognostic impact of these alterations is still debatable. Several 
studies have been conducted to investigate this issue but small patient cohorts who 
were treated with different treatment protocols hampered precise evaluation 
(Attarbaschi et al., 2004; Stams et al., 2006). For example, investigating the prognostic 
effect of the abnormalities involving normal chromosome 12 or 21 and der(21)t(12;21) 
was the main focus in most studies and conflicting data was generated (Table 1-10) 
(Attarbaschi et al., 2004; Stams et al., 2006; Peter et al., 2009).  
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Study Comments 
(Attarbaschi et al., 2004) 
The non-rearranged ETV6 allele influence adversely the 
outcome 
(Stams et al., 2006) 
The subgroups with either an additional ETV6/RUNX1 fusion 
gene or without any secondary aberration involving the ETV6 
and RUNX1 genes did worse in terms of disease-free survival 
(Peter et al., 2009) 
High frequencies of additional aberrations of ETV6 or RUNX1 
genes, with the exception of ETV6 deletions in relapsed than 
in diagnostic samples 
Table 1-10 Conflicting results of the prognostic effect of the abnormalities involving ETV6 or 
RUNX1 genes from selected study groups. 
1.6 Summary and aims 
The translocation, t(12;21)(p13;q22)/ETV6-RUNX1, is a transforming event and 
responsible for the generation and maintenance of a pre-leukaemic clone (Hong et al., 
2008). The high rate detection in the cord blood of healthy neonates, the high 
discordance rate for BCP-ALL among monozygotic twins and the latency period indicate 
that postnatal genetic alterations are needed to promote the leukaemic transformation 
(Wiemels et al., 1999; Mori et al., 2002). Typically this cytogenetic subgroup is found in 
25% of BCP-ALL cases, with a peak incidence between the ages of 3–6 years (Golub et 
al., 1995; Romana et al., 1995a). This cytogenetic subgroup is usually associated with 
favourable outcome but relapses do occur at a rate of 13% (Moorman et al., 2010b). 
Interestingly, ETV6-RUNX1 fusions transcripts are rarely found in the adolescent/adults, 
infants and DS. 
The primary objective of this project was to investigate the secondary abnormalities and 
clonal evolution in ETV6-RUNX1 positive acute lymphoblastic leukaemia. The strategies 
for achieving this were: 
1. To quantify copy number of interesting genes associated with ETV6-RUNX1 BCP-
ALL and to identify their incidence in different UK ALL trials utilising Multiplex 
ligation-dependent probe amplification (MLPA). 
2. To identify and characterise additional genetic abnormalities in ETV6-RUNX1 
BCP-ALL involving the derivative 12 der(12)t(12;21). 
 60 
 
3. To evaluate the potential relevance of specific gene copy number alterations in 
the relapse cases and to back-track FISH some of the important genetic lesions 
from relapse to diagnosis and vice versa. 
4. To investigate infants, young adults, those with Down syndrome that might 
constitute atypical group of patients with unique spectrum of abnormalities. 
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Chapter 2. Materials and Methods 
  
 62 
 
2.1 General chemicals and Equipment 
All details and specifications are standard unless stated otherwise. General lab 
chemicals and equipment were purchased from Scientific Laboratory Supplies 
(Nottingham, UK), VWR (Lutterworth, Leicestershire, UK) or Fisher Scientific 
(Loughborough, Leicestershire, UK), Sigma-Aldrich Company Ltd (Poole, Dorset, UK) and 
STARLAB (UK), Ltd. 
2.2 Patient Cohorts and Material 
A total of 423 patients included in this study were confirmed cases of ETV6-RUNX1 
positive BCP-ALL identified by either fluorescence in situ hybridisation (FISH) or 
quantitative PCR (qPCR) and treated using either UKALL97/99 (April 1997- June 2002) 
(n=147) for age group 1-18 years (Vora et al., 2006) or UKALL2003 (October 2003- July 
2011) (n=271) including children and young adults with age range of 1-25 years. To note, 
the young adults were added in September 2006 up to the age of 20 years and then the 
upper age limit increased to 25 years in June 2008  (Qureshi et al., 2010). As per National 
Cancer Institute (NCI) criteria: patients were classified as standard risk if they were aged 
1-9 years with a WCC < 50 x109/L at initial presentation, whereas those of >= 10 years 
or a WCC >= 50 x109/L were considered as high risk. Further cases were added from 
those treated on UKALLXII protocol (n=5). This trial recruited patients in the age range 
15- 55 years registered between 1993 and 2006 (Rowe et al., 2005). In addition, treating 
clinicians obtained approval from the local ethical committee and written informed 
consent was given by patients or parents/ guardians on entry to the clinical trials. The 
demographic and clinical details are described in the relevant results chapters. This 
study used fixed cell suspensions (see section 2.5) and DNA (see section 2.6), prepared 
from diagnostic bone marrow material of each patient sample.   
2.3 Cytogenetic analysis 
The identification of the chromosomal abnormalities is pivotal in the diagnosis and risk 
stratification of acute lymphoblastic leukaemia. Standard karyotyping has a resolution 
of 5-10 Mb. However, the low mitotic index and the poor chromosomal morphology 
represent obstacles in the chromosomal analysis of the leukaemic cells. In addition, 
karyotyping is labour-intensive and requires culturing of cells. 
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The samples and the relevant karyotype data were provided by the UK Cancer 
Cytogenetics Group (UKCCG) laboratories. Karyotypes were reviewed by the 
cytogeneticists of the Leukaemia Research Cytogenetics Group (LRCG). The Clinical Trial 
Service Unit and Epidemiological Studies Unit (CTSU) supplied patient details as 
previously described (Harrison et al., 2001; Moorman et al., 2010b). The final karyotypes, 
accompanied by clinical and patient details were entered to the LRCG database enabling 
the storage, retrieval and analysis of data. 
2.4 Cell lines 
All cell lines, kind gifts of different group members, were received as growing cells in 
suspension and were maintained in culture in RPM1-1640 growth medium, HEPES-
modified, supplemented with 2 mM L-Gln and 10% FCS. Further processing was done to 
produce fixed cells (see section 2.5) and DNA (see section 2.6) to be used for confirming 
specific deletions by FISH and as positive controls for real time qPCR experiments, 
respectively. Specific features of the cell lines are described in more detail in the relevant 
results chapters. Cell lines used in this study included:  
1) Human BCP-ALL REH cell line which was derived from the peripheral blood of a 
15-year-old female patient in relapse, positive for t(12;21) translocation and 
expressing the ETV6-RUNX1 fusion gene (Rosenfeld et al., 1977; Matsuo and 
Drexler, 1998). 
2) The KG1 cell line was established from the bone marrow of a 59-year-old 
Caucasian male with erythroleukaemia that evolved into AML (Koeffler and 
Golde, 1978; Koeffler and Golde, 1980). 
3) The Kasumi-1 cell line was derived from the peripheral blood of a 7 year old boy 
with AML in 2nd relapse after bone marrow transplantation, positive for 
t(8;21)(q22;q22) rearrangement and expressing RUNX1-RUNX1T1 (AML1-ETO) 
(Asou et al., 1991). 
2.5 Harvesting cells for FISH  
Cells in suspension were treated with 0.075M potassium chloride (KCl) in a tube, 
incubated for 15 minutes at 37 °C, then centrifuged at 1500 rpm for 7 min. Supernatant 
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was then discarded, and pellet re-suspended. Fresh 3:1 Methanol: Acetic Acid fixative 
was added a few drops at a time with constant mixing to avoid clumping and further 
fixative added to 7ml. The fixative washing steps were repeated and the sample was 
stored in at -20 °C. 
2.6 DNA extraction 
DNA was extracted from either viable or fixed cells using the Qiagen DNeasy kit (Qiagen, 
Valencia, CA, USA) according to manufacturer’s instructions. Concentrated DNA stocks 
were stored at -80°C. The extractions were performed by members of the LRCG team 
including myself. It is worth noting that the DNA extracted from the viable cells is 
preferable than those extracted from fixed cells especially for the use of single 
nucleotide polymorphism (SNP) genotyping (see section 2.10). 
2.7  DNA quantification using the NanoDrop-1000 
DNA concentration and purity were measured using the Nanodrop spectrophotometer 
(Thermo Scientific) by determining the amount of light that a sample absorbs. It is able 
to measure DNA concentration in a sample volume of 1 µl.  DNA efficiently absorbs UV 
light, with an absorption maximum at 260 nm. Thus, contaminants such as proteins and 
carbohydrates impact negatively on the purity of DNA by affecting the absorbance rate 
owing to their different absorption maximums. The amount of the contaminants is 
measured using the optical density (OD) of the sample at wavelengths of 260 and 280 
nm, and reports a nucleic acid concentration as well as an OD260 / OD280 ratio. The 
optimum working concentrations differ between different techniques such as multiplex 
ligation- dependent probe amplification (MLPA), SNP genotyping and qPCR. In MLPA and 
qPCR, an optimum concentrations of 20ng/µl (4-100ng/µl acceptable) and 5ng/μL are 
required, respectively, while in SNP arrays, 750ng of genomic DNA at a concentration of 
50ng/µl should be provided. However, in general, the 260/280 ratio should be ~1.8 and 
a ratio <1.5 indicates protein contamination. 
2.8 Fluorescence in situ hybridisation (FISH) 
FISH provides a powerful molecular cytogenetic technique that has higher resolution 
compared to the classic cytogenetic banding techniques (interphase FISH > 20 kb, 
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metaphase FISH > 100 kb v standard karyotyping (5-10 Mb) (see section 2.3). It has the 
ability to specifically target genomic regions of interest in either dividing or non-dividing 
cells as well as in situ tissue preparations. It is based on the principle that the 
denaturation of the fluorescently labelled DNA probe and the complementary target 
DNA sequence allows the annealing of complementary DNA sequences (Figure 2.1). 
Thus, the target DNA can be visualized using a fluorescence microscope. This assay is 
useful in wide range of applications including enumeration of chromosomes and 
detection of different chromosomal rearrangements (e.g. translocations, deletions, 
inversion) that are below the resolution of conventional cytogenetic methods (i.e. g-
banding). Furthermore, it enables the use of the panel of disease- specific FISH probes 
for risk stratification/ therapeutic management, quantitation of minimal residual 
disease, detection of cytogenetic remission/ relapse, monitoring cross-sex bone marrow 
transplantation patients for engraftment status (chimerism). It allows identification of 
chromosome aberrations irrespective of the cell cycle stage. In addition, it has the 
advantage of maintaining tissue architecture; however, the nuclear truncation artefact 
and overlapping cells can make the analysis difficult.  
There are different types of FISH probes that are designed for specific regions of a 
chromosome. For the purpose of this project, three different DNA probe types were 
used: 1) locus specific, 2) subtelomeric and 3) Alpha satellite (centromeric) probes. 
These probes are described in the relevant results chapters. Locus specific probes can 
identify reciprocal translocations, gene deletions, amplifications and chromosome 
inversions and in this study, most of these probes were derived from BAC clones. In 
contrast, the subtelomeric and centromeric probes were ordered as predesigned 
commercially available probes (Vysis and Cytocell, respectively). The subtelomeric 
probes target the most distal unique sequences of a chromosome and they are useful 
for chromosome enumeration and integrity, while the centromeric probes recognize a 
highly repetitive alpha-satellite DNA sequence located at the centromere of each 
chromosome. 
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Figure 2.1 Principles of Fluorescence in situ hybridisation (FISH). A. a DNA probe and a target 
sequence are basic elements of FISH, B. The probe is composed of nucleotides that have been 
directly modified to contain fluorophores (white circles), C. Denaturation occurs in both the 
labelled probe and the target sequence, D. Annealing of complementary DNA sequences. Figure 
was taken from (O'Connor, 2008). 
2.8.1 Bacterial artificial chromosome (BAC) clones selection 
Bacterial artificial chromosome (BAC) clones were mainly used in this study as they 
produced strong FISH signals. Fosmid probes were occasionally used. BAC clones are 
larger than fosmid clones and they contain inserts of approximately 100 kb, whereas 
fosmid clones have inserts of up to 40 kb in size. These locus specific clones were 
selected using both Ensembl and Human Genome Browser Gateway (UCSC) genome 
browsers. They were purchased from Roswell Park Cancer Institute (New York, USA) and 
BACPAC resources (California, USA) and were received as bacterial stabs that were 
stored at 4°C. Some clones were already available in house and stored as glycerol stocks 
at -80°C. 
2.8.2 Culturing BAC clones 
Bacteria from the bacterial stabs or glycerol stocks were streaked using a sterile 
inoculation loop onto an agar plate (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% 
(w/v) NaCl, 1.5% (w/v) agar in deionised water) containing 12.5μg/ml chloramphenicol. 
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These plates were incubated overnight at 37°C. The antibiotics were important to 
prevent loss of the plasmid carrying the target DNA or the selection of faster- growing 
mutants. The following day, a single colony was incubated in 200ml of growth medium 
(1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl) supplemented with 
12.5μg/ml chloramphenicol and was kept overnight in a shaking incubator at 37°C (C24 
Incubator Shaker – New Jersey, USA). 
2.8.3 DNA extraction 
DNA was extracted from the cell culture using Nucleobond Xtra Midi kit (Clontech 
laboratories, Inc., California, USA) according to manufacturer’s instructions. The 
resultant DNA was stored at -20°C after they were quantified in terms of concentrations 
and purity using the NanoDrop-1000 as previously described in section 2.7. The 
concentration of the DNA should be at least 57ng/µl for probe labelling procedures.      
2.8.4 Nick Translation (probe labelling) 
Direct labelling of probes was carried out to introduce labelled nucleotides into the 
probe sequence and to decrease the size of the probe DNA to an optimum range of 100-
500 base pairs (bp) to yield good signals. The preferred method used was Nick 
Translation (Abbott Diagnostics, Illinois, USA) and the procedures were followed 
according to the manufacturer’s instructions. The labelled probes were stored at -20°C. 
The following steps were followed according to a previously published protocol with 
slight modifications highlighted below (Schwab and Harrison, 2011).    
2.8.5 Slide Preparation/ Hybridisation 
Both cell pellets and slides were washed in fresh fixative (3:1 Methanol: Acetic acid), 
then the cell suspension was dropped onto the slide. For good results, the cells should 
appear grey and flat with no overlapping between cells but at a sufficient high density 
for easy scoring on high power. The cells were allowed to age by placing slides onto a 
hot plate at 60°C for 10-15 minutes. The commercial probes and hybridisation buffer 
(Cytocell) were combined in a 1:10 dilution, while Home-grown probes were diluted in 
a 1:1 ratio and added to the aged slide. The slides were covered by coverslips which 
were sealed with rubber cement to prevent the cells drying out and slides were 
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transferred to a temperature controlled hotplate (Hybrite, Abbott Diagnostics, Illinois, 
USA) at 72°C for 5 minutes (commercial probes) or 75°C for 5 minutes (home-grown 
probes) to co-denature the probe and DNA, followed by hybridisation at 37°C O/N. 
2.8.6 Post-hybridisation washes/ Counterstaining 
Post-hybridisation washing is the process of stringent cleaning aimed at removing 
background signals which result from the creation of weak bonds from the non-
specifically bound probe during hybridisation. The slides were soaked in 20X SSC 
solution (3M NaCl, 300mM trisodium citrate – Invitrogen) diluted 1:10 in deionised 
water in order to remove the coverslips. The slides were then soaked in Wash 1 solution 
(2% (v/v) 20X SSC, 0.3% (v/v) NP40 in deionised water) for 2 minutes at 72°C. Then they 
were soaked in Wash 2 solution (10% (v/v) 20X SSC, 0.1% NP40 in deionised water) for 
a further 2 minutes at room temperature and they were removed from the wash and air 
dried. Vectashield mounting medium, containing 4’, 6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories, Peterborough, UK), was applied to the slides as a counterstain to 
enable visualization of the signals. 
2.8.7 Analysis 
Slides were examined using an Axioplan fluorescence microscope (Karl Zeiss, Germany) 
or Olympus BX61 equipped with appropriate filters and Cytovision software (Leica 
Microsystems, UK).  However, automated capture was carried out in cases with poor 
FISH signal intensities. The automated capture allows the user to select any area in the 
slide with good density of cells, thus it results in the optimization of the scanned area 
allowing the classification and scoring of cells automatically.  
2.8.8 Establishment of the cut-off values and algorithm strategy for FISH review 
It is vital to ensure the accuracy of the generated results, thus cut-off values for each 
probe set were determined in order to reduce the impact of false positive results. In this 
study, three bone marrow samples from normal individuals were hybridised with each 
individual probe and a minimum of 100 nuclei were scored. The false positive rate for 
each probe in each normal control was calculated by dividing the number of cells 
displaying a non-normal pattern by the total number of cells analysed. The cut-off level 
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is the mean false-positive rate plus 3x standard deviations. This was determined for each 
probe set, apart from the mapping deletion probes described in Chapter 4.  
For all FISH tests, a minimum of 50-100 interphase cells were scored (by myself) and, 
with the exception of deletion mapping, were independently checked by a colleague. 
Checking for deletion mapping was carried out only for probes delineating the 
boundaries of the deletion. The different cut off values and algorithms used for each 
individual probe set are described in the relevant chapters.  
2.9 Multiplex Ligation- Dependent Probe Amplification (MLPA) 
2.9.1 Overview 
Multiplex Ligation- dependent Probe Amplification is a polymerase chain reaction (PCR) 
based method for detecting copy number changes in DNA sequences down to the level 
of a single nucleotide. Unlike standard multiplex PCR, MLPA is able to detect copy 
number changes of multiple targets (more than 40 different small (50 bp) DNA 
sequences) with a single primer pair in a single reaction. MLPA shows high concordance 
with FISH (Coll-Mulet et al., 2008; Schwab et al., 2010). The advantage is that it is a low 
cost simple technique that has a higher throughput than FISH. MLPA can also identify 
focal genetic aberrations which are below the resolution of FISH. In this study, the SALSA 
MLPA kit P335 IKZF1 (MRC Holland, The Netherlands) was used to determine the copy 
number of those genes most frequently deleted in BCP-ALL: ETV6, BTG1, PAX5, 
CDKN2A/B, IKZF1, RB1, EBF1 and genes within the pseudoautosomal region (PAR1): 
CRLF2, CSF2RA and IL3RA as described previously (Schwab et al., 2010). Those cases with 
potential IKZF1 deletions were further investigated using the P202 IKZF1 kit that 
provided more extensive coverage of this gene and its adjacent regions. It was used to 
confirm deletions in cases with single probe deletions detected by the P335 kit. Genomic 
DNA from healthy donors was used as control samples.  
2.9.2 Experimental set-up 
The MLPA probes, composed of two separate nucleotide sequences each with either 
forward (Y) or reverse (X) primer sequence attached, were hybridized to the target 
sequences after denaturation (Figure 2.2, Table 2-1). It is worth noting that the forward 
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primer is fluorescently labelled so that the amplicons can be visualized using capillary 
electrophoresis. In addition, one of the probes contains a stuffer sequence that varies in 
length so that a range of up to 50 targets can be amplified and separated by size in a 
single experiment. The hybridized MLPA probes undergo ligation and only ligated probes 
are exponentially amplified during a PCR reaction that uses a single PCR primer pair, 
enabling the identification of copy number changes of multiple targets. The amount of 
ligated product represents the number of target sequences in the sample. The steps 
were followed according to the manufacturer’s instructions.  
 
 
Figure 2.2 Principles of MLPA techniques. Four main steps were followed including: 
Denaturation, hybridization, ligation, amplification and fragment analysis. Figure was adapted 
from www.mrc-holland.com. 
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Stage Temperature  Time 
Denaturation 
  
98°C¶  5 min¶ 
 98°C* 40 min* 
Hybridization 
  
95°C   1 min  
60°C  16 hr. 
Ligation 
  
  
54°C  15 min 
98°C 5 min 
4°C Overnight 
Before the addition of Polymerase Master 
Mix  
60°C 7 min 
Amplification (35 cycles) 
  
  
  
  
95°C  30 sec 
60°C  30 sec 
72°C  60 sec 
72°C  20 min 
4°C unlimited 
Table 2-1 Different stages of the MLPA procedure. ¶ for viable cell extractions * for fixed cell 
pellet extractions, min minutes, sec seconds, hr. hours. 
2.9.3 Analysis 
Data were analysed using GeneMarker V1.85 analysis software (SoftGenetics, USA). 
Relative copy number was obtained after normalisation of peaks against controls. Probe 
ratios between 0.75 and 1.3 were considered to be within the normal range, with 2 being 
the normal copy number, while values below 0.75 or above 1.3 indicated loss or gain of 
genetic material, respectively, and corresponded to copy numbers of 1 and 3, 
respectively. A value below 0.25 indicated biallelic loss which represented a copy 
number of 0. At least two neighbouring probes within a gene were required to be 
deleted for the loss to be deemed valid, however, some exceptions did exist (i.e. isolated 
ETV6 exon 8 deletions) and they were further investigated in section 4.4.3.1. 
2.10 Single nucleotide polymorphism (SNP) genotyping  
2.10.1 Overview 
Single nucleotide polymorphism (SNP) genotyping is used for the detection of copy 
number abnormalities, loss of heterozygosity (LOH) and allele specific analyses at the 
genome level using probes that are hybridised to a chip. The probes are designed to 
detect SNPs and copy number variants (CNVs) that exist within the general population 
(1000 Genomes Project, etc.). SNPs are genetic variations at the single nucleotide level 
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within the genome that appear in a significant proportion (more than 1%) of the 
population, while CNVs are regions of chromosomes at the level of a particular gene that 
vary in copy number in humans. There are many factors that are playing roles in the 
success of this method and they include high quality DNA, the availability of matched 
reference samples, optimal normalization of the raw microarray data and the 
computational algorithm (Mullighan, 2011).       
This study used a platform with one of the highest resolution levels to detect these 
genetic variants, namely the Affymetrix SNP 6.0 array. This platform is a variation of DNA 
microarray that has a high level coverage of 90.5% of 3400 copy number variants and a 
total of 946,000 non-polymorphic copy number probes, thus providing a higher 
resolution for the detection of chromosomal aberrations.  
2.10.2 Principles of the technique 
SNP 6.0 arrays were processed offsite by AROS Applied Biotechnology (Aarhus, 
Denmark) according to the manufacturer’s instructions (Affymetrix). For each sample, 
approximately 750 ng DNA was used. DNA was either extracted from viable or fixed cells 
(refer to section 2.6). In brief, total genomic DNA was digested with both Nsp I and Sty I 
restriction enzymes and adaptors were ligated to the DNA fragments which facilitated 
their recognition by a generic primer (Figure 2.3). Amplification of the adaptor-ligated 
DNA fragments followed and the PCR amplification products were combined and 
purified. Finally, the library was hybridized to probes, which had been fragmented and 
labelled, for matching allele. A comprehensive genotyping profile was generated based 
on the pattern of probe: DNA hybridisation enabling the determination of 
heterozygosity and homozygosity for each allele. 
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Figure 2.3 Overview on the SNP 6 array processing which involved mainly the following steps: 
Digestion of sample DNA using both Nsp I and Sty I restriction enzymes, ligation of the 
fragmented DNA to adaptors to be recognized by a generic primer,  amplification of the adaptor-
ligated DNA fragments, purification, fragmentation/labelling and hybridization to probes for 
matching alleles. Figure was taken from www.affymetrix.com.  
2.10.3 Analysis 
Raw array-generated data in the form of .CEL files were received from AROS. Affymetrix 
CEL files were analysed for initial quality control, followed by Affymetrix Birdseed 
algorithm, Version 2.0 to generate SNP genotype calls on all samples using Affymetrix 
Genotyping Console software (version 4.1.1.834). All samples passed the Affymetrix 
recommended contrast quality control and SNP call rate threshold. Copy number, allele 
ratio, and allele specific copy number data analysis were performed. HapMap270 data 
was used as a reference model for LOH analysis due to unavailability of matched 
germline DNA. Detected regions of CNA which mapped to regions of known genetic 
variation were identified by the software and were excluded from further analysis. 
2.11 Real-time polymerase chain reaction (qPCR) using TaqMan Copy Number 
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Assays 
2.11.1 Overview 
The TaqMan Copy Number Assays are characterised as a fast and simple method for 
obtaining specific copy number data within the human genome. TaqMan Copy Number 
Assays are run simultaneously with a TaqMan Copy Number Reference Assay in a duplex 
qPCR. The Reference Assay detects a sequence that is known to exist in two copies in 
the genome (for example, RNase P (14q11.2) - the standard reference and TERT 
(5p15.33) - an alternative reference assay). Each TaqMan Copy Number Assay contains: 
two unlabelled primers for amplifying the target sequence of interest and one TaqMan 
Minor Groove Binder (MGB) probe for detecting the target sequence of interest. The 
MGB probe includes both 6-carboxyfluorescein (FAM) reporter dye and a 
nonfluorescent quencher (NFQ) with a MGB. However, the reference assay probe 
contains VIC reporter dye and 6-carboxytetramethylrhodamine (TAMRA) quencher. As 
heterogeneous leukaemic samples were tested in this study, the reference DNA 
sequence might not be present in normal copy number; therefore two different 
reference assays were used. A more detailed description of the probes used is given in 
the relevant chapters (5 and 6). 
2.11.2 Experiment set-up 
Reactions were run on an Applied Biosystems Real-Time PCR System according to the 
manufacturer’s instructions. DNA was either extracted from viable or fixed cells (section 
2.6). Each sample was diluted to 5 ng/ul using Nuclease-free water (NFW). Applied 
Biosystems recommends running the following samples on each plate: genomic DNA 
(gDNA) samples with unknown target copy number, a sample that does not contain a 
DNA template (NTC), a calibrator sample- which was known to have two copies of the 
target sequence- and a positive control sample. The NTC sample shows the background 
fluorescence and allows for the detection of contamination. It is strongly recommended 
to use four replicates for each gDNA sample in order to generate the reliable copy 
number calls. Standard 96-well plate was used with a total volume of 20ul in each well 
that constituted of TaqMan Genotyping Master Mix, TaqMan copy number target, 
 75 
 
reference assays, nuclease-free water and gDNA. The target, reference probes and 
Genotyping Master Mix were all supplied from Applied Biosystem. 
The experiment setup was performed using ViiATM 7 Real-Time PCR System (ViiA™ 7 
Software v1.X) and the Absolute Quantitation method was chosen to capture the CT 
data from the duplex PCR run. The qPCR cycles were defined as detailed in Table 2-2. 
Stage Temperature Time 
Hold 95 °C 10 min 
Cycle 
(40 Cycles) 
95 °C 15 sec 
60 °C 60 sec 
Table 2-2 Stages of qPCR using TaqMan Copy Number Assays. 
2.11.3 Principles of the technique 
During the PCR reaction, the genomic DNA template was denatured and each set of 
assay primers annealed to its specific target sequences (Figure 2.4). Similarly, each 
TaqMan probe annealed specifically to the complementary sequence which was been 
generated by the forward and reverse primers. When the target sequence was present, 
the probe hybridized to the target sequence; thus during each round of PCR, the DNA 
polymerase cleaved the probes that were hybridized at the 5’ end where the reporter 
dye is attached. This resulted in separation of the quencher and reporter dyes leading 
to an increase in the level of fluorescence as the reporter became unquenched. However, 
when the target sequence was deleted, the probe did not hybridize and the reporter 
dye remained quenched and therefore failed to emit a fluorescent signal. Accumulation 
of the different PCR products resulting from the amplification of both the target and 
reference sequences during each cycle was detected by the real time PCR machine and 
they are represented by FAM and VIC signals, respectively. The relative levels of the two 
reporter dyes, as represented by cycle threshold (CT) values, are indicative of different 
starting amount of DNA. 
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Figure 2.4 Principles of qPCR techniques for the detection of target (left) and reference (right) 
DNA sequences in a duplex reaction. a. Components of the copy number and reference assays 
(assay primers and TaqMan probe), b. Denaturation of the DNA template followed by annealing 
of the assay components, c. DNA polymerase cleaves the probes that are hybridized at the 5’ 
end where the reporter dye is attached, resulting in signal generation. The figure was taken from 
www.appliedbiosystem.com. 
 
2.11.4 Analysis 
ViiA™ 7 Real-Time PCR System was used to analyse the real time PCR data and the 
Absolute Quantitation method was used to capture the CT data from the duplex PCR run. 
The CT values were determined as the fractional cycle number where the level of 
fluorescence increased above the baseline threshold. Of note, the threshold for CT 
determination was set during the exponential amplification phase, in which all reagents 
were still in excess. The baseline threshold should be set in the initial cycles of PCR where 
there is little change in fluorescence signal but should not overlap with the area in which 
the amplification signal begins to rise above background (Figure 2.5). It is worth noting 
that both the threshold and baseline should be the same for each specific target probe 
assay in multiple experiments. Applied Biosystems CopyCaller Software imported and 
analysed real-time PCR result files from copy number assay experiments that used 
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absolute quantitation settings to determine the copy number of the target in each 
sample. This Software analysed copy number data with or without a calibrator sample 
using the comparative cycle threshold (ΔΔCT) method that determined the relative 
quantitation (RQ) (Figure 2.6). The method measured the CT difference (ΔCT) between 
target (FAM) and reference (VIC) sequences in all replicates of the test samples. The 
mean ΔCT (μ ΔCT) value of the test samples was then compared to the μ ΔCT value of the 
calibrator sample to give the ΔΔCT value. The copy number of the target sequence in a 
test sample was calculated by the software to be the copy number of the target 
sequence in the calibrator sample multiplied by the relative quantity (RQ) which was 
calculated from the ΔΔCT value. 
Quality metric assignment, namely confidence and absolute z-score metrics, were taken 
into consideration. The former metric is the probability that the assigned copy number 
is the correct copy number relative to any of the other possible assigned copy numbers 
for the group of analysed samples. However, the absolute z-score metric is defined as 
the absolute value of the number of standard deviations separating the replicate mean 
ΔCT of a sample from the mean subdistribution of the assigned copy number. A specific 
algorithm was generated in Chapter 5 pertaining to the accuracy of data based on their 
quality metrics.   
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Figure 2.5 Representative plot of real time quantitative polymerase chain reaction. Two 
phases are shown in the plot: amplification and plateau phases, baseline is set in the initial cycles 
of PCR where there is little change in fluorescence signal, threshold line is located at the base of 
the amplification phase, CT values represent the intersection between the amplification curve 
and threshold line. ΔRn is an increment of fluorescent signal at each time point. The ΔRn values 
(Y- axis) are plotted versus the cycle number (X-axis). Figure was taken from 
http://www.ncbi.nlm.nih.gov/projects/genome/probe/doc/TechQPCR.shtml.  
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Figure 2.6 Flow chart describing the comparative cycle threshold (ΔΔCT) method calculation 
of the target copy number in a test sample. s: test sample, c: calibrator sample, CT value: cycle 
threshold, Δ : difference, μ: mean, RQ: relative quantity, cns, cnc: copy number of the target 
sequence in a test and calibrator samples, respectively.  
 
2.12 Statistical Analyses 
Statistical analysis was performed using intercooled STATA, version 11.0 (StataCorp, 
USA), particularly Wilcoxon Rank Sum for non-parametric assays. Comparisons between 
categorical groups and subgroups were assessed using the Chi-squared using 
appropriate variations (e.g. Fisher's exact test) when required. As this study was 
hypothesis generating rather than hypothesis testing/validating no formal p value 
adjustment was used but all tests were conducted using a 1% level of significance to 
account for multiple testing. t-test was used to determine if the means of two groups 
were significantly different from each other. 
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Chapter 3. Spectrum of key secondary abnormalities in ETV6-RUNX1 
positive BCP-ALL 
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3.1 Introduction 
Robust functional studies have demonstrated that ETV6-RUNX1 fusion gene by itself is 
unable to generate leukaemogenic transformation. Rather, it acts as an initiating factor 
which aids in the generation and maintenance of the preleukaemic stem cells as 
suggested from xenograft modelling (Bernardin et al., 2002; Tsuzuki et al., 2004; Fischer 
et al., 2005; Sabaawy et al., 2006; Hong et al., 2008; Schindler et al., 2009). The need for 
the acquisition of the postnatal genetic alterations is further indicated by the number of 
healthy neonates carrying this fusion who do not develop overt leukaemia, the low 
concordance rate (~ 5-10%) for BCP-ALL among monozygotic monochorionic twins and 
the variable length of the latency period to clinically detectable leukaemia (Wiemels et 
al., 1999; Mori et al., 2002). A large and growing body of genomic studies on ETV6-
RUNX1 have identified recurrent genetic aberrations involved in B cell development/ 
differentiation, cell cycle regulation, nuclear hormone receptor transcriptional 
regulation, glucocorticoid receptor signalling, drug resistance and regulation of 
apoptosis including BTG1, PAX5, EBF1, ETV6, CDKN2A/B, TBL1XR1, NR3C1, NR3C2 and 
BMF, CD200/BTLA (Forestier et al., 2007; Lilljebjorn et al., 2007; Mullighan et al., 2007; 
Kawamata et al., 2008; Mullighan et al., 2008b; Parker et al., 2008; Lilljebjorn et al., 
2010). Thus the interaction of these alterations is needed for the leukaemic 
development and progression (see section 1.4.1.4). Previous genomic studies have 
focused on the overall frequencies, common breakpoints of these genetic alterations 
and their associations with different primary genetic groups. However, the distribution 
of these aberrations among different ETV6-RUNX1 subgroups in terms of demographic 
and clinical features was lacking. In addition, it was important to shed light on comparing 
this cytogenetic group with other BCP-ALL subtypes in terms of the frequency of CNA 
and their characteristic features including type and extent of deletions along with 
associated other gene alterations. These important elements still have to be determined 
in order to point out to the possible driving leukaemogenic factors in ETV6-RUNX1 
positive cases. 
3.2 Aims and Objectives 
This study aims to identify the frequency and type of the CNA  along with their distinct 
clinical and genetic features in ETV6-RUNX1 BCP-ALL targeting genes involved in B cell 
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development/ differentiation and cell cycle regulation including: ETV6, PAX5, CDKN2A/B, 
BTG1, RB1, IKZF1, EBF1 and genes within the pseudoautosomal region 1 (PAR1) of the 
sex chromosomes. The potential relevance of these alterations to ETV6-RUNX1 
subgroups as compared to other BCP-ALL is to be assessed accordingly. 
The main objectives in this study are to:  
1- Screen a large cohort of ETV6-RUNX1 patients for the genes mentioned earlier 
using an accurate and reliable high throughput method: multiplex ligation-dependent 
probe amplification (MLPA).  
2- Describe the incidence and clinical features of the different gene alterations in 
the ETV6-RUNX1 overall cohort.  
3- Compare the CNA profile observed in ETV6-RUNX1 cases with other BCP-ALL. 
3.3 Patients and Methods 
Patients included in this study were confirmed cases of ETV6-RUNX1 positive BCP-ALL 
and treated using either UKALL97/99 or UKALL2003 (see section 2.2). National Cancer 
Institution (NCI) criteria were followed to assess the risk (see section 1.3.5). The 
diagnostic cell pellets were utilised for DNA extraction, for those patients with no 
available DNA, using the QIAGEN DNeasy tissue and blood kit according to the 
manufacturer’s instructions (section 2.6). Comprehensive MLPA screening was carried 
out on a representative cohort of BCP-ALL (n=1019), including ETV6-RUNX1 cases 
(n=397), by the Leukaemia Research Cytogenetic Group (LRCG) team, including myself, 
using the SALSA MLPA kit P335 IKZF1 and for certain cases, the P202 IKZF1 kit was used 
(see section 2.9) (Schwab et al., 2013). Intercooled STATA, version 11.0 was used for the 
statistical analysis (see section 2.12). 
3.4 Results 
3.4.1 Cohort Description 
A total of 397 cases were found to have ETV6-RUNX1 positive BCP-ALL. They had a 
median age of 4 years with few infants (before their second birthday) (5%) and older 
children (aged 10 years and above) (9%). In addition, there were few cases with an age 
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of 15 years and more (1.5%). To note, the majority of cases (75%) were classified as 
standard NCI risk and there was a reduction in the incidence of relapses from 
UKALL97/99 to UKALL2003 (13.5% to 3.7%). Many of these relapses were late relapses 
(> 6 months of end of treatment) (~70%).  
3.4.2 Cytogenetic abnormalities 
The majority of patients had an abnormal karyotype (n= 238/397, 60%), whilst the 
remainder either had a normal (n=66/397, 17%), or a failed cytogenetic result (less than 
20 normal cells were regarded as a fail) (n=90/397, 23%) or data was unavailable 
(n=3/397, 0.5%). It is worth noting that the cytogenetics failure rate was high in support 
of previously reported rate (Harrison et al., 2005) (26%) which might be explained by 
the lower mitotic index seen in ETV6-RUNX1 cases. Of these cases with successful 
cytogenetics (n=304), the most prevalent abnormalities were: 12p loss (31%), gain of 
chromosome 21 (15%) and add/del 6q (11%). Other visible abnormalities which 
occurred at a lower rate included: add/del 11q (6%), add/del 9p (5%) and near 
tetraploidy (4%) (Table 3-1) (Appendix A). 
FISH studies were helpful in distinguishing between gain 21 and gain der(21)t(12;21) 
owing to the higher resolution of FISH. Thus, 35 out of 46 cases with visible gain 21 had 
FISH results and 23 cases (66%) showed concordant FISH and cytogenetic results, while 
the remaining 12 cases revealed either gain der(21)t(12;21) (n=11, 31%) or no evidence 
of neither gain 21 nor gain der(21)t(12;21) (n=1, 3%). Among 23 concordant cases, three 
of them exhibited an additional gain der(21)t(12;21); thus four copies of chromosome 
21 in total. In the overall cohort, among the remaining cases with no visible gain 21 and 
with available FISH data (n= 302), gain 21 was found in further 36 cases (12%).  
On the other hand, four out of 5 cases with cytogenetically visible gain der(21)t(12;21) 
had FISH and MLPA data and all cases showed concordant cytogenetic, MLPA and FISH 
results. Overall, 41 out of 333 remaining cases with no visible gain der(21)t(12;21) and 
with available FISH data showed gain der(21)t(12;21). Among 42 cases, 13 cases had 
cytogenetically visible gain 21 but FISH and MLPA ETV6 profiles indicated gain 
der(12)t(12;21), while 26 cases had concordant FISH and MLPA results but not 
cytogenetically visible. The remaining three cases showed gain der(21)t(12;21) by FISH 
but not by MLPA owing to either low proportion of the abnormal clones (13% and 6% of 
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the total cells) (n=2) or an artefact in either MLPA or FISH data (n=1). The MLPA profile 
of gain der(21)t(12;21) can be identified by the presence of both gain in the copy number 
of ETV6 exons 1-5 and normal copy number of ETV6 exon 8. 
Taking together, in the overall cohort with available FISH studies (n=337), a total of 52 
cases (17%) exhibited gain 21, 38 cases (11%) had gain der(21)t(12;21) and further 7 
cases (2%) harboured both alterations. 
Abnormality No. (%) 
Total no. of successfully tested cases 304 (100) 
add/del (12)p 94 (31) 
Gain 21 46 (15) 
add/del (6)q 33 (11) 
add/del (11)q 18 (6) 
del/add (9)p 14 (5) 
Near tetraploidy 11 (4) 
Gain 16  9 (3) 
del/add (13)q 8 (3) 
del/add (3)q 7 (2) 
add(16)(p)/(q) 6 (2) 
del(5)q  6 (2) 
Gain der(21)t(12;21) 5 (2) 
Gain 10, 16 5 (2) 
Gain 10 4 (1) 
Table 3-1 Cytogenetic abnormalities and their frequencies in ETV6-RUNX1 cohort. add: added 
material, del: deleted material, near tetraploidy: 80 or more chromosomes.  
 
3.4.3 Copy number alterations/Rearrangements in ETV6-RUNX1 BCP-ALL 
Overall, 77% of ETV6-RUNX1 cases (n=307) exhibited an alteration of at least one of the 
eight genes in the MLPA kit: 151 (38%) patients had one, 115 (29%) had two, 41 (10%) 
had three or more losses (Table 3-2, Table 3-3, Table 3-4 and Appendix A). There were a 
total number of 508 alterations with an average number of 1.26 abnormalities per case. 
The most prevalent gene deletion was ETV6 that constituted 52% of the cases. Moreover, 
PAX5, CDKN2A/B and BTG1 alterations were the common deletions that represented 
23%, 23% and 15%, respectively. However, the remaining alterations including RB1, 
EBF1, IKZF1 and PAR1 occurred at lower frequencies (8%, 4%, 3% and 1%, respectively). 
There was no significant association between these alterations and other clinical/ 
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demographic features including: sex, age, WCC, relapses and other gene deletions. 
However, two thirds of the ETV6 deleted cases had WCC >10X 109/L (p=0.02). In 
addition, CDKN2A/B and BTG1 losses were absent in those less than 2 years old as 
compared to older patients (p=0.02). Furthermore, half of IKZF1 deletions were assigned 
to the high risk category (p=0.02).   
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  Cohort 
Gene deletions 
ETV6 CDKN2A/B PAX5 BTG1 RB1 EBF1  IKZF1  PAR1 
N. of cases 397 (100) 206 (100) 91 (100) 91 (100) 60 (100) 30 (100) 14 (100) 12 (100) 4 (100) 
Sex (M:F) 216:181  103:103 48:43 43:48 29:31 15:15 7:7 4:8 4:0 
ratio 1.19 1 1.11 0.9 0.94 1 1 0.5  4 
Age (years)   
Median 4 4 4 3 4.5 5 5 7 8 
1 21 (5) 7 (3) 0 (0) 5 (5) 0 (0) 1 (3) 1 (7) 0 (0) 0 (0) 
2-9 342 (86) 185 (90) 82 (90) 82 (90) 51 (85) 24 (80) 11 (79) 9 (75) 3 (75) 
 10+ 34 (9) 14 (7) 9 (10) 4 (4) 9 (15) 5 (17) 2 (14) 3 (25) 1 (25) 
WCC‡ (X 109/L)   
Median 11.6 14.7 14.3 15 10.5 12.4 8.9 14.1 22.7 
<10 178 (45) 79 (38) 32 (35) 35 (38) 28 (47) 12 (40) 7 (50) 6 (50) 2 (50) 
10-49.9 147 (37) 82 (40) 37 (41) 33 (36) 21 (35) 15 (50) 6 (43) 2 (17) 1 (25) 
≥50 72 (18) 45 (22) 22 (24) 23 (25) 11 (18) 3 (10) 1 (7) 4 (33) 1 (25) 
NCI Risk¥   
Standard 296 (75) 151 (73) 62 (68) 64 (70) 42 (70) 23 (77) 11 (79) 6 (50) 2 (50) 
High 101 (25) 55 (27) 29 (32) 27 (30) 18 (30) 7 (23) 3 (21) 6 (50) 2 (50) 
 
Table 3-2 Number and percentages (%) of ETV6-RUNX1 BCP-ALL patients with different gene deletions stratified by sex, age and white cell count and NCI risk 
status. all p values >0.01 (not significant), thus not included in the table, ‡ white cell count, ¥ National Cancer Institute (standard risk: aged 1-9 years with a WCC < 50 x109/L at 
initial presentation, high risk category: ≥10 years and a WCC ≥ 50 x109/L.
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  Cohort 
Gene deletions 
ETV6 CDKN2A/B PAX5 BTG1 
No. of cases 397 206 91 91 60 
ALL97/99  126 (100) 74 (100) 30 (100) 34 (100) 26 (100) 
No. Relapses 17 (13) 11 (15) 8 (27) 3 (9) 4 (15) 
Early* 6 (35) 3 (27) 4 (50) 0 0 
Late‡ 11 (65) 8 (73) 4 (50) 3 (100) 4 (100) 
ALL2003  271 (100) 132 (100) 61 (100) 57 (100) 34 (100) 
No. Relapses 10 (4) 1 (1) 1 (2) 1 (2) 0 (0) 
Early* 3 (30) 1 (100) 0 0 0 
Late‡  7 (70) 0 1 (100) 1 (100) 0 
Table 3-3 Correlation between different gene deletions and types of relapses in ETV6-RUNX1 patients treated on ALL97/99 and ALL2003. all p values >0.01 (not 
significant), thus not included in the table, * within 18 months of the diagnosis until 6 months from the end of treatment (male: 3 years, female: 2 years), ‡ after 6 months off 
treatment, no reported relapses in EBF1, IKZF1, RB1 deleted cases and only one PAR1 rearranged case was relapsed, thus not included in this table. 
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Cohort 
Gene deletions 
ETV6 CDKN2A/B PAX5 BTG1 RB1 EBF1 IKZF1 PAR1 
N. of cases 397 (100) 206 (100) 91 (100) 91 (100) 60 (100) 30 (100) 14 (100) 12 (100) 4 (100) 
Deletions 
ETV6 206 (52) 
CDKN2A/B 91 (23) 54 (26) 
PAX5 91 (23) 47 (23) 21 (23) 
BTG1 60 (15) 33 (16) 14 (15) 12 (13) 
RB1 30 (8) 16 (8) 3 (3) 6 (7) 4 (7) 
EBF1 14 (4) 10 (5) 1 (1) 4 (4) 4 (7) 0 (0) 
IKZF1 12 (3) 8 (4) 1 (1) 5 (5) 4 (7) 2 (7) 0 (0) 
PAR1 4 (1) 1 (0.5) 1 (1)  2 (2) 2 (3) 2 (7) 0 (0) 1 (8) 
Table 3-4 Correlation among different gene deletions within ETV6-RUNX1 BCP-ALL. all p values >0.01 (not significant), thus not included in the table. 8 
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3.4.3.1 Copy number alterations in B- cell differentiation genes  
A.  PAX5 
 PAX5 deletions were one of the common B- cell differentiation gene alterations within 
ETV6-RUNX1 positive BCP-ALL and occurred in 23% of cases (n=91). All deleted cases 
harboured monoallelic deletions with the majority of them (38%) being restricted to 
exons 2-6, followed by losses affecting exons 1-10, exons 1-6, exons 2-5 which 
represented 18%, 16% and 12%, respectively. The remaining cases exhibited different 
breakpoints at lower incidences (Figure 3.1). 
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Figure 3.1 Comparison of PAX5 deletion breakpoints between ETV6-RUNX1 and other BCP-ALL 
cases. PAX5 gene (10 exons) is displayed with the six MLPA probes used from the SALSA MLPA 
kit P335 IKZF1 (Red arrows) that covered PAX5 exons 1, 2, 5, 6, 8 and 10; PAX5 deletion 
breakpoints are highly variable; PAX5 exons (2-6) losses constituted the predominant deletion 
in ETV6-RUNX1, while entire gene loss is the commonest in other BCP-ALL; the total number of 
PAX5 losses in ETV6-RUNX1 and other BCP-ALL cases (91 and 178 cases); * other miscellaneous 
losses presented at lower frequencies (1% each) including:  exon 1, exons 1, 6-10, exons 1, 8-10, 
exons 2, 6-8, exons 2-5, 8-10, exons 2-6, 10, exons 5-8 and exons 6-8; solid lines are heterozygous 
losses. 
PAX5 losses occur in all age groups but with varying proportions and a median age of 3 
years. There was no difference in terms of sex, WCC and NCI risk groups distributions 
within ETV6-RUNX1 patients (Table 3-2). Furthermore, there were no associations 
between PAX5 losses and other gene deletions tested in this study (Table 3-4) in spite 
of their high co-occurrence rate with CDKN2A/B losses (23%, n=21). Out of these 21 
cases, patients had failed (n=6, 29%) or normal cytogenetics (n=1, 5%) or abnormal 
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karyotype with no 9p abnormality (n=5, 24%) or with 9p abnormality (n=9, 43%). Overall, 
a total of 10 (16%) out of 61 PAX5 deleted cases with successful cytogenetic data showed 
visible abnormalities affecting 9p with nine of them showed concurrent CDKN2A/B loss 
(90%). There were different structural abnormalities observed including: dicentric 
chromosomes affecting chromosome 9 (dic(9)p) (n=7, 11%), partial deletion 9p (del(9)p) 
(n=1, 2%) and additional material on 9p (add(9)p) (n=2, 3%). Among those cases with 
dicentric chromosomes, 5 cases showed dic(9;12) (71%) and one case each exhibited 
either dic(9;18) (14%) or dic(6;9) (14%). Interestingly, all dic(9;12) and dic(9;18) patients 
showed whole PAX5 gene loss except the case with dic(6;9) which showed loss of PAX5 
gene exons (2-6), however, all of these dicentric chromosomes (n=7) had concurrent 
CDKN2A/B deletions. In addition, the entire loss of ETV6 gene (n=4) or its telomeric 
exons (1-5) (n=1) were observed in all dic(9;12) cases (n=5) along with concurrent 
deletions of both PAX5 and CDKN2A/B. 
B.  EBF1 
The EBF1 gene consists of 16 exons and the SALSA MLPA kit P335 IKZF1 contains four 
probes covering EBF1 exons 1, 10, 14 and 16. EBF1 deletions were considered as rare 
alterations that occurred in BCP-ALL patients and only 4% (n=14) of ETV6-RUNX1 
patients harboured these aberrations. The majority of the cases showed loss of the 
entire EBF1 gene (loss of all probes) (n=12) while the remaining two cases had deletions 
restricted to exons (1-10) and all deletions were monoallelic. These losses were not 
reported to be associated with any of the demographic or clinical features (Table 3-2). 
Patients with these losses were predominately allocated in the standard NCI risk group 
(n=11, 79%) and this might explain the observed good outcome with no reported 
relapses in either treatment protocols. In total, 11 out of 14 deleted cases had successful 
cytogenetic results with only one of them showing visible deletion at the long arm of 
chromosome 5 (5q). 
C.  IKZF1 
IKZF1 deletions occurred in around 3% (n=12) of ETV6-RUNX1 cases. The extent of IKZF1 
deletion sizes varied with the most frequent ones either restricted to exons (2-3) (n=5, 
42%) or exons (4-8) (n=3, 25%), while the remaining cases occurred at lower frequencies: 
 92 
 
exons (2-7) (n=1, 8%), exons (2-8) (n=1, 8%), exon (1) (n=1, 8%) or the entire gene (n=1, 
8%) (Figure 3.2). All deleted cases showed monoallelic deletions. Furthermore, all 
deletions were further validated by another detailed IKZF1 MLPA kit (P202) with a higher 
probe density that confirmed these deletions. This kit is composed of 18 probes covering 
IKZF1 gene: six of them (exons 1-2 and 5-8) are similar to those in P335 kit while one 
probe overlaps with one of the probes contained in P335 kit (exon 3). However, the 
remaining probes (n=11) encompass IKZF1 exons 1 (n=2), exon 2 (n=1), exon 3 (n=2), 
exon 4 (n=2), exon 5 (n=1), exon 6 (n=1), exon 7 (n=1) and exon 8 (n=1) in order to 
confirm the deletion of single probes obtained from the P335 IKZF1 kit. In addition, there 
are additional probes on either side of the IKZF1 gene (3’ and 5’ regions) which have 2 
and 1 probes, respectively, to aid in the estimation of the extent of deletion on 7p. 
Overall, the results were consistent using both kits and the new kit added the advantage 
of confirming the case with a single probe loss targeting exon 1. Furthermore, it 
estimated the extent of deletions in three cases with either loss of the entire gene (n=1) 
or deletions of exons (4-8) (n=1) or exons (2-8) (n=1). Thus, the deletion of the former 
case was shown to involve both flanking breakpoints of IKZF1 gene indicative of 
extensive deletion on 7p that was not detected cytogenetically owing to failed results. 
However, the remaining two cases exhibited deletions extending to the 3’ region of the 
gene and none of them were identified cytogenetically owing to possible smaller 
deletion (below the cytogenetic resolution) and failed results, respectively. 
Confirmatory FISH, using fosmid probe specific for the IKZF1 gene (40 kb), was available 
for only one case with deletion restricted to exons (2-7) and was shown to harbour the 
deletion as a major clone (59%). IKZF1 losses cases occurred mainly in the age group (2-
9) years with a median age of 7 years (Table 3-2). Although half of IKZF1 deleted cases 
were in the high NCI risk within this ALL subtype, none of them relapsed. There were no 
associations with other gene deletions (Table 3-4). Among 9 cases with successful 
cytogenetic, none had a visible cytogenetic abnormality involving the short arm of 
chromosome 7 (7p). 
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Figure 3.2 Comparison of IKZF1 deletion breakpoints between ETV6-RUNX1 and other BCP-ALL 
cases. IKZF1 gene (8 exons) is displayed with the eight MLPA probes used from the SALSA MLPA 
kit P335 IKZF1 (Red arrows) that covered IKZF1 exons 1, 2, 3, 4, 5, 6, 7 and 8; IKZF1 deletion 
breakpoints are highly variable; IKZF1 exons (2-3) and exons (4-8)  losses constituted the 
predominant IKZF1 deletion types in ETV6-RUNX1, while the entire gene loss and exons (4-7) 
were the commonest in other BCP-ALL; ¥ the classic deletion with IK6 isoform production; the 
total number of IKZF1 losses in ETV6-RUNX1 and other BCP-ALL cases (12 and 187 cases); ¶ other 
miscellaneous losses presented at lower frequencies (1% each) including:  exon 1, exons 1-3, 
exons 1, 4-7, exons 1-4, exons 1-5, exons 3, exons 3-5, 7-8, exons 3-8, exons 4,6-7, exons 4-5 and 
exons 4-5,7; solid lines are heterozygous losses. 
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3.4.3.2 Copy number alterations in cell cycle control genes  
D.  CDKN2A/B 
The MLPA kit contains three probes covering CDKN2A (exons 1 and 4) and CDKN2B (exon 
2). CDKN2A/B losses were one of the common deletions representing around 23% (n=91) 
of ETV6-RUNX1. The majority of deleted cases encompassed the entire CDKN2A/B genes 
(n=87, 96%), while the remaining four cases harboured deletions restricted to either 
CDKN2A (n=2, 2%) or CDKN2B (n=2, 2%). CDKN2A/B losses were either monoallelic (n=72, 
79%) or biallelic (n=19, 21%). They occurred in all age groups, except younger children 
<2 years old who lacked any reported case, at varying incidences with a median age of 
4 years (Table 3-2). There was no significant association between these aberrations and 
other demographic and clinical features. However, 27% of the deleted cases treated on 
UKALL97/99 at presentation relapsed, while only 2% of deleted cases that received more 
advanced treatment (UKALL2003) relapsed (Table 3-3). Furthermore, there were no 
associations between CDKN2A/B losses and other gene deletions tested in this study 
(Table 3-4) apart from the previously described high co-occurrence rate with PAX5 losses 
in 23% (see section 3.4.3.1 A. ). Among 67 deleted CDKN2A/B cases with successful 
cytogenetics, 25% (n=17) showed visible 9p alterations including add(9p) (n=4, 6%), 
del(9p) (n=5, 7%) and dicentric chromosomes affecting chromosome 9 (dic(9p)) (n= 8, 
12%). 6 out of 8 cases with dic(9p) showed dic(9;12) (75%) and one case each exhibited 
either dic(9;18) (13%) or dic(6;9) (13%). A total of 8 cases (47%) with visible 9p 
abnormalities did not show concurrent PAX5 loss because of possible distal breakpoints 
that were not encompassing PAX5 gene. 
E.  RB1 
There were five MLPA probes encompassing RB1 exons 6, 14, 19, 24 and 26 on the MLPA 
P335 kit. In total, 30 cases (8%) showed loss of RB1. The size of RB1 deletions differed 
to either affecting the entire gene (n=22) or restricted to exons (19-26) (n=6) and various 
deletion extents existed but at lower frequencies including monoallelic loss of exons (14-
26) (n=1) or biallelic deletion of exons (19-26) with associated monoallelic loss of exons 
(6-14) (n=1). RB1 deletions were either monoallelic or biallelic. The majority of these 
cases were allocated in the age group (2-9) years with a median age of 5 years (Table 
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3-2). There was no single relapse case reported in these patients and this might be 
explained by the fact that most cases (77%) were categorised as standard NCI risk. In 
total, 10 out of 24 cases (42%) with successful cytogenetic results were shown to 
harbour visible cytogenetic abnormalities including deletions of the long arm of 
chromosome 13 (del(13q)) (n=4) and loss of the entire chromosome 13 (n=3), while the 
remaining cases (n=3) exhibited either add(13q) (n=1) or translocations with different 
partners (n=2).  
3.4.3.3 Copy number alterations in transcription regulating genes  
F.  ETV6 
Deletions of ETV6 were the most prevalent alterations which represented 52% (n=206) 
of ETV6-RUNX1 cases. The most common deletion involved the entire gene (n=149, 72%), 
exons (2-8) (n=18, 9%), exons (1-5) with associated biallelic exon 8 loss (n=9, 4%), exons 
(1-5) (n=8, 4%) and other miscellaneous deletions (Figure 3.3). Among these losses, 
either monoallelic (n= 195) or biallelic deletions (n=11) did occur with the later type 
restricted to exon 1 (n=2, 18%) or exon 8 (n=9, 82%) and accompanied by monoallelic 
losses of other exons of ETV6. These losses predominated in the age group (2-9) years 
(90%) with a median age of 4 years (Table 3-2). It is worth noting that around quarter of 
the cases were classified as high NCI risk which was attributed to their tendency to have 
a high WCC. There were no associations found between ETV6 aberrations and other 
gene losses investigated in this study (Table 3-4). 
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Figure 3.3 Comparison of ETV6 deletion breakpoints between ETV6-RUNX1 and other BCP-ALL 
cases. ETV6 gene (8 exons) is displayed with the six MLPA probes used from the SALSA MLPA kit 
P335 IKZF1 (Red arrows) that covered ETV6 exons 1 (two probes), 2, 3, 5 and 8; the entire gene 
loss is the commonest in both ETV6-RUNX1 and other BCP-ALL; the total number of ETV6 losses 
in ETV6-RUNX1 and other BCP-ALL cases (206 and 103 cases); € other miscellaneous losses 
presented at lower frequencies (1% or less each) including: exons 3-5, exons 5-8, exon 8 with 
biallelic exon 1, biallelic exons 5-8, exons 1-2, exons 1-2, 8, exons 2-5, exons 3, 8,  exons 2-5 with 
biallelic exon 8 and exons 2-8 with biallelic exon 1; # other miscellaneous losses presented at 
lower frequencies (1% or less each) including: exons 1, 3-5, exons 1, 3-8, exons 1-2, 5, exons 3,8, 
exons 3-5 and exons 3-8. Solid lines are heterozygous losses, while dashed lines are homozygous. 
In total, 76 out of 161 ETV6 deleted cases (47%) with successful cytogenetic analysis 
were observed to harbour visible cytogenetic abnormalities of either the entire 
chromosome 12 (n=1, 0.6%) or its short arm (12p) (n=75, 47%). The most frequent 
alterations among 76 cases were both deletion of 12p (n=37, 23%) and additional 
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material on chromosome 12p (add(12p)) (n=25, 16%). In addition, dicentric 
chromosomes were detected in 12 cases (16%) including: dic(9;12) (n=6, 50%), dic(12;13) 
(n=2, 17%), dic(8;12) (n=1, 8%), dic(12;20) (n=1, 8%), dic(12;15) (n=1, 8%) and dic(12;19) 
(n=1, 8%). They resulted in either the entire loss of ETV6 gene (n=11, 92%) or its 
telomeric exons (1-5) (n=1, 8%); the latter case harboured dic(9;12).   
FISH studies were available on 175 (85%) of ETV6 deleted cases and 76% (n=137) of cases 
had concordant FISH and MLPA results. However, the remaining 38 cases (22%) showed 
deletion by MLPA but not by FISH owing to the small region of deletions that were below 
FISH resolution; occurring intragenic in the gap between the ETV6 BA probes used.  
Among the non-deleted ETV6 cases by MLPA (n=190) in the overall cohort, 161 cases 
(85%) had successful FISH studies and a total of 42 cases showed ETV6 deletions which 
were missed by the MLPA detection threshold criteria or sensitivity (see section 2.9.3) 
(Appendix B). Among 42 cases, 9 cases (21%) exhibited lower ETV6 MLPA probe ratios, 
below the MLPA detection threshold, varying between 0.76-0.89 and FISH studies 
showed ETV6 deletions in proportions of 26% or more (range: 26%-84%). However, 30 
cases (71%) harboured ETV6 deletions by FISH only, owing to either a low proportion of 
deleted clones (25% or less of the total cells, below the MLPA resolution) (n=13, 31%) or 
being masked by gain of der(21)t(12;21) resulting in normalizing the copy number of 
ETV6 exons (1-5) in MLPA in 17 cases (40%). The remaining 3 cases (7%) showed 
artefacts in either MLPA or FISH studies. 
In the overall cohort (n=397), using MLPA and FISH, ETV6 loss represented around 62% 
(n=245) of ETV6-RUNX1 cases.  
G.  BTG1 
The MLPA P335 IKZF1 kit contains four probes for BTG1 gene (consists of two exons); 
two of them cover exons 1 and 2, while the remaining two probes target the 3’ region 
of the gene that has no other genes involved but represents a highly conserved 
promoter region of the BTG1 gene. BTG1 deletions constituted around 15% (n=60) of 
ETV6-RUNX1 cases. The most frequent deletions were restricted to the probes covering 
exon 2 and the adjacent 3’ end region with retention of exon 1 (n=53, 88%) and all of 
them were monoallelic losses except four cases which were biallelic. In addition, there 
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were a further 6 cases (10%) that showed retentions of both exon 1 and 2 with deletions 
restricted to the 3’ end regions, however, the remaining case (2%) exhibited a mixture 
of the above deletion extents resulting in both biallelic deletion of 3’ end region and 
monoallelic deletion of exon 2 with retention of exon 1. The majority of BTG1 losses 
(85%) were in the age group (2-9) years with a median age of 4.5 years and none of the 
infant patients exhibited BTG1 deletions (Table 3-2). There was no significant difference 
in the prevalence of these deletions and other demographic or clinical categories. There 
was no association between the occurrence of these deletions and other gene losses 
(Table 3-4). To note, 2 out of 44 cases (5%), with successful cytogenetic results, showed 
visible cytogenetic abnormalities of the long arm of chromosome 12 including: deleted 
12q [del(12)(q)]. 
3.4.3.4 Rearrangements of Pseudoautosomal region 1 (PAR1) 
Pseudoautosomal region 1 (PAR1) encompassed different genes including CRLF2, 
CSF2RA, IL3RA and P2RY8 genes. These genes were each covered by a single MLPA probe 
which targets CRLF2 exon 4, CSF2RA exon 10, IL3RA exon 1 and P2RY8 exon 2. The PAR1 
rearrangements were identified by deletion of both CSF2RA /IL3RA genes with retention 
of both CRLF2 and P2RY8 genes, thus resulting in the formation of the fusion gene 
P2RY8-CRLF2 (Russell et al., 2009). In total, only 4 ETV6-RUNX1 positive cases showed 
this rearrangement with a median age of 8 years (ages: 17, 8, 7 and 3 years old) (Table 
3-2). These rearrangements were not associated with any gene losses in this ALL subtype 
(Table 3-4). 
3.4.4 Comparison between ETV6-RUNX1 positive and other BCP-ALL subtypes.  
It is essential to understand the unique pathobiology of ETV6-RUNX1, thus the 
identification of potential differences in demographic, clinical and genetic 
characteristics is vital. This can be achieved by comparing the ETV6-RUNX1 dataset with 
other BCP-ALL subtypes (Table 3-5) that utilised the data generated from the 
comprehensive MLPA screening on a representative cohort of BCP-ALL and other 
available cytogenetic and FISH data. There was a three fold increase in the number of 
patients aged 10 years and older in other BCP-ALL patients as compared to ETV6-RUNX1 
(p<0.0001). Otherwise, there were no differences in terms of sex or WCC distribution. 
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Three quarters of the ETV6-RUNX1 cases were classified as a standard risk category 
which might explain why the relapse rate was half that seen in other BCP-ALL subtypes 
in either treatment protocols (p<0.0001) (Table 3-6). It is worth noting that late relapses 
constituted around two third of the relapse cases in ETV6-RUNX1 as compared to 
approximately one third in other BCP-ALL (p<0.0001).   
  
Cytogenetic subgroups   
ETV6-RUNX1 Other BCP-ALL P-value 
No. of cases 397 (100) 1019 (100)   
Age (years)     
Median 4 5  
1 21 (5) 80 (8) 
<0.0001* 2-9 342 (86) 643 (63) 
10+ 34 (9) 296 (29) 
Sex (M:F)  216:181  551:468  
0.9 
Ratio 1.19 1.18 
WCC (X 109/L)     
Median 11.6 12.3  
<10 178 (45) 442 (43) 
0.8 10-49.9 147 (37) 378 (37) 
≥50 72 (18) 199 (20) 
NCI Risk Group     
Standard 296 (75) 577 (57) 
<0.0001* 
High 101 (25) 442 (43) 
Table 3-5 Comparison of the demographics and clinical features between ETV6-RUNX1 
positive and other BCP ALL patients. * statistically significant, WCC: white cell count, NCI: National 
Cancer Institute (standard risk: aged 1-9 years with a WCC < 50 x109/L at initial presentation, high risk 
category: ≥10 years and a WCC ≥ 50 x109/L).
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Cytogenetic subgroups   
ETV6-RUNX1  
(n= 397) 
Other BCP-ALL 
(n= 1019) 
P-value 
ALL97/99‡ (n=498) 126 (100) 372 (100)   
No. of Relapses 17 (13) 97 (26) 0.004* 
Early 6 (35) 62 (64) 
0.003* 
Late 11 (65) 35 (36) 
ALL2003¥ (n=918) 271 (100) 647 (100)   
No. of Relapses 10 (4) 78 (12) <0.0001* 
Early 3 (30) 61 (78) 
<0.0001* 
Late 7 (70) 17 (22) 
Table 3-6 Comparison of the incidences and type of relapses between ETV6-RUNX1 positive 
and other BCP ALL patients in UKALL97/99 and UKALL2003. * statistically significant, ‡ after a 
median follow-up time of 9.2 years, ¥ after 5 years follow-up time (ALL2003 cohort is not a representative 
cohort, had many relapses that were attributed to the availability of material). 
 
Overall, the ETV6-RUNX1 group is highly heterogeneous and when considering the eight 
genes screened for by MLPA had an average of 1.26 CNA per case compared to 0.92 
alterations per case among other BCP-ALL (p<0.0001) (Table 3-7). Around 77% of ETV6-
RUNX1 cases harboured an alteration of at least one of these genes, while approximately 
half of other BCP-ALL cases showed normal MLPA profiles in all genes. Thus, the ETV6-
RUNX1 group was found to have increasing number of gene deletions compared to other 
BCP-ALL subtypes, especially those exhibiting one or two alterations (67% v 41%) (Figure 
3.4). It is worth noting that NCI risk had no effect on the increasing tendency to acquire 
multiple alterations in ETV6-RUNX1 as compared to other BCP-ALL cases (Figure 3.5). 
Thus, only 34% of high risk other BCP-ALL showed any aberrations as compared to ~ 60% 
of standard risk other BCP-ALL (p<0.0001). ETV6 and BTG1 losses are five times more 
common in ETV6-RUNX1 as compared to other BCP-ALL (p<0.0001), while alterations 
affecting the IKZF1 gene were less prevalent (3% v 18%) (p<0.0001). It is worth noting 
that although the cytogenetically visible 9p alterations were slightly more common in 
other BCP-ALL as compared to ETV6-RUNX1 (10% v 5%), both CDKN2A/B and PAX5 
deletions were common alterations in both groups with PAX5 aberrations being slightly 
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 more prevalent (23% v 17%) among ETV6-RUNX1 cases as compared to other BCP-ALL 
subtypes (p=0.02).  
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Total cohort  
Cytogenetic subgroups   
ETV6-RUNX1 
n= 397 (100) 
Other BCP-ALL 
n= 1019 (100) 
P-value 
Deletions       
ETV6 206 (52) 103 (10) <0.0001* 
9p 14 (5)# 138 (10)¥ NA 
CDKN2A/B 91 (23) 300 (29) 0.02 
PAX5 91 (23) 178 (17) 0.02 
BTG1 60 (15) 34 (3) <0.0001* 
6q 33 (11)# 44 (3)¥ NA 
RB1 30 (8) 67 (7) 0.5 
11q 18 (6)# 36 (3)¥ NA 
EBF1 14 (4) 17 (2) 0.03 
IKZF1 12 (3) 187 (18) <0.0001* 
PAR1 4 (1) 78 (8) <0.0001* 
Average CNA  1.26 0.92 <0.0001* 
Table 3-7 Comparison of the incidences of different genetic alterations between ETV6-RUNX1 
positive and other BCP ALL patients. * statistically significant, # percentages were calculated from 
304 cases with successful cytogenetic, ¥: data was extracted from (Moorman et al., 2010b), NA not 
available.   
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Figure 3.4 Bar chart showing the percentage of patients with increasing numbers of CNA within 
ETV6-RUNX1 and other BCP ALL subtypes. 
 
 
Figure 3.5 Bar chart showing the percentage of patients with increasing numbers of CNA within 
ETV6-RUNX1 and other BCP ALL subtypes based on National Cancer Institute categories (High 
and Standard risk).  
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PAX5 losses showed variant breakpoints with around 60% of ETV6-RUNX1 cases 
exhibited deletions retaining exon 1 with variable extents including the losses restricted 
to exons 2-6 that constituted 38% of the deleted cases. However, the majority of the 
deleted cases in other BCP-ALL targeted the whole gene (n=79, 44%) and the remaining 
deleted cases showed various breakpoints at lower frequencies (Figure 3.1). Unlike 
ETV6-RUNX1 cases, other BCP-ALL cases exhibited PAX5 deletions that frequently 
involved exon 1 (p=0.006). In addition, intragenic amplifications of PAX5 affecting exons 
2 and/or 5, with a copy number range of (5-9) were detected in other BCP-ALL subtypes 
(n=11, 1%) but none were found in ETV6-RUNX1 cases. 
The extent of IKZF1 deletions was highly variable with the most frequent ones in ETV6-
RUNX1 restricted to exons (2-3) (n=5, 42%) which were less prevalent in other BCP-ALL 
(5%, respectively) (p<0.0001). However, 33% and 31% of IKZF1 deleted cases in other 
BCP-ALL exhibited losses encompassing the entire gene and exons (4-7), respectively. 
IKZF1 deletions targeting exons (4-7) seemed to occur less frequently in ETV6-RUNX1 
(p=0.02) (Figure 3.2). 
Although the entire loss of ETV6 gene constituted the commonest deletion type in both 
ETV6-RUNX1 and other BCP-ALL cases (72% and 48%, respectively), they were 
associated to ETV6-RUNX1 cases, in particular (p<0.0001). In addition, other BCP-ALL 
cases harboured frequent ETV6 losses restricted to exon 1 or exons (1-2) which 
represented a quarter of the deleted cases, while these types of deletions occurred less 
frequently in ETV6-RUNX1 cases (2%) (p<0.0001) (Figure 3.3).  
BTG1 losses were mainly characterised by the deletions encompassing exon 2 and the 
3’ region with retention of exon 1 in both ETV6-RUNX1 (88%) (See section 3.4.3.3 G. ) 
and BCP-ALL (82%) cases. It is worth noting that exon 1 was retained in ETV6-RUNX1 
group, while around 15% of deleted cases in other BCP-ALL had lost exon 1 as a whole 
gene deletion either restricted to the gene itself (without the involvement of the probes 
covering the 3’ region) (3%) or extended further to the adjacent 3’ region (12%). 
3.5 Discussion 
The present study highlighted the spectrum of genetic abnormalities in a total of 397 
ETV6-RUNX1 cases that have been treated on UK ALL trials. The potential relevance of 
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these alterations to this cytogenetic subgroup was assessed by comparing them with a 
total of 1019 of other BCP-ALL cases (Schwab et al., 2013). An MLPA approach was 
chosen owing to its ability to generate accurate and reliable data with high throughput 
(Schwab et al., 2010) using a single kit (P335 IKZF1) that targets those genes recurrently 
involved in BCP-ALL (Lilljebjorn et al., 2007; Mullighan et al., 2007; Kawamata et al., 2008; 
Mullighan et al., 2008b). These gene aberrations have been shown to be responsible for 
BCP-ALL development due to their significant biological roles in B cell development/ 
differentiation (PAX5, IKZF1, EBF1, ETV6 and BTG1), cell cycle regulation (RB1 and 
CDKN2A/B) and those genes encompassing the PAR1 region (CRLF2, CSF2RA and IL3RA).  
Overall, ETV6-RUNX1 cases showed a tight demographic profile with three quarters of 
patients assigned to the standard risk category. Considering the eight genes tested by 
MLPA, there was a noticeable increase in the number of aberrations irrespective of NCI 
risk with a mean of 1.26 alterations per case compared to 0.92 abnormalities per case 
in other BCP-ALL cases. It is worth noting that this observed increase in the number of 
alterations in ETV6-RUNX1 might be a reflection of the manner in which these genes 
were selected for inclusion in the kit, i.e. based on the prevalence of deletions in 
previous patient cohorts which comprised 25% ETV6-RUNX1 positive cases (Lilljebjorn 
et al., 2007; Mullighan et al., 2007; Kawamata et al., 2008; Mullighan et al., 2008b). 
However, previous genomic studies showed an overall increase of deletions in ETV6-
RUNX1 as compared to other BCP-ALL subgroups (6 v 3.1 losses per case, respectively) 
(Mullighan et al., 2007). The plausible explanation might be that ETV6-RUNX1 fusion 
gene has a positive impact on the persistence and expansion of the pre-leukaemic cells 
through its inhibitory effects on TGF-β (Siegel and Massague, 2003; Bierie and Moses, 
2006), miRNA-494 and miRNA-320a (Diakos et al., 2010), and activating effects on EPOR 
(Inthal et al., 2008; Torrano et al., 2011) and mTOR pathway (Fuka et al., 2011; Fuka et 
al., 2012; Tijchon et al., 2013) (see section  1.5.4). This clonal expansion in turn increases 
their susceptibility to acquire further aberrations/ mutations owing to the 
overwhelming proliferative stress.  
Furthermore, the enrichment of focal deletions rather than amplifications might be 
attributed to the undergoing aberrant RAG recombinase activity which represents a 
driving mechanism in ETV6-RUNX1, in particular (see section  1.4.1.3) (Mullighan and 
Downing, 2009a; Kuiper and Waanders, 2014; Papaemmanuil et al., 2014). 
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ETV6-RUNX1 patients exhibited a wide range of genetic abnormalities facilitating 
leukaemic transformation and progression. The PAX5 transcriptional factor gene 
aberrations seem to represent the main driver in blocking the lymphoid differentiation 
rather than IKZF1 alterations in ETV6-RUNX1, unlike other BCP-ALL group that showed 
enrichment of both these alterations (23%, 3% v 17%, 18%, respectively). It is worth 
noting that IKZF1 losses tended to occur at an older age, thus the rarity of these losses 
in ETV6-RUNX1 might be a reflection of the three fold reduction in the number of 
patients aged 10 years and older as compared to other BCP-ALL patients (9% v 29%, 
respectively) rather than differences in the biology/ evolution. In addition, the lower 
frequency of IKZF1 losses, which are linked to overall poor outcome (Mullighan et al., 
2009b), might explain the favourable outcome among ETV6-RUNX1 compared to other 
BCP-ALL cases.  
Further proliferation and survival of these undifferentiated cells usually require further 
alterations like activating kinase/ cytokine receptor (e.g. CRLF2) genes (e.g. PAR1 
rearrangements). However, ETV6-RUNX1 cases harboured PAR1 alterations less 
frequently than patients with other BCP-ALL (1% v 8%, respectively). The frequency of 
CRLF2 rearrangements is related to older age similar to IKZF1 losses. Hence, alternative 
aberrations including those targeting EPOR, which are enriched in ETV6-RUNX1, may 
play a role in the survival properties of these cells (see section 1.5.4) (Inthal et al., 2008; 
Torrano et al., 2011).  
The alterations implicated in lymphoid differentiation and proliferation are coupled with 
further aberrations necessary for altering different cellular processes including 
transcriptional regulators/ co-regulators (e.g. ETV6 and BTG1) and cell cycle control 
genes (e.g. CDKN2A/B). Both ETV6 and BTG1 losses were associated with ETV6-RUNX1 
and constituted 63% and 15% of cases compared to 10% and 3%, respectively, of other 
BCP-ALL group, however CDKN2A/B were common in both groups (23% and 29%, 
respectively), in agreement with previous studies (Mullighan et al., 2007; Lilljebjorn et 
al., 2010). Although ETV6-RUNX1 had a unique distribution of genetic abnormalities 
compared to those with other BCP-ALL, there were no distinct subgroups separating 
those with or without the deletions in terms of demographic or clinical features which 
may be due to a high level of similarity among ETV6-RUNX1 patients.  
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Recently, survival analysis was carried out on part of the present cohort of ETV6-RUNX1 
patients who were treated on UKALL97/99 and concluded a lack of impact of these 
additional abnormalities targeting the eight genes on outcome (Enshaei et al., 2013). In 
contrast to these findings, high levels of IKZF1 and BTG1 deletions were previously 
reported among relapse cases as compared to the newly diagnosed cases in BCP-ALL 
(39.3% and 14.3%  vs 8.9% and 6.7%), respectively (Hogan et al., 2011).   
The ETV6 gene acts as a transcriptional repressor involved in haematopoiesis and 
angiogenesis (see section 1.5.3). Whole gene deletion was the predominant type of loss 
in either group; however other deletion breakpoints existed at lower incidences. ETV6 
losses had conflicting outcome results among ETV6-RUNX1 cases, some reports showed 
lack of impact on outcome (Barbany et al., 2012; Enshaei et al., 2013), while other study 
groups suggested a good prognostic value (Stams et al., 2006; Peter et al., 2009; Ko et 
al., 2011). On the other hand, only one study indicated an adverse effect on outcome 
(Attarbaschi et al., 2004), which agrees well with other studies which postulated that 
the heterodimerization between the retained ETV6 and ETV6-RUNX1 fusion gene 
hampers the potency of the fusion protein (McLean et al., 1996; Lilljebjorn et al., 2010). 
Thus, ETV6 loss of function co-operated with ETV6-RUNX1 fusion gene resulting in the 
progression of leukaemogenesis (Morrow et al., 2007; Tijchon et al., 2013). The plausible 
explanation in the differences in outcome might be due to different treatment protocols 
used or the presence of other factors which might be able to influence outcome in an 
independent manner.  
The BTG1 gene plays an integral role in differentiation, proliferation, cell survival and 
glucocorticoid responsiveness. It is worth noting that BTG1 alterations are contributing 
factors for leukaemia development through focal deletions and inactivating mutations 
(Papaemmanuil et al., 2014). In the present study, the majority of BTG1 losses (88%) in 
the ETV6-RUNX1 group, similar to other BCP-ALL, retained exon 1 and extended from 
exon 2 (last exon) to involve the adjacent 3’end region of the gene that is a highly 
conserved promoter region, in agreement with previous studies (Waanders et al., 2012). 
This finding concurs accords with the shared mechanism of abberant RAG activity that 
is responsible for the generation of these losses similar to that seen in IKZF1 deletions 
and the enrichment of this mechanism among ETV6-RUNX1 might explain the 
association of these deletions to this cytogenetic subgroup. Deletions targeting exon 2 
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usually result in the generation of truncated BTG1 transcrpits of no functional use (van 
Galen et al., 2010). In the present study, all ETV6-RUNX1 relapse cases with BTG1 loss 
were late in UKALL97/99 (Table 3-3). Furthermore, none of the BTG1 deleted cases was 
relapsed in UKALL2003 which might be because the follow up in UKALL2003 is currently 
quite short resulting in underestimation of the true relapse incidence rate. These 
findings suggest an alternative effect of BTG1 loss other than glucocorticoid resistance 
which one would expect to result in early relapses due to poor therapy response. The 
effect of BTG1 alterations is not well understood and the different glucocorticoid 
responses of different cell line models harbouring BTG1 deletions might depend on the 
cellular and genetic context in which these lesions occur. 
The IKZF1 gene is an important transcriptional factor involved in the regulation of the 
lymphocyte differentiation. In the present study, the extent of IKZF1 deletions was 
variable and interestingly it differed between ETV6-RUNX1 and other BCP-ALL groups in 
which the classic IKZF1 deletions (exons 4-7) are common in other BCP-ALL than in ETV6-
RUNX1 (31% v 0%), respectively (p=0.02). However, ETV6-RUNX1 had losses restricted 
to exons (2-3) (42%) which were less frequent in other BCP-ALL (5%) (p=<0.0001). Thus, 
these differences in the architecture of these deletions might contribute to the 
generation of several alternatively spliced variants. These variants are usually 
transcribed to encode different isoforms that vary in the number of N-terminal zinc 
finger motifs which determine the DNA binding properties. The non DNA binding 
isoforms, that lack sufficient number of N-terminal zinc fingers, function as dominant 
negative factors and their overexpression result in leukaemogenic transformation 
(Iacobucci et al., 2008; Iacobucci et al., 2009). Thus, the extent of deletions will alter the 
expression of different isoforms. Deletions of exons (4-7) resulted in the formation of 
non-DNA binding isoform (Ik6) due to the inability to encode the N-terminal DNA binding 
domain, while losses targeting exon 2 would inhibit the protein translation owing to 
compromising the start translation site (Iacobucci et al., 2008; Iacobucci et al., 2009). 
These deletions are more likely to have similar effects as the whole gene deletion except 
those losses restricted to the non-coding exon 1 which might not have an impact on 
IKZF1 function. It is worth noting that none of the ETV6-RUNX1 IKZF1 deleted cases 
relapsed. 
 109 
 
The most important limitation of this study lies in the fact that this screening focused on 
a selected number of genes, assuming that other recurrent genes, identified by previous 
genomic studies, are infrequent. Chapter 5 looked at a wider range of genes in the 
diagnostic- relapse pairs. Furthermore, the resolution of the MLPA technique used 
would underestimate those microdeletions that were present in <30% of cells. Although 
the FISH studies would identify abnormal clones present at low levels, they are more 
likely to miss genetic rearrangements sized <20kb or <100kb using interphase or 
metaphase FISH, respectively. Although the incidence of ETV6 losses by FISH (53%) was 
similar to that by MLPA (52%), 21% of the cases had discordant results. Accordingly, a 
combination of both techniques is ideal in estimating the true incidence of a specific 
abnormality. 
In conclusion, these studies have confirmed that the ETV6-RUNX1 group is unique with 
tight demographic profile. ETV6 and BTG1 losses were more common compared to other 
ALL cases, while alterations affecting the IKZF1 gene, which is involved in lymphoctye 
development pathway, were much less prevalent and did not appear related to poor 
outcome. However, among the genes investigated, there were neither distinct CNA 
profiles nor were there any obvious subtypes defined by these CNA. These findings 
extend those of smaller previous studies and confirm the findings of studies which have 
been conducted concurrently with this one by other groups. Collectively, these 
observations have broadened our understanding of the key differences discriminating 
ETV6-RUNX1 with other BCP-ALL subtypes. 
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Chapter 4. Secondary abnormalities involving the der(12)t(12;21) in ETV6-
RUNX1 positive BCP-ALL 
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4.1 Introduction 
ETV6-RUNX1 positive pre-leukaemic cells need secondary abnormalities for their 
conversion into leukaemic blasts. ETV6 deletions have been implicated as important 
secondary events which constitute around two thirds of ETV6-RUNX1 cases (Mullighan 
et al., 2007; Lilljebjorn et al., 2010). There are other frequent alterations including +21, 
+der(21)t(12;21), +10, +16 and deleted (6q) which represent 12%, 12%, 9%, 9% and 20%, 
respectively, of ETV6-RUNX1 cases. Considerable research has been devoted to 
characterising the additional abnormalities involving der(21)t(12;21)/ETV6-RUNX1 and 
normal chromosomes 21 or 12 , which are believed to contribute to leukaemogenesis. 
For the purpose of evaluating the prognostic impact of these abnormalities, 
comprehensive FISH screening for ETV6 deletions, +21 and +der(21)t(12;21) was 
performed on 247 ETV6-RUNX1 positive BCP-ALL cases by other LRCG members using 
novel dual colour (DC) break-apart (BA) probes targeting either the ETV6 or the RUNX1 
loci (Enshaei et al., 2013). Interestingly, the study revealed additional unexpected 
abnormalities suggesting der(12)t(12;21) involvements in a total of 30 out of 247 cases. 
The observed signal patterns were suggestive of either an interstitial deletion (n=20) or 
a duplication of the der(12)t(12;21) (n=10) (Figure 4.1).  
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Figure 4.1 Ideograms show the different signal patterns given by ETV6 (left) and RUNX1 (right) 
dual color (DC) breakapart (BA) probes: in a normal [0R 0G 2F] (A), [0R 0G 2F] (B), a standard 
t(12;21) [1R 1G 1F] (C), [1R 1G 1F] (D), unexpected observed signal patterns of: [1R 0G 1F] 
suggesting a deleted 12p sequences (3’ETV6 sequences) of der(12)t(12;21) (E), [0R 1G 1F] 
suggesting a deleted 21q sequences (5’RUNX1 sequences) of der(12)t(12;21) (F), collective signal 
patterns of [1R 2G 0F] (G) and [1G 2R 1F] (H) suggesting duplicated der(12)t(12;21). 
 
4.2 Aims and Objectives 
The aim of this Chapter is to investigate incidental findings of earlier FISH screening by the 
LRCG group. Subsequent identification of the genes responsible in driving the 
development of the leukaemia would underscore our understanding of the evolution of 
this cytogenetic subtype.   
The main objectives in this Chapter are: 
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1. Characterisation of the deleted der(12)t(12;21) and determination of the size of 
the deletions and  the important genes affected. 
2. Confirmation of the duplicated RUNX1-ETV6 chimeric gene and identification of 
the responsible mechanism behind its formation and its effect on 
leukaemogenesis. 
3. Investigate whether these two abnormalities which lead to copy number 
alterations affecting ETV6 can be detected using the MLPA P335 kit which has 
seven probes spanning ETV6 exons (1-8). 
4.3 Patients and Methods 
4.3.1 Patient cohort 
The cohort included in the first part of the study were those treated using ALL97/99 
protocol, while the second part, which investigated the third aim, involved patients who 
were registered in both trials ALL97/99 and UKALL2003 (see section 2.2). A total of 49 
patients with suitable material were included in this Chapter. Most of the data included 
in this Chapter was recently published (Al-Shehhi et al., 2013).  
4.3.2 Methods 
4.3.2.1 FISH  
All FISH studies were performed as described in section 2.8. Different probe sets were 
applied to accomplish the following objectives: 
A.  Mapping der(12)t(12;21) deletion  
Deletion mapping of der(12)t(12;21) was performed using two different probe sets, 
depending on the region of the deletion and comprised differentially labelled target and 
control probes (Appendix C).  
Using the ETV6 BA probe, a signal pattern of 1R 0G 1F was suggestive of a deletion of 
3’ETV6 sequences on der(12)t(12;21) (Figure 4.1 E.). Therefore, these cases were 
screened using a series of target probes mapping along 12p (12p11.21- 12p13.2). For 
each FISH test, the 5’RUNX1 probe (21q22.12) was used as the control probe (labelled 
 114 
 
red) combined with a target probe (labelled green). In a cell with a standard t(12;21) 
translocation, one would observe a signal pattern of 1R 1G 1F indicating a normal 
chromosome 21, normal chromosome 12 and intact der(12)t(12;21), respectively 
(Figure 4.2 B). Thus in each test, a signal patterns of 2R 1G 0F or 2R 0G 0F would suggest 
the 3’ETV6 sequence deletions at der(12)t(12;21) with or without intact non- rearranged 
ETV6, respectively (Figure 4.2 C). 
On the other hand, those with suggestive deleted 5’RUNX1 sequences (21q sequences) 
of der(12)t(12;21) indicated by the unexpected signal pattern of 0R 1G 1F using RUNX1 
BA probe (Figure 4.1 F.), target probes mapping along 21q from 21q22.12-21q22.3 were 
serially applied. For each FISH test, 3’ETV6 probe (12p13.2) was used as the control 
probe (labelled green) combined with a target probe (labelled red). In a cell with a 
standard t(12;21) translocation, a signal pattern of 1R 1G 1F is expected indicating a 
normal chromosome 21, normal chromosome 12 and intact der(12)t(12;21), 
respectively (Figure 4.2 B). Thus in case of cells with deleted 5’RUNX1 sequences at 
der(12)t(12;21) with associated intact or deleted non-rearranged ETV6, one would 
observe a signal pattern of 1R 2G 0F or 1R 1G 0F, respectively (Figure 4.2 D). 
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Figure 4.2 Ideograms show the signal patterns generated from the mapping deletion probes 
targeting either 3’ETV6 or 5’RUNX1 sequences of der(12)t(12;21): in a normal [2R 2G 0F] (A), a 
standard t(12;21) [1R 1G 1F] (B), a deleted 3’ETV6 region [2R 1G 0F] (C) and a deleted 5’RUNX1 
region of der(12)t(12;21) cells [1R 2G 0F] (D). 
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B.  Confirmation of the origin of deleted 12p sequences 
In order to confirm the origin of deleted 12p sequences, three colour FISH was carried 
out using home-grown probes which comprised of the control probe (5’RUNX1 probe) 
(labelled red), a known intact 3’ETV6 probe (labelled green) and a known deleted 3’ETV6 
target probe (labelled gold). In a standard translocation, a signal pattern of 1R 1F (green-
gold) 1F (green-red-gold) would be observed representing the normal chromosome 21, 
normal chromosome 12 and intact der(12)t(12;21), respectively (Figure 4.3 B). Thus, a 
signal pattern of 1R 1F (green-gold) 1F (red-green) would indicate the presence of a 
normal chromosome 21, normal chromosome 12 and deletion of the gold probe from 
the der(12)t(12;21), respectively (Figure 4.3 C). 
 
Figure 4.3 Ideograms of the home grown probes used in the three colour FISH: A. a normal 
signal pattern [2R 0G 2F (green-gold)], B. a standard t(12;21) with signal pattern of [1R 1F (green-
gold) 1F (green-gold-red)] and C. deleted 3’ETV6 sequences (gold probe) from der(12)t(12;21) 
indicated by the signal pattern of [1R 1F (green-gold) 1F (green-red)]. 
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C.  Investigations of a possible duplicated der(12)t(12;21) 
In order to investigate those patients with the unexpected signal patterns of 1R 2G 0F 
and 1G 2R 1F, using ETV6 and RUNX1 BA probes, respectively, (Figure 4.1 G-H), 
suggestive of duplicated RUNX1-ETV6 fusion gene on der(12)t(12;21), a home grown 
dual colour single fusion (DC SF) probe was applied. The DC SF probe was comprised of 
the 5’RUNX1 probe (labelled red) and 3’ETV6 probe (labelled green). In a cell with a 
standard t(12;21) translocation, a signal pattern of 1R 1G 1F would be observed 
indicating a normal chromosome 21, a normal chromosome 12 and an intact 
der(12)t(12;21), respectively (Figure 4.2 B). Thus, in each FISH test, a signal pattern of 
1R 0G 2F, showing an extra fusion signal with associated loss of the green signal was 
sought (Figure 4.4). 
 
 
Figure 4.4 The expected signal pattern of the suggested duplicated RUNX1-ETV6 fusion gene 
using 5’RUNX1 (labelled red)/3’ETV6 (labelled green) DS SF probe set. A signal pattern of 1R 
0G 2F is shown. 
To confirm the number of chromosomes 12 and to assess the genetic stability by 
obtaining the relative number of chromosome 12 centromeres and 12p subtelomeres in 
those cases with duplicated RUNX1-ETV6 fusion gene, FISH using a commercial probe 
set was carried out. The probe set consisted of centromeric 12 (CEP 12) probe (labelled 
red, Cytocell) and subtelomeric 12p (subtel 12p) probe (labelled green, Vysis). This probe 
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set would give a signal pattern of 2R 2G 0F in either normal or a standard t(12;21) cells. 
Thus, the number of the centromeres and the subtelomeres was investigated.  
D.  Investigation of cases with isolated ETV6 exon 8 deletions 
In order to identify further cases with deleted 3’ETV6 sequences of der(12)t(12;21), 
cases with isolated deletions of ETV6 exon 8 (3’ETV6 region) by MLPA  (see section 
4.3.2.2), whether mono or biallelic losses, were further investigated by FISH studies. 
Firstly, application of ETV6 and RUNX1 DC BA probes was carried out to uncover the 
possible abnormalities responsible for the isolated  ETV6 exon 8 losses (e.g. deletions of 
either the non-rearranged ETV6 or 3’ETV6 sequences of der(12)t(2;21) (Figure 4.1). If 
the observed signal patterns suggested that both ETV6 alleles were intact using ETV6 DC 
BA probe, a home grown fosmid probe targeting ETV6 exon 8 (labelled green) was used 
as a target probe to identify smaller deletions. This fosmid probe was combined with the 
5’ETV6 probe (labelled red) (Figure 4.5), thus, this probe set was considered similar to 
ETV6 DC BA, but it was able to identify smaller deletions undetectable by the ordinary 
ETV6 DC BA probe. 
In order to define the deletion sizes in those new cases with 3’ETV6 sequences of 
der(12)t(12;21),  FISH mapping was done (see section 4.3.2.1 A. ). 
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Figure 4.5 The locations of ETV6 exon 8 [3’ ETV6] probes with either 5’ETV6 or 5’RUNX1 probes. 
A. ETV6 gene at 12p13.2, composed of 8 exons in which the t(12;21) breakpoint occurred within 
intron 5; Locations of the green and red probes used in the ETV6 DC BA probe (RP11-525I3 or 
ETV6 exon 8 - RP11-434C1), B. The breakpoint at der(12)t(12;21); locations of the green and red 
probes used in the 3’ETV6-5’RUNX1 SF DC probe (RP11-525I3 or ETV6 exon 8 - RP11-396G11). 
E.  Investigations of cases with isolated ETV6 exons 1-5 deletions  
 To identify further cases with duplicated RUNX1-ETV6 fusion gene, cases with MLPA 
ETV6 profile of isolated exons 1-5 losses were further investigated by FISH using both 
BA probes targeting ETV6 and RUNX1 loci (Figure 4.1). In case of suspected duplication, 
further application of 5’RUNX1/3’ETV6 DC SF probe was carried out (see section 4.3.2.1. 
C. ). 
4.3.2.2 MLPA 
Genomic DNA from nine diagnostic bone marrow samples was extracted using standard 
procedures. In one case, the DNA was extracted from the same fixed cell pellet as used 
for FISH (see section 2.6). DNA was analysed using the SALSA MLPA kit P335 (MRC 
Holland, Amsterdam, The Netherlands). Data was analysed using GeneMarker V1.85 
analysis software (SoftGenetics) (see section 2.9).  
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4.3.2.3 SNP6 
Five DNA samples were hybridized to Affymetrix Genome-Wide Human SNP Array 6.0 at 
AROS Applied Biotechnology (Aarhus, Denmark) according to the manufacturer’s 
instructions (Affymetrix) (see section 2.10). 
4.4 Results 
4.4.1 Characterisation of the deletion of der(12)t(12;21) 
A total of 18 patient samples with indirect evidence for a deletion of der(12)t(12;21) 
were mapped using FISH. Firstly, they were divided into three groups and investigated 
separately because they differed in terms of the status of non-rearranged ETV6 and 
whether the deleted sequences affected the 3’ETV6 or 5’RUNX1 part of the fusion gene. 
Groups A and B were both characterised by loss of 3’ETV6 and its adjacent chromosome 
12 sequences centromeric of the breakpoint but had either an intact (n=10) or deleted 
(n=5) non-rearranged ETV6, respectively. However, the third group (C) (n=3) consisted 
of patients with deletion of 5’RUNX1 and contiguous chromosome 21 sequences 
telomeric of the breakpoint. 
4.4.1.1 Deleted 3’ETV6 sequences from der(12)t(12;21) 
In order to determine the proximal breakpoint and hence the size of the deletion of the 
3’ETV6 region deletions, probes mapping along 12p from 12p11.21-12p13.2 were 
serially applied to all 15 samples. The deletion was fully mapped in these cases except 
for patients 3052 (Group A) and 4358 (Group B) where a lack of material prevented 
completion of all required tests (Figure 4.6). Among 13 deletions fully mapped, the 
median size of the deletion was 3.24 Mb with a range of 0.35-13.37Mb. A minimum 
region of deletion, defined by patient 3990 (Group B), was observed spanning 0.35Mb 
and comprising two genes: LRP6 and BCL2L14. Although patients 3052 (group A) and 
4112 (group B) showed evidence of variant t(12;21) translocations involving an 
additional chromosome, the FISH patterns were consistent with a deletion of 3’ETV6 
from the der(12)t(12;21) (Appendix E). 
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Figure 4.6 Deletion mapping of der(12)t(12;21) cases within ETV6-RUNX1 positive BCP-ALL. 
Left: Group A: deletion of  3’ETV6 sequences from der(12)t(12;21) plus intact non-rearranged 
ETV6, Group B: deletion of 3’ETV6 sequences from der(12)t(12;21) plus deletion of non-
rearranged ETV6, Group C: deletion of 5’RUNX1 sequences from der(12)t(12;21). Right: 
Additional cases of deleted der(12)t(12;21) which were uncovered by their ETV6 MLPA profile 
with further FISH tests. Note: Groups A & B: Deletion starts at 12.02 Mb (within ETV6 intron 5), 
Group C: Deletion starts at 36.26 Mb (within RUNX1 intron 1), the size determined using data 
from ENSEMBL version no.60, ¶ owing to insufficient material, Other complementary tests were 
done ‡MLPA, SNP6 and three colour FISH, ¥ MLPA and SNP6, * Three colour FISH. 
Three colour FISH was attempted in four cases (3135, 4287, 4854 and 4947) to confirm 
that the deletion was from the der(12)t(12;21) rather than the normal chromosome 12. 
It was successful in patients 3135 and 4287 (group A), where it showed a signal pattern 
of 1R 1F (green-gold) 1F(green-red) confirming that the target probe was deleted from 
the der(12)t(12;21) rather than from the non-rearranged chromosome 12 (Figure 4.7) 
(Appendix E). 
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Figure 4.7 Confirmation of the origin of the der(12)t(12;21) deletion using three colour FISH. 
A-D: shows serial application of the green (A), gold (B) and red(C) probes in a single metaphase 
in patient no. 3135 showing a signal pattern of 1R 1F(green-gold) 1F(green-red) confirming that 
the gold (target) probe was deleted from the der(12)t(12;21) (D) [der(12)t(12;21), normal 
chromosome 12 and  normal chromosome 21 indicated by (red-blue), green and yellow circles, 
respectively. 
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MLPA was performed on four patients (3135, 3189, 4969 and 3066). The MLPA ETV6 
profiles of patients 3135, 3189 and 4969 (Group A) revealed monoallelic deletion of 
ETV6 exon 8 but retention of the remaining exons. However, patient no. 3066 (Group B) 
showed biallelic deletion of exon 8 with associated monoallelic deletion of exons 1-5 
(Appendix A); consistent with loss of the non-rearranged ETV6.  
The size of the deleted regions in all three patients 3135, 3189 and 4969 was identified 
by SNP6 (Figure 4.8), which was concordant with FISH, ranging from 1.16 Mb- 3.07 Mb. 
In addition, the genomic profiles varied between these patients and no distinct pattern 
of abnormalities was identified due to the small number of cases (Appendix F). 
To conclude, FISH, MLPA and SNP array data were concordant for the presence of 
deletions on der(12)t(12;21), which resulted in loss of 3’ETV6 sequences and contiguous 
centromeric sequences. 
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Figure 4.8 SNP6 based genomic profile of chromosome 12 in patient 3189. SNP array showed loss (12)(12.04[p13.2]-15.11[p12.3]), delineated by two red lines, the 
deletion starts within ETV6 (enclosed in red square) intron 5 (t(12;21) breakpoint) with centromeric extension encompassing different important genes. 
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4.4.1.2 Deleted 5’RUNX1 sequences of der(12)t(12;21)  
In order to determine the distal breakpoint and hence the size of the deletion of 
5’RUNX1 sequences, FISH was performed on three patients using different deletion 
probe sets. FISH studies revealed deletions with a median size of 1.00Mb (range 0.78-
2.46 Mb) (Figure 4.6). The Common region of deletion (CRD) did not encompass any 
known genes and was defined by patient 4917. Although patient 3319 showed evidence 
of variant t(12;21) translocations involving an additional chromosome, the FISH patterns 
were consistent with a deletion of 5’RUNX1 from the der(12)t(12;21) (Appendix E). No 
further material was available in order to investigate these cases using MLPA and SNP6. 
Interestingly, all patients with either types of deleted der(12)t(12;21), exhibited the 
deleted clone in all ETV6-RUNX1 positive cells indicating that the deletions occurred at 
the same time as the translocation (Appendix E). 
4.4.2 Gain of RUNX1-ETV6 fusion gene on a der(12)(21qter→21q22.12::12p13.2-
12p12.3::12p12.3→12qter) 
FISH experiments were performed on seven cases, using the DC SF probe to investigate 
the origin of the extra der(12)t(12;21) signals. They confirmed two copies of the RUNX1-
ETV6 fusion in all cases suggested by the signal pattern of 1R 0G 2F in an average of 55% 
of ETV6-RUNX1 positive cells. Thus, these signal patterns were often seen in conjunction 
with the standard abnormal signal patterns (1R 1G 1F) indicating that this abnormality 
represented a secondary event. In addition, metaphases from patient 3726 showed that 
the two fusion signals were on separate chromosomes (Figure 4.9, Table 4-1 and 
Appendix E).  
Further FISH, using commercial probe set consisting of CEP 12 and subtel 12p probes, 
revealed the presence of only two chromosome 12 centromeres and the loss of one 12p 
subtelomeric region in all cases in comparable proportions as the duplicated clone 
detected earlier using the DC SF probe. This FISH test was applied in order to prove the 
assumption of the associated loss of normal chromosome 12 and to assess the genetic 
stability of each patient by comparing the number of chromosome 12 centromeres and 
telomeres (Table 4-1, Appendix E).  
 126 
 
 
Figure 4.9 The observed signal pattern of 1R 0G 2F in patient no. 3726 with suggested 
duplicated RUNX1-ETV6 fusion gene using the DC SF probe seen in: an interphase (A) and a 
metaphase cells (B). 
 
I.D. 
ETV6 DC BA 
 1R 2G 0F %*  
RUNX1 DC BA  
2R 1G 1F %* 
5'RUNX1/3'ETV6 DC SF 
1R 0G 2F %*  
2X CEP12/ 1X Subtel 12p 
3726¥ 30% 33% 38% 21% 
4281¥ 100% 100% 61% 100% 
3472‡ 17% 12% NA NA 
4040‡ 31% 18% NA NA 
4637‡ 100% 100% 92% 100% 
3130 62% 61% 74% 77% 
4136 92% 96% 94% 87% 
4560 76% 62% 69% 60% 
4678 100% 100% 92% 100% 
4934 81% 94% NA NA 
Table 4-1 Detailed FISH studies of ETV6-RUNX1- Positive BCP- ALL Patients with duplicated 
RUNX1-ETV6 fusion gene. DC: dual colour, BA: break-apart, DC SF: dual colour single fusion, CEP: 
centromeric probe, Subtel: subtelomeric probe, * percentages calculated relative to the ETV6-RUNX1 
positive cells, ¥ MLPA, SNP6 done, ‡ MLPA done, NA: not performed owing to lack of material. 
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MLPA on five patients (4281, 4637, 4040, 3726 and 3472) showed monoallelic deletions 
of ETV6 exons 1-5 but retention of exon 8. However, the latter two patients showed 
lower borderline ratios of exons 1-5 owing to low proportion of the abnormal clone 
constituting 30% and 17% of the ETV6-RUNX1 positive cells, respectively (Table 4-1). In 
addition, MLPA revealed a normal copy number of BTG1 gene, located at the long arm 
of chromosome 12 (12q), in three cases but the remaining two cases had monoallelic 
loss that encompassed exon 2 and the nearby 3’region with retention of exon 1 
(Appendix A).  
SNP array analysis of the two analysed cases (4281 and 3726) revealed the presence of 
two chromosomes 12 with copy number neutral loss of heterozygosity (CNN-LOH) 
spanning a variable region of the short arm of chromosome 12 in both patients 
including: 12(12.02[p13.2]-19.87[p12.3]) and 12(12.02[p13.2]-22.91[p12.1]), 
respectively. The latter abnormality was clearly shown in patient 4281 as it constituted 
the major clone, unlike in patient 3726. In addition, three copies of a part of the long 
arm of chromosome 21 21(36.39[q22.12] → 48.10[qter]) and one copy of the 
subtelomeric region of 12p del(12)(0.19[pter]→19.87[p12.3]) were detected (Figure 
4.10, Appendix F). 
 128 
 
 
Figure 4.10 SNP6 based genomic profile of chromosome 12 in two patients with duplicated 
RUNX1-ETV6 fusion gene. a. patient 4281 showed del(12)(0.19[pter]→19.70[p12.3]) (Area A) 
with adjacent three different patterns of heterozygosity defined by areas B, C and D respectively; 
starting from the copy number neutral loss of heterozygosity (CNN-LOH) (12)(12.02[p13.2]-
19.87[p12.3]), complex heterozygosity with neutral copy number (12)(19.87[p12.3]-
28.06[p11.22) followed by normal heterozygous chromosome 12(28.06[p11.22]-133.85[qter]), 
respectively, b. patient number 3726 exhibited similar pattern like in patient 4281 but less clear 
owing to low proportion of the clone harbouring the duplicated RUNX1-ETV6 fusion gene. The 
centromeric breakpoints of area B and C differ between both patients. The complex 
heterozygosity in area C might be suggestive of multiple independent mitotic recombination 
events in the same patient. 
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To summarise, FISH, MLPA and SNP array findings confirmed initial observations of the 
presence of an extra RUNX1-ETV6 fusion gene which could not be due to a simple gain 
of the der(12)t(12;21) and loss of the normal chromosome 12. Instead these data 
pointed to a secondary event which involves mitotic recombination between the normal 
chromosome 12 and the der(12)t(12;21), resulting in the formation of a 
der(12)(21qter→21q22.12::12p13.2-12p12.3::12p12.3→12qter) (Figure 4.11). This 
derived  chromosome consists of a copy of the der(12)t(12;21) from the 21q telomere, 
including the RUNX1-ETV6 fusion site, to 12p13.2 and thereafter material from the other 
chromosome 12 that was not involved in the original t(12;21) translocation. The mitotic 
recombination point not only differed between the two patients but the area of complex 
CNN LOH (Area C) observed in both patients suggests the presence of multiple 
independent mitotic recombination events in the same patient. Collectively, these 
rearrangements result in the loss of the non-rearranged ETV6 allele with the contiguous 
telomeric sequences, duplication of the reciprocal RUNX1-ETV6 fusion gene, as well as 
the CNN-LOH of a region on the short arm of chromosome 12.  
 
Figure 4.11 Identification and proposed mechanism of the duplicated RUNX1-ETV6 reciprocal 
fusion gene formation. This mechanism corresponded to the observed signal pattern obtained 
by RUNX1-ETV6 DC SF probe. ‡: der(12)(21qter → 21q22.12::12p13.2-12p12.3::12p12.3→
12qter.  
4.4.3 Detection of additional cases with either deletion or gain of the 
der(12)t(12;21) based on their MLPA ETV6 profile 
A total of 397 ETV6-RUNX1 cases with available MLPA data, including 74 patients who 
have been included in the comprehensive FISH screening, were reviewed for the 
presence of suggestive MLPA ETV6 profiles of the 3’ ETV6 sequence deletions or 
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duplications of RUNX1-ETV6 fusion gene. Cases with the MLPA profile of isolated 
monoallelic or biallelic deletion of ETV6 exon 8 were investigated for deleted 3’ETV6 
sequences of der(12)t(12;21). However, the MLPA ETV6 profile of normal copy number 
of exon 8 with monoallelic deletion of exons 1-5 were studied for the possible presence 
of the duplicated RUNX1-ETV6 fusion gene. 
4.4.3.1 MLPA ETV6 profile of 3’ETV6 sequences deletions of der(12)t(12;21) 
A total of 36 (9%) cases with isolated exon 8 deletions, excluding the 4 cases who had 
FISH suggesting deleted der(12)t(12;21) (section 4.4.1), were observed within the ETV6-
RUNX1 cohort (Appendix A). 20 out of 36 cases were investigated by FISH using ETV6 
and RUNX1  DC BA probes. The FISH studies revealed different scenarios of FISH signal 
patterns that indicated the presence of different abnormalities (Figure 4.12).  
Among these 20 cases, there were 6 cases (30%) with 3’ETV6 deletion of der(12)t(12;21) 
(Figure 4.12 A-C), two of them had non-rearranged ETV6 loss. A further 6 cases (30%) 
exhibited gain der(21)t(12;21) and loss of the non-rearranged ETV6 gene (Figure 4.12 
D). However, the isolated ETV6 exon 8 deletions in the remaining 8 cases could not be 
explained despite the application of both BA probes. Among these 8 cases, there were 
two patients with biallelic deletion of ETV6 exon 8 who harboured gain der(21)t(12;21) 
with associated loss of the non-rearranged ETV6 (Figure 4.12 E).These two cases are 
more likely to harbour a microdeletion targeting ETV6 exon 8 at der(12)t(12;21), 
undetectable by the ETV6 BA probe, rather than independent deletion of the non-
rearranged ETV6 owing to the 100% involvement of ETV6-RUNX1 positive cells with this 
abnormal clone. Two additional cases with monoallelic deletion of exons 1-5 and biallelic 
loss of exon 8 did not show a deletion at der(12)t(12;21) using the ETV6 BA probe but 
loss of the non-rearranged ETV6 in all ETV6-RUNX1 positive cells suggesting that the loss 
of the other allele of exon 8 originated from der(12)t(12;21) (Figure 4.12 G). On the other 
hand, the remaining four cases exhibited monoallelic deletion of ETV6 exon 8, however, 
the ETV6 BA probe did not show any evidence of deletion at either non-rearranged ETV6 
or der(12)t(12;21) (Figure 4.12 F). Further FISH studies using a probe targeting 
specifically ETV6 exon 8 were successful in one of the four cases (see section 4.3.2.1 D. 
). The FISH study revealed that the deletion originated from the non-rearranged 
chromosome 12 rather than der(12)t(12;21). 
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 FISH mapping was performed on the six cases with evidence of 3’ETV6 deletion of 
der(12)t(12;21) by BA probes. However, the determination of the deletion sizes was not 
completed in all cases owing to insufficient material (Figure 4.6, Appendix G).  
To sum up, among 20 cases with isolated MLPA ETV6 exon 8 losses, there was a total of 
10 cases (50%) with deletion of 3’ETV6 sequences of der(12)t(12;21) by MLPA and FISH 
results. The remaining cases (n=10) of the isolated ETV6 exon 8 losses represented other 
abnormalities in seven cases including: gain der(21)t(12;21) with associated loss of the 
non-rearranged ETV6 (n=6, 30%) and deleted 3’ETV6 sequences (including exon 8) of the 
non-rearranged ETV6 (n=1, 5%). However, the remaining three cases were failed to 
identify the origin of the deletion due to insufficient material.     
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Figure 4.12 Different resultant signal patterns obtained from the application of ETV6 DC BA probe in 20 ETV6-RUNX1 patients with isolated ETV6 exon 8 deletions. 
The FISH results were correlated individually with other FISH data generated by RUNX1 DC BA and TEL/AML1 ES, where available, as well as with the MLPA ETV6 
profile. 
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4.4.3.2 MLPA ETV6 profile of Gain of RUNX1-ETV6 fusion gene 
Overall, 5 out of 397 cases (1%), excluding the two cases who had FISH suggesting 
duplicated RUNX1-ETV6 fusion gene (section 4.4.2), were identified to have retention of 
normal copy number of exon 8 with monoallelic deletion of exons 1-5 by MLPA. 
Unfortunately, no further material was available to investigate these cases, thus no 
confirmed cases were obtained (Appendix G). 
4.5 Discussion 
The ETV6-RUNX1 fusion gene alone is insufficient to initiate clinical leukaemia. 
Accordingly, further investigations are required in order to identify and characterise 
additional abnormalities that might contribute to leukaemogenesis. Previous screening, 
using BA probes targeting the ETV6 and RUNX1 loci, observed abnormal signal patterns 
suggestive of deletions or duplications targeting the RUNX1-ETV6 fusion gene located 
on der(12)t(12;21). The present study has confirmed these novel alterations using 
several complementary methods including FISH, MLPA and SNP6 arrays. FISH was used 
for the confirmation of the deletions, followed by mapping the deletions and 
ascertaining the origin of deletion. Further FISH tests were performed on cases with 
duplicated der(12) to confirm and understand the responsible mechanism. MLPA and 
SNP arrays further validated these findings and identified the likely mechanism of the 
duplication. There were no differences in terms of demographic and clinical features 
between groups with these abnormalities and all patients showed good outcome.  
Deleted der(12)t(12;21) was detected in 8% (n=20) ETV6-RUNX1 cases, targeting either 
side of the breakpoint but no reported cases with deletion spanning the breakpoint 
itself. No previous reports have identified either of these abnormalities The deletion of 
3’ETV6 sequences at der(12)t(12;21) was more frequent and larger as compared to the 
5’RUNX1 deletions. Deleted 5’RUNX1 sequences have been inferred previously, 
suggested by loss of the small extra signal using the commercial TEL-AML ES probe 
(Jabber Al-Obaidi et al., 2002; Martineau et al., 2005; Rothman et al., 2005; Konn et al., 
2010). However, these were subclonal. The deleted der(12)t(12;21) in this present study 
most likely occurred at the same time as the translocation, as evidenced by both the 
100% involvement of ETV6-RUNX1 positive cells and the consistent deletion boundaries 
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with the translocation breakpoint. In contrast, loss of the extra signal was shown to be 
present in subclones suggesting that the two abnormalities do not overlap completely. 
The plausible explanation for the failure in identifying these deletions was the lack of 
the routine use of probes directly localised to der(12)t(12;21). In addition, genomic copy 
number studies may mistakenly identify deletions of 3’ETV6 sequences at 
der(12)t(12;21) as intragenic deletions of the non-rearranged ETV6 allele.  
These deletions join a list of submicroscopic deletions that accompany primary 
chromosomal rearrangements in leukaemia including t(9;22), inv(16), t(8;21) and MLL 
gene rearrangements (Rothman et al., 2005). For instance, der(9)t(9;22) deletions, 
involving either 5’ABL1, 3’BCR or both, are detected in 9-33% of CML patients who 
showed unfavourable outcome especially those with 5’ABL losses treated on different 
treatment protocols (Vaz de Campos et al., 2007). However, the prognostic value of 
der(9)t(9;22) deletions lacked significance in patients treated uniformly on imatinib 
(Castagnetti et al., 2010; Huh et al., 2011). Like der(12)t(12;21), the 3’BCR deleted region 
is smaller than 5’ABL deletions in der(9)t(9;22) (Vaz de Campos et al., 2007). 
Furthermore, there are often deletions of 5’MYH11 (16p13) or 3’CBFB which are 
detected in ~20% (Tirado et al., 2010) and 8% (Kelly et al., 2005) of AML with inv(16), 
respectively. There are also reported deletions restricted to 5’RUNX1T1 sequences that 
constitute 9% of t(8;21) cases (Godon et al., 2002). Similarly, MLL rearrangements are 
associated with 3’ MLL deletions representing 20–25% of MLL rearranged cases (Konig 
et al., 2002). It has been suggested that the loss of one or more tumour suppressor genes 
may promote leukaemogenic progression through a secondary event or directly. 
Furthermore, it was hypothesized that patients with these deletions may be more prone 
to genetic instability favoring subsequent additional genetic alterations. In contrast to 
these suggested mechanisms, there was no observed increase in the frequency of 
additional abnormalities during disease progression (Vaz de Campos et al., 2007). 
It has been hypothesized that the nature of sequences flanking translocation breakpoint 
regions might play a role. High density flanking Alu repeats, known to facilitate 
illegitimate recombination, are distributed in non-random patterns within the vicinity of 
deletion breakpoints giving rise to a possible deletion mechanism (Kolomietz et al., 
2001; Kolomietz et al., 2002). The findings of this present study suggested concomitant 
occurrence of der(12) deletions and the translocation as seen in der(9) deletions in 
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t(9;22) patients, hence, the deletions must have occurred after the breakage of the 
chromosomes and prior to the illegitimate fusion of the chromosomes. Consequently, 
the deletions will not be under selective pressure, and hence not likely to be drivers. 
However, we cannot rule out a bystander effect. 
The shared characteristic among all der(12) deletions was the loss of the reciprocal 
RUNX1-ETV6 fusion gene that consists of the last three exons of ETV6, which contains 
the ETS domain, and the non-functional exon 1 or exons 1-2 of RUNX1. This is in 
agreement with a previous study in which the expression of RUNX1-ETV6 was found 
concomitantly with the ETV6-RUNX1 fusion products in only 76% of t(12;21) positive ALL 
cases (Stams et al., 2005). It was hypothesized that the RUNX1-ETV6 fusion gene would 
act through the function of this isolated ETS domain and may behave in a similar manner 
to the non-rearranged ETV6 when this gene is deleted.  
Duplicated RUNX1-ETV6 fusion gene was identified in 4% (n=10) ETV6-RUNX1 cases and 
occurred subclonally in ETV6-RUNX1 positive cells. Hence, it may be considered as a 
secondary abnormality, however, its role in leukaemogenesis needs to be determined. 
Initially it was thought to be a simple gain of the der(12)t(12;21) or the result of an 
independent translocation, as suggested in previous studies based upon observations of 
extra ES signals (Ma et al., 2001; Jalali et al., 2003; Martineau et al., 2005; Rothman et 
al., 2005). However, SNP arrays revealed a layer of complexity in the formation of this 
aberration, which may have arisen through mitotic recombination between the normal 
chromosome 12 and the der(12)t(12;21) yielding der(12)(21qter →21q22.12::12p13.2-
12p12.3::12p12.3→12qter). This is an entirely novel chromosome abnormality not 
reported previously, to the best of my knowledge. This abnormal chromosome resulted 
in duplicated regions of chromosome 21q and chromosome 12p as well as CNN LOH of 
regions of 12p but not CNN LOH of 12q as would be assumed by simple gain of 
der(12)t(12;21) and loss of the normal chromosome 12. 
In one previous study, it was postulated that RUNX1-ETV6 high expression was an 
independent prognostic factor in ETV6-RUNX1 which confers worse outcome, but no 
available patient details were provided to assess the possible mechanisms behind this 
high expression (Stams et al., 2005). In addition, the latter study has described the lack 
of relationship between this expression and drug resistance which indicates that the 
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effect of RUNX1-ETV6 might result in cell regrowth rather than drug toxicity related 
pathways (Stams et al., 2005). It is worth noting that the discrepant clinical outcome 
between patients in the present study, who had an excellent outcome, and those in the 
Stams paper is likely to be due to advances in treatment rather than evidence that the 
two groups are necessarily distinct. Clearly the der(12)(21qter →21q22.12::12p13.2-
12p12.3::12p12.3→12qter) results in other events which could also be contributing to 
leukaemogenesis via the unmasking of cancer driver mutations either by the inactivation 
of tumour-suppressor genes or the activation of oncogenes.  
There are several candidate genes on chromosome 12p within the CRD which could be 
acting as tumour suppressor genes, such as LRP6, BCL2L14, DUSP16, CREBL2 and 
CDKN1B (Kiyokawa et al., 1996; Guo et al., 2001; Masuda et al., 2001). Interestingly, 
these genes were among those genes targeted in the CNN LOH region. These genes have 
been reported in many cancer types, apart from leukaemia, including: lung, breast and 
prostate. BCL2L14 encodes a protein that is belonged to BCL2 protein family which forms 
hetero- or homodimers and it may act as anti or pro-apoptotic regulator (Guo et al., 
2001). LRP6 protein belongs to the low density lipoprotein receptor gene family and is 
involved in the regulation of different cellular activities including cell differentiation, 
proliferation and migration through its interaction with the Wnt/beta-catenin pathway. 
DUSP16 is a member of the dual specificity protein phosphatase that is involved in the 
inactivation of target kinase pathways including the c-Jun amino-terminal (JNK) and 
extracellular signal-regulated (ERK) kinases. CREBL2 encodes a protein responsible in the 
regulation of CREB1 transcriptional activity required in the adipose cells differentiation 
and cell cycle regulation. CDKN1B is involved in the regulation of the cell cycle 
progression resulting in G1 arrest in particular. No somatic mutations have been 
reported in these genes (Montpetit et al., 2004; Papaemmanuil et al., 2014), thus loss 
of one allele with resultant haploinsufficiency is a possible mechanism of their 
leukaemogenic effects. Recently, a comprehensive evaluation of the genomic copy 
number alterations in a large number of ETV6-RUNX1 relapse cases revealed significant 
association of CDKN1B loss with a shorter remission duration and lower rates of event 
free survival of 42% at ten years compared to 81% in those without the loss (Bokemeyer 
et al., 2013), however, this prognostic significance is lost in multivariate analysis. On the 
other hand, this gene  is considered as a possible candidate for the prognostic 
 137 
 
stratification of AML across all cytogenetic subgroups, hence its low expression resulted 
in good outcome, while the high expression carried a worse prognosis (Haferlach et al., 
2011; Haferlach et al., 2012). Thus, these genes may act as tumour suppressor genes 
that might contribute to the leukaemogenic progression in those patients with 
der(12)t(12;21) abnormalities.   
Isolated ETV6 exon 8 losses were previously either not considered as real losses (Schwab 
et al., 2010) or counted as non-rearranged ETV6 deletion (Krentz et al., 2013). However, 
the occurrence of these isolated deletions in 3’ETV6 sequence deletions at 
der(12)t(12;21) (see section 4.4.1.1) highlighted the necessity to further investigate 20 
isolated exon 8 deleted cases. In addition, investigations of possible cases of duplicated 
RUNX1-ETV6 fusion gene were attempted but none of the cases had sufficient material.  
 Further cases with deleted 3’ETV6 sequences of der(12)t(12;21) were identified in 
around 50% (n=10) of cases with isolated ETV6 exon 8 losses by MLPA. Among the 
remaining 10 cases, 6 cases exhibited deleted non-rearranged ETV6 with gain of 
der(21)t(12;21) which explained the isolated ETV6 exon 8 loss, while one case showed 
deleted non-rearranged ETV6. However, the origin of the deletion could not be 
determined in the remaining three cases. In my view, the isolated ETV6 exon 8 loss 
should not be overlooked but needs to be complemented with FISH studies and 
interpreted with caution as they may indicate deletions of der(12)t(12;21) and not just 
standard ETV6 deletions from the untranslocated chromosome 12. 
It is now well established the ETV6-RUNX1 ALL harbours several additional abnormalities 
including these two additional aberrations targeting the RUNX1-ETV6 fusion gene that 
is located on the der(12)t(12;21) resulting either in its deletion or duplication. 
Considerable research studies have focussed on the primary products of the 
chromosomal translocations but the reciprocal fusion gene alterations have been 
overlooked. Both abnormalities affect the reciprocal RUNX1-ETV6 fusion product, which 
may contribute to leukaemogenesis by either eliminating or amplifying its expression. 
However, other consequences such as loss of tumour suppressor genes and 
amplification of oncogenes may also play a role. In conclusion, this study has defined 
novel abnormalities in ETV6-RUNX1 BCP-ALL which affect der(12)t(12;21) and may 
implicate new genes in leukaemogenesis. 
 138 
 
Chapter 5. Investigations of relapse related genes in ETV6-RUNX1 positive 
BCP-ALL 
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5.1 Introduction  
Despite the overall favourable outcome of patients with ETV6–RUNX1 (Pui, 2004; 
Moorman et al., 2010b), up to 13% of cases still experience relapses which occur usually 
after cessation of treatment and occasionally many years later. Thus, identification of 
the CNAs responsible for these relapses at the time of diagnosis is necessary to develop 
targeted therapy as a rational strategy to improve outcome. Paired genomic analysis of 
the diagnosis and relapse samples in BCP-ALL pointed to the possible implications of 
genes involved in cell cycle regulation, B cell development, glucocorticoid receptor 
signalling and drug resistance, including IKZF1, CDKN2A/B, ETV6, EBF1, NR3C1, NR3C2, 
BTG1, TBL1XR1 and CD200/BTLA (Mullighan et al., 2008b). Most of these alterations 
were retained at relapse, while some aberrations were more often acquired at relapse 
including IKZF1, EBF1 and NR3C1 (Mullighan et al., 2008b; Kawamata et al., 2009). In 
addition, a notable increase in the number of CNA was found from the diagnosis to 
relapse with number of deletions exceeding gains (Mullighan et al., 2008b). It has been 
suggested that the relapse clone can derive from either major or minor subclones 
detected at diagnosis regardless of time to relapse (Ford et al., 2001; Konrad et al., 2003; 
Mullighan et al., 2008b). In addition, a de novo origin from a premalignant stem cell was 
also suggested as indicated by the significant differences between the diagnostic and 
the relapse clones (Mullighan et al., 2008b). These genomic studies focussed on the 
overall cohort of BCP-ALL without giving much attention to the relapse specific 
characteristics in the individual cytogenetic subgroups including ETV6-RUNX1. In 
addition, these studies are potentially more likely to miss alterations presenting at low 
level clones. Newly diagnosed ETV6-RUNX1 cases were shown to harbour an increased 
number of alterations with an average of 6.68 aberrations per case and ETV6 losses 
constituted the most prevalent deletions (70%) (Mullighan et al., 2007). Therefore, a 
detailed analysis of a series of diagnosis-relapse pairs to examine clonal heterogeneity 
and evolution using several techniques is needed. The cytogenetics and FISH data were 
already available and MLPA P335 IKZF1 results were provided by Chapter 3. Accordingly, 
MLPA was done on the relapse samples and an extensive literature review was carried 
out to identify informative genes to be tested further (Table 5-1). The final list of genes 
was chosen based on their frequencies and relationship to relapses either by their 
functions or poor treatment response in any type of cancer. Since the glucocorticoid 
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drugs are integral components in the treatment, those genes involved in glucocorticoid 
resistance were chosen. CD200/BTLA, TBL1XR1, NR3C2 and NR3C1 genes constitute the 
top highest ranking, and a frequency of >10% was used as a cut off value. However, FHIT 
and TOX genes were not selected because of their low frequencies and they were not 
involved in glucocorticoid responsiveness.  
TBL1XR1 is required for nuclear hormone receptor transcriptional repression via the 
SMRT/N-CoR complex and deletion has been reported to be associated with relapses 
among ETV6-RUNX1 positive BCP-ALL (Parker et al., 2008), although further validation 
was recommended. NR3C1 and NR3C2 genes are involved in the glucocorticoid and 
mineralocorticoid binding receptors, respectively and their loss contributed to poor 
treatment response (Mullighan et al., 2008b); however, CD200/BTLA genes play roles in 
establishment functions in the immune system. 
Although BMF losses occur at a lower frequency, it represents an integral component in 
the anti-or pro- apoptotic regulation and plays an important role in glucocorticoid- 
mediated induction of apoptosis (Pinon et al., 2008; Ploner et al., 2008). Accordingly, 
BMF screening was considered in the above list of genes.  
It is important to investigate the potential relevance of these CNAs to the ETV6-RUNX1 
relapse cases and to identify their associations with other relapse specific demographic 
or clinical features. 
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Abnormality  Cytoband Function 
Frequency% 
 in ETV6-RUNX1 
Frequency% 
 in other BCP-ALL 
CD200/BTLA 3q13.2 Immune system or during B-cell differentiation 13 4 
TBL1XR1 3q26.32 Nuclear hormone receptor transcriptional repression via the SMRT/N-CoR complex 13 0.69 
NR3C1 5q31.3 Nuclear hormone receptors binding glucocorticoids 13 2 
NR3C2 4q31.23 Nuclear hormone receptors binding mineralocorticoid/ glucocorticoids 11 0.69 
FHIT 3p14.2 Induction of apoptosis  8.5 3 
TOX 8q12.1  T-cell development regulator 8.5 4 
BMF 15q15.1 Anti- or pro-apoptotic regulators  6 2 
Table 5-1 Literature search of other important gene deletions in ETV6-RUNX1 cases. Gene functions were obtained from gene cards, frequencies were extracted from 
(Mullighan et al., 2007; Lilljebjorn et al., 2010).   
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5.2 Aims and Objectives 
ETV6-RUNX1 fusion gene by itself is unable to drive the pre-leukaemic cells to overt 
leukaemia, thus additional abnormalities are required for the leukaemic transformation, 
progression and emergence of relapse. This Chapter aims to describe the genetic 
landscape at diagnosis of patients who did and did not go on to relapse and also describe 
the landscape at relapse for the former group in order to assess the potential relevance 
of these genetic alterations to the evolution of relapses. 
The main objectives in this study are: 
1. Screen the diagnostic samples of ETV6-RUNX1 patients who did and did not go 
on to relapse for gene deletions targeting TBL1XR1, BMF, NR3C1, NR3C2 and 
CD200/BTLA using both real - time copy number qPCR and FISH. 
2. Utilisation of the available MLPA (generated in Chapter 3) and cytogenetics data 
to gain further insight on the genetic landscape of the relapse and non-relapse 
cases at diagnosis.   
3. Evaluate the potential relevance of the copy number alterations of these genes 
in the relapse cases. 
4. Comparison of the genetic landscape of the relapse cases using matched 
presentation and relapse samples with BM involvement based on the 
cytogenetic, FISH and molecular data by back-tracking FISH some of the 
important genetic lesions from relapse to diagnosis (and vice versa).
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5.3 Patients and Methods 
5.3.1  Patient cohort 
This study comprised of a group of 18 relapse cases and a further 16 cases, who had no 
history of relapse, within ETV6-RUNX1 positive BCP-ALL. The comparison group was 
chosen on the basis of being typical patients with no history of adverse events, any Down 
syndrome and age range of (2-9) years. All patients were treated on ALL97/99 at initial 
presentation, except one relapsed case that was treated on ALL2003. At relapse, seven 
out of 18 cases were treated according to the ALLR3 protocol, while the remaining 11 
cases were treated off protocol (Appendix J).  
There was a variable availability of materials in the relapse cases. A total of 13 out of 18 
relapse cases had both diagnostic samples of DNA and fixed cells, while the remaining 
five cases had just DNA. At relapse, half of the cases (n=9) did not have any materials 
and the remaining half (n=9) had either both DNA and fixed cells (n=3) or only fixed cells 
(n=5) or just DNA (n=1) (Appendix J). However, the amount and quality of the relapsed 
samples (fixed cells in particular) were not ideal, so they were reserved for important 
tests needed to confirm the genetic lesions presented at diagnostic samples.  
A total of 14 out of 16 non-relapse cases had DNA and fixed cells, whereas the remaining 
two patients had DNA only (Appendix J).  
5.3.2 Real-time polymerase chain reaction (PCR) using TaqMan Copy Number 
Assays 
One target probe was chosen for each gene apart from TBL1XR1 and NR3C2 which were 
previously known to have variable deletion breakpoints; hence two target probes were 
selected. In addition, no target probe assay for CD200 was selected because BTLA gene 
deletion usually co-occurrs with CD200 (Lilljebjorn et al., 2010). Two reference probe 
assays were used for each patient in separate reactions: RNase P and TERT (see section 
2.11). All seven target probe assays were tested initially on normal controls to ensure 
efficiency. In each PCR run, the following samples were included: calibrator (mixture of 
different normal DNA; promega), positive control (monoallelic or/and biallelic deletion), 
non-template control (No DNA) and patient samples. 
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5.3.2.1 Selection of the positive gene deletion controls 
All positive controls chosen for this study were detailed in Appendix K. The chosen genes 
are detailed in Table 5-2. 
Genes location Controls* Techniques‡ References¥ 
NR3C1 5q31.3 
REH, 9467 
(L707)  
FISH, qPCR Sanger cancer genome project 
NR3C2 4q31.23 KG1 FISH, qPCR Sanger cancer genome project 
BMF 15q15.1 KASUMI-1 FISH, qPCR Sanger cancer genome project 
TBL1XR1 3q26.32 4037, 4281 FISH, qPCR, SNP  NA 
BTLA 3q13.2 9859 qPCR, SNP NA 
Table 5-2 Genes tested and the positive controls used. * cell lines or patient number used as 
positive controls, ‡ Techniques used to identify and confirm the deletion and performed by LRCG 
members including myself, ¥ positive cell lines were selected based on previous SNP profiles obtained 
from Sanger cancer genome project, NA: not applicable. 
5.3.2.2 Sensitivity assay of the Real-time polymerase chain reaction (PCR) using 
TaqMan Copy Number Assays 
The KG1 cell line, which used as a positive NR3C2 deletion control, was chosen to test 
the sensitivity of this technique. The sensitivity was tested using serial dilution assays, 
with increasing proportions (0, 5, 10, 20, 25, 30, 40, 60, 80 and 100%) of the KG1 cell line 
titrated against decreasing proportions (100, 95, 90, 80, 75, 70, 60, 40, 20 and 0%) of 
normal DNA (Promega). The quantitative PCR was carried out using both 5’NR3C2 and 
RNase P as target and reference probe assays respectively. Based upon the first 
sensitivity assay results, a second assay was performed to estimate the approximate cut 
off value, for which the following serial dilutions included: 0, 10, 30, 50, 55, 60, 65, 70, 
80 and 100%.  
5.3.2.3 Cohort screening 
Patients were screened using the six target gene probe assays targeting: NR3C1, 
5’NR3C2, TBL1XR1, 5’TBL1XR1, BTLA and BMF. Each target assay was combined with 
either reference assays separately as duplex qPCR reactions in individual patients in 
order to ensure the copy number status of each target. An intact gene would give a 
predicted copy number of 2 using both reference assays. Discrepant predicted copy 
number estimates necessitated repetition of some tests, especially those with low 
quality metrics. Borderline discrepancies between the calculated copy numbers were 
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not considered as discordant if an existing low proportion of the abnormal clone was 
detected by FISH. Data must be interpreted with caution and it needs to be correlated 
with available cytogenetic, FISH, MLPA and genomic data. In addition, karyotypes were 
reviewed for any gain or loss of either whole or part of chromosome 14 and 5 that might 
encompass the reference genes. RNase P gene status can be predicted from IGH gene 
status, located at 14q, by looking at the IGH BA FISH test results, whereas, possible TERT 
gene status can be obtained by viewing the MLPA profile of both EBF1 gene and other 
reference genes, located at 5p and 5q, included in the MLPA P335 IKZF1 kit.  
5.3.3 Fluorescence in situ hybridisation (FISH) 
At the start of FISH study, the efficiency and the cut off values of all seven home grown 
probes targeting different genes [NR3C2 (n=2), NR3C1 (n=1), BMF (n=1), BTLA (n=1), 
CD200 (n=1) and TBL1XR1 (n=1)] were determined (section 2.8.8). These cut off values 
are given in Appendix D. Each probe set contained both target (labelled green) and 
control (labelled red) probes. The target was considered to be deleted if a signal pattern 
of one or zero green signal was observed. The detailed information on the individual 
probe set used is shown in Appendix C and the locations of both the probe assays and 
the target BAC or fosmid clones in relation to the gene is demonstrated in Figure 5.1. 
Initial screening, with all six home grown probes targeting different genes, was applied 
to the diagnostic samples of all patients in each group. To note, any discrepancies 
existing between the qPCR and FISH data, owing to possible different mapping regions 
of each probe, were further investigated by FISH, using other specific probes that 
encompass the target qPCR assay used. These specific probes were targeting 5’NR3C2 
and 3’ or 5’ TBL1XR1. For all FISH tests, a minimum of 100 interphase cells were scored, 
apart from a few cases with limited material in which a minimum of 50 interphase cells 
were analysed. Furthermore, an algorithm for FISH review was generated in order to 
alleviate bias (Table 5-3). Individual evaluation of each case followed a specific algorithm 
that was generated in this study to ascertain the status of each gene tested based on 
both results FISH and qPCR (Appendix I). For the back-tracking FISH, there were 
additional FISH probes used targeting PAX5 exons 2&7, ETV6 exons 1&2, BTG1 and 
CDKN2A/B (Appendix C, Appendix D). 
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Figure 5.1 The location of both the different target probe assays and the FISH probes in 
relation to different genes investigated in this study. The probe assay is denoted in a red 
coloured shape and the BAC or Fosmid clones are shown in orange colour.  The genes 
investigated included: A. BTLA, B. BMF, C. NR3C1, D. NR3C2 and E. TBL1XR1. 
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  % deleted clone (X) Decision 
 MFPR + 4 * SD < X =< 30  Accept with no review 
X < MFPR + 4 * SD Accept with review 50 cells 
MFPR + 3* SD  > X > MFPR + 2 * SD Accept with review 100 cells 
X < MFPR + 2 * SD Reject 
Table 5-3 FISH review algorithm. MFPR: mean false positive rate, SD: Standard Deviation. 
5.3.4 Multiplex ligation dependent probe amplification (MLPA) 
Analysis of the available MLPA data, using the SALSA MLPA kit P335 IKZF1, which were 
generated in Chapter 3, was carried out to further extend the genetic landscape (section 
2.9).  
5.4 Results 
5.4.1 Cohort Description 
A total number of 18 patients with relapsed ETV6-RUNX1 BCP-ALL were tested in this 
study (Table 5-4) with blast purity at initial presentation averaging 94%, whereas at 
relapse the data was lacking for most cases except four cases with 0% (isolated CNS 
relapse), 35%, 70% and 95%. Time to first relapse from diagnosis ranged from less than 
6 months to 6 years 2 months (Appendix A and Appendix J). 
A further comparison group of 16 patients (Table 5-4), with no history of relapse, was 
investigated similarly to evaluate the potential relevance of the copy number gene 
alterations to the relapse cases. The blast purity averaged around 92% (Appendix A and 
Appendix J). 
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ETV6-RUNX1 positive BCP-ALL   
Relapse group Non- relapse group P-value 
No. of cases 18 (100) 16 (100)   
Age (years)       
Median 5 4.5  
1 1 (6) 0 (0) 
NA‡ 2-9 16 (88) 16 (100) 
≥10  1 (6) 0 (0) 
Sex (M:F)  10:08 08:08 
0.75 
Ratio 1.25 1.00 
WCC (X 109/L)       
Median 35.2 6.9  
<10 4 (22) 10 (63) 
0.02 10-49.9 8 (44) 1 (6) 
>= 50 6 (33) 5 (31) 
NCI Risk Group       
Standard 11 (61) 11 (69) 
NA‡ 
High 7 (39)  5 (31) 
No. Relapses       
Early 6 (33) NA 
NA 
Late 12 (67) NA 
Location of relapses    
BM 10 (56) NA 
NA CNS 4 (22) NA 
Both 4 (22) NA 
Outcome after first relapse    
Complete remission  14 (78) NA* 
NA 
Death 4 (22) NA* 
Table 5-4 The demographic and clinical features of the relapse and the non-relapse groups 
within ETV6-RUNX1 BCP-ALL. WCC: white cell count, NCI: National Cancer Institute, BM: bone marrow, 
CNS: central nervous system, Early relapse: within 18 months of the diagnosis until 6 months from the 
end of treatment (male: 3 years, female: 2 years), Late relapse: after 6 months off treatment, NA: not 
applicable, * all non-relapse cases had complete remission until the submission of this thesis, ‡ all non-
relapse cases were chosen to be from 2-9 years. 
 
5.4.1.1 Cytogenetic abnormalities 
Three quarters (n=10, 77%) of 13 relapse cases with successful cytogenetic results 
showed abnormal karyotypes in their diagnostic samples. The most prominent 
cytogenetic alterations included deleted or additional material at 12p (del/add(12)(p)) 
(n=3, 23%), deleted additional material at 9p (del/add(9p)) (n=2, 15%), gain 
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chromosome 21 (+21) (n=2, 15%), gain der(21)t(12;21) (+der(21)t(12;21)) (n=1, 8%) and 
deleted 6q (del(6)(q)) (n=1, 8%) (Appendix A).  
Further estimation of the frequency of both +21 and +der(21)t(12;21) was carried out 
on the available FISH studies targeting either ETV6 or RUNX1 loci (n=14 relapse cases). 
Among 14 cases, one case showed gain of chromosome 21 (+21) (7%), a further one case 
exhibited gain der(21)t(12;21) (+der(21)t(12;21)) (7%), while one additional case 
harboured both alterations (7%).  
A total of 12 cases (86%) out of the 14 non-relapse cases with successful cytogenetic 
results showed abnormal karyotypes. They exhibited del/add(12)(p) (n=4, 29%), 
del/add(9p) (n=2, 14%), del(11q) (n=2, 14%), +21 (n=1, 7%), del(6q) (n=1, 7%) and gain 
chromosome X (+X) (n=1, 7%) (Appendix A). 
Similarly, the frequency of both +21 and +der(21)t(12;21) was further estimated utilising 
the available FISH studies targeting either ETV6 or RUNX1 loci (n=14 non-relapse cases). 
Among 14 cases, three cases showed gain of chromosome 21 (+21) (21%) but none of 
the cases exhibited +der(21)t(12;21)).  
5.4.2 Real-time polymerase chain reaction (PCR) using TaqMan Copy Number 
Assays 
5.4.2.1 Sensitivity assay of the Real-time polymerase chain reaction (PCR) using 
TaqMan Copy Number Assays 
The first sensitivity assay revealed that the calculated copy number for the target gene 
decreased in relation to increasing proportion of cell line DNA (Table 5-5 and Figure 5.2). 
Furthermore, the dilutions 60% and 80% were found to have a copy number of 1, 
whereas the remaining dilutions less than 60% were showing normal copy number. 
Based upon the first sensitivity assay results, a second sensitivity assay was performed 
to further refine cut off value. The monoallelic deletion with a copy number of 1 was not 
detected when it presented in a proportion of 50% or less of cells (Table 5-6).   
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Serial dilutions CN Calculated CN Predicted Confidence |Z-Score| 
KG1-05 2.05 2 0.98 0.16 
KG1-10 1.94 2 0.99 0.02 
KG1-20 1.96 2 0.99 0.02 
KG1-25 2.01 2 0.98 0.09 
KG1-30 1.82 2 0.99 0.16 
KG1-40 1.77 2 0.99 0.34 
KG1-60 1.46 1 < 0.50 2.2 
KG1-80 1.27 1 0.65 1.39 
KG1-100 0.87 1 > 0.99 0.04 
Table 5-5 The first sensitivity detection test of monoallelic deletion of NR3C2 gene in KG1 cell 
line. Confidence and z-score indicated the quality metrics of the PCR run. KG1: Positive control of 
NR3C2 monoallelic deletion, CN: copy number, Confidence: the probability that the assigned copy number 
is the correct copy number relative to any of the other possible assigned copy numbers for the group of 
analysed samples, |Z-Score|: absolute value of the number of standard deviations separating the replicate 
mean ΔCT of a sample from the mean subdistribution of the assigned copy number. Predicted CN of 1 is 
monoallelic deletion, while 2 is normal copy number, for algorithm to evaluate the data: see Appendix I.  
 
 
 
Figure 5.2 Histogram showing the decrease in the copy number with increasing proportion of 
cell line DNA. The samples are on the x-axis whereas the y-axis represents the copy number of 
the target gene. 
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Serial dilutions CN Calculated CN Predicted Confidence |Z-Score| 
KG1-10 2.24 2 0.94 0.24 
KG1-30 1.93 2 0.58 0.04 
KG1-50 1.57 2 < 0.50 1.41 
KG1-55 1.48 1 < 0.50 0.5 
KG1-60 1.44 1 < 0.50 0.35 
KG1-65 1.36 1 < 0.50 0.08 
KG1-70 1.36 1 < 0.50 0.09 
KG1-80 1.12 1 0.99 0.37 
KG1-100 0.98 1 > 0.99 0.02 
Table 5-6 The second sensitivity assay for the detection of monoallelic deletion of NR3C2 gene 
in KG1 cell line.  
 
5.4.2.2 Cohort screening 
A total of 18 diagnostic samples of cases that went on to relapse were investigated 
successfully using the six different target probes. Overall, 61% (n=11) of the relapse 
cases did not harbour any gene deletions, while the remaining cases (n=7, 39%) 
exhibited a total number of nine aberrations with a mean of 0.5 alterations per sample. 
Eight patients (44%) had one alteration and the remaining case (6%) had three. TBL1XR1 
and NR3C2 losses were the most frequent alterations constituting 22% (n=4) and 17% 
(n=3) of the relapse cases, respectively. TBL1XR1 deletions were restricted either to the 
intragenic probe (n=2, 50%), or to the 5’TBL1XR1 probe (n=1, 25%) or encompassed both 
probes (n=1, 25%). In addition, two out of 17 cases (12%) with successful results showed 
BTLA deletions. It is noteworthy that all deletions were monoallelic. There were no 
deletions detected in NR3C1 and BMF genes (Table 5-7).   
Overall, eight (50%) out of 16 non-relapse cases, which were successfully screened using 
six different target probes, did not exhibit any gene deletions. The remaining half of the 
cases harboured a total of 10 aberrations, thus there was an average of 0.63 alterations 
per case. A total of six patients (38%) had one alteration and a further two patients (19%) 
exhibited two alterations. These deletions were frequently affecting TBL1XR1 (n=5, 31%) 
and NR3C2 (n=3, 19%), whereas the remaining two deletions targeted NR3C1 (n=1, 6%) 
and BMF (n=1, 6%). Four (80%) out of five TBL1XR1 deleted cases compromised the 
probe covering the 5’TBL1XR1 area and the remaining deletion (20%) extended further 
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to affect both the intragenic and 5’ region. There were all monoallelic deletions with no 
BTLA deletions detected (Table 5-7).
 153 
 
 
Reg.ID NR3C1  NR3C2  5'NR3C2 TBL1XR1 5'TBL1XR1 BTLA  BMF  Collective No. 
of CNA 
 q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
 
Relapse Group 
2712 N N NA N N NA N 5 N NA F F N N 1 
2774 N NA NA NA N NA N NA N NA N NA N NA 0 
2850 N N NA 48 D NA D NA N NA D NA N F 3 
3098 N NA NA NA N NA N NA N NA N NA N NA 0 
3181* N N NA N N NA N N N NA N N N N 0 
3359 N NA NA NA D NA N N N NA N NA N NA 1 
3431 N NA NA NA D NA N NA N NA N NA N NA 1 
3562 N F NA N N NA N N N NA N F N N 0 
3588 N NA NA NA N NA N NA N NA N NA N NA 0 
3700 N N NA N N NA N N N NA D 100 N N 1 
3703* N NA NA F N NA N N N NA N NA N NA 0 
3833 N NA NA F N NA N N N NA N NA N NA 0 
4036* N N NA N N NA N N N NA N N N N 0 
4044 N N NA N N NA N N D 80 N N N N 1 
4902* N N NA N N NA N N N NA N N N N 0 
5062* N F NA F N NA N F N NA N F N F 0 
5597* N N NA N N NA D 100 D NA N F N N 1 
10875*‡ N N NA N N NA D 44 N NA N N N N 1 
Non- Relapse Group 
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Reg.ID NR3C1  NR3C2  5'NR3C2 TBL1XR1 5'TBL1XR1 BTLA  BMF  Collective No. 
of CNA 
 q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
 
2897 N N NA N N NA N N N NA N NA N N 0 
3026 D 100 NA N N NA N N N NA N 46 N N 2 
3711 N N NA N N NA N F N NA N N N N 0 
3761 N NA NA N D NA N F D NA N NA N N 2 
4011 N N NA N N NA N N N NA N N N N 0 
4288 N N NA N N NA N N N NA N N N N 0 
4439 N N NA N N NA N N N NA N NA N N 0 
4536 N N NA N D 73 N N N NA N N N N 1 
4569 N NA NA NA N NA N NA N NA N NA N NA 0 
4609 N N NA N N NA N N D 65 N N N N 1 
4995 N N NA N N NA N N D 100 N F N N 1 
5647 N N NA N N NA N N N NA N N N N 0 
5659 N N NA F N NA N N N NA N N N N 0 
5721 N NA NA NA D NA D NA D NA N NA N NA 2 
5807 N NA NA N N NA N F N NA N NA D F 1 
5914 N N NA N N NA N N D 81 N N N N 1 
Table 5-7 FISH and q PCR data of the relapse and the non-relapse cases . * treated on ALLR3 at relapse, ‡ treated on UKALL2003 at presentation, ¥ percentages are 
relative to ETV6-RUNX1 positive cells, F failed, D deleted, N normal, NA not available.
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5.4.3 Fluorescence in situ hybridisation (FISH) 
A total of 13 out of 18 diagnostic samples from the relapse cohort were tested using all 
six screening FISH probes with additional specific probes, whenever needed. Seven 
samples (54%) showed normal FISH studies for all genes tested. The remaining six 
samples (46%) exhibited a total of 6 alterations affecting different genes including: 
TBL1XR1 (4 out of 12 successful tests, 33%), NR3C2 (1 out of 10 successful tests, 10%) 
and BTLA (1 out of 4 successful tests, 25%) with a mean of 0.46 alterations per sample 
at diagnosis. To note, the four TBL1XR1 deletions were shown to encompass either the 
intragenic probe (n=3) or the 5’ probe (n=1) of the gene. Overall, these monoallelic 
deletions were identified to be secondary events that constituted an average of 60% of 
ETV6-RUNX1 positive cells. The deleted clones represented as major clones in three 
cases, whereas the remaining three cases harboured deletions that occurred at a 
proportion less than 50%. Both NR3C1 and BMF genes were shown to be intact in all ten 
samples with successful results (Table 5-7). 
Overall, a total of 13 out of 16 non-relapse cases were successfully screened using six 
screening FISH probes with additional specific probes, whenever needed. Around 62% 
of samples (n=8) did not show any gene deletions, whereas the remaining five cases 
(38%) exhibited a total of six different gene deletions yielding an average of 0.46 CNA 
per individual. These losses targeted the following genes: TBL1XR1 (3 out of 11 
successful tests, 27%), NR3C1 (1 out of 11 successful tests, 9%), NR3C2 (1 out of 12 
successful tests, 8%) and BTLA (1 out of 10 successful tests, 10%). To note, TBL1XR1 
deletions were restricted to the 5’ probe. All deletions occurred at subclonal levels with 
an average of 80% (range: 46%-100%) of ETV6-RUNX1 positive cells. Overall, the 
deletions were monoallelic except two cases with biallelic deletions targeting the 5’ part 
of either TBL1XR1 or NR3C2 genes. BMF deletions were not detected in this cohort 
(Table 5-7). 
5.4.4 Consistency between qPCR and FISH data 
It is worth noting that 10 out of 19 deletions, detected by qPCR, had FISH studies and all 
these deletions (n=10) had concordant qPCR and FISH results.  
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On the other hand, a further two deletions were detected by FISH only but not with 
qPCR, owing to the low proportion of the deleted clones that constituted 5% (TBL1XR1, 
2712) and 46% (CD200/BTLA, 3026) of ETV6-RUNX1 positive cells, respectively (below 
qPCR resolution).  
5.4.5 Multiplex ligation dependent probe amplification (MLPA) 
All 34 cases were successfully screened by MLPA at diagnosis (Appendix A). 
Among the 18 relapse cases, 17% (n=3) of the diagnostic samples did not harbour any 
gene deletions. The remaining 15 cases (83%) exhibited a total of 26 CNAs giving a mean 
of 1.4 alterations per case. One third of patients (n=6) had one, 7 (39%) had two and two 
(11%) had three alterations. The most frequent losses targeted ETV6 (n=11, 61%) and 
CDKN2A/B (n=8, 44%), while the remaining deletions affected BTG1 (n=4, 22%) and 
PAX5 (n=3, 17%).   
A total of 15 (94%) out of 16 non-relapse patients, who were successfully screened, 
showed an alteration of at least one of these genes with a total of 25 aberrations. The 
average number of alterations was 1.6 aberrations per case with 63% of patients (n=10) 
had two alterations, while the remaining five cases exhibited one alteration (31%). These 
deletions targeted ETV6 (n=14, 88%), PAX5 (n=4, 25%), BTG1 (n=2, 13%), CDKN2A/B 
(n=2, 13%), RB1 (n=2, 13%) and EBF1 (n=1, 6%).  
5.4.6 Comparisons between the relapse and non-relapse cohorts 
As expected, around two thirds of the non-relapse patients had WCC<10x109/L 
compared to 22% of the relapse cases. Based on this small number of cases, there were 
no noticeable genetic differences between the relapse and non-relapse groups 
considering the eight genes tested by MLPA. There was a comparable number of 
deletions (n=26 and n=25) in the relapse and non-relapse groups with a similar mean of 
1.4 and 1.6 alterations per case, respectively (p=0.7). It is worth noting that none of the 
alterations were particularly associated with relapse, however, CDKN2A/B losses 
constituted 44% of the relapse cases compared to 13% of the non-relapse cases (p=0.06). 
Both groups showed frequent losses targeting ETV6 (61% v 88%), TBL1XR1 (28% v 31%), 
PAX5 (17% v 25%), BTG1 (22% v 13%), NR3C2 (17% v 19%) and CD200/BTLA (12% v 6%) 
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genes (Table 5-8). TBL1XR1 losses showed variable breakpoints targeting the gene itself 
or restricted to the 5’ region of the gene or both in both groups (Figure 5.3). 
  
ETV6-RUNX1 positive BCP-ALL 
Relapse group Non- relapse group P-value 
No. of cases (%) 18 (100) 16 (100)   
Deletions       
12p 3 (17) 4 (25) 0.7 
ETV6 11 (61) 14 (88) 0.1 
9p 2 (11) 2 (13) 1.0 
CDKN2A/B 8 (44) 2 (13) 0.06 
PAX5 3 (17) 4 (25) 0.7 
TBL1XR1 5 (28) 5 (31) 1.0 
BTG1 4 (22) 2 (13) 0.7 
NR3C2 3 (17) 3 (19) 1.0 
BTLA 2 (12)* 1 (6) 1.0 
Gain 21 2 (11) 1 (6) 1.0 
6q 1 (6) 1 (6) 1.0 
NR3C1 0 1 (6) 0.5 
BMF 0 1 (6) 0.5 
EBF1 0 1 (6) 0.5 
11q 0 2 (13) 0.2 
Gain X 0 1 (6) 0.5 
RB1 0 2 (13) 0.2 
Table 5-8 The genetic landscape of the diagnostic samples of the relapse and non-relapse cases. 
No IKZF1 or PAR1 rearrangements in either group, * percentage was calculated from the total number of 
patients tested successfully (n=17). 
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Figure 5.3 Different TBL1XR1 breakpoints in the relapse and non-relapse cases. The non-
relapse cases harboured TBL1XR1 losses restricted to the 5’ region in 80% of deleted cases, while 
the TBL1XR1 deletions in the relapse cases encompassed the gene itself with variable 
breakpoints in 80% of the deleted cases, ● intact, × deleted. 
 
5.4.7 The clonal evolution of the relapsed clones 
A total of nine presentation-relapse matched pairs, with BM involvement, were 
backtracked by FISH for some of the important genetic lesions from relapse to diagnosis 
(Table 5-9). Overall, 6 (67%) out of 9 cases showed the same abnormalities at diagnosis 
and relapse, while the remaining three cases (33%) exhibited either loss (n=1) or 
acquisition (n=2) of at least one genetic abnormality.  
Among those cases with similar abnormalities (n=6), the dynamics of progression at both 
time points were determined in four cases. A total of 3 out 4 cases had one of the 
abnormalities at presentation regressed at relapse but the rest of the abnormalities 
maintained at the same level relative to ETV6-RUNX1 positive cells from diagnosis to 
relapse. The remaining case showed a static profile of abnormalities at both time points. 
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On the other hand, among the remaining three out of 9 cases, the dynamics of 
progression at both time points were determined in two cases. One of the cases had 
acquired an aberration at relapse which was detected molecularly and not confirmed by 
FISH, while the rest of the abnormalities showed reverse pattern of progression. The 
remaining case had lost one of the abnormalities at relapse. 
Furthermore, the latter two patients exhibited further two alterations which had 
different pattern of evolution. One of the patients showed reverse pattern of 
progression, in which one of the aberration expanded at relapse, while the other 
aberration regressed. However, the other patient had similar pattern of progression in 
which both of them regressed at relapse, whereas the rest of aberrations showed almost 
similar levels at both time points.  
Although the dynamics of progression was not identified in the remaining three out of 
9 cases, two of the cases showed same genetic abnormalities at both time points. 
However, the remaining case had acquired one genetic lesion at relapse but the rest of 
aberrations presented in both time points. 
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Patient No. 
Diagnosis  Relapse 
Pattern of Evolution 
Cytogenetic FISH Molecular Cytogenetic FISH Molecular 
2712 N 
TBL1XR1 [5%] N 
F 
TBL1XR1 [0%] NA 
A+B+C >>>> B+C Gain 21 [7%] NA Gain 21 [4%] NA 
ETV6 exons 1&2 [64%] Yes ETV6 exons 1&2 [73%] NA 
2850 
add(9)(p13) CDKN2A/B [NA] Yes 
NA 
CDKN2A/B [46%] NA 
                    D>>>>D 
Rest: Cannot be determined 
 
del(12)(p11) ETV6 exons 3-5 [NA] Yes ETV6 exons 3-5 [27%] NA 
  
BTG1 [NA] Yes BTG1 [43%] NA 
NR3C2 [48%] Yes NR3C2 [35%] NA 
TBL1XR1 [NA] Yes TBL1XR1 [27%] NA 
CD200/BTLA [NA] Yes CD200/BTLA [68%] NA 
3431 N 
ETV6 exons 2-8 [NA] Yes 
NA 
ETV6 exons 2-8 [26%] NA 
Cannot be determined BTG1 [NA] Yes BTG1 [72%] NA 
NR3C2 [NA] Yes NR3C2 [70%] NA 
3700 N 
ETV6 [96%] Yes 
NA 
ETV6 [99%] NA 
A+B >>>> A+b 
BTLA [100%] Yes BTLA [41%] NA 
3703 Comp. 
ETV6 [74%] Yes 
N 
ETV6 [89%] NA 
A+B* >>>> A+b* 
BTG1 [NA] Yes BTG1 [2%] NA 
4036 Comp. 
CDKN2A/B [100%] Yes del(9)(p21p21) CDKN2A/B [100%] Yes 
A+B+C >>>> A+B+C ETV6 [100%] Yes add(12)(p1) ETV6 [100%] Yes 
BTG1 [100%] Yes   BTG1 [91%] Yes 
4902 N PAX5 exons 2-7 [86%] Yes Normal PAX5 exons 2-7 [100%] Yes A+B >>>> A+b 
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Patient No. 
Diagnosis  Relapse 
Pattern of Evolution 
Cytogenetic FISH Molecular Cytogenetic FISH Molecular 
ETV6 [98%] Yes ETV6 [78%] Yes 
10875 N 
Gain der(21) [5%] No Gain 21 Gain der(21) [51%] Yes 
a+B >>>> A+b+C TBL1XR1 [48%] Yes 
  
TBL1XR1 [17%] No 
CDKN2A/B [0%] No CDKN2A/B [F] Yes 
      3181 
del(12)(p) ETV6 exon 8 [26%] Yes 
Failed 
ETV6 exon 8 [NA] Yes 
Cannot be determined 
Only acquisition of C   
PAX5 exons 1-2 [NA] Yes PAX5 exons 1-2 [NA] Yes 
CSF2RA, IL3RA [N] N CSF2RA, IL3RA [NA] Yes 
Table 5-9 Cytogenetics, FISH and Molecular data of the nine matched diagnosis/relapse cases. NA: Not performed, N: normal, F: Failed, Comp. complex, * the pattern of 
evolution can be perceived from the MLPA data (Abnormality B detected by MLPA at presentation but it occurred in only 2% of ETV6-RUNX1 positive cells (below the MLPA threshold 
detection), the percentages shown represent the proportion of the abnormal clone relative to ETV6-RUNX1 positive cells. A, B, C, D, E and F denote to any aberration in general but 
taking into consideration the existent number of aberrations. A>>>>a, a>>>>A, A>>>>A indicates regression, expansion, maintenance at the same level of the abnormal clone from 
diagnosis to relapse, respectively. If the difference between percentages at both time points ≤15%, so the clone level was maintained, if the diagnostic clone level was more than 
the relapse clone in >15%, thus the diagnostic clone regressed and vice versa.  
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5.5 Discussion 
This Chapter employed the data generated from the copy number qPCR, FISH, 
cytogenetic and MLPA data on 18 ETV6-RUNX1 relapse cases. The cohort was tested for 
selected genes known to be associated with ETV6-RUNX1 BCP-ALL and to some extent 
implicated in relapse (Mullighan et al., 2007; Mullighan et al., 2008b; Parker et al., 2008; 
Lilljebjorn et al., 2010). The potential relevance of these alterations to the emergence of 
relapses was evaluated by extending the investigations to other ETV6-RUNX1 patients 
who did not go onto relapse. The decision made around the choice of techniques was 
somehow difficult. The ideal way of investigating these patients is to carry out a 
technique with higher resolution and good sensitivity e.g. SNP arrays that can provide 
both the copy number and the heterozygosity profiles at a genomic level. However, 
limited availability of good quality DNA prohibited this technique. Thus, specific genes 
were selected to screen the chosen cohort and MLPA was initially chosen as the second 
alternative method that enables detection of copy number alterations of up to 50 
different genomic DNA. As compared to array studies, it represents a low cost and 
simple alternative method to array-based techniques for many routine applications. 
Unfortunately, there was no predesigned MLPA kit which containing the genes of 
interest (TBL1XR1, BMF, NR3C1, NR3C2 and CD200/BTLA). Designing a custom MLPA kit 
was attempted but failed due to poor coverage of all genes selected. As a result, both 
TaqMan copy number real-time qPCR and FISH were chosen as screening techniques. 
Based on the sensitivity assays, qPCR technique was able to detect monoallelic deletions 
when present in a proportion of cells greater than 50%, although lower proportions 
were still detected but with borderline values and low quality metrics. However, all FISH 
probe sets used were able to detect deleted clones presented in a proportion as low as 
4%. Although there was a probability of missing deletions either not covered by the 
selected FISH probes or smaller than the probe used. It is worth noting that both 
techniques were laborious with high consumption of material; hence, the number of 
probes was restricted to the most common known deletions.  
It would be more informative if non-relapse cases were matched in terms of the 
demographic information, e.g. age, sex and WCC, but the availability of materials 
hampered this approach, however, they were comparable. Surprisingly, there were no 
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differences found between both group of patients in terms of number of deletions and 
the genes involved. This study showed that CDKN2A/B losses constituted 44% of the 
relapse cases compared to 13% of the non-relapse group, in agreement with previous 
studies that reported higher frequencies of these losses in relapsed BCP-ALL cases 
(Maloney et al., 1999; Graf Einsiedel et al., 2002; Irving et al., 2005a; Mullighan et al., 
2008b; Yang et al., 2008). In contrast to our findings, similar frequencies of CDKN2A/B 
losses between the relapse and newly diagnosed BCP-ALL cases have been recently 
identified (35.7% v 33.9%, respectively) (Hogan et al., 2011). In line with the latter study, 
the proportions of the CDKN2A/B losses in the diagnostic and relapse samples of ETV6-
RUNX1 relapse cases, in particular, were almost similar (33% v 25%) (Kuster et al., 2011) 
and corresponded to the overall incidence of these losses in non-relapse ETV6-RUNX1 
cases (22%) (Lilljebjorn et al., 2010). CDKN2A/B genes have previously been identified 
as tumour suppressor genes that were deregulated by several mechanisms in ALL 
including: focal deletions, DNA hypermethylation and down-regulation occurring either 
in the same or different patients (Hogan et al., 2011). The enrichment of these losses in 
both diagnosis and relapse indicates that they are needed in both the initial 
leukaemogenic transformation and emergence of relapse and are not necessarily 
relapse-specific alterations. It is worth noting that a positive correlation was observed 
between CDKN2A/B losses and adverse risk factors (e.g. high peripheral blast count, 
WCC and older age at relapse) in the relapse samples of ETV6-RUNX1 cases (Bokemeyer 
et al., 2013), however, CDKN2A/B deletions lacked any prognostic value in BCP-ALL and 
ETV6-RUNX1 cases in particular.  
Although BTG1 and CD200/BTLA are slightly higher in the relapse cases as compared to 
non-relapse cases (22% v 13%, 12% v 6%, respectively), they were not statistically 
significant. In agreement with these findings, one previous study found enrichment of 
these alterations in the ETV6-RUNX1 relapse cases as compared to the non-relapse cases 
(21% v 13%, 36% v 15%) (Kuster et al., 2011). BTG1 losses were previously reported to 
be associated with drug resistance with emergence of early relapses (defined as within 
18 months of the diagnosis until 6 months from the end of treatment). Drug resistance 
has been postulated to be due to the reduction in the expression of the glucocorticoid 
receptor that negatively impacts on the glucocorticoid sensitivity (van Galen et al., 2010). 
This present study showed that all BTG1 deleted relapse cases were late (after 6 months 
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off treatment) and thus unlikely to be driven by drug resistance related aberrations. 
Hence, other genetic alterations might be responsible for these late relapses rather than 
BTG1 deletions.  
Both relapse and non-relapse groups displayed similar frequencies of common losses in 
their diagnostic samples targeting ETV6, PAX5, TBL1XR1 and NR3C2 (61% v 88%, 17% v 
25%, 28% v 31%, 17% v 19%, respectively) which suggest the necessity of these 
alterations in the initiation of leukaemia as well as relapse development. In concordance 
with previous studies that identified both deletions of the ETV6 and PAX5 genes, 
transcription factors required for B cell development, to represent common alterations 
in both relapse and non-relapse ETV6-RUNX1 cases (57% v 70%, 21% v 28%, respectively) 
(Kuster et al., 2011). However, higher frequencies of TBL1XR1 losses were observed in 
ETV6-RUNX1 relapse cases compared to non-relapse cases (29% v 13%) (Kuster et al., 
2011), but the proportion of these losses in relapse cases was consistent to our findings. 
On the other hand, NR3C2 losses were enriched in the relapse samples rather than the 
diagnostic samples of the relapse cases (14% v 0%) (Kuster et al., 2011), however, NR3C2 
losses constituted 11% of the non-relapse cases comparable to that seen in the relapse 
samples (11%). 
This study showed that TBL1XR1 losses exhibited variable breakpoints in both groups; 
relapse group harboured deletions of the gene itself in 80% of the deleted cases, while 
non-relapse cases showed frequent deletions restricted to the 5’ region of the gene. It 
has previously been reported that the reduction in expression was similar regardless of 
the deletion extent (Parker et al., 2008). Interestingly, the relationship between 
TBL1XR1 deletions and the disruption of the capacity of SMRT/N-CoR to bind receptor 
molecules has been described resulting in inappropriate control of gene expression 
through the RAR and THR signalling pathways (Parker et al., 2008). Taken together, 
TBL1XR1 deletions might not be relapse-specific alterations, though they seem to 
constitute an essential element in the development of ETV6-RUNX1 leukaemia.  
None of the relapse cases in this study showed deletions of NR3C1 and BMF. This could 
be due the detection methods that were designed to detect the common region of 
deletion or reflect the small number of patients tested. It has been previously reported 
that NR3C1 alterations almost exclusively prevail at relapse (Kuster et al., 2011), this 
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might explain their absence in the diagnostic samples of the relapse cases in the present 
study. However, BMF losses were previously observed to be preserved at relapse with 
an incidence rate higher than that seen in non-relapse cases in ETV6-RUNX1 (16.6% v 
2.8%). These genes were reported to be involved in glucocorticoid resistance in ETV6-
RUNX1 owing to their known functions in glucocorticoid mediated apoptosis resulting in 
poor treatment response (Kuster et al., 2011). The dexamethasone resistance was 
attributed to their negative impact on the expression of the glucocorticoid receptor and 
the glucocorticoid induced regulation of the pro- and anti-apoptotic BCL2 pathways, 
respectively. The present study is in agreement with previous studies showing the 
frequency of the somatic mutation of the NR3C1 involved in glucocorticoid receptor 
expression is reported to be rare (Hillmann et al., 2000; Irving et al., 2005b; Tissing et al., 
2005). 
Individual patients with BM relapses were investigated by back-tracking FISH for the 
important genetic lesions from relapse to diagnosis in order to identify the possible 
origin of the relapse clone. Overall investigations confirmed that all genetic aberrations 
in relapse samples, irrespective of time to relapse, were able to be identified in the 
diagnostic samples as a minor or major clone, except two patients (10875, 3181) who 
showed acquisition of one alteration each. It is worth noting that both two acquired 
alterations were detected molecularly at relapse with no confirmed FISH studies, thus 
technical artefacts might play a factor or they might be present in small diagnostic 
compartments in which a large number of cells is needed to be screened for their 
detection. In addition, possible origin from ancestral clones might be another 
explanation. Interestingly, subclonal diversity at diagnosis had been observed in these 
data as evidenced by FISH, hence this might contribute to the variability of the intra-
clonal origins of relapse, in line with previous reports (Mullighan et al., 2008b; Kuster et 
al., 2011; van Delft et al., 2011). Taken together, the relapse clone is most probably 
derived from either a major or a minor clone present in the diagnostic sample, 
irrespective of time to relapse. In addition, de novo ALL arising from persisting pre-
leukaemic clones harbouring ETV6-RUNX1 seems less likely since this kind of evolution 
would result in the acquisition of distinct genetic aberrations that are not identified in 
the diagnostic samples (Ford et al., 2001; Konrad et al., 2003; van Delft et al., 2011). 
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In conclusion, frequent CDKN2A/B losses in the relapse cases might be indicative of 
being a responsible factor in initiating the leukaemia in both first and recurrent diseases. 
Otherwise, no other potential copy number alterations were implicated in contributing 
to relapse biology. A high degree of clonal relatedness between the two points 
(diagnosis and relapse) was observed with an evidence of low level sub-clones at 
diagnosis emerging as the major clone at relapse. This is in agreement with Mullighan 
who postulated that alterations in the majority of relapse cases had a strong relationship 
with the diagnostic clone, whereas unrelated leukaemia was found in very low 
proportion (6%) (Mullighan et al., 2008b). 
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Chapter 6. The genetic landscape of patients with ETV6-RUNX1 positive 
BCP-ALL and an atypical demographic and clinical profile 
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6.1 Introduction 
ETV6-RUNX1 BCP-ALL is characterised by tight demographic features in which the 
majority of cases are aged between 3-6 years and mostly assigned to the NCI standard 
risk group which, in part, explains the favourable outcome (Golub et al., 1995; Romana 
et al., 1996; Moorman et al., 2010b). ETV6-RUNX1 fusion gene is known to arise in utero 
as an initiating factor but is unable to cause overt leukaemia (Andreasson et al., 2001). 
A latency period is needed for the additional genetic alterations to accumulate and aid 
in leukaemic transformation (Wiemels et al., 1999; Mori et al., 2002; Greaves and 
Wiemels, 2003; Hong et al., 2008; Ma et al., 2013). The latency period is usually broad 
with a typical peak between the ages of 3–6 years. However, in infant (before their 
second birthday) cases, this latency period is shorter and is therefore presumably due 
to accelerated emergence of full blown leukaemia. On the other hand, a prolonged 
latent period occurs in the older age (adolescent/young adults) (AYA) at around 3.4% 
incidence rate (Jabber Al-Obaidi et al., 2002; Moorman et al., 2010b). Infants and adults 
are usually characterised by the predominance of other cytogenetic subtypes including 
MLL rearrangements and BCR-ABL1 BCP-ALL, respectively, which confer poor outcome 
(Moorman, 2012). In addition, Down syndrome (DS) group is a common genetic 
syndrome that is associated with a high incidence of different types of leukaemia 
including acute lymphoblastic leukaemia (20- fold increase) (Lange, 2000). Thus DS ALL 
accounts for around 1-3% of all childhood ALL (Whitlock, 2006; Forestier et al., 2008b; 
Malinge et al., 2009) and is characterised by lower incidences of both favourable (e.g. 
t(12;21) and high hyperdiploidy) and unfavourable (e.g. t(9;22), MLL rearrangements 
and hypodiploidy) cytogenetic subtypes. ETV6-RUNX1 constitutes 10-15% of DS ALL as 
compared to 25% of non-DS ALL patients (Buitenkamp et al., 2012; Buitenkamp et al., 
2013a; Patrick et al., 2014). However, DS ALL is enriched with two genetic entities that 
are considered the hallmark of this disease including JAK2 mutations and CRLF2 
overexpression that are seen in 19% and 62% of cases, respectively (Kearney et al., 2009; 
Russell et al., 2009; Hertzberg et al., 2010). Taking into consideration the emphasis on 
the main bulk of ETV6-RUNX1 cases, not much attention has been paid to the atypical 
cases (infants, AYA and DS). Thus, the identification of specific markers unique to each 
subgroup could be useful in delineating the critical events responsible for the 
leukaemogenic progression.       
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6.2 Aims 
The aim of this Chapter is to assess whether or not the spectrum of secondary 
abnormalities in atypical ETV6-RUNX1 patients are unique and informative about that 
subtype and ETV6-RUNX1 as a whole. 
The main objectives in this chapter are to:  
1- Utilise the MLPA (Chapter 3) and cytogenetic data for characterising the genetic 
landscape with respect to cell cycle regulation, B cell development and 
differentiation of these atypical groups including: AYA (n=36), infants (n=21) and 
DS (n=13). 
2- Screen these patients for different gene deletions involving TBL1XR1, BMF, 
NR3C1, NR3C2 and CD200/BTLA genes that are involved in the nuclear hormone 
receptor transcriptional regulation, glucocorticoid receptor signalling, drug 
resistance and regulation of apoptosis using copy number q PCR and FISH 
3- Investigate the genomic profiles of four Down syndrome cases using SNP arrays 
in order to uncover new genetic markers. 
4- Compare the genetic profiles of different subgroups (infant v non-infant, AYA v 
non-AYA and DS v non-DS) in order to assess the potential relevance of specific 
genetic markers to any of the subgroups.  
6.3 Patients and Methods 
6.3.1 Patient cohort 
A total of 73 cases of different subgroups within ETV6-RUNX1-positive BCP-ALL was 
studied including different atypical groups namely: infants (before their second birthday) 
(n=21), adolescents/ young adults (AYA) (age of 10-51 years) (n=39), Down syndrome 
(DS) (n=13). Each subgroup was compared with non-infant (n=381), non-AYA (n=363) 
and non-DS (n=389). There were a variable number of investigated cases in each 
subgroup (Table 6-1). Patients were treated on ALL97, UKALL2003 or UKALLXII at initial 
presentation (see section 2.2).  
170 
Subgroup Total cases 
Cytogenetic MLPA q PCR* FISH¥ 
DNA Fixed cells 
Successful Failed NA Successful Failed NA Successful Failed NA Successful Failed NA 
Infants 21 16 5 0 21 0 0 12 0 9 10 0 11 12 10 
AYA 39 33 6 0 39 0 0 13 0 26 9 0 30 13 9 
DS¶ 13 9 4 0 12 1 0 9 0 4 4 0 9 9 4 
Table 6-1 Different atypical subgroups of patients included in this study with the number of cases investigated in each based on the availability of material. AYA: 
adolescents/ young adults, DS: Down syndrome, the availability of materials was assessed before the start of FISH and q PCR screening, ¶ among the 13 cases; four cases were 
investigated using SNP6 arrays, NA not done, * there were failed and NA tests within a case pertaining to different target genes [Infants: BTLA (2 NA, 1Failed), AYA: BMF (3 NA, 1 
Failed), NR3C2 (1 Failed), NR3C1 (2 Failed), BTLA (3 NA), DS: NR3C1 (2 Failed), NR3C2 (3 Failed), BTLA ( 1 Failed, 5 NA), TBL1XR1 (1 NA), BMF (5 NA)], ¥ there were failed and NA tests 
within a case pertaining to different target genes [Infants: BTLA (1 Failed), NR3C1 (1 failed), AYA: NR3C1 (1 NA), NR3C2 (2 NA), BMF (1 NA), BTLA (1 NA), DS: NR3C2 (2 NA), NR3C1 (1 
NA), BMF (1NA), BTLA (1 NA)]. 
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6.3.2 Methods 
The techniques used to study these patients were similar to those in Chapter 5; utilising 
the MLPA (using the SALSA MLPA kit P335) (see section 2.9) and cytogenetic data, 
followed by the FISH and q PCR screening of specific genes (NR3C1, NR3C2, TBL1XR1, 
BMF and CD200/BTLA) using the same positive gene deletion controls (see section 5.3.2 
and 5.3.3). To note, the q PCR sensitivity assay was not repeated in this study because it 
was already described in Chapter 5 (see section 5.3.2.2) Four DS DNA samples were 
hybridized to Affymetrix Genome-Wide Human SNP Array 6.0 (see section 2.10). 
6.4 Results 
6.4.1 Infant group 
6.4.1.1 Cohort Description 
A total of 21 infant cases were investigated; two of them were also Down syndrome 
cases and one was an early relapse case. They were compared with 381 non-infant cases 
who were aged from 2-50 years with a median age of 4 years (Table 6-2 and Appendix 
A). There were no differences in the sex distribution between both subgroups. 81% of 
the infants cases had WCC >10X 109/L with a median of 25 X 109/L, while around half of 
the non-infant cases had WCC <10 X 109/L (p=0.02).  
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ETV6-RUNX1 subgroups   
infants Non-infants P-value 
No. of cases 21 (100) 381 (100)   
Sex (M:F)  13:8 206:175 
0.5 
Ratio 1.6 1.2 
WCC (X 109/L)     
Median 25 10.6  
<10 4 (19) 179 (47) 
0.02 10-49.9 10 (48) 137 (36) 
≥50 7 (33) 65 (17) 
Table 6-2 Comparison between the infant and non-infant cases within ETV6-RUNX1 cases in 
terms of sex and WCC. WCC white cell count, M male, F female, significant P-value if <0.01. 
 
6.4.1.2 The genetic comparison between the infants and non-infant subgroups 
The level of the genetic diversity among both infants and non-infants groups was 
estimated using the available data on eight genes including: ETV6, BTG1, PAX5, 
CDKN2A/B, RB1, EBF1, IKZF1 and PAR1 in infant and non-infant groups (n=21, n=380, 
respectively). Infant cases harboured fewer aberrations (n=14) with a mean of 0.67 
alterations per case, while non-infant cases had a total of 507 alterations with an 
average of 1.3 aberrations per case (p=0.001). A total of 8 infant patients (38%) had no 
alterations in any of the eight genes tested, while 12 patients (57%) had one alteration 
and only a single case (5%) showed two alterations. On the other hand, 79% of non-
infant cases showed alterations in at least one of the selected genes (n=299): a total of 
142 (37%), 115 (30%) and 42 (11%) patients had one, two and three or more aberrations 
(Appendix A and Appendix L).  
Deletions at 12p were the most common abnormality in infants and non-infants 
subgroups constituting comparable proportions of 25% and 31%, respectively (Table 6-3, 
Appendix A and Appendix L). 12p deletions were reflected by the increase incidence of 
ETV6 losses detected by MLPA (33% and 53% in infants and non-infants subgroups, 
respectively). To note, all ETV6 deleted cases in infant cases affected the entire gene 
similar to that seen in non-infant cases who harboured whole ETV6 gene deletions in 
72% of cases. CDKN2A/B losses were commonly found in non-infant cases compared to 
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the infant cases (24% v 0%, p=0.006). BTG1 and TBL1XR1 losses constituted 17% and 
25%, respectively, of the non-infant cases, while none of these deletions were observed 
in infant cases (p=0.03 and 0.05, respectively). It is worth noting that NR3C2, 
CD200/BTLA and 6q losses occurred in both groups at variable proportions. In addition, 
gain chromosome 21 and gain der(21)t(12;21) were seen in both groups as estimated 
from the available cytogenetic and FISH data. 
Around 60% of PAX5 deletions in infant cases showed mostly intragenic losses restricted 
to exons 2-6 (n=3) that were also considered as the commonest type of deletions in non-
infant subgroup (35%). 
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ETV6-RUNX1 subgroups   
Infants Non- infants P-value 
No. of cases 21 (100) 381 (100)   
Deletions       
12p 4/16 (25) 91/292 (31) 0.8 
ETV6 7/21 (33)  201/380 (53) 0.08 
9p 0/16 (0)  15/292 (5)  1.0 
CDKN2A/B 0/21 (0) 93/380 (24)  0.006* 
PAX5 5/21 (24) 88/380 (23)  1.0 
NR3C2 1/14 (7) 10/51 (20) 0.4 
CD200/BTLA 1/14 (7) 7/47 (15) 0.7 
6q 1/16 (6)  34/292 (12)  1.0 
RB1 1/21 (5) 32/380 (8) 1.0 
EBF1 1/21 (5) 13/380 (3) 0.5 
BTG1 0/21 (0) 64/380 (17) 0.03 
TBL1XR1 0/14 (0) 13/51 (25) 0.05 
11q 0/16 (0)  18/292 (6)  0.6 
NR3C1 0/14 (0) 3/50 (6) 1.0 
BMF 0/14 (0) 2/50 (4) 1.0 
IKZF1 0/21 (0) 12/380 (3) 1.0 
13q 0/16 (0) 8/292 (3) 1.0 
PAR1 0/21 (0) 4/380 (1) 1.0 
Gains       
+10 2/16 (11) 7/292 (2) 0.07 
+16 1/16 (6) 13/292 (4)  0.5 
+21¥ 1/21 (5) 58/366 (16) 0.2 
+Der(21)t(12;21)¥                         0/21 (0) 47/363 (13) 0.09 
Near tetraploidy 0/16 (0) 11/292 (4)  1.0 
Table 6-3 Genetic comparison between the infant and non-infant cases within ETV6-RUNX1 
cases. * P value of ≤ 0.01 is statistically significant. ¥ Frequency was estimated from the cases with 
successful cytogenetic or FISH studies.  
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6.4.2 Adolescents and young adults (AYA) group 
6.4.2.1 Cohort Description 
A total of 39 AYA cases were investigated; two of them were also Down syndrome cases. 
The majority of patients (n= 28, 72%) were aged from 10-14 years, whereas the 
remaining cases were distributed in the age groups of 15-17 (n= 7, 18%) and 21-50 years 
(n=4, 10%) with a median age at diagnosis of 12 years. These cases were compared with 
363 non-AYA cases who were aged from 1-9 years with a median age of 4 years (Table 
6-4, Appendix A). There were no differences in the sex distribution between both 
subgroups. Two thirds of the AYA cases had WCC <10 X 109/L with a median of 6 X 109/L, 
while half of the non-AYA cases had WCC >10 X 109/L (p=0.002).    
  
ETV6-RUNX1 subgroups   
AYA Non-AYA P-value 
No. of cases 39 (100) 363 (100)   
Sex (M:F)  20:19 199:164 
0.7 
Ratio 1.05 1.2 
WCC (X 109/L)     
Median 6.2 12.5  
<10 26 (66) 157 (43) 
0.02 10-49.9 8 (21) 139 (38) 
≥50 5 (13) 67 (18) 
Table 6-4 Comparison between the AYA and non-AYA cases within ETV6-RUNX1 cases in terms 
of sex and WCC. P value of ≤0.01 is statistically significant, WCC white cell count. 
6.4.2.2 The genetic comparison between the AYA and non-AYA subgroups 
Considering those cases with available data on the eight MLPA genes in AYA and non-
AYA groups (n=39, n=362, respectively), both AYA and non-AYA cases exhibited a similar 
level of genetic diversity (p=0.1). 74% of AYA cases (n=29) exhibited at least one 
alteration in one of the genes with a total of 60 alterations, averaging 1.5 deletions per 
case (range: 0-4). Similarly, a total of 282 non- AYA cases (78%) harboured a total of 461 
aberrations with a mean of 1.3 alterations per case (range: 0-5). A higher frequency of 
AYA cases tended to harbour 3 or more deletions compared to non-AYA cases (23% v 
9%, respectively, p=0.02). However, a similar proportion of each AYA and non-AYA 
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subgroups (28% and 29%, respectively) exhibited two alterations (Appendix A, Table 5-7 
and Appendix L). 
Deletions at 12p were the most frequent cytogenetic abnormalities in both subgroups 
(24% and 32%) and accordingly ETV6 losses, detected by MLPA, constituted 41% and 
53% in AYA and non-AYA subgroups, respectively (Table 6-5, Appendix A and Appendix 
L). Interestingly, BTG1, RB1 losses and near tetraploidy (80 or more chromosomes) were 
enriched in the AYA compared to the non-AYA subgroup (33% v 14%, p=0.002), (21% v 
7%, p=0.003) and (15% v 2%, p=0.003), respectively). BTG1 deletions commonly affected 
exon 2 with variable extensions to the 3’ region in the non-AYA subgroup as compared 
to the AYA subgroup (92% v 62%, p=0.01). However, AYA cases showed the entire loss 
of the gene in 23% (n=3) and none of the non-AYA cases exhibited this type of loss 
(p=0.007). On the other hand, RB1 losses commonly encompassed the entire gene in 
88% of the deleted cases in non-AYA subgroup compared to the AYA subgroup (37%) 
(p=0.01). CD200/BTLA losses occurred in 36% of AYA cases, while they constituted 8% 
of the non-AYA subgroup (p=0.03). Although 9p deletions occurred in both groups at 
lower frequencies (9% and 4%), CDKN2A/B and PAX5 were common alterations in both 
subgroups (AYA and non-AYA subgroups) (28% and 15% v 23% and 24%, respectively). 
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ETV6-RUNX1 subgroups   
AYA Non- AYA P-value 
No. of cases 39 (100) 363 (100)   
Deletions       
12p 8/33 (24) 87/275 (32) 0.4 
ETV6 16/39 (41) 192/362 (53) 0.2 
CD200/BTLA 4/11 (36) 4/50 (8) 0.03 
BTG1 13/39 (33) 51/362 (14) 0.002* 
9p 3/33 (9) 12/275 (4) 0.2 
CDKN2A/B 11/39 (28) 82/362 (23) 0.4 
PAX5 6/39 (15) 87/362 (24) 0.2 
NR3C2 3/12 (25) 8/53 (15) 0.4 
TBL1XR1 3/13 (23) 10/52 (19) 0.7 
6q 7/33 (21) 28/275 (10) 0.06 
RB1 8/39 (21) 25/362 (7) 0.003* 
NR3C1 1/11 (9) 2/53 (4) 0.4 
11q 3/33 (9) 15/275 (5) 0.4 
BMF 1/12 (8) 1/52 (2)  0.3 
IKZF1 3/39 (8) 9/362 (2) 0.1 
EBF1 2/39 (5) 12/362 (3) 0.6 
PAR1 1/39 (3) 3/362 (1) 0.3 
Gains       
near tetraploidy 5/33 (15) 6/275 (2) 0.003* 
+Der(21)t(12;21)¥ 5/37 (14) 42/350 (12) 0.8 
+21¥ 4/37 (11) 55/350 (16) 0.6 
+10 1/33 (3) 8/275 (3) 1.0 
+16 1/33 (3) 13/275 (5) 1.0 
Table 6-5 Genetic comparison between the AYA and non-AYA cases within ETV6-RUNX1 cases. 
* P value of ≤ 0.01 is statistically significant. ¥ Frequency was estimated from the cases with successful 
cytogenetic or FISH studies.   
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6.4.3 Down syndrome group 
6.4.3.1 Cohort Description 
A total cohort of 13 DS cases were studied and the majority of them were in the age 
group of 2-9 years with a median age of 3 years at diagnosis (range: 1-15). They were 
compared to non-DS cases (n=389) that had a wide range of age (1-50) years with a 
median age of 6 years (Table 6-6, Appendix A). There were no differences in the 
distribution of WCC levels and sex between both subgroups. Among DS cases treated on 
ALL2003 at initial presentation (n=8), there was a single relapse case which occurred > 
6 months after the end of treatment.    
  
ETV6-RUNX1 subgroups   
DS Non-DS P-value 
No. of cases 13 (100) 389 (100)   
Age (years)     
Median 3 4  
1 2 (15) 19 (5) 
0.09 2-9 9 (69) 333 (86) 
10+ 2 (15) 37 (10) 
Sex (M:F)  8:5 211:178 
0.8 
Ratio 1.6 1.2 
WCC (X 109/L)     
Median 14.9 11.1  
<10 4 (31) 179 (46) 
0.3 10-49.9 5 (38) 142 (37) 
≥50 4 (31) 68 (17) 
Table 6-6 Comparison between DS and non-DS cases within ETV6-RUNX1 cases in terms of sex 
and WCC. P value of ≤0.01 is statistically significant, WCC white cell count. 
6.4.3.2 The genetic comparison between DS and non-DS subgroups 
DS cases exhibited slightly fewer number of alterations (n=11), considering the eight 
MLPA genes, with an average of 0.92 alterations per case (range: 0-2) compared to the 
non-DS cases that harboured a total of 510 aberrations with a mean of 1.3 alterations 
per case (range: 0-5) (p=0.04) (Appendix A, Table 5-7 and Appendix L). There was no 
association of any gene alterations to any of the subgroups (Table 6-7, Appendix A, Table 
5-7 and Appendix L). PAX5 losses were the most common gene deletions in DS cases 
(42%), while ETV6 deletions represented the commonest type of alterations in the non-
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DS cases (53%). NR3C1 losses constituted 18% of DS cases, while they represented 8% 
of the non-DS cases (p=0.07).
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ETV6-RUNX1 subgroups   
DS Non- DS P-value 
No. of cases 13 (100) 389 (100)   
Deletions       
12p 2/9 (22) 93/299 (31) 0.7 
ETV6 3/12 (25) 205/389 (53) 0.08 
9p 0/9 (0) 15/299 (5) 1.0 
PAX5 5/12 (42) 88/389 (23) 0.2 
CDKN2A/B 2/12 (17) 91/389 (23) 0.7 
NR3C1 2/11 (18) 1/53 (2) 0.07 
NR3C2 1/10 (10) 10/55 (18) 1.0 
BTG1 1/12 (8) 63/389 (16) 0.7 
6q 0/9 (0) 35/299 (12) 0.6 
RB1 0/12 (0) 33/389 (8) 0.6 
11q 0/9 (0) 18/299 (6) 1.0 
EBF1 0/12 (0) 14/389 (4)  1.0 
13q 0/9 (0) 8/299 (3) 1.0 
IKZF1 0/12 (0) 12/389 (3) 1.0 
PAR1 0/12 (0) 4/389 (1) 1.0 
TBL1XR1 0/10 (0) 13/55 (24) 0.2 
BMF 0/9 (0) 2/55 (4) 1.0 
CD200/BTLA 0 /7 (0) 8/54 (15) 0.6 
Gains       
+21¥ 0/13 (0) 59/374 (16) 0.2 
+Der(21)t(12;21)¥ 0/13 (0) 47/374 (13) 0.4 
+16 0/9 (0) 14/299 (5) 1.0 
near tetraploidy 0/9 (0) 11/299 (4) 1.0 
+10 0/9 (0) 9/299 (3) 1.0 
Table 6-7 Genetic comparison between the DS and non-DS cases within ETV6-RUNX1 cases. * 
P value of ≤ 0.01 is statistically significant. ¥ Frequency was estimated from the cases with successful 
cytogenetic or FISH studies.   
 
6.4.3.3 The genomic profile of Down syndrome ETV6-RUNX1 cases 
Among the four DS cases that were successfully investigated by SNP6 arrays (3428, 3472, 
3684 and 21820), there were a total of 23 deletions including mainly focal losses (<1Mb) 
(n=17) and three copy number gains sized >1Mb (Figure 6.1). Overall, all four patients 
were found to exhibit different genomic profiles with multiple aberrations averaging 6.5 
alterations per case. Thus, patient 3428 had 14, patient 3472 had 6, patient 3684 had 4 
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and patient 21820 had one alteration. The previously identified known CNAs were 
observed in different proportions in the four cases and these losses targeted the 
following regions: 3p14.2 (FHIT, n=1), 6q (n=1), 9p13.2 (PAX5, n=2), 9p21.3 (CDKN2A/B, 
n=1), 11q (n=1), 12p (n=2), 12q21.33 (BTG1, n=1) and 20p12.2 (C20orf94, n=1) (Figure 
6.2). In addition, gain of chromosome Xq was identified in two patients but with slightly 
different breakpoints. CDKN2A/B, PAX5 and BTG1 losses, detected initially by MLPA, 
were confirmed by SNP6 arrays. On the other hand, none of the patients harboured 
deletions encompassing NR3C1, NR3C2, TBL1XR1, CD200/BTLA and BMF genes. 
Interestingly, patient 3428, harboured loss of chromosome 18q (18)(70.00[q22.3]-
78.08[q23]). However, patient 3472 showed copy number neutral Loss of heterozygosity 
[CNN LOH] at chromosome 18 (18)(72.42[q22.3]-74.33[q23]) which clearly overlapped 
with the former region of loss which contained some important genes involved in 
transcriptional regulation including ZNF407, TSHZ1 and ZNF516 (Figure 6.3, Appendix F). 
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Figure 6.1 Ideogram represent the alterations detected by SNP6 arrays in the four Down syndrome cases. The only recurrent alterations (at least in two patients) 
included gain of chromosome Xq and deleted 9p targeting PAX5 gene (occurred in two patients each); Deletions (red lines), gains (blue lines) and CNN LOH (green 
lines). 
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Figure 6.2 Log2 ratio and copy number plots of focal deletions detected by SNP6 arrays in the 
four Down syndrome cases. Biallelic deletion of C20orf94 (A) and monoallelic deletion of FHIT 
(B) in patient 3428, Two independent deletions of CDKN2A/B [monoallelic and biallelic deletions] 
(C) and monoallelic deletion of BTG1 (D) in patient 3472, Monoallelic deletion of PAX5 in patient 
3684 (E). Among these genes, only PAX5 deletion was identified in two patients 3684 and 21820.  
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Figure 6.3 SNP 6.0 profile for chromosome 18 from patient no. 3472 (blue) and 3428 (green) showing overlapped loss of heterozygosity at chromosome 18q 
LOH(18)(72.42[q22.3]-74.33[q23]) either with a copy number  neutral or a copy number of 1, respectively ( red lines). 
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6.5 Discussion 
ETV6-RUNX1 BCP-ALL has been characterised by a narrow range of demographic and 
clinical features; however, outlier subgroups do exist including infants, DS and AYA. This 
study has investigated a total of 21, 13 and 39 cases, respectively, to assess whether or 
not the spectrum of secondary abnormalities in these patients are unique and 
distinguish them from ETV6-RUNX1 as a whole. To the best of my knowledge, this is the 
first study that has substantially increased our knowledge about these unusual 
subgroups. Thus, the frequencies of selected gene alterations that are known to be 
frequent in ETV6-RUNX1 were estimated by different cytogenetic and molecular 
techniques in these atypical subgroups and each subgroup was compared with other 
ETV6-RUNX1 subgroups. 
As Expected, this study showed that the infant subgroup (n=21) was more likely to have 
high WCC with 80% of cases having a WCC >10 X 109/L as compared to half of the non-
infant cases (n=381) and this may reflect the aggressiveness of this disease in this 
subgroup of patients. However, based on selected number of genes incorporated in this 
study, infant cases displayed fewer alterations as compared to those diagnosed at their 
second birthday or older (0.67 v 1.3 alterations per case, respectively). Thus, this striking 
finding might indicate that mutations rather than CNA are the genetic determinants in 
infant subgroup or other unique CNA, undiscovered by previous genomic studies that 
were more probably focussed on the main bulk of typical cases, might play a role. In 
agreement with these findings, a previous genomic study investigated four ETV6-RUNX1 
infant cases aged less than 1 year showed decreased number of CNAs along with 
increased number of the copy number neutral (CNN) regions compared to older children 
and those aged 10 years or older with a mean of 2.75 v 5 v 11.7 alterations per case, 
respectively (Emerenciano et al., 2009). In parallel with these findings, infant MLL 
leukaemia also showed reduced CNAs but increased CNN-LOH regions, however, MLL 
rearrangements are thought to be sufficient by themselves to drive the leukaemogenic 
processes unlike ETV6-RUNX1 fusion gene  (Bardini et al., 2010; Bardini et al., 2011; 
Dobbins et al., 2013). Thus, the characteristic stable genome in infants might be 
attributed to their age group rather than the genetic subtype. 
 186 
 
ETV6 and PAX5 losses were encountered in both infants and non- infants (33% and 24% 
v 53% and 23%, respectively) indicating that these alterations are necessary genetic 
lesions that complement with each other for leukaemic transformation and progression 
(Tijchon et al., 2013).  
Furthermore, lack of CDKN2A/B alterations and the lower incidence of RB1 losses (5%) 
in infants might suggest that cell cycle control pathway is not crucial in their disease 
progression or other genetic lesions might directly or indirectly affect this pathway. 
Hence, there is scope for investigating a number of ETV6-RUNX1 infant cases using 
whole genome or exome sequencing that enable the discovery of possible gene 
mutations especially in the CNN loss of heterozygosity (CNN LOH) identified regions as 
well as uncovering new alterations that might be responsible for the accelerated 
leukaemic conversion. 
 Unlike the infant subgroup, the AYA subgroup tended to have low WCC with a median 
of 6 X 109/L as compared to those aged less than 10 years. Nevertheless, they are still 
assigned to the high risk category owing to their older age. There was no difference in 
the degree of genetic diversity in AYA subgroup as compared to those aged less than 10 
years (1.5 v 1.3 alterations per case) but they differed in the nature and frequencies of 
alterations. Enrichment of BTG1 losses in the AYA subgroup (33%, p=0.002) might 
contribute to relapses in this subgroup of patients owing to the possible drug resistance 
related to BTG1 losses. BTG1 is known to regulate glucocorticoid receptor- dependent 
transcriptional response, thus its loss would result in glucocorticoid resistance (van 
Galen et al., 2010). However, another report postulated that BTG1 loss effect is cellular 
dependent owing to the pleiotropic treatment responses in cell lines harbouring these 
losses (Waanders et al., 2012). It is worth noting that the poor outcome encountered in 
those patients with NCI high risk might be attributed to the increase frequency of BTG1 
losses rather than age per se. In addition, RB1 deletions were frequent in this subgroup 
(21%) which further underscore the previously reported association between BTG1 
losses and other deletions targeting RB1, EBF1 and ETV6 that are usually needed for the 
leukaemia development and they were shown to develop in multiple subclones with 
different deletion sizes (Waanders et al., 2012). Furthermore, the frequency of 6q 
deletions was slightly increased among the AYA subgroup compared to the non-AYA (21% 
v 10%) and it is worth noting that FOXO3 is a target gene of common 6q deletions 
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(Bakker et al., 2004). Interestingly, BTG1 was reported to act as a downstream target of 
FOXO3 as identified from DNA microscreens (Bakker et al., 2007), hence disruption of 
both was suggested to constitute a combined mechanism leading to leukaemia 
development in ALL. The classic BTG1 loss commonly affects the second exon with a 
variable involvement of the 3’ region along with the retention of the first exon among 
ETV6-RUNX1 cases. Interestingly, 23% of BTG1 deletions in the AYA group showed entire 
loss of the gene rather than the typical distinctive pattern in spite of no concomitant 
occurrence of whole gene loss of ETV6 that would indicate possible monosomy 12. It is 
noteworthy that many of the different deletions generate truncated proteins that 
consist of the open reading frame with consequent loss of two conserved C-terminal 
protein interaction domains but they are highly unstable with no essential function 
(Waanders et al., 2012). Hence these losses might act as whole allele deletion with 
reduced expression and subsequent loss of function.  
Furthermore, near tetraploidy was significantly associated with AYA subgroup (15% v 
2%, p=0.003) and this aneuploidy is usually a good prognostic factor (Attarbaschi et al., 
2006; Raimondi et al., 2006). CD200/BTLA alterations seemed to be frequent in AYA 
subgroup and they might be needed for leukaemic development in this group of patients. 
DS cases seemed to have similar demographic and clinical features in terms of age, sex 
and WCC distribution compared to non-DS cases (n=389). However, this subgroup 
showed decreased number of alterations with a mean of 0.92 v 1.3 alterations per case 
in non-DS cases which might be attributed to the selected genes that could be less 
frequent in this subgroup. In support of this explanation, the genomic profiles of the 
four cases showed a mean number of deletions of 5.75 losses per case. Another possible 
explanation might be the fact that DS cases already have gain 21 which may drive the 
leukaemogenic process (Roy et al., 2012). Although BTG1 losses were frequent among 
ETV6-RUNX1 as a whole, DS seemed to harbour fewer BTG1 losses (8%) in this study, 
which disagrees with a previous report that postulated a high frequency among DS ALL 
(Lundin et al., 2012). This is in agreement with a recent report that did not confirm a 
high incidence of these losses in a large series of DS ALL (Buitenkamp et al., 2013b).  
A previous report evidenced the associated good outcome of ETV6-RUNX1 DS ALL 
(Buitenkamp et al., 2013a) as compared to non-ETV6-RUNX1 DS ALL patients who were 
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shown to have inferior outcome. The plausible explanation of the differences in 
outcome might be attributed to the enrichment of JAK2 mutations and CRLF2 
overexpression with associated IKZF1 losses (Kearney et al., 2009) in non-ETV6-RUNX1 
DS ALL. None of the ETV6-RUNX1 DS ALL exhibited these aberrations which might 
suggest that they are mutually exclusive. 
It is worth noting that all four DS cases, analysed with SNP array, showed distinct 
genomic profiles. The only striking finding was the 18q region alteration that contains 
important genes including ZNF407, TSHZ1 and ZNF516, which are zinc finger proteins 
playing roles in transcriptional regulations. These genes were found in the overlapping 
region common to two patients harbouring either monoallelic loss or CNN LOH. This may 
indicate the possibility of having mutations in the other alleles, consistent with the two-
hit hypothesis of TSG inactivation (Knudson, 1971). To the best of my knowledge, there 
are no previously reported alterations in this region in ETV6-RUNX1 as a whole which 
further necessitate investigations to gain further insight in this region in terms of their 
roles in leukaemia development and their prognostic impact.  
The limitation of this study lies in the selection of the techniques that rely on a selected 
number of genes found to be prevalent in the previous genomic studies in the bulk of 
ETV6-RUNX1 cases. Since the aim of the project was to look at the spectrum of 
secondary abnormalities in atypical patients are unique and informative about that 
subtype and ETV6-RUNX1 as a whole, genomic studies might be appropriate to spot 
these differences. However, the availability of good quality material and the relatively 
large number of cases to be studied were the main reasons against utilising SNP arrays. 
The frequencies of CD200/BTLA, TBL1XR1 and NR3C2 losses tended to be higher in AYA 
compared to the previously reported incidences among the bulk of ETV6-RUNX1 cases 
(36%, 23% and 25% v 13%, 12% and 9%, respectively) (Lilljebjorn et al., 2007; Mullighan 
et al., 2007; Kawamata et al., 2008; Lilljebjorn et al., 2010). On the other hand, NR3C1 
losses occurred in 18% of DS cases, a proportion that was higher than the previously 
reported lower incidence (6%) among ETV6-RUNX1 cases. Hence, further validation of 
these findings should be carried out by investigating a large number of atypical patients. 
In conclusion, the atypical groups showed diversity in terms of the nature and 
frequencies of CNAs which might suggest different pathogenic processes responsible for 
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the evolution of leukaemia. When considering the eight MLPA genes, both infants and 
DS subgroups showed less number of CNAs with a mean of 0.67 and 0.92 aberrations 
per case as compared to non-infants and non-DS groups which exhibited each an 
average of 1.3 alterations per case, respectively. However, the AYA subgroup displayed 
a similar diversity of alterations as compared to those aged less than 10 years (1.5 v 1.3 
alterations per case, respectively). CDKN2A/B losses were common in older children and 
AYA subgroups as compared to infants (24% v 0%, p=0.006). In addition, BTG1, RB1 
losses and near tetraploidy are commoner in the AYA group as compared to those under 
the age of 10 years (33% v 14%, 21% v 7% and 15% v 2%, respectively). On the other 
hand, there were no genetic aberrations distinguishing DS ETV6-RUNX1 subgroup from 
other ETV6-RUNX1 but they are definitely different from non-ETV6-RUNX1 DS subgroup 
sue CRLF2 rearrangements that are enriched in the latter subgroup. Further 
collaboration is needed to expand the number of cases to validate the associations with 
co-operating alterations using whole genome analysis. 
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Chapter 7. Summary and Discussion 
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7.1 Overview  
 
B-precursor acute lymphoblastic leukaemia (BCP-ALL) is the most common childhood 
malignancy, characterised by a wide range of primary chromosomal abnormalities that 
provide important diagnostic and prognostic information. The chromosomal 
translocation, t(12;21)(p13;q22), resulting in the ETV6-RUNX1 fusion gene, is the most 
common chromosomal abnormality in childhood BCP-ALL (Golub et al., 1995; Romana 
et al., 1995b; Moorman et al., 2010b). ETV6-RUNX1 fusion gene is by itself unable to 
generate clinical leukaemia (Andreasson et al., 2001), indicating the necessity for 
additional co-operating lesions for leukaemic transformation (Wiemels et al., 1999; Mori 
et al., 2002; Greaves and Wiemels, 2003; Hong et al., 2008; Ma et al., 2013).  
The nature and frequencies of additional genetic alterations differs among different 
cytogenetic subtypes which might, in part, explain their leukaemic development, clinical 
phenotype and subsequent impact on outcome. Thus, exploring the distinct genetic 
landscape of ETV6-RUNX1 compared to other BCP-ALL subtypes was necessary to gain 
further understanding of the relevant driving genetic lesions in ETV6-RUNX1 as shown 
in Chapter 3.   
Considerable research has demonstrated the importance of the ETV6-RUNX1 fusion 
gene in the expansion and the maintenance of preleukaemic stem cells, thus allowing 
vulnerable acquisition of multiple co-operating lesions responsible for full blown 
leukaemia (Hong et al., 2008). However, not much attention has been paid to the 
leukaemogenic effects of the product of the reciprocal RUNX1-ETV6 chimeric gene. 
Nevertheless, high expression of RUNX1-ETV6 protein was reported to be an 
independent adverse factor that more likely arose from cell regrowth rather than drug 
resistance (Stams et al., 2005). Chapter 4 began as a reflection of the abnormal findings 
observed in a previous comprehensive FISH screening that aimed to detect and assess 
the prognostic impact of ETV6 deletions, gain of chromosome 21 and gain of 
der(21)t(12;21) (Enshaei et al., 2013). These abnormal findings suggested the possibility 
of RUNX1-ETV6 alterations with either their deletions or duplications contributing to the 
leukaemogenic progression. Thus further confirmation and postulation of the possible 
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mechanisms arising from RUNX1-ETV6 chimeric gene alterations were reported in 
Chapter 4.   
ETV6-RUNX1 BCP-ALL is characterised by a good outcome; however, relapses occur at a 
rate of 13-20% (Moorman et al., 2010b). Previous genomic studies of relapsed BCP-ALL 
revealed an increase in the number of aberrations, mainly deletions, from diagnosis to 
relapse (Mullighan et al., 2008b). Thus, Chapter 5 focussed on utilising cytogenetic, FISH 
and MLPA data that covered a selection of genes that are recurrently deleted in BCP-
ALL, including CDKN2A/B, PAX5, ETV6, IKZF1 and BTG1. Further screening for the 
presence of other possible relapse related genes targeting TBL1XR1, BMF, NR3C1/2 and 
CD200/BTLA was carried out in the diagnostic samples of ETV6-RUNX1 relapses using 
both FISH and qPCR. These genes are involved in cell cycle regulation, B cell 
development and glucocorticoid receptor signalling and drug resistance. To assess the 
potential relevance of these alterations in the relapse cases, a comparison group of non-
relapse cases was investigated in a similar manner. To test the hypothesis that all genetic 
aberrations detected at relapse were clonally related to the diagnostic samples and did 
not arise as a secondary leukaemia, back-tracking by FISH for all detected genetic lesions 
from relapse to diagnosis was performed. 
It is worth noting that the majority of genomic studies of ETV6-RUNX1 cases have 
focussed on typical cases and little is known about the genetic makeup of rare cases 
including DS, infants and AYA. These cases are commonly affected by other genetic 
entities involving CRLF2 overexpression/ JAK2 mutations (Kearney et al., 2009; 
Mullighan et al., 2009a; Russell et al., 2009), MLL rearrangements and Philadelphia 
chromosome which confer poor outcome (Moorman, 2012). Thus, Chapter 6 aimed to 
assess whether or not the spectrum of secondary abnormalities in atypical ETV6-RUNX1 
patients were unique in terms of their frequencies and diversity compared to other 
ETV6-RUNX1 patients. This was accomplished by utilising all available cytogenetic, FISH 
and MLPA data with additional investigations including FISH, q PCR and SNP array (where 
available) covering all important genes. 
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7.2 What is the overall spectrum of secondary abnormalities in ETV6-RUNX1 
positive cases and is it the same as other subtypes of ALL? 
Previous genomic studies have focused on overall frequencies and the common 
breakpoints of the genetic alterations in ETV6-RUNX1 cases (Mullighan et al., 2007; 
Lilljebjorn et al., 2010). However, little is known regarding the distribution and 
association of these aberrations among different ETV6-RUNX1 subgroups. In addition, it 
is important to shed light on the possible driving leukaemogenic factors in ETV6-RUNX1 
positive cases compared to other BCP-ALL subtypes. Thus, the study of the genetic 
differences may help to understand the mechanism of leukaemic development in both 
groups.  
7.2.1 ETV6-RUNX1 inherently favours a higher degree of genetic diversity 
ETV6-RUNX1 cases displayed a higher diversity of alterations, deletions in particular, as 
compared to other BCP-ALL subtypes evidenced from our data (1.28 v 0.95 alterations 
per case) as well as other previous genomic studies (6 v 3.1 deletions per case) 
(Mullighan et al., 2007). Nevertheless, the increase in the number of alterations might 
be an artefact given the fact that ETV6-RUNX1 positive cases constitute 25% of the 
overall BCP-ALL cohort.  
Despite this genetic diversity, ETV6-RUNX1 patients showed a good outcome, indicating 
possibly a lack of impact of the increased number of aberrations on prognosis, as 
reported recently (Enshaei et al., 2013). In support of these findings, Chapter 5 showed 
that there were no differences in the mean number of alterations per case between the 
relapse and non-relapse cases on analysis of the eight significant genes (2 v 2.25, 
respectively) (see section 5.4.6). The ETV6-RUNX1 fusion gene has inherent abilities to 
favour the expansion of the pre-leukaemic cells, thus increases their susceptibility to 
acquire further aberrations/ mutations owing to the overwhelming proliferative stress 
(see section 1.5.4). The ETV6-RUNX1 fusion gene has a positive impact on the 
persistence and expansion of the pre-leukaemic cells through its inhibitory effects on 
TGF-β (Siegel and Massague, 2003; Bierie and Moses, 2006), miRNA-494 and miRNA-
320a (Diakos et al., 2010), and activating effects on EPOR (Inthal et al., 2008; Torrano et 
al., 2011) and mTOR pathway (Fuka et al., 2011; Fuka et al., 2012; Tijchon et al., 2013). 
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7.2.2 The characteristic genetic alterations associated with ETV6-RUNX1  
This study showed that the common genetic deletions associated with ETV6-RUNX1 are 
those targeting ETV6 (52%), BTG1 (15%), CDKN2A/B (23%) and PAX5 (23%) consistent 
with previous studies (Mullighan et al., 2007; Lilljebjorn et al., 2010). The latter two 
deletions occurred commonly in other BCP-ALL cases suggesting their essential roles in 
leukaemia development in all groups. However, BTG1 and ETV6 losses were enriched in 
ETV6-RUNX1, which suggests that these genetic abnormalities play a collaborative role 
in the development of this BCP-ALL subtype. Higher frequencies of TBL1XR1 and NR3C2 
deletions were seen in typical ETV6-RUNX1 patients in this study, constituting 31% and 
19% of cases, respectively, which were more frequent than previously reported in the 
overall cohort (Lilljebjorn et al., 2010). However, other BCP-ALL cases seemed to 
harbour fewer deletions targeting TBL1XR1 and NR3C2 genes (0.69% each). Thus, 
disruption of both pathways affecting B- cell development and nuclear hormone 
response constitutes the main components of pathogenesis in ETV6-RUNX1, each 
occurring in around one quarter (Lilljebjorn et al., 2010). On the other hand, ETV6-
RUNX1 cases exhibited less frequently IKZF1 and PAR1 alterations; while these 
aberrations were associated with other BCP-ALL subgroups. This might explain the 
favourable outcome seen in ETV6-RUNX1 as IKZF1 losses are associated with a poor 
outcome (Mullighan et al., 2009b). It is worth noting that the rarity of IKZF1 losses in this 
ALL group might be explained by their tendency to occur at an older age (>10 years) 
which constituted just 9% of ETV6-RUNX1 cases. 
7.2.3 Aberrant RAG activity drives the most frequent focal deletions in ETV6-RUNX1 
positive cases 
It is worth noting that ETV6, BTG1, TBL1XR1, IKZF1 and CDKN2A/B deletions are 
generated by aberrant RAG recombinase activity (Mullighan and Downing, 2009b; 
Kuiper and Waanders, 2014; Papaemmanuil et al., 2014). This aberrant mechanism 
represents a driving mechanism in ETV6-RUNX1, in particular (see section 1.4.1.3). The 
RAG activity can be evidenced by the presence of the recombination signal sequences 
(RSSs) (which bind the RAG complex) and RSS- like motifs (small but highly conserved 
segments) which were determined in 12% and 40% of the alterations in ETV6-RUNX1 
cases, respectively (Kuiper and Waanders, 2014; Papaemmanuil et al., 2014). In addition, 
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the non-templated sequences were one of the features of a RAG mediated mechanism 
presenting at 70% of the breakpoints in ETV6-RUNX1 and resulted from terminal 
deoxynucleotidyl transferase (TdT) activity. Furthermore, these RAG mediated 
rearrangements are enriched in active promoters/ enhancers especially those with RSS- 
like motifs and are repetitive in space/ time (Kuiper and Waanders, 2014; Papaemmanuil 
et al., 2014). 
7.2.4 The proposed functional effect of ETV6 losses and gain of der(12)t(12;21)  
ETV6 plays an important role as a transcriptional repressor involved in haematopoiesis 
and angiogenesis (see section 1.5.3). It has been postulated that ETV6 heterodimerizes 
with the ETV6-RUNX1 fusion gene, resulting in reduction of its potency (McLean et al., 
1996; Morrow et al., 2007; Lilljebjorn et al., 2010; Tijchon et al., 2013). Thus the fusion 
gene would drive leukaemogenesis as a result of ETV6 loss. Accordingly, the duplication 
of der(21)t(12;21) would increase the ratio of ETV6-RUNX1 protein over ETV6 protein, 
resulting in further aggravation of the disease. It is worth noting that ETV6 showed lower 
transcript expression in ETV6-RUNX1 positive cases irrespective of the deletion status of 
ETV6. Thus ETV6 may also be silenced by inactivating point mutations or 
hypermethylation (Stams et al., 2005). If so, these alterations would likely have a 
negative effect on outcome, based on their pathogenic sequelae. However, there is no 
evidence to suggest a prognostic effect possibly due to effective modern treatment (see 
section  1.5.7) (Attarbaschi et al., 2004; Stams et al., 2006; Peter et al., 2009; Ko et al., 
2011; Barbany et al., 2012; Enshaei et al., 2013). 
7.2.5 Possible contribution of BTG1 losses on the outcome of NCI high risk patients  
The BTG1 gene plays an integral role in differentiation, proliferation, cell survival and 
glucocorticoid responsiveness. In a previous study, BTG1 losses occurred among ETV6-
RUNX1 patients and were particulary enriched in older patients (> 10 years old) (33% v 
11%). Thus, the observed poor outcome of NCI high risk patients with ETV6-RUNX1 (OS 
of 85% and 86% versus 97% and 97% in ALL97 and ALL99, respectively) (Enshaei et al., 
2013) may be driven by the higher incidences of BTG1 losses rather than age per se. In 
agreement with these findings, BTG1 losses were reported to be significantly higher 
among relapse patients with BCP-ALL (Hogan et al., 2011) which might be attributed to 
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poor therapy respone related to the glucocorticoid resistance. BTG1 gene promotes 
glucocorticoid induced apoptosis through the regulation of the glucortiocoid receptor 
expression, thus BTG1 loss renders leukaemic cells refractory to glucorticoid treatment 
(van Galen et al., 2010).   
7.2.6 PAX5 deletions have different breakpoints in ETV6-RUNX1 and other BCP-ALL  
Although PAX5 gene deletions were common across cytogenetic subgroups including 
ETV6-RUNX1 (see Figure 3.1), the architecture of the deletion breakpoints differed 
between ETV6-RUNX1 cases and other BCP-ALL subtypes. PAX5 is an integral component 
in the initiation of early B-cell development, known as the guardian of B-cell identity and 
regulator of terminal B-cell differentiation (Familiades et al., 2009; Tijchon et al., 2013). 
The resultant expression of these deletions is dependent on the extent of exons involved 
(Mullighan et al., 2007; Familiades et al., 2009). The predominant intragenic PAX5 
deletions in this study in ETV6-RUNX1 positive patients retained exon 1 and had a 
variable pattern of exon deletion (60%). It has been reported previously that deletions 
retaining exon 1 resulted in the generation of mutant alleles with altered transcriptional 
activity owing to the disruption of either the DNA- binding domain or the transactivation 
domain (Mullighan et al., 2007; Familiades et al., 2009).  
On the other hand, other BCP-ALL cases exhibited PAX5 whole gene loss (44%), resulting 
in reduced expression of the normal PAX5 protein. Hence, their negative impact would 
occur in the later stages of differentiation, when both PAX5 alleles are required. 
Furthermore, PAX5 amplification of exons 2 or 5 has not yet been reported among ETV6-
RUNX1 patients, although it represents 1% of other BCP-ALL cases, resulting in a mutant 
allele. PAX5 alterations do not generally have an impact on outcome in BCP-ALL patients 
and in ETV6-RUNX1 positive cases in particular (Mullighan and Downing, 2009a; Enshaei 
et al., 2013). However, patients with PAX5 mutant alleles tended to have a higher 
estimated cumulative relapse rate at 3 years as compared to those with deleted alleles 
(48% v 22%) (Familiades et al., 2009). Taking into consideration that the mutant allele is 
frequent in ETV6-RUNX1 positive cases, there was no observed increase in the number 
of relapses as compared to other BCP-ALL in the present study. Thus, the prognostic 
impact of the two types of deletions needs to be validated in another trial group.  
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7.2.7 Lack of the classic IKZF1 exons 4-7 deletions among ETV6-RUNX1 positive 
cases  
The rarity of IKZF1 losses and the lack of the classic exons 4-7 deletions among ETV6-
RUNX1 patients in the present study may explain the disparity in the prognostic value of 
IKZF1 deletions compared to other BCP-ALL. Although the common deletions found in 
both groups are more likely to have similar effects as the whole allele deletion, none of 
the IKZF1 deleted ETV6-RUNX1 cases relapsed. Thus, deletions targeting exons 4-7 with 
the formation of non-DNA binding isoform (Ik6) (Iacobucci et al., 2008; Iacobucci et al., 
2009) may have additional significance in the emergence of relapse compared to other 
abnormal variants of IKZF1.   
In conclusion, data from this thesis supports the hypothesis that ETV6-RUNX1 
represents a distinct group that differs in terms of the nature of genetic abnormalities 
from other BCP-ALL groups. These differences may explain the different biological and 
genetic features and clinical responses of both groups.    
7.3 Methodologies for detecting secondary abnormalities  
The identification of secondary abnormalities in ETV6-RUNX1 is crucial to understand 
the mechanism of leukaemic transformation and progression of the disease. These 
abnormalities may be present in low proportions of cells at initial presentation but can 
emerge as major clones at relapse, indicating their possible requirement in disease 
recurrence. Thus, it is important to employ techniques with the highest detection rate. 
In addition, it is necessary to utilize different techniques in order to resolve the 
discrepant results which may occur, for instance, in estimating the frequencies of gain 
of chromosome 21, gain of der(12)t(12;21) and ETV6 deletions. Furthermore, the high 
cost of SNP arrays and the inadequacy of suitable material necessitates the development 
of other screening techniques to detect common aberrations with important biological 
roles.    
7.3.1 Cytogenetics versus FISH  
Gain of chromosome 21 and gain of der(21)t(12;21) are common abnormalities in ETV6-
RUNX1 positive cases and their effects on prognosis are debatable. These alterations 
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may be detected cytogenetically; however, the apparently visible gain of chromosome 
21 may be mistaken for gain of der(21)t(12;21). Cytogenetic analysis is an important 
component of diagnosis and risk stratification of ALL, nevertheless, the characteristic 
low mitotic index and poor chromosome morphology of ETV6-RUNX1 positive cases, as 
evidenced from the higher failure rate of the cytogenetic studies (23%), negatively affect 
the comprehensive assessment of these chromosomal abnormalities by cytogenetic 
analyses. Thus, FISH studies were warranted owing to their specificity and sensitivity in 
distinguishing between these alterations (see section 3.4.2), which differ in biological 
functions and possibly outcome. Gain of der(21)t(12;21) might be more pathogenic 
resulting from the presence of additional ETV6-RUNX1 fusion genes. Stams postulated 
an associated worse event free survival rate for the gain of der(21)t(12;21) as compared 
to those with other additional abnormalities involving ETV6 or RUNX1 genes (4 years EFS 
of 60% v 79%) (Stams et al., 2006), consistent with a previous study (Martineau et al., 
2005). FISH is a molecular cytogenetic technique that is easy to use at a higher resolution 
compared to the classic cytogenetic banding techniques (see section 2.8). It allows the 
identification of the chromosomal aberrations irrespective of the cell cycle stage, and 
thus it overcomes the issue of low mitotic index and poor morphology.   
7.3.2 FISH versus MLPA 
ETV6 deletions are considered the most prevalent alteration in ETV6-RUNX1 positive 
cases and their frequencies in this study were estimated by MLPA and FISH. However, 
the discrepancy in the frequency of ETV6 deletions between FISH and MLPA data drew 
our attention to the necessity for the application of both techniques in order to refine 
the estimated frequency. Although MLPA is able to detect smaller deletions below FISH 
resolution, larger deletions, detectable by FISH, can be missed if only present in a low 
proportion (below MLPA sensitivity) (see section 3.4.3.3F. ). However, the correlation 
between MLPA and FISH data pertaining to ETV6 losses, in particular, is a contributing 
factor in considering the need for a clear algorithm for "calling" deletions using MLPA. 
The MLPA data presented in this project was based on the requirement of the loss of at 
least two neighbouring probes within a gene for the deletion to be deemed valid, and 
thus not considering the isolated ETV6 exon 8 losses as real deletions. Accordingly, the 
incidence of existing secondary abnormalities, including the deletion of either the whole 
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ETV6 gene or 3’ETV6 sequences of der(12)t(12;21) that result in an isolated ETV6 exon 
8 deletion can be underestimated (see section 4.4.3.1). 
7.3.3 SNP arrays versus other methods (MLPA, FISH, qPCR) 
A considerable number of genomic studies of ETV6-RUNX1 positive BCP-ALL have 
identified certain prevalent alterations that may be screened by other techniques, 
including FISH, MLPA and qPCR. The main reasons for advocating these screening 
techniques instead of SNP arrays include the difficulty in obtaining high quality DNA, 
matched normal reference samples, optimal normalization of the raw microarray data, 
and the computational algorithm (Mullighan, 2011). In addition, SNP arrays are unable 
to detect aberrations occurring in low proportions of cells (25% or less of the total cells 
is below SNP resolution). Nevertheless, the characteristic variable deletion breakpoints 
in some genes, including TBL1XR1, PAX5 and IKZF1, necessitate the need for good 
coverage across the whole gene that can be ideally provided by SNP arrays. MLPA kits 
provide a high intensity of probes for IKZF1 and PAX5, although TBL1XR1 does not have 
any predesigned kits for detection of the deletion. Hence, copy number qPCR techniques 
were chosen in both Chapters 5 and 6 to screen for TBL1XR1 and other gene losses. 
However, these techniques require large amounts of DNA owing to the need to run four 
replicates of the same reaction for each sample and target probe, using two different 
reference probes in separate reactions. At least one or two probes were chosen for each 
target, which in turn increases the likelihood of detecting deletions with different 
breakpoints. In addition, the application of FISH probes was useful in confirming or 
uncovering further losses. 
7.3.4 Detection of sequence mutations  
In one study, whole genome sequencing of ETV6-RUNX1 positive cases revealed a low 
mutational burden compared to CNA (Papaemmanuil et al., 2014). Activating mutations 
affecting genes involved in the Ras signalling pathway (NRAS, KRAS and SAE1) were 
considered significantly recurrent in ETV6-RUNX1 positive BCP-ALL. To the best of my 
knowledge, it remains unknown whether these mutations constitute a distinct subgroup 
of clinical importance; however, mutational studies of these genes in a large cohort of 
ETV6-RUNX1 cases, or relapse cases in particular, might be an appropriate approach. 
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Furthermore, the lower frequency of CNA in infants with ETV6-RUNX1 suggests that the 
application of exome sequencing in a large series of infants would possibly identify 
aggressive mutations responsible for the accelerated course of this disease.    
In conclusion, the application of screening methods including FISH, MLPA and qPCR 
techniques have uncovered the most common abnormalities in ETV6-RUNX1 positive 
BCP-ALL. The combination of these techniques improves the accuracy of estimating the 
frequencies of these alterations.   
7.4 Does RUNX1-ETV6 play a role in the development of ETV6-RUNX1 ALL? 
7.4.1 Abnormalities of RUNX1/ETV6 fusion gene 
Chapter 4 addressed novel abnormalities affecting the reciprocal products of the 
translocation t(12;21), specifically the RUNX1-ETV6 fusion gene, located on the 
der(12)t(12;21), which might contribute to leukaemogenic progression during the 
course of the disease.  
The reciprocal products of the translocation t(12;21)(p13;q22), and the RUNX1-ETV6 
fusion gene in particular, may undergo different rearrangements resulting from possible 
illegitimate recombination events, owing to the enrichment of Alu repeats flanking the 
translocation breakpoint. Thus, these multiple recombination events may be 
responsible for either the deletion of der(12)t(12;21) at either side of the breakpoint 
(see section 4.4.1), or the generation of the complex der(12) with a duplicated RUNX1-
ETV6 chimeric fusion gene (see section 4.4.2). 
7.4.2 Pathogenesis of deleted der(12)t(12;21)   
The der(12)t(12;21) deletions most likely occurred in utero at the same time as the 
translocation, indicated by their presence in all ETV6-RUNX1 positive cells and the 
consistent deletion boundaries of the translocation breakpoint. It is worth noting that 
deletions of the 3’ETV6 sequences were larger and more common than 5’RUNX1 losses 
of der(12)t(12;21) and encompassed different potential tumour suppressor genes. 
Despite the prenatal origin of these deletions, no accelerated leukaemic transformation 
occurred, indicating their inability to drive leukaemogenesis directly. However, bearing 
in mind the heterogeneous nature of the deletion breakpoints, one can expect a variable 
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phenotypic effect because of the lack of selective pressure. Thus, loss of the tumour 
suppressor genes may variably influence acquisition of additional abnormalities based 
on the extent of the deletions and the affected genes. Both LRP6 and BCL2L14 genes, 
found in the minimum region of deletion, are involved in different cellular activities, 
including: cell differentiation, proliferation and apoptosis, and their losses are also 
encountered in different types of cancer.  
On the other hand, the lack of RUNX1-ETV6 fusion gene formation is considered a shared 
characteristic of these deletions. This effect might be a contributing factor in disease 
progression because the ETV6 ETS domain will be lost in cases with 3’ETV6 sequence 
deletions. It has been previously hypothesized that this might possibly be equivalent to 
the consequence of the deleted non-rearranged ETV6 (Stams et al., 2005). Although the 
RUNX1-ETV6 fusion gene was lacking in cases with 5’RUNX1 sequence losses, the ETS 
domain remained intact, possibly resulting in a reduced leukaemogenic effect than in 
cases with 3’ETV6 sequence loss. Thus, it would be interesting to firstly elucidate the 
leukaemogenic potential of the RUNX1-ETV6 chimeric protein with and without ETV6-
RUNX1 protein by retroviral transduction of either both fusion genes or RUNX1-ETV6 
alone, respectively, in a haematopoietic cell line. Secondly, the evaluation of the 
consequences of both 3’ETV6 and 5’RUNX1 sequence deletions at der(12)t(12;21) could 
be compared by knocking down the ETS domain.     
7.4.3 Previously reported similar deletions in ETV6-RUNX1    
To the best of my knowledge, no previous studies have identified these novel alterations 
as the probes localized specifically to der(12)t(12;21) are not in routine use. Another 
possibility is that they may be mistaken for deletions of the non-rearranged ETV6 allele 
detected by molecular and genomic studies. However, 5’RUNX1 sequence losses have 
previously been referred to as the loss of the small extra red signal when using the 
commercial TEL-AML ES probe (Jabber Al-Obaidi et al., 2002; Martineau et al., 2005; 
Rothman et al., 2005; Konn et al., 2010). The latter finding was shown to occur in 
subclones rather than in major clones, suggesting they are different alterations or that 
the resolution of FISH for the detection of the small RUNX1 FISH signal on 
der(12)t(12;21) is too low. 
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7.4.4 Previously reported related deletions in other BCP-ALL subtypes    
Other primary chromosomal abnormalities, particularly t(9;22)(q34;q11.2); 
inv(16)(p13.1;q22), t(8;21)(q22;q22) and the MLL gene rearrangements (Rothman et al., 
2005), have been reported to be accompanied by deletions affecting the reciprocal 
products. The biological effects and impact on the outcome of these deletions is not yet 
known, apart from der(9)t(9;22) deletions which have been shown to lack prognostic 
value in the imatinib era but not in the pre-imatinib era (Castagnetti et al., 2010; Huh et 
al., 2011). It is worth noting that all der(12)t(12;21) deleted patients had a favourable 
outcome up to the time of thesis submission. However, the small sample size warrants 
further evaluation of these deletions, which can be accomplished by prospective 
screening, in order to validate their prognostic value. In addition, it has been postulated 
that variant rearrangements of these chromosomal abnormalities are more prone to 
such deletions, as seen in der(9)t(9;22) losses (Reid et al., 2003). In agreement with this 
notion, our findings have shown that 17% of patients with deletions at der(12)t(12;21) 
had variant t(12;21) involving an additional chromosome.  
7.4.5  Pathogenesis of the complex der(12) [der(12)(21qter →21q22.12::12p13.2-
12p12.3::12p12.3→12qter)]     
High expression of the RUNX1-ETV6 fusion protein may arise from duplication of the 
RUNX1-ETV6 fusion gene on the complex der(12) [der(12)(21qter →21q22.12::12p13.2-
12p12.3::12p12.3→12qter)] (see section 4.4.2). The duplicated RUNX1-ETV6 fusion 
gene indicates further progression of the disease as it occurred in only a proportion of 
ETV6-RUNX1 positive cells, as a result of possible illegitimate mitotic recombination 
between the normal chromosome 12 and the der(12)t(12;21). Several possible driving 
genetic events resulted from this complex rearrangement, including loss of the non-
rearranged ETV6 allele with the contiguous telomeric sequences, duplication of the 
reciprocal RUNX1-ETV6 fusion gene, and the CNN-LOH of a region on the short arm of 
chromosome 12. ETV6 losses are well recognised alterations in ETV6-RUNX1 positive 
cases and have a negative impact on the transcriptional activity required for B-cell 
development. Other genes were affected in both regions of the deleted telomeric 12p 
and CNN-LOH region of centromeric 12p, but it is difficult to identify the target genes. 
Interestingly, however, LRP6, BCL2L14, DUSP16, CREBL2 and CDKN1B genes, implicated 
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in der(12)t(12;21) losses, were encompassed within the CNN-LOH region. As there are 
no reported mutations in these genes from whole exome analyses (Lilljebjorn et al., 
2012; Papaemmanuil et al., 2014), haploinsufficiency may be responsible for driving 
leukaemogenesis owing to their possible roles as tumour suppressor genes (see section 
4.5). A syngeneic murine model would be a good approach to assess alternately the 
leukaemogenic effect of haploinsufficiency of these losses by monoallelic conditional 
inactivation of each gene.     
Furthermore, the additional RUNX1-ETV6 fusion genes suggested the presence of an 
extra ETS domain that may compete with the intact non-rearranged ETV6, owing to their 
similar binding sites that might result in disruption of the ETV6 and RUNX1 
transcriptional process. It is worth noting that the non-rearranged ETV6 was deleted in 
all cases with a complex der(12), hence the ETS domain is likely to be an essential player 
in leukaemogenic progression. In agreement with this hypothesis, high expression of 
RUNX1-ETV6 proteins was postulated to confer a poor outcome (Stams et al., 2005), 
which was attributed to cell regrowth rather than drug toxicity related pathways. 
However, all patients with this alteration experienced a good outcome up to the point 
of thesis submission. This discrepant clinical outcome may be due to optimal treatment 
rather than coming from distinct subgroups. Nevertheless, it would be interesting to 
measure the expression levels of RUNX1-ETV6 proteins in either patient samples or cell 
lines harbouring a complex der(12) in order to demonstrate the presence of high 
expression. Prospective screening for this alteration would be an ideal approach to 
increase the number of cases for comprehensive evaluation of the prognostic 
significance.  
7.4.6 Importance of the reciprocal products of different translocations in BCP-ALL 
As most reciprocal products are not consistently expressed with the primary products in 
different types of cancer, they are not considered as vital for leukaemic transformation 
(Rego and Pandolfi, 2002). Thus, the RUNX1-ETV6 fusion gene might play an essential 
role in leukaemogenesis owing to the consistent expression of both products in 76% of 
ETV6-RUNX1 cases (Stams et al., 2005), similar to translocations t(9;22) and t(15;17) 
(Sanders et al., 2011). The important roles of the reciprocal products in leukaemogenic 
development have been postulated in the latter two chromosomal abnormalities, while 
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the importance of the reciprocal products of t(4;11) is still debatable. It was suggested 
that AF4-MLL is an integral element that is expressed in around 80% of t(4;11) cases 
(Kowarz et al., 2007) and  contributes to leukaemogenic progression (Bursen et al., 2004; 
Bursen et al., 2010; Wilkinson et al., 2013). However, another study revealed the lack of 
influence of this reciprocal fusion gene on the leukaemogenic process (Kumar et al., 
2011). These contradictory results might be attributed to the different methods used; 
the latter study (Kumar et al., 2011) utilized AF4-MLL siRNA for the knockdown of the 
AF4-MLL protein, while a more recent study has confirmed the inefficient knockdown of 
this protein by AF4-MLL siRNA (Wilkinson et al., 2013).  
To sum up, the RUNX1-ETV6 fusion gene might be of importance in the development of 
ETV6-RUNX1 BCP-ALL because of the presence of the ETS domain, which may be 
responsible for the disruption of transcriptional activity. In addition, alterations 
targeting this fusion gene may contribute to further progression of the disease. Thus, 
acknowledging the importance of the ETV6-RUNX1 fusion gene in initiation of the 
disease and the possibility of its interaction with the RUNX1-ETV6 fusion gene highlights 
the therapeutic potential of inhibiting these fusion genes.          
7.5 What are the mechanisms of relapse in ETV6-RUNX1 ALL?  
Relapse BCP-ALL is considered heterogeneous in terms of its biological and clinical 
features. The clinical response to various modalities of treatment varies with different 
cytogenetic subtypes. The ETV6-RUNX1 subtype is one of the good risk cytogenetic 
subgroups that is characterized by favourable prognosis, although some relapses do 
occur (13%) (Moorman et al., 2010b; Enshaei et al., 2013). Two thirds of relapses 
occurred late in contrast to other BCP-ALL subtypes that were enriched with early 
relapses (64%), suggesting that ETV6-RUNX1 relapses might be attributed to alternate 
mechanisms of leukaemia development, rather than drug resistance. Considerable 
genomic studies on newly diagnosed ETV6-RUNX1 positive cases have revealed 
additional genetic aberrations that are responsible for leukaemic transformation. These 
alterations target multiple genes involved in B-lymphocyte development/ 
differentiation, cell cycle regulation, transcriptional repression and glucocorticoid 
receptor signalling/ drug resistance (Mullighan et al., 2007; Kawamata et al., 2008; 
Lilljebjorn et al., 2010). 
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7.5.1 What are the key genetic drivers? 
This project revealed the frequent occurrence of CDKN2A/B losses in the diagnostic 
samples of the relapse cases (44%) in agreement with previous studies (Maloney et al., 
1999; Graf Einsiedel et al., 2002; Irving et al., 2005a; Mullighan et al., 2008b; Yang et al., 
2008). Similar frequencies were seen between relapse and non-relapse cases in other 
studies in BCP-ALL  (Hogan et al., 2011) and ETV6-RUNX1 positive BCP-ALL (Kuster et al., 
2011). CDKN2A/B is an important element in cell cycle regulation and acts as a tumour 
suppressor gene. It is worth noting that at least three alternatively spliced variants 
encoding different proteins exist, two of them act as inhibitors of CDK4 and CDK6 kinases. 
These kinases normally bind to cyclin D, resulting in the formation of the protein 
complex that phosphorylates the RB protein. RB1 acts as a transcriptional repressor of 
E2F1 target genes and interaction of both RB1 and E2F1 assist in cell cycle regulation. 
Thus, the resultant phosphorylated and inactive form of RB1 will be unable to interact 
and repress the transcription activity of E2F1 proteins, yielding an increase in cell 
proliferation (Sherr, 2001; Naqsh e Zahra et al., 2013; Studniak et al., 2013). The 
remaining isoform variant (p14-ARF) is structurally different and acts through MDM2 
inhibition resulting in activation of the TP53/RB pathway (Sherr, 2001). MDM2 is an 
important negative regulator of the TP53/RB pathway. Thus, loss of CDKN2A function 
would impact negatively on the cell cycle control pathway, yielding further proliferation 
and survival of cells. Thus, the plausible explanation of the higher frequency of 
CDKN2A/B alterations in ETV6-RUNX1 positive relapse cases may be attributed to their 
essential role in leukaemic transformation of the relapse clone rather than drug 
resistance, which is in agreement with enrichment of late relapses observed in this study. 
Interestingly, ETV6-RUNX1 was found to induce MDM2 overexpression through binding 
to its promoter yielding subsequent inactivation of the TP53 pathway (Kaindl et al., 
2014). As alluded to above, the TP53 pathway may be a potential target for targeted 
therapy which would aim to inhibit those proteins responsible for TP53 pathway 
inactivation, including MDM2 overexpression. The in vitro exposure of Nutlin-3 was 
found to act as an analogue of P53 and resulted in reduction of MDM2 expression with 
subsequent P53 pathway activation (Kaindl et al., 2014).   
Furthermore, this study showed that BTG1 alterations were seen in 22% of ETV6-RUNX1 
positive relapse cases compared to 13% of the non-relapse cases (p=0.7), consistent 
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with a previous study (Kuster et al., 2011). However, BTG1 alterations are usually linked 
to drug resistance with the emergence of early relapses resulting from their negative 
impact on glucocorticoid sensitivity (van Galen et al., 2010). It is worth noting that all 
BTG1 deleted ETV6-RUNX1 positive relapses occurred late in this study and thus were 
unlikely to be driven by drug resistance related aberrations. 
TBL1XR1 deletions occurred in almost similar proportions in ETV6-RUNX1 positive 
relapse and non-relapse cases, in disagreement with a previous study that postulated 
their possible association with relapse (Parker et al., 2008). TBL1XR1 acts as a 
transcriptional regulator that binds to the co-repressors of nuclear hormone receptors 
involved in regulation of reproduction, differentiation and homeostasis. TBL1XR1 
deletions are characterised by highly variable breakpoints that may have prognostic 
significance (Parker et al., 2008). The relapse cases in this study showed intragenic 
deletions, while non-relapse cases had deletions affecting the 5’ region of the gene; 
despite this, the possible involvement of exon 1 was not ruled out. In agreement with 
these findings, previous genomic studies of ETV6-RUNX1 positive relapse cases showed 
intragenic involvement of TBL1XR1 rather than the 5’ region (22% v 11%) (Kuster et al., 
2011). It is worth noting that the common region of deletion of the 5’ region was 
reported to contain LOC339845 (Parker et al., 2008), which shares similar features to 
ASS, a gene that has been reported to be involved in chronic myeloid leukaemia (Bacher 
et al., 2005). Interestingly, a similar reduction in TBL1XR1 expression was seen with both 
deletion types. Thus the biological impact of TBL1XR1 would be expected to be similar 
in all deleted cases, resulting in disruption of the capacity of SMRT/N-CoR complex to 
bind receptor molecules, yielding inappropriate control of gene expression through the 
RAR and THR signalling pathways (Parker et al., 2008). In addition, disruption of other 
pathways, including NF-Ƙβ (Perissi et al., 2004) and Wnt- β-catenin mediated 
transcription (Li and Wang, 2008), has been postulated to be affected. Further 
evaluation of the prognostic impact of different TBL1XR1 deletions is recommended in 
a larger series of ETV6-RUNX1 positive patients using FISH and qPCR, to allow further 
evaluation of the functional consequences of the different deletions and determine 
whether the generation of truncated proteins may play a role in the progression of 
disease.  
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This study showed that there are no specific genetic lesions responsible for relapse 
emergence, in agreement with several studies conducted on matched diagnosis-relapse 
pairs in ALL (Staal et al., 2003; Beesley et al., 2005; Bhojwani et al., 2006; Mullighan et 
al., 2008b; Staal et al., 2010). Nevertheless, these studies have highlighted the possible 
involvement of several pathways in nearly half of their cohort including: cell cycle 
regulation, B-cell signalling and proliferation.       
7.5.2 Possible mechanisms behind reduction in relapse rate 
On contemporary protocols, the relapse rate of ETV6-RUNX1 positive patients has 
declined, as seen, for instance, in ALL97/99 and UKALL2003 (13% v 4%), owing to the 
administration of higher doses of asparaginase, vincristine and dexamethasone. In vitro 
drug sensitivity studies have revealed that ETV6-RUNX1 positive leukaemic cells are 
more sensitive to these anti-cancer agents, although the mechanism behind this 
sensitivity is not yet clear (Ramakers-van Woerden et al., 2000; Krishna Narla et al., 
2001). However, it has been postulated that the expression of apoptosis-regulating 
genes, which aid apoptosis-induced chemotherapy, may have a role. Interestingly, in 
vitro studies of ETV6-RUNX1 positive leukaemic cells indicated high expression of Fas 
proteins along with low expression of BCL2, which possibly renders these leukaemic cells 
more sensitive to the apoptosis inducing effects of the specific drugs (Krishna Narla et 
al., 2001). Fas proteins act as pro-apoptotic factors that belong to the tumour necrosis 
factor receptor family, while BCL2 proteins have anti-apoptotic functions.  
Furthermore, ETV6-RUNX1 positive lymphoblasts have the ability to accumulate lower 
amounts of methotrexate polyglutamates (Whitehead et al., 2001), thus ETV6-RUNX1 
positive patients have benefited from the administration of higher doses of 
methotrexate. Taken together, the inter-individual variability of the clinical response to 
treatment might be explained by the pharmacokinetic and pharmacogenomics features 
of the leukaemic cells in any one patient sample. 
7.5.3 Possible targeted therapy to avoid toxicity-related chemotherapy 
Given the fact that intensive therapy, comprising higher doses of asparaginase, 
vincristine and dexamethasone, has potential toxic effects (see section 1.3.6), targeted 
therapy should be considered. It seems that the inherent characteristic of ETV6-RUNX1 
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to favour proliferation and survival of the pre-leukaemic cells may in part constitute the 
main mechanism of relapse emergence. Several experiments have demonstrated the 
functional effect of the ETV6-RUNX1 fusion gene in activation of different pathways 
related to proliferation (e.g. EPOR/JAK/STAT, mTOR) and inactivation of apoptosis-
induced pathways (e.g. TGF-β, TP53, pro-apoptotic microRNAs) (see section  1.5.4). Thus, 
blocking the binding capacity of this fusion gene could be tested in a murine model in 
order to assess the subsequent reduction in leukaemia growth rate and to possibly 
design a suitable inhibitor drug. In my view, targeting important pathways individually, 
including the mTOR pathway may not be appropriate because other cell signalling 
pathways may compensate for their inhibition or activation. However, targeting a 
particular pathway may be of use in the era of personalised medicine which aims to 
tailor therapy to a patient’s genetic architecture.      
In conclusion, there are no specific relapse-predicting biomarkers in ETV6-RUNX1 
positive relapses. The characteristic enrichment of late rather than early relapses may 
be due to the nature of the ancestral ETV6-RUNX1 positive clones to have a long latency 
period in order to acquire new genetic lesions or expand existing abnormal clones that 
emerge as relapse clones. The higher doses of asparaginase are positively associated 
with the favourable outcome of ETV6-RUNX1 BCP-ALL, owing to the higher in vitro 
sensitivity of ETV6-RUNX1 positive cells to this anti-cancer agent. Nevertheless, 
designing inhibitors against the ETV6-RUNX1 fusion gene may be of clinical benefit in 
order to reduce toxicity related chemotherapy.    
7.6 Is there anything to be learnt from studying outliers with ETV6-RUNX1 ALL? 
7.6.1 The demographic features of ETV6-RUNX1 ALL are very tight 
Unlike other cytogenetic subgroups, ETV6-RUNX1 positive patients are characterised by 
very specific demographic features; patients are mostly aged from 3-6 years with two 
thirds of cases in the standard NCI risk category. These features may in part justify the 
characteristic favourable outcome (Golub et al., 1995; Romana et al., 1996; Moorman 
et al., 2010b). Nevertheless, there are subsets of patients who rarely harbour the ETV6-
RUNX1 fusion gene, including infants, DS and AYA subgroups; considered as atypical 
groups. Given the fact that the ETV6-RUNX1 fusion gene has been a poor initiator of 
leukaemia in multiple murine models, a latency period is required for the accumulation 
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of those additional abnormalities which are necessary for further progression of the 
disease. A large and growing body of literature has underscored the presence of 
genomic aberrations in the majority of ETV6-RUNX1 cases. However, it is not yet known 
whether the spectrum of secondary abnormalities in these atypical ETV6-RUNX1 
positive patients is unique and informative for each subgroup. This study has highlighted 
the possibility of differences in the nature and frequencies of genetic alterations among 
these different ETV6-RUNX1 positive subgroups. Thus these differences may uncover 
the different biological features responsible for the development of leukaemia at 
different time points and possibly a different clinical course of the disease. 
7.6.2 What happens outside this scenario - is it clinically relevant? 
7.6.2.1 Age 
The rarity of infants may indicate that the ETV6-RUNX1 fusion gene exhibits a benign 
course of disease as compared, for instance, to MLL rearrangements. However, one 
should consider the possible reasons behind the accelerated emergence of leukaemic 
transformation in this small number of cases. For example, high levels of pre-existing 
pre-leukaemic cells bearing ETV6-RUNX1, the increase in inherent abilities to develop 
leukaemia or the acquisition of aggressive alterations/mutations might play a role.  
Infants with ETV6-RUNX1 positive BCP-ALL showed less genetic diversity in this study, 
which could be expected with the shorter latency period. Nevertheless, masked somatic 
mutations cannot be ruled out as an increase in CNN-LOH regions in infants in this ALL 
subtype has been postulated (Emerenciano et al., 2009). It is worth noting that the 
stable genome in this group of patients might be related to the age group rather than 
the cytogenetic subtype, since infant MLL rearranged ALL is also characterized by fewer 
genetic imbalances (Bardini et al., 2010; Bardini et al., 2011; Dobbins et al., 2013). 
Despite fewer alterations in infants, this study has shown that ETV6 and PAX5 alterations 
still constitute the most common genetic abnormalities in infant ETV6-RUNX1 BCP-ALL, 
as seen in ETV6-RUNX1 leukaemia as a whole, which suggested their essential role in 
leukaemic transformation. In addition, although CDKN2A/B losses were common in 
ETV6-RUNX1 positive cases in general, they seemed to play no role in leukaemia 
development in the infant subgroup. Furthermore, despite the strong association of 
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BTG1 losses and ETV6-RUNX1, leukaemic progression in the infant subgroup did not 
require BTG1 losses compared to non-infant cases. The overall findings in this subgroup 
necessitate further investigations that utilize genomic sequencing in order to 
comprehensively investigate the driving mechanisms. 
The development of clinical leukaemia may be delayed up to an older age in a minority 
of ETV6-RUNX1 carriers. One plausible explanation is that these patients require a much 
longer time to accumulate additional abnormalities because of possible low pre-existing, 
pre-leukaemic cell levels bearing ETV6-RUNX1. In agreement with this notion, the 
observed pre-leukaemic cell level of 10-3 to 10-4 in neonatal blood has been found to 
decrease to a cell level of 10-5 to 10-6 in adult life (Olsen et al., 2006). Unsurprisingly, the 
AYA subgroup accumulated multiple alterations in this study, which may be explained 
by the longer latency period but at a mean level comparable to that seen in non-AYA 
cases. However, the distribution of alterations differed among both subgroups. Our 
findings showed that BTG1, RB1 losses and near tetraploidy were significantly associated 
with the AYA subgroup and constituted higher frequencies compared to that seen in 
non-AYA subtypes.  
It is worth noting that the frequencies of RB1 losses were similar in both adult and 
paediatric BCP-ALL cases in a previous study (Okamoto et al., 2010), which might suggest 
that RB1 deletions are of particular importance in leukaemic development of the AYA 
subgroup with ETV6-RUNX1. As described in section 7.5.1, the RB1 gene is a negative 
regulator of the cell cycle and acts as a tumour suppressor gene involved in other cancer 
types including retinoblastoma, osteogenic sarcoma and bladder cancer (Jehanne et al., 
2014; Kansara and Thomas, 2014). Thus, disruption of the RB1/TP53 pathway is more 
likely in this subgroup of patients resulting in increased cell survival and proliferation. 
RB1 losses occurring in retinoblastoma usually follow the classic two-hit hypothesis of 
tumour suppressor gene inactivation in which both alleles of the tumour suppressor 
gene must be mutated (Knudson, 1971). Given that the majority of RB1 deletions in this 
study are heterozygous and the mutational rate of RB1 is low (2%) (Papaemmanuil et 
al., 2014) in ETV6-RUNX1 positive patients, haploinsufficiency might play a role in this 
subset of patients. Our findings showed that the AYA subgroup encountered focal losses 
restricted to exons 19-26 rather than the entire gene, unlike the non-AYA subgroup. The 
functional consequences of these focal deletions are still not yet defined, however, it 
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has been postulated that they generate truncated proteins with altered functions in 
association with deletions of LPAR6 (Schwab et al., 2013). LPAR6 is located within the 
RB1 gene and encodes G-protein-coupled receptors that preferentially respond to 
adenosine and uridine nucleotides. These receptors are involved in a diverse range of 
physiological and pathological events including neurotransmission, neoangiogenesis, 
fibrosis and cancer (Sokolov et al., 2013). Therefore, it is important to assess the 
expression and function of different RB1 deletions and the consequent LPAR6 loss and 
to shed light on their prognostic role in leukaemic transformation and progression.             
Furthermore, in the present study, 6q deletions were found in 21% of the AYA cases 
compared to 10% in non-AYA cases. In addition, 43% of cases with 6q deletions exhibited 
concurrent BTG1 losses. This is in agreement with a previous study which reported that 
both BTG1 and 6q deletions were more common in adult compared to paediatric BCP-
ALL cases (Okamoto et al., 2010). The FOXO3 gene has been postulated to be the target 
of 6q deletions owing to its lower expression in ALL cell lines compared to normal cell 
lines, suggesting a role for this gene in disease progression (Okamoto et al., 2010). 
FOXO3 is a transcriptional activator involved in apoptosis and BTG1 is a downstream 
target of FOXO3, resulting in a possible synergistic mechanism which negatively affects 
cell proliferation. Disruption of FOXO3 transcriptional activity results from the AKT-
dependent phosphorylation of FOXO3 that aids in the exportation of FOXO3 to the 
cytoplasm through the enhancement of the FOXO3/14-3-3 interaction.  
Hence, the driving mechanisms responsible for leukaemic conversion in AYA seems to 
rely on aberrations commonly found in association with ETV6-RUNX1, which are 
enriched in the AYA subgroup, suggesting different pathogenic processes.  
 
7.6.2.2 DS ALL 
DS ALL is characterized by enrichment of JAK2 mutations and CRLF2 overexpression, 
seen in 19% and 62% of cases, respectively (Kearney et al., 2009; Russell et al., 2009; 
Hertzberg et al., 2010). However, this study has shown that ETV6-RUNX1 DS ALL seems 
to be mutually exclusive of CRLF2 overexpression, which points to the possible existence 
of other alterations responsible for the development of disease in this subgroup.  
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This study has shown that ETV6-RUNX1 non-DS BCP-ALL cases frequently harbour 
abnormal karyotypes (79%) compared to ETV6-RUNX1 DS BCP-ALL cases (56%) similar 
to the picture seen in DS ALL and non-DS ALL in general (Lundin et al., 2014). 
Nevertheless, the degree of genetic diversity in ETV6-RUNX1 DS ALL was comparable to 
that seen in ETV6-RUNX1 as a whole, based on the genomic profiles of four DS cases. In 
addition, previous gene expression studies revealed clustering of two ETV6-RUNX1 DS 
ALL cases with ETV6-RUNX1 non-DS ALL cases (Hertzberg et al., 2010).  
Although both groups displayed a similar degree of genetic diversity, the role of 
constitutional trisomy 21 opens a fascinating layer of complexity. It is worth noting that 
constitutional trisomy 21 may play a role in the development of leukaemia in DS ALL but 
the mechanism is not yet clear. However, its involvement in disruption of foetal liver 
haematopoiesis has previously been postulated (Roy et al., 2012). Furthermore, a recent 
report demonstrated the influence of triplication of a 21q22 region on B cell 
proliferation in both in vivo and in vitro experiments through the overexpression of 
genes marked with H3K27me3 including HMGN1 gene (a nucleosome remodelling 
protein) (Lane et al., 2014). In agreement with the previous report, a recent report have 
postulated the differential enrichment of the H3K4me3 between the trisomy 21 
discordant monozygotic twins suggesting its possible role in the epigenetic 
modifications in DS (Letourneau et al., 2014). HMGN1 acts as a modulator of gene 
expression through its involvement in histone modification (Postnikov and Bustin, 2010; 
Zhu and Hansen, 2010).  
Human chromosome 21 contains around 33.7 Mb and encompasses 364 genes, 31 
antisense transcripts and 5 different miRNAs (Malinge et al., 2009). The DS critical region 
was identified by the genotype-phenotype correlation of children with partial trisomy 
21 suspected of having DS, narrowing the list of genes with possible implications in the 
disease. Nevertheless, the functional influences of these genes are still not yet 
characterised. There are some genes in this region that are considered potentially 
important including ERG, RUNX1, GABPA and ETS2 (Malinge et al., 2009). It is worth 
noting that RUNX1 and other HSA21 proteins including DYRK1A and BRWD1 were 
reported to be involved in the epigenetic modification (Huang et al., 2003; Canzonetta 
et al., 2008; Bakshi et al., 2010).    
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RUNX1 is a transcriptional factor involved in leukaemia, often as result of loss of function 
mutations (Izraeli, 2004); however, the leukaemogenic effect of three copies of RUNX1 
is still not yet known. It has been hypothesized previously that trisomy 21 may express 
different relative levels of RUNX1 isoforms that might in turn aid tumour development 
(Malinge et al., 2009). On the other hand, the remaining candidate genes (ERG, GABPA 
and ETS2) encode ETS transcription factors involved in megakaryocytic differentiation. 
It is worth noting that these ETS transcription factors have been observed in different 
types of cancer, apart from GABPA. Nevertheless, GABPA and ERG are thought to 
contribute in leukaemic transformation of DS ALL through their involvement in either B- 
lymphocyte development or the pathogenesis of pre-B-ALL, respectively (Malinge et al., 
2009). 
Given the fact that a small proportion of DS ALL exhibited ETV6-RUNX1 and that they 
lack the classic genetic features of DS ALL (CRLF2 overexpression and JAK2 mutations) 
(Buitenkamp et al., 2012; Buitenkamp et al., 2013a; Patrick et al., 2014), one may expect 
that this subset of patients might constitute a sporadic form of DS ALL or just be a 
distinct form of DS-ALL, like we see in ALL in general. 
ETV6-RUNX1 DS ALL cases were previously reported to experience a good outcome 
(Buitenkamp et al., 2013a) as compared to non-ETV6-RUNX1 DS ALL patients, who were 
shown to have inferior outcome. The adverse outcome in the latter group was attributed 
to enrichment of CRLF2 rearrangements and JAK2 mutations. It is worth noting that DS 
was considered to be an independent adverse prognostic factor in standard risk patients 
based on multivariate analysis, but this finding was not repeated in a cohort of high risk 
patients (Malinge et al., 2009). This implies the importance of maintaining the intensity 
of therapy in all DS ALL cases is important to achieve a comparable outcome to non- DS 
ALL patients. Therefore, the reduction in chemotherapy in DS ALL patients might be a 
crucial decision to be taken, however, given the possibility that ETV6-RUNX1 DS ALL 
might be a biologically different subgroup; a trial with treatment modification should be 
considered. 
To sum up, the observed differences in the nature and frequency of CNA among atypical 
subgroups (i.e. AYA, infants and DS) underscore possible differences in their biological 
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development. Thus, consideration of these biological differences might aid clinical 
management and improve outcomes through the adjustment of treatment regimes. 
7.7 Overall summary of thesis  
The translocation t(12;21)(p13;q22)/ETV6-RUNX1, is found in 25% of childhood BCP-ALL 
(Golub et al., 1995; Romana et al., 1996; Moorman et al., 2010). It is a transforming 
event and is responsible for the generation and maintenance of a pre-leukaemic clone 
(Andreasson et al., 2001). The high detection rate in the cord blood of healthy neonates, 
the high concordance rate among monozygotic twins and the latency period to clinically 
detectable leukaemia all indicate that postnatal genetic alterations are needed to 
promote the transformation into overt leukaemia (Wiemels et al., 1999; Mori et al., 
2002; Greaves and Wiemels, 2003; Hong et al., 2008; Ma et al., 2013). Despite the 
characteristic favourable outcome in ETV6-RUNX1, some relapses do occur. ETV6-
RUNX1 is less common among AYA, infants and DS patients. This project investigated 
the spectrum of secondary abnormalities and clonal evolution in ETV6-RUNX1 ALL using 
FISH, MLPA, SNP arrays and copy number qPCR.  
The ETV6-RUNX1 group is highly heterogeneous and, when considering the eight genes 
screened for by MLPA, had an average of 1.28 CNA per case compared to 0.95 
alterations per case among other BCP-ALL. ETV6 and BTG1 losses were much more 
common compared to other ALL cases (52% v 10%; 15% v 3%, respectively). An 
alteration affecting the IKZF1 gene, which is involved in B-cell development pathway, 
was less prevalent (3% v 18%). 
Novel abnormalities affecting the RUNX1-ETV6 reciprocal fusion gene, either by deletion 
or duplication, may contribute to leukaemogenesis by either eliminating or amplifying 
RUNX1-ETV6 expression, loss of tumour suppressor genes (e.g. LRP6 and BCL2L14) or 
amplification of oncogenes.  
Patients with CDKN2A/B deletions showed a higher frequency (44%) in the relapse cases 
(p=0.06). A high degree of clonal relatedness was observed between diagnosis and 
relapse. Low level sub-clones at diagnosis were seen emerging as the major clone at 
relapse. 
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Atypical groups (i.e. AYA, infants and DS) showed diversity in terms of the nature and 
frequencies of CNA. The infant group showed fewer CNA compared to non-infants. 
CDKN2A/B deletions are common in older children and AYA groups compared to infants 
(24% v 0%, p=0.006). BTG1 and RB1 losses are commoner in AYA group as compared to 
non-AYA (33% and 14% v 21% and 7%, respectively).    
In conclusion, this study enhances our understanding of the spectrum of secondary 
abnormalities in ETV6-RUNX1 BCP-ALL as a whole and other unusual subgroups. The 
detailed analysis of a series of diagnosis-relapse pairs in ETV6-RUNX1 positive cases has 
provided valuable insight into the clonal evolution of relapse driving markers.    
7.8 Future publications  
A number of publications are to be written: 
1- A Review of ETV6-RUNX1 BCP-ALL including different aspects of the disease in 
terms of epidemiology, clinical characteristics, structure/ function of ETV6, 
RUNX1, both reciprocal products, genetic landscape (alterations in copy number, 
sequences, DNA methylation), clonal heterogeneity and emergence of relapse 
and the prognostic significance of specific genetic abnormalities. 
2- A Research paper on the detailed analysis of a series of diagnosis-relapse pairs in 
ETV6-RUNX1 positive cases to examine clonal heterogeneity and evolution using 
several techniques. 
3-  A Research paper on the potential genetic differences between different 
atypical subgroups of ETV6-RUNX1 BCP-ALL, their influence on outcome and any 
suggested therapeutic modifications in any specific subgroup. 
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Appendix A. Individual demographic, clinical and different gene copy number alterations information of patients with 
ETV6-RUNX1 BCP-ALL.        
 
 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
2615 4/M 46,XY,del(12)(p11p13),inc e 2-3' N WG WG N N e 2-6 N 
2712* 5/M Failed N N N N N N N N 
2760 6/F Failed N WG N N N N N N 
2774* 10/F 47,XX,+5,del(9)(p21),del(9)(p23) N WG N N N N WG N 
2850* 7/F 
46,XX,?t(3;16)(p21;p13),del(12)(p11)/ 45,idem,-
X,add(9)(p?13)/ 46,XX 
e 2-3' WG N e 3-5 N N N N 
2874 6/F 
46,XX,add(3)(p21),del(6)(q12q23),del(12)(p13),a
dd(12)(p11)/ 46,XX 
N N N WG N N N N 
2880 7/M Failed 3' N N N e 4-8 R e 2-5 e 19-26 
2892 8/M 47,XY,t(12;21)(p13;q21),+der(21)t(12;21) N N N N N N N N 
2897‡ 3/F 46,XX,t(2;11)(p?21;p14)/ 46,XX e 2-3' N N WG N N N N 
3026‡ 5/F 
48,XX,+X,t(3;20)(q2?7;q1?),del(12)(p13)t(12;15)(
p1;q1?),t(12;21)(p13;q22),+21/ 
48,idem,add(9)(p?)/ 46,XX 
N N N WG N N N N 
3058 5/M 46,XY,del(6)(q21q25),add(12)(p13)/ 46,XY N N N N N N N N 
3066 1/M 47,XY,+10/ 46,XY N N N 
mono 
e 1-5, 
bi e 8 
N N N N 
3098* 5/M 46,XY,t(12;21)(p13;q22)/ 46,XY N WG N N N N N N 
3119Ψ 6/F 46,XX,add(12)(p)/ 46,XX N N N e 8¥ N N N N 
3135Ψ 9/M 
46,XY,der(9)del(9)(p21)del(9)(q34),del(11)(q?13
q?23),t(12;21)(p13;q22),der(20)t(8;20)(q13;?p)/ 
e 2-3' WG N e 8¥ N N N N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
46,XY 
3136 2/M 46,XY,del(12)(p11.2p13) N N N N N N N N 
3142 5/M Failed N WG N N N N WG N 
3181*
Ψ 
5/F 46,XX,?del(12)(p)/ 47,XX,+mar/ 46,XX46,XX N N N e 8¥ N N e 1-2 N 
3189Ψ 1/F 46,XX N N N e 8¥ N N N N 
3190 3/F Failed N N N WG N N e 1-6 WG 
3194Ψ 4/M 
51,X,+X,-
Y,+9,del(12)(p12),t(12;21)(p13;q22),+18,+21,+21
,+der(21)t(12;21)/ 46,XY 
N N N e 8¥ N N N N 
3208 6/F Failed N N N N WG N N N 
3217 5/M Failed N N N e 2-8 N N N N 
3250 4/M 46,XY e 2-3' WG N e 1-5 N N N N 
3269Ψ 3/M 
46,XY,der(14;21)(q10;q10)t(12;21)(p13;q22),ider
(21)t(12;21)(p13;q22)/ 46,idem,del(13)(q14)/ 
46,XY 
N N N e 8¥ N N N WG 
3296 3/F 46,XX e 2-3' N N WG N N N N 
3301 3/M 47,XY,add(12)(p1?3),+21/ 46,XY N N N N N N e 1-2 N 
3304 6/M 
49,XY,+X,+4,+10,dic(12;13)(p11;p11),i(17)(q10),
+21/ 46,XY 
N N N WG e 2-7 N N N 
3359*
Ψ 
5/F 
47,XX,add(12)(p1),+21 
N N N e 8¥ N N N N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
3409 2/F 
46,XX,del(12)(p11p13)/ 
49,idem,+10,+16,+21,inc/ 
50,XX,+10,del(12)(p11p13),+16,+19,+20/ 46,XX 
N N N WG N N N N 
3418¥ 5/M 47,XY,+21c N N N N N N WG N 
3428¥ 9/M 
47,XY,?r(6)(::p?25q2?1::),-
10,add(12)(p1?3),add(18)(q23),+21c,+r 
N N N WG N N N N 
3431* 3/M 46,XY e 2-3' N N e 2-8 N N N N 
3453 10/F 
46,X,add(X)(q2?8),del(8)(p11),del(11)(q23),del(1
2)(p13)[cp]/ 46,XX 
N WG N WG e 2-3 N WG N 
3472¥ 2/F Failed e 2-3' WG N N N N N N 
3516 8/F 45,X,-X/ 46,XX N N N WG N N N N 
3521 6/M 47,XY,+21/ 48,XY,+X,+21/ 46,XY e 2-3' N N N N N e 2-6 N 
3532 3/F 
47,XX,t(8;12)(p10;p10),del(11)(q?14q2?5),+21/ 
46,XX 
e 2-3' N N N N N N N 
3562* 1/M 
46,XY,der(10)t(10;12)(p11;q2?),ider(12)(p11)t(1
0;12)(p11;q2?),t(12;21)(p13;q22)/46,XY 
N N N WG N N N N 
3588* 6/F 47,XX,del(6)(q?15q2?1),+21/ 46,XX N N N e 2-8 N N N N 
3602Ψ 11/F 
46,XX,del(11)(q23),der(12)t(12;21)(p13;q22)ins(
12;?)(q2?2;?),der(21)t(12;21)(p13;q22),+21,inc 
N N N e 8¥ N N N e 19-26 
3648 3/F 
46,XX,der(2)t(2;21)(q2?4;q2?),del(12)(p11p13),t
(12;21)(p13;q22) 
3' N N WG N N N N 
3671Ψ 6/F 48,XX,+16,+21/ 46,XX N N N e 8¥ N N N N 
3672 4/F 46,XX N N N WG N N N N 
3684¥ 1/F 47,XX,+21c N N N N N N e 2- N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
10 
3700* 4/M 46,XY N N N WG N N N N 
3703* 2/M 
46,XY,t(12;13)(p13;q14)/ 47,XY,+10/ 46,XY,-
8,+10,t(12;13)(p13;q14)/ 
46,XY,t(3;12)(q21;p11)/ 
51,XY,+8,+10,+14,+16,+21 
e 2-3' N N WG N N N N 
3711‡ 3/M 46,XY,del(6)(q2?1q2?3),del(12)(p13)[cp]/ 46,XY N N N WG N N N N 
3726 4/M 46,XY,add(11)(q2?2)/ 46,XY N WG N N N N N N 
3728 3/F 47,XX,del(12)(p),+21/ 46,XX e 2-3' N N WG N N N N 
3738 3/M Failed N N N N N N N N 
3748 3/M 
48,XY,add(9)(p?),?del(12)(p1?p1?),+16,+21/ 
46,XY 
N WG N N N N WG N 
3750 4/M 46,XY N N e 1-10 WG N N N N 
3761‡ 5/M 46,XY N N N WG N N WG N 
3778 3/F 46,XX,del(9)(q2),der(13)t(X;13)(p1;q),dup(17)(q) N N N N N N N N 
3787 4/F 45,XX,der(12;17)(q10;q10)/ 46,XX N N N WG N N e 2-6 N 
3801 2/M 46,XY,del(12)(p1?p1?)/ 46,XY N N N WG N N N N 
3805 4/M 
46,XY,der(1)t(1;?11)(q;q),der(6)ins(6;?1)(q;q),del
(11)(q?21)/ 46,XY 
N N N WG N N N N 
3833* 4/F Failed N WG N WG N N N N 
3861 3/F Failed N N N WG N N N N 
3878 7/M 
46,XY,t(3;9)(p22;q3?4),del(5)(q?31),?del(11)(q?2
2q?23),del(13)(q22q32),inc 
N N N WG N N N N 
3913 7/F 45,XX,der(12;22)(q10;q10)/ 46,XX e 2-3' N N WG e 2-3 N e 2-6 N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
3997 2/M 
46,XY,t(10;13)(q22;q3?),add(12)(p1?),del(12)(p1
?p1?)/ 46,XY 
e 2-3' N N WG N N e 2-6 N 
4011‡ 3/F 
45,X,-
X,dup(1)(?p),dup(4)(?p),der(12)t(12;14)(p;q),t(1
2;21)(p13;q22),-
13,del(18)(q),+del(18)(?q),der(19)t(13;19)(q;?p),
der(20)t(10;20)(?q;q)/ 46,XX 
N N N WG N N e 1-6 N 
4013 4/F 
44-
46,XX,add(11)(q23),del(11)(q2?2),add(12)(p?),+
mar[cp]/ 46,XX 
N N N N N N N N 
4036* 6/M 
46,XY,?der(7)t(7;19)(q1;p1),?der(11)t(7;11)(q1;q
1),t(12;21)(p13;q22),?der(19)t(11;19)(q1;p1)/ 
46,XY 
e 2-3' WG N WG N N N N 
4040 4/F 46,XX,del(12)(p1?2),inc/ 46,XX,inc e 2-3' WG N e 1-5 N N e 2-6 N 
4044* 3/F 45,X,-X,t(4;15)(q21;q?14)/ 46,XX N WG N WG N N N N 
4094 2/M 46,XY,add(4)(q?31),del(13)(q14)/ 46,XY N N N N N N e 2-6 WG 
4153 3/M Failed N N N WG N N e 2-5 N 
4202 5/M Failed e 2-3' WG N N N N N N 
4250 3/M Failed N N N WG N N N N 
4253 2/M 
44-
46,XY,der(1;12)(?p10;?q10),del(3)(q2?),del(11)(
p11.2),-17,add(19)(q13.?3)[cp]/46,XY 
N WG N WG N N N N 
4281 4/M 46,XY,add(6)(q1?)[14]/ 46,XY N WG N e 1-5 N N N N 
4288‡ 6/M 45,XY,-13/ 46,XY N N N WG N N N WG 
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4323 7/M 46,XY,?del(8)(p1?),del(12)(p1?) 3' N N WG N N N N 
4373 2/M 45,XY,dic(12;13)(p1?;p1?),?add(9)(p?)/ 46,XY N N N WG N N e 2-6 N 
4425Ψ 5/M Failed N WG N e 8¥ N N e 2-6 N 
4439‡ 9/M 
46,XY,del(9)(p?2),add(12)(p1?),add(18)(q?)/ 
46,XY 
N N N WG N N N N 
4524Ψ 1/M 46,XY N N N 
bi e 
8¥  
N N N e 19-26 
4528 3/F 46,XX,del(6)(q),del(12)(p)/ 46,XX e 2-3' N N e 2-8 N N N N 
4536‡ 4/M 
46,XY,der(12)t(12;21)(p13;q22),der(15)t(X;15)(q
?;q2?) 
N N N WG N N N N 
4541 3/M 46,XY e 2-3' N N e 2-8 e 2-3 N N N 
4554 2/M 45,XY,del(12)(p)/ 45,XY,dic(9;12)(p1;p1) N N N N N N N N 
4569‡ 7/F 46,XX,del(11)(q13),t(12;17)(q24;q21)/ 46,XX N WG N N N N e 1-6 N 
4598 3/M 46,XY N N N N N N N WG 
4609‡ 4/F 
46,XX,t(12;21;9;18)(p13;q22;p1;q2)ins(18;5)(q?2
;q?q?)t(5;11)(q?;q2),dup(21)(q?) 
N N N N N N N N 
4616 3/M 
46,XY,der(1)t(1;14)(q2?;q1?),add(3)(p2?),del(6)(
q1?q2?),der(7)t(1;7)(q2?;p?1),-
12,del(13)(q1?q?3),+mar1,+mar2/ 
47,idem,+mar/ 46,XY 
N N N N N N e 2-8 WG 
4620 3/M Failed N N N N N N N N 
4637 4/F 46,XX N N N e 1-5 N N e 2-6 N 
4675 11/F 
80-82<4n>,XX,-X,-X,-2,-6,del(6)(q?),-11,-12,-
13[cp]/ 46,XX 
N N N N N N N N 
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4688 5/M 47,XY,t(13;17)?(q12;p11),+21/ 46,XX N N N N N N N N 
4698 4/M 46,XY/ 45,XY,dic(9;12)(?) N WG N WG N N WG N 
4707Ψ 3/M 94-96,inc N N N e 8¥ N N N N 
4731 3/M 46,XY N N WG WG N N N N 
4739 4/F 
46,XX,t(9;18;12;21)ins(18;5)(9qter>9p1::21q22>
qter;18pter>q2::5q31.3>q12::9p1>pter;12qter>
12p13::18q2>qter;21pter>21q22::12p13>pter)t(
5;11)(5pter>q12::11q2>qter;11pter>11q2::5q31
.3>qter),del(12)(p13p13) 
N N N e 1 N N N N 
4758Ψ 3/M 47,XX,del(12)(p11),+21/ 48,idem,+16/ 46,XY e 2-3' N N e 8¥ N N N N 
4778 5/M 46,XY,add(12)(p13)/ 46,XY N N N WG N N N N 
4875 3/M 
47,XY,+21/ 47,idem,add(5)(q?3)/ 48,idem,+10/ 
46,XY 
N N N e 2-8 N N N N 
4894 5/F 47,XX,+21/ 46,XX N N N 
mono 
e 1-5, 
bi e 8 
N N N N 
4902* 3/M Failed N N N WG N N e 2-7 N 
4905¥ 3/F 47,XX,del(12)(p1?),+21c/ 47,XX,+21c f f f f f f f f 
4932 6/F Failed e 2-3' N N WG N N N N 
4936 4/M 46,XY,dic(9;12)(p1?3;p11.2)/ 46,XY N WG N WG N N WG N 
4944 3/F 46,XX,?add(12)(p1?),?add(13)(p),inc N WG N WG N N N N 
4969Ψ 6/M 46,XY,del(9)(p2?),+21/ 46,XY N WG N e 8¥ N N N N 
4995‡ 8/F 
44,X,-X,dic(8;12)(p1?;p1?),inv(9)(p11q13)c/ 
46,XX,inv(9)(p11q13)c 
N N WG WG N N N N 
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5038 2/F 46,XX,t(2;12;7)(q?11;p?12;p?11)/ 46,XX N N N N N N e 2-6 N 
5053 1/M 47,XY,del(6)q(1q2),+21,inc[cp]/ 46,XY N N N N N N e 2-6 N 
5062* 2/F Failed N WG N N N N N N 
5068 5/F Failed e 2-3' N WG e 2-8 N N N N 
5072 4/M Failed N N N WG N N e 2-6 N 
5597* 6/M 
46,XY,der(2,5,15)t(2;15)(q?3;q1?)ins(5;2)(q13;q?
2q?3),t(12;21;8)(p13;q22;q11)/ 46,idem,-
der(2)t(2;15)(q?3;q1?)ins(5;2)(q13;q?2q?3),+t(2;
6)(p1?;q1?3)del(2)(p1?p2?)t(2;15)(q?3;q1?)ins(5
;2)(q13;q?2q?3),-6 /46,XY 
N WG N WG N N N N 
5628 1/F Failed N N N WG N N N N 
5647‡ 5/F 46,XX N WG N e 3-8 N N N N 
5659‡ 3/F Failed N N N WG N N 
e 2-
10 
N 
5721‡ 3/M 45-46,XY,add(11)(q23),add(12)(p?),inc/ 46,XY e 2-3' N N WG N N N N 
5796 4/M 46,XY,del(12)(p12),inv(12)(p11.2q22) N WG N WG N N N N 
5802 11/F 
45,X,-X,t(11;12;21)(p11;p13;q22)/ 
45,idem,del(3)(p21)/ 46,XX 
N N e 1-10 WG N N N N 
5807‡ 5/M 
47,XY,-12,-13,-15,+16,-
17,+21,+mar1,+mar2,+mar3[10] 
N N N WG N N N WG 
5848 2/F Failed N N N N N N e 1-6 N 
5849 3/F Failed N N N WG N N N N 
5859Ψ 5/M 47,XY,+21/ 46,XY N WG N e 8¥ N N N N 
5874 14/F 46,XX,add(12)(p11)/ 46,XX N WG N WG N N N N 
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5884 5/F del(11)(p11p15),add(12)(p1),inc N N N N N N e 2-5 N 
5914‡ 4/M Failed N N N WG N N N N 
7038¥ 13/M 47,XY,+21c N N N N N N N N 
7149 7/F Fail N N N N N N N N 
7239 5/M 46,XY N N N N N N N N 
7258 3/M 
45,XY,dic(12;20)(p11;p1),?t(12;21)(p13;q22)/ 
45,idem,-11,+mar/ 46,XY 
N N WG WG N N N N 
7292 3/M 
46,XY,der(1)t(1;21)(p36;q22),add(9)(p22),del(12
)(p13p13),der(12)?(1pter-
>1p36::21q22::12p13::12p11->12p13::12q15-
>12qter),der(21)t(12;21)(p13;q22) 
N N N WG N N N N 
7361 5/M 
46,XY,?t(12;21)(p13;q22),add(16)(p13),inc/ 
47,idem,del(12)(p11p13),+21,inc 
e 2-3' N WG WG N N N N 
7551 4/M 46,XY,add(12)(p1),?t(12;21)(p13;q22),inc e 2-3' N N WG N N N N 
7552 3/F 
46,XX,add(12)(p1),?t(12;21)(p13;q22),inc/ 
47,idem,+21,inc 
N N N N N N N N 
7571 2/M 46,XY,add(12)(p1),?t(12;21)(p13;q22) N N N WG N N N N 
7613Ψ 3/M 46,XY N N N e 8¥ N N N N 
7646 2/F Failed N N N WG N N N N 
7780 11/M 
46,XY,add(3)(q2),add(12)(p1),t(12;21)(p13q22),a
dd(16)(?q2),add(17)(q2),inc[cp] 
N WG N WG N N N N 
7809 14/M 70~85,XXYY,?del(6)(q1),inc[cp]/ 46XY N N N N N N N N 
8153 2/M Failed N WG N N N N e 2-5 N 
8161Ψ 13/M 46,XY,del(8)(q13q22),add(12)(p13),add(15)(q?2 e 2-3' N N e 8¥ N N N N 
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6) 
8444 5/M Failed e 2-3' WG N N N N N N 
8517 4/M 46,XY,add(4)(p1?5),?i(21)(q10),inc/ 46,XY N N N N N N N N 
8906¥ 3/F 47,XX,t(4;4)(q10;q10),+21c/47,XX,+21c N N N N N N N N 
9034 4/M 46,XY,del(6)(q?2),del(12)(p?1),inc[cp]/ 46,XY N WG N N N N N N 
9050 7/F 46,X,-X,-6,add(12)(p?),+16,+r[cp]/ 46,XX N N N WG N N N WG 
9148 12/M 
46,XY,add(1)(p?36),add(2)(p?23)/ 
47,idem,+X,del(6)(q?14),t(8;13)(p?22;q?13) 
N N N e 3-8 e 2-3 N N WG 
9264 5/M 
47,XY,-11,+der(21)t(12;21)(p12;q22),+mar/ 
46,XY 
N N N N N N N N 
9265 6/F 
78-90<4n>,XXX,-X,-
3,add(3)(q2),+4,+6,add(6)(q2)x2,-9,-11,-12,-
15,+20[cp] 
N N N N N N N N 
9378 6/F 
46,XX,der(11)del(11)(p11)t(11;?15)(q2?3;q1),ad
d(12)(p1),-15,+mar/ 46,XX 
N N N WG N N N WG 
9381 1/M 46,Y,i(X)(q10) N N N N N N N N 
9412 2/M 46,XY,add(9)(q34)/ 46,XY N N N WG N N e 2-6 N 
9424 2/M 46,XY N N N WG N N N N 
9426 8/F 46,XX N N N e 3-8 N N N N 
9429 3/M 46,XY,del(6)(q13q23)/ 46,XY e 2-3' N N WG N N N N 
9516 3/M ?46,del(11)(q2),inc N N N N N N N N 
9533 4/M 
45,XY,der(12)t(12;13)(p1;q1),?der(12;21)t(12;21
)(p13;q22)del(21)(q22q22),-13[cp]/46,XY 
N N N WG N N N N 
 264 
 
 
 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
9535 4/M 
46,XY,del(6)(q1q2),?t(12;21)(p13;q22)/ 
46,idem,add(12)(p13)/ 46,XY 
N N N WG N N N N 
9849 2/M 46,XY,del(8)(p?21)/ 47,idem,+mar/ 46,XY N WG N e 2-8 N N N N 
9855 3/M Failed N N N N N N N N 
9867 3/M Failed e 2-3' N N N N N N N 
9868 4/M 46,XY N N N WG N N N N 
9873 8/M 46,XY,idic(21)(p1)/ 46,idem,add(12)(p1)/ 46,XY N WG N N N N N N 
9879¥ 15/M 47,XY,+21c N N N WG N N N N 
10036 3/F Failed 3' N N N N N e 2-6 N 
10060 3/M 46,XY N N N e 2-8 N N N N 
10065 5/F 
46,X,-
X,del(6)(q13q23),add(8)(p1),del(11)(q22q25)[cp]
/ 46,XX 
N N N N N N N N 
10073 2/F Failed N N N WG N N e 2-5 N 
10076 5/M Failed N N N WG N N N N 
10083 2/F 
46,XX,add(6)(q11),dic(9;18)(p1?3;p11),+21/ 
46,XX 
N WG N N N N WG N 
10086
Ψ 
4/M 
49,XY,t(3;15)(q27;q1?5),+10,del(12)(p11p13),+1
6,add(18)(q2),+21 
N N N e 8¥ N N N N 
10170 6/F 
46,XX,?t(12;21)(p13;q22),del(22)(q11q12)/ 
47,idem,-X,+16,+21/ 48,idem,-X,+10,+16,+21 
e 2-3' N N N N N N N 
10216 17/M 
67~76,+3,+4,+6,+9,+12,+14,+16,+17,+18,+21,inc
/ 46,XY 
e 2-3' N N N N R N e 14-26 
10252 8/M 48,XY,?add(6)(q1),del(12)(p1),+21,+mar/ 46,XY N N N e 8¥ N N N N 
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Ψ 
10253 3/F Failed N N N WG N N e 1-6 N 
10259 2/F 45,XX,-8,der(12)t(8;12)(q11.2;p11.2)/ 46,XX N N N WG N N e 2-6 N 
10267 1/M 46,XY,t(3;6)(q29;q1?3),del(12)(p1?1p13)/ 46,XY N N N N N N N N 
10282 15/M 
46,XY,del(6)(q13q25),-18,+mar/ 
46,idem,t(2;12)(q33;p13)/ 86~92,idemx2[cp]/ 
46,XY 
N N N N N N N N 
10296 3/M 46,XY,add(12)(p13),inc[cp]/ 46,XY N N N N N N N N 
10325 8/F Failed N WG N WG N N N N 
10348 6/F Failed N N N WG N N N N 
10353 5/M Failed N N N 
bi e 5-
8 
N N N N 
10397 4/M 47,XY,+21,inc[cp]/ 46,XY N N N N N N N N 
10398
Ψ 
5/M 
43-45,XY,del(1)(p3),-2,add(6)(q2),-
14,add(16)(p1),-22,+mar1,+mar2,inc[cp]/46,XY 
N WG N e 8¥ N N N N 
10411 4/M 46,XY N WG N N N N N N 
10472 12/F 46,XX,del(6)(q1?),add(19)(p13)/ 46,XX N N N WG N N N N 
10505 3/M 46,XY N N N e 5-8 N N N N 
10514 4/F 46,XX,add(3)(q2?1),add(12)(p10) N N N WG N N N N 
10572 3/M 46,XY,t(1;12)(q3?2;p13),del(6)(q21)/ 46,XY N N N WG N N N N 
10590 4/M 46,XY e 2-3' N N e 3-5 N N e 2-6 N 
10628 5/F 46,XX,del(3)(p13p26),del(6)(q1q2),add(10)(p13) N WG N e 1-2 N N N N 
10688 2/M 47,XY,+21/ 48,XY,+10,+21 N WG N N N N N N 
 266 
 
 
 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
10690 2/M 46,XY,inv(7)(p13q22)c/ 47,idem,+21 N N N N N N N N 
10694 5/M 
49~51,XY,+?5,?add(6)(q?),+?14,+16,+20,+21,inc[
cp]/94~97,XXYY,+4,?add(6)(q?),+16,+21,+21,inc[
cp]/46,XY 
N N N N N N N WG 
10826 3/M 
46,XY,del(3)(q2?6),add(14)(q?24),add(18)(p11)/ 
46,XY 
N WG N e 3,8 N N N N 
10874 6/F 46,XX,del(12)(p13)/46,XX N N N N N N N N 
10875* 5/M Failed N N N N N N N N 
10892 2/M 46,XY N N N WG N N N N 
10921 3/F Failed N WG N N N N N N 
10928 2/F Failed N N N N N N N N 
10956 3/M 
46~47,XY,?add(12)(p1),?t(12;21)(p13;q22),?+21[
cp] 
N N N WG N N N N 
10960 9/F Not Done N WG N WG N N N N 
11001 6/F Failed N WG N N N N N N 
11052
Ψ 
6/M 
Failed 
N N N 
bi e 
8¥  
N N N N 
11054 3/M Failed N N N N N N N N 
11106 5/F 
47~51,XX,-2,add(3)(p21),-
6,+10,+16,+21,+r,+mar1,+mar2,inc[cp] 
N N N N N N N WG 
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11110 4/F 
46,XX,-
5,der(7)t(7;12)(q22;q15),der(8)t(8;12)(p11.2;p11
.2),add(9)(p12),der(12)del(12)(q13q24.3)ins(12;
?)(q13;?),der(12)t(12;21)(p13;q22)del(12)(q12),
add(13)(q34),add(16)(p13.2),add(20)(q13.3),+m
ar[cp]/ 46,XX 
e 2-3' WG N WG  N N N N 
11142 12/M Failed N N N e 3-5 N N N N 
11157 3/M 
48,XY,t(1;13;19)(q21;q1;q13),add(2)(q3),?t(12;2
1)(p13;q22),?del(12)(p13p13),+21,+mar,inc[cp]/ 
46,XY 
N N N e 2-8 N N N N 
11182 7/F 46,X,-X,?t(12;21)(p13;q22)/ 46,XX N N N N N N N N 
11183 6/M 46,XY,?add(12)(p1)/ 46,XY N WG N WG N N N N 
11311 4/F Failed N WG N WG N N e 1-6 N 
11312 4/F 46,XX e 2-3' N N WG N N N WG 
11385 2/M 46,XY N CDKN2B  N e 1 N N N N 
11468 4/F 
45,XX,dic(12;15)(p11;p1)/ 46,idem,+16/ 
45,XX,dic(8;12)(p1;p11)/ 46,XX 
e 2-3' N N WG N N N N 
11541 2/F 46,XX N CDKN2A N e 2-8 N N e 2-8 N 
11542 10/F Failed 3' N WG N N N e 1-6 N 
11545 2/F Failed N N N WG N N N N 
11558 7/M 49,XY,+16,+21,+21/ 46,XY N N N N N N N N 
11562
Ψ 
5/F 
46,XX 
N N N e 8¥ N N N N 
11567 1/F Failed N N N WG N N e 2-6 N 
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11576 3/M 47,XY,+21/ 46,XY N WG N N N N N N 
11636
Ψ 
4/F 
46~48,XX,der(6)t(6;12)(q12;q11.2)ins(6;?)(q12;?
),del(7)(q32q35),del(12)(p13),der(12)add(12)(p1
1.2)add(12)(q13)t(12;21)(p13;q22),del(15)(q13q
26),der(21)t(12;21)(p13;q22),+der(21)t(12;21)[c
p] 
N N N e 8¥ N N N N 
11638 1/M Failed N N WG N N N N N 
11675 2/M 46,XY N WG N N N N N N 
11680 3/M 46,XY N N N N N R e 1-6 N 
11707 6/F 
47~48,XX,der(6)add(6)(p2?2)del(6)(q?13q?21),+
21,+mar[cp]/ 46,XX 
N N N N e 4-8 N N N 
11710 3/M Failed N N N N N N e 2-6 WG 
11763 2/F 46,XX N N N N N N N N 
11773 5/M Failed N N N WG N N N WG 
11777 7/F Failed e 2-3' N N N e 2-8 N N N 
11783 1/M 47,XY,+10,add(12)(p12)/ 46,XY N N N WG N N N N 
11833 5/F Failed N N N N N N N N 
11852 2/M 46,XY,-12,add(19)(?p13.1),+mar/ 46,XY N N N N N N e 2-6 N 
11854 4/F 46,XX N N N WG N N N N 
11855 4/M Failed N N N N N N e 1-2 N 
11908 12/F 
46~47,+2,del(3)(q21q27),t(3;12)(p21;q24.1),?8,d
el(9)(p13p24),del(12)(q22q24.1),t(12;21;13)(p13
;q22;q14)[cp]/ 46,XX 
e 2-3' WG N N N N N N 
11931 2/F ?,<4n>,add(6)(q?),add(12)(p?),add(14)(q?),inc N N N N N N N N 
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11962 3/F 46,XX,del(12)(p1?1),add(19)(p13.3)/ 46,XX N N WG WG N N e 2-6 N 
12018 1/M 
46~47,X,-Y,-10,-12,add(12)(p11.2),-14,-
15,+16,+21,+1~5mar[cp]/ 46,XY 
N N N N N N N N 
12050 11/F 45~46,X,-X,+mar[cp]/ 46,XX N N N N N N N e 19-26 
12086 3/M 46,XY,del(9)(p21p?21),t(12;21)(p13;q22)/ 46,XY N WG N N N N N N 
12127 4/F 46,XX N N N e 2-8 N N N N 
12133 2/M 46,XY,t(2;7)(p11.2;q36)/46,XY N N N WG N N e 1-6 N 
12173 3/M 
46,Y,add(X)(q1),t(1;14)(q21;p1),der(6)add(6)(p1)
add(6)(q1),?t(12;21)(p13;q22),add(22)(p1)/?,?id
emx2,inc/46,XY 
N N N N N N N N 
12244 2/F 46,XX N N N N N N N N 
12246 4/M 46,XY N N N N N N N N 
12249 3/M 79~84,inc[cp]/ 46,XY N N N N N N N N 
12251 5/M 46,XY,?t(12;21)(p13;q22),del(12)(p11p13),inc N WG N WG N N N N 
12287 2/M Failed N N N e 2-8 N N N N 
12290
Ψ 
3/F Failed e 2-3' N N e 8¥ N N N N 
12348 5/F Failed N N N WG N N N N 
12351 5/M 
45~46,XY,-Y,?del(4)(p15),idic(21)(q10)[cp]/ 
46,XY 
N N N N N N N N 
12358 1/F 46,XX,?del(4)(q?q?),-10,add(10)(p?),+mar N N N N N N WG N 
12446 7/F Failed N N N 
mono 
e 2-5,  
bi e 8 
N N N N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
12455 2/M Not done N N N WG N N N N 
12457 2/F 46,XX N WG N N N N N N 
12529 3/F 46,XX N N N 
mono 
e 1-5,  
bi e 8 
N N e 2-6 N 
12531 2/F 46,XX N N N WG N N N WG 
12725 12/M 84~86,add(6)(q?),inc/46,XY N N N N N N N N 
12733 4/F Failed N N N N N N N N 
12737 3/M Failed N WG N N N N N N 
12795 3/M 47,XY,+add(21)(?p10)/46,XY N WG N WG N N N N 
12797 6/F 
46,XX,t(11;12;21)(q13;p13;q22)[/46,idem,del(6)(
q21) 
N WG N WG N N N N 
12819 2/F 
46,XX,add(5)(p1?5),add(9)(p11),add(12)(p13),idi
c(21)(p11)/46,XX 
N N N N N N N N 
12846 8/M 47,XY,+21,add(21)(p1)x2/48,idem,+18/46,XY e 2-3' N N N N N N N 
12901 3/F 46,XX,del(12)(p1?1-2p1?3)/46,XX N N N WG N N e 2-6 N 
19598 2/M 
45,XX,?dic(6;15)(q11;p1),add(11)(p15),del(13)(q
1?3q33)/46,XY 
N N N N N N e 2-6 WG 
19647 3/M Failed N N N WG N N N N 
19685 3/F 45,XX,dic(6;9)(q13;p13),add(16)(p13)/46,XX N WG N 
mono 
e 1-5,  
bi  e 8 
N N e 2-8 N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
19687 3/F 
46,XY,-
9,der(12)add(12)(p11.2)add(12)(q24.1),add(15)(
q21),+mar/46,XY 
N N N 
mono 
e 1-5,  
bi e 8 
N N N N 
19688 2/M 46,XY,del(11)(q22)/46,XY,idem,rea(14) N N N N N N N N 
19735 4/M Failed N N N WG N N e 1-6 N 
19795 5/M 46,XY,add(11)(q13),i(21)(q10)/46,XY N N N N N N N N 
19801 3/M Failed N N N N N N N N 
19851 1/M Failed N N N WG N N N N 
19993 7/F ?96,XXXX,t(12;21)(p13;q22)x2,+21,inc/46,XX N N N N N N N N 
20123 1/F 46,XX,?del(9)(q34q34),?t(12;21)(p13;q22) N N N N N N N N 
20164 4/M 
46,XY,-
10,ins(12;?)(q13;??),+mar/45,idem,dic(9;12)(p1;
p1)/46,XY 
N WG N e 1-5 N N WG N 
20215 1/M 46,XY,add(12)(p11),-13,+?21/46,XY N N N WG N N N N 
20220 1/F 46,XX N N N N N N N N 
20223 6/M 48,XY,+21,+mar[cp]/46,XY N N N WG N N N N 
20311 10/M 
46,XY,add(3)(q25),del(6)(q21q27),add(17)(p11.2
),add(19)(p13)/46,XY 
3' N N N N N N N 
20383¥ 1/M 
47,XY,del(7)(q22q34),add(20)(q11),+21c/47,XY,+
21c 
N N N N N N N N 
20385 2/M Failed N N N N N N e 2-6  N 
20394 3/F 46,XX e 2-3' N N N N N N N 
20395 4/M 
45,XY,dic(9;12)(p13;p13)[8]/46,idem,+mar/46,X
Y 
N WG N WG N N N N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
20406 5/F 46,XX N N N e 3-8 N N e 2-8 N 
20410¥ 3/M Failed N WG N N N N e 2-6  N 
20453 5/F 46,XX,der(12)t(12;?15)(p?13;?q?)/46,XX e 2-3' N N WG N N e 2-6  N 
20519 2/F Failed N N N N N N e 2-6  N 
20521 3/F 
46,XX,add(12)(p1?),?t(12;21)(p13;q22),+mar,inc
[cp]/45,XX,der(8;12)(q10;q10),?t(12;21)(p13;q2
2)/46,XX 
N N N WG N N N N 
20571 8/F 
45,X,-
X,?del(12)(p1?p13),?t(12;21)(p13;q22),inc/46,XX 
N WG N e 2-8 N N N N 
20620 9/M 46,XY N N N N N N N N 
20624 8/M 
47,XY,add(11)(q2),add(12)(p1),?t(12;21)(p13;q2
2),add(19)(p1),add(20)(q13),+der(21)t(12;21)[cp
]/46,XY 
N N N N N N N N 
20626 3/F 46,XX,del(12)(p12) N N N WG N N e 2-6  N 
20627 2/M 46,XY N WG N N N N N N 
20634 2/M 46,XY,del(12)(p12p13),?t(12;21)(p13;q22)/46,XY N N N WG N N N e 19-26 
20694 2/M 46,XY N N N WG N N N N 
20723 6/M 
46,XY,der(2)?t(2;?)(?p11.2;?),?dup(21)(q22)[cp]/
46,XY 
N WG N N N N e 1-6  N 
20733 3/M 
46,XY,?t(12;21)(p13;q22)/?46,idem,add(19)(p13
) 
N N N N N N N N 
20739 3/F Failed e 2-3' N N 
bi e 1,  
mono 
e 8 
N N N N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
20747 3/M 46,XY,del(6)(q?13q?21)/46,XY N N N WG N N N N 
20749 5/F 46,XX N N N 
e 1-2, 
8 
e 2-3 N N N 
20751 3/F 45,X,-X/46,XX N N N e 5-8 N N N N 
20752 6/F 46,XX N N N e 5-8 N N N N 
20754¥ 5/M 46,XY,der(14;21)(q10;q10),+21c N N N WG N N WG N 
20755 4/M Failed N N N 
mono  
e 1-5,  
bi  e 8 
N N N N 
20760 10/M 
87,XYY,-X,-1,-3,+5,-6,-9,+10,-14,-
15,inc[cp]/46,XY 
N N N N N N N N 
20768
Ψ 
1/M 
46~47,XY,+21,?add(22)(q1)[cp] 
N N N e 8¥ N N N N 
20770 4/F 
46,XX,?t(12;21)(p13;q22)/45,X,-
X,add(12)(p1),?t(12;21)(p13;q22) 
N N N N N N N N 
20776 7/F 46,XX,del(5)(q1?5q3?3),del(12)(p1?3)/46,XX N WG N WG N N N N 
20878 6/F 
46,XX,del(5)(q13q23),add(16)(p12),-
17,add(21)(p11),+add(21)(p11)/46,XX 
e 2-3' N N WG N N 
e 2-
10 
N 
20951 5/F 46,XX N N N N N N e 1-6 N 
21190 12/F Failed 
mono 
e 2, bi  
3'  
WG N WG N N N N 
21200
Ψ 
6/F 
48,XX,del(5)(q2?2q3?5),+10,+21 
N N WG 
bi e 
8¥  
N N N N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
21250 9/F 
47,XX,?del(12)(p13p13),?t(12;21)(p13;q22),?+21
/46,XX 
N CDKN2A N e 2-8 N N N N 
21316 3/F 46,XX,del(12)(p11p13)/46,XX N N N 
mono 
e 2-8,  
bi  e 1 
e 1 N e 2-8 N 
21335 3/M 
46,XY,del(4)(p12),i(6)(p10),add(11)(p11),?add(1
2)(p1?2),-15,+mar[cp]/46,XY 
N N N N N N N N 
21340 3/M 46,XY N N N WG N N N N 
21367 3/F Failed N N N e 2-5 N N e 2-5 N 
21390 4/F Failed e 2-3' N N N N N N N 
21398 6/F 72-74,XX,-X,-6,+10,+14,+17,+4mar[cp]/46,XX N N N N N N WG N 
21430 4/M Failed N N N N N N N N 
21435 2/M 46,XY,add(12)(p1),-14,-14,+2mar/46,XY N N N N N N N N 
21436 12/M Failed e 2-3' WG N WG N N N N 
21559 3/M 46,XY N N N 
mono 
e 1-5,  
bi e 8 
N N N N 
21571 4/M ?85~92,XXYY,?t(12;21)(p13;q22)x2,inc[cp]/46,XY N N N e 2-8 N N N N 
21606 4/M 46,XY,t(4;12)(q21;p13)/46,XY N N N N N N N N 
21618 4/M 
46,XY,add(2)(p1),add(7)(p1),add(12)(p1)/46,ide
m,t(3;10)(q21;q26)/46,XY 
N N N WG N N e 2-6 N 
21667 3/M 46,XY,del(11)(q23),i(21)(q10)[cp]/46,XY N WG N N N N N N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
21709 7/M 
47,XY,?add(7)(q3?2),-
12,?del(13)(q?2q?3),+der(21)t(12;21)(p13;q22),
+mar/46,XY 
e 2-3' N N N N N N N 
21732 5/F Failed N WG N e 1 N N N WG 
21741 3/M 
91~92,XXYY,add(4)(p12)x2,add(5)(q31),-
6,del(6)(q1q2)x2,-
9,add(12)(p1?)x2,add(12)(p13)x2,-14,-
17,+1~4mar[cp]/46,XY 
N N N e 1-5 N N N N 
21797 2/F Failed N WG N WG N N N N 
21820¥ 2/M Failed N N N N N N e 2-8 N 
21870 7/M 46,XY,del(12)(p12)/46,XY N N N WG N N N N 
21871 8/M 
46,XY,add(1)(p36),t(1;12)(p34;p13),add(2)(p?),a
dd(6)(q1),add(22)(q13),inc[cp]/46,XY 
N N WG N N N N N 
21910 3/F 47,XX,+21/46,XX N N N N N N e 2-6 N 
21926 2/F 46,XX,inc N WG N WG N N N N 
21991 8/M 
46,XY,add(6)(q1),?t(12;21)(p13;q22)/46,XY,?t(12
;21)(p13;q22) 
N WG N e 1 N R N N 
22010 3/F 45,XX,dic(12;19)(p11;q13),add(13)(q?14)/46,XX N N N WG N N N WG 
22021 7/F 
85~91,XX,-X,-
X,+6,+6,add(6)(q1)x2,del(6)(q1q2)x2,-8,-
12,add(12)(p1),-13,-14,-15,-
16,+21,+21,+1~3mar[cp]/46,XX 
N N N 
mono 
e 1-5,  
bi  e 8 
N N N WG 
22029 4/F 
44,X,-
X,del(11)(q22q23),der(12)t(12;16)(p13;q13),-
N N N WG N N N N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
16,add(21)(p12)/46,XX 
22044
Ψ 
1/F Failed N N N e 8¥ N N e 2-6 N 
22047 3/F Failed N N N N N N e 1-2 N 
22089 11/F Failed N N N N N N N N 
22107 4/F Failed N WG N WG N N N N 
22115 4/M 46,XY,inv(12)(p13q13)/46,XY N N N N N N e 2-5 N 
22131 12/F 46,XX N N N WG N N N 
mono e 
6-14,  
bi e 19-
26 
22164 2/F 
46,XX,del(12)(p?11.2)/46,idem,del(12)(p?11.2)/
46,XX 
N N N WG N N N N 
22195 4/F 
46,XX,der(12)t(12;14)(p13;q2?),der(14)t(14;21)(
q2?;q2?),der(14)t(14;21)(q2?;q2?),+der(14)t(14;
?)(q2?;?),-15,?der(21)t(12;21)(p13;q22),-
22,+der(?)t(?;14)(?;q2?)/46,XX 
N N N N N N e 2-5 N 
22196 2/F 46,XX N N N WG N N N N 
22236 5/M 47,XY,del(12)(p12),+21/46,XY N N N WG N N e 2-6 N 
22240 15/M 46,XY,add(11)(q22)/46,XY N N N N N N N N 
22247 6/F 
46,XX,del(12)(p?13)/92,XXXX,del(12)(p?13)x2/4
6,XX 
N N N WG N N N N 
22264 17/F 46,XX N WG N e 1-5 N N N N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
22268 9/F 45,X,-X,add(9)(q?22),del(12)(p11) e 2-3' CDKN2B  N e 2-8 N N N N 
22270 10/M 46,XX e 2-3' N N N N N N N 
22289 4/M Failed N N N e 1-5 N N e 2-5 N 
22324 13/M 
91<4n>,XXYY,add(3)(q?),del(4)(q2),del(5)(q22q3
1),-6,-7,?+8,-9,+?10,+?10,-
11,add(12)(p11),?del(12)(p11p13)x2,-13,-
14,+?16,-17,-20,+22,+2mar 
e 2-3' N N 
bi e 
8¥  
N N N N 
22344 9/M 46,XY N WG N WG N N N N 
22372 5/F Failed e 2-3' WG N WG N N N WG 
22384 8/F Failed N WG N N N N N N 
22403 2/F 46,XX N WG N N N N N e 19-26 
22419 3/F 
45,X,-X,add(2)(p1),add(3)(p1),t(14;18)(q1;p1),-
15,-17,-20,+3mar,inc/46,XX 
N N N N N N N N 
22467 5/F 46,XX,add(16)(q2?1)[10]/46,XX e 2-3' N N N N N N N 
22561 3/M 46,X,-Y,add(12)(p?12),add(12)(q?24),+mar N WG N e 2-8 N N N N 
22562 4/M 46,XY N N N N N N N N 
22565 3/F 44,X,-X,dic(9;12)(p1?1;p1?1)/46,XX N WG N WG N N WG N 
22574
Ψ 
4/F 
46,X,-X,-
4,del(11)(q23q25),add(12)(p11),+21,+mar/46,XX 
e 2-3' N N e 8¥ N N N N 
22581 2/M 46,XY,t(2;5)(p11.2;q33),add(12)(p13)/46,XY N N N WG N N N N 
22639
Ψ 
3/M 46,Y,add(X)(p2),inc N N N e 8¥ N N e 2-5 N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
22668 3/F 46,XX N N N 
mono 
e 1-5,  
bi e 8 
N N e 1-6 N 
22721 11/F 
48~49,XX,del(1)(q21),add(2)(p?1),?add(11)(p1),-
12,-14,-17,+?18,+21,+21,+2mar,inc[cp]/46,XX 
N N N N N N N N 
22752 4/M Failed N N N N N N e 1-6 N 
22758 3/M 46,XY,inc N N N N N N N N 
22778 4/F 
46,XX,add(9)(p21),add(12)(p13),add(14)(q11.2)[
cp]/46,XX 
N WG N WG N N N N 
22809 3/F 46,XX,add(9)(q34)/46,XX N N N N N N N N 
22817 3/M 46,XY,del(12)(p11.2),?inv(12)(p1q21~23)/46,XY N N N WG N N N N 
22974 3/F 46,XX N N N WG N N N N 
23001 4/M 46,XY e 2-3' N N N N N N N 
23013 15/F 46,XX,del(12)(p12p13)/46,XX N N N WG e 4-8 N e 1-5 N 
23017 4/F 46,XX,add(12)(p11.2)/46,XX N N N N N N e 1-6 N 
23084 4/M 
46,XY,add(6)(q21),t(10;17)(p13;q11.2),-
12,der(20)t(12;20)(q13;q13.3),+mar/46,XY 
N N N N N N N N 
23087 13/M 46,XY,t(3;16)(p21;p13)[cp]/46,XY N N N N N N N N 
23120 5/F 45,X,-X,t(8;12)(p21;p13),add(15)(q24)[cp]/46,XX N N N N N N N N 
23121 4/F 46,XX,add(12)(p13)/46,XX N N N WG N N N N 
23125 2/M Failed N WG N WG N N WG N 
23128 3/M 46,XY N WG N N N N N N 
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 Reg. 
ID 
Age€/
Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS PAR1 PAX5 RB1 
23138 3/M 
46,XY,dic(9;12)(p1;p1),der(13;14)(q10;q10)/45,X
Y,der(13;14)(q10;q10) 
N WG N WG N N WG N 
23148 2/M 
38~47,X,-Y,add(1)(p3?),-
2,?del(6)(q2?1),?add(7)(p?),-11,-13,-
15,+21,+1~9mar,inc[cp] 
N N N N N N N N 
23198 5/F 
46,XX,t(4;13)(p1?3;q14),del(12)(p1),-
20,add(21)(q1),-21,+3mar/46,XY 
N N N WG N N N WG 
23240 6/F 
46~47,XX,add(12)(p1),add(19)(p13),add(20)(p1),
+21,inc[cp]/46,XX 
N WG WG WG N N e 2-5 N 
23275
Ψ 
2/F Failed N N N e 8¥ N N e 2-6 N 
24247 14/F 45,X,-X,del(12)(p11),add(17)(p13)/46,XX N WG N WG N N N N 
24347¥ 2/F Failed N N N N N N N N 
Adolecents/ young adults (added from Chapter 6) not included in Chapter 3 
Reg. 
ID 
Age  
/Sex 
Karyotype 
MLPA  
BTG1 CDKN2A/B EBF1 ETV6 IKAROS 
PAR
1 
PAX5 RB1 
7597 21/M 46,XY N WG N N N N e 2-5 e 19-26 
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Note: €  in years,  ¥ : Down syndrome cases, *: The relapse cases studied in Chapter 5, ‡: The non-relapse group studied in Chapter 5, Ψ: isolated ETV6 exon 8 not included in the 
total number of non-rearranged ETV6 deletions,  N: Normal, R: rearrangement, e: exons, WG: whole gene, 3': 3' end region, mono: monoallelic deletion, bi: biallelic deletion. 
 
  
1927 27/F 
96-97<4n>,XX,-X,-X,+5,del(6)(q?),add(9)(p22), 
del(12)(?p13),+13,i(17)(q10),+18,+18, +22[cp] 
/ 46,XX 
WG N N WG N N N N 
3367 24/F 
45,X,-
X,der(3,9,12,21)t(3;12;21)(q1?;p13;q22)t(3;9)(q2
?;q1?) 
,del(6)(q1?)[2]45,idem, -del(6),+der(6) 
del(6)(q1?)rdup(6)(pter>q1?) 
e 2-3' WG N N N N N N 
1780 15/M 46,XY WG N N N N N N WG 
3936 50/M >70,inc/ 46,XY WG N N WG N N e 2-10 WG 
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Appendix B. ETV6 deletions detected by FISH but masked by MLPA detection threshold criteria and sensitivity.  
Reg I.D FISH ETV6_Ex01A ETV6_Ex01B ETV6_Ex02 ETV6_Ex03 ETV6_Ex05 ETV6_Ex08 
3269 Del ETV6+ gain der(21) (2 copies) (36%) 1.364 1.348 1.244 1.316 1.292 0.746 
3359 Del ETV6+ gain der(21) (1 copy) (93%) 1.011 0.945 1.026 0.959 0.925 0.529 
3472 Del ETV6 (16%) 0.893 0.929 0.945 0.977 0.478 1.069 
3602 Del ETV6+ gain der(21) (1 copy) (55%) 0.981 1.016 0.992 1.018 1.012 0.605 
3684 Del ETV6 (7%) 0.974 0.993 0.917 0.975 0.901 0.945 
3726 Del ETV6 (26%) 0.876 0.859 0.892 0.864 0.906 0.978 
4013 Del ETV6 (37%) 0.979 0.961 0.94 0.908 0.961 0.937 
4554 Del ETV6 (6%) 0.997 0.96 0.954 0.949 0.972 0.987 
4616 Del ETV6 (13%) 0.947 0.901 0.91 1.02 0.804 0.928 
4620 Del ETV6 (66%) 0.81 0.83 0.791 0.862 0.823 0.853 
4707 Del ETV6+ gain der(21) (1 copy) (35%) 1.05 0.999 1.008 1.082 0.861 0.611 
4758 Del ETV6+ gain der(21) (1 copy) (92%) 1.046 1.075 0.956 1.015 0.954 0.584 
5038 Del ETV6 (16%) 0.924 0.953 0.858 0.93 0.914 0.899 
7149 Del ETV6 (30%) 0.81 0.888 0.878 0.907 0.852 0.733 
7552 Del ETV6 (54%) 0.85 0.98 0.948 0.958 0.864 1.073 
9873 Del ETV6+ gain der(21) (1 copy) (29%) 0.986 1.068 0.929 0.955 0.815 0.802 
Del ETV6 (23%) 
10083 Del ETV6+ gain der(21) (1 copy) (39%) 1.053 1.173 1.162 0.865 1.005 0.923 
10252 Del ETV6+ gain der(21) (1 copy) (93%) 0.882 0.917 0.92 0.979 0.895 0.636 
11001 Del ETV6 (6%) 0.98 0.928 0.917 0.933 0.909 0.921 
11052 Del ETV6+ gain der(21) (1 copy) (14%) 0.928 0.984 0.896 0.977 0.956 0.353 
11636 Del ETV6+ gain der(21) (1 copy) (90%) 1.03 0.958 0.936 0.939 0.95 0.566 
11675 Del ETV6 (11%) 0.945 1.014 0.612 0.868 0.944 0.948 
11707 Del ETV6+ gain der(21) (1 copy) (8%) 1.353 1.313 1.292 1.252 1.309 0.98 
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Reg I.D FISH ETV6_Ex01A ETV6_Ex01B ETV6_Ex02 ETV6_Ex03 ETV6_Ex05 ETV6_Ex08 
11833 Del ETV6 (18%) 0.878 0.945 0.516 0.838 0.911 0.865 
12018 Del ETV6 (11%) 0.981 0.947 1.015 0.903 1.003 0.85 
12244 Del ETV6+ gain der(21) (1 copy) (5%) 1.03 1.024 0.884 0.939 0.88 1.109 
12737 Del ETV6+ gain der(21) (1 copy) (51%) 0.943 0.959 0.929 0.959 1.051 0.715 
Del ETV6 (15%) 
19688 Del ETV6 (51%) 0.87 0.949 0.941 0.834 0.973 0.941 
20311 Del ETV6 (5%) 0.971 0.867 0.808 0.927 0.952 0.917 
20519 Del ETV6 (26%) 0.811 0.771 0.824 0.765 0.7 0.816 
20624 Del ETV6+ gain der(21) (1 copy) (64%) 0.987 0.998 0.958 0.877 1.106 0.729 
20627 Del ETV6 (19%) 0.915 0.95 0.755 0.756 0.827 0.882 
Del ETV6+ gain der(21) (1 copy) (18%) 
20733 Del ETV6+ gain der(21) (1 copy) (8%) 1 1.021 1 1.03 1.008 1.093 
20770 Del ETV6 (85%) 0.884 0.927 0.91 0.883 0.898 0.792 
20951 Del ETV6 (25%) 0.954 0.983 0.997 0.978 1.007 0.967 
21200 Del ETV6 (14%) 1.105 1.114 1.118 1.074 1.149 0.203 
Del ETV6+ gain der(21) (1 copy) (13%) 
21335 Del ETV6 (12%) 0.905 0.948 0.965 1 1.009 0.947 
21390 Del ETV6 (28%) 0.818 0.838 0.743 0.851 0.75 0.842 
21435 Del ETV6 (66%) 0.795 0.787 0.769 0.809 0.837 0.772 
23017 Del ETV6 (84%) 0.832 0.827 0.776 0.762 0.837 0.781 
23084 Del ETV6 (18%) 0.955 1.004 1.059 0.947 0.928 0.818 
23275 Del ETV6 (16%) 0.952 0.988 0.951 0.931 0.936 0.623 
Note:  MLPA probe ratios: Probe ratios between 0.75 and 1.3 were considered to be within the normal range, with 2 being the normal copy number, while values below 0.75 or 
above 1.3 indicated loss or gain of genetic material, respectively, and corresponded to copy numbers of 1 and 3, respectively. A value below 0.25 indicated biallelic loss which 
represented a copy number of 0. 
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Appendix C. The detailed list of FISH clones used in this study.    
Clone name Br. Version no. Start breakpoint End breakpoint Chromosome position Genes 
RP11-525I3 E 60 12086278 12183936 12p13.2   
RP11-434C1 E 46 11529145 11739576 12p13.2 ETV6 
RP11-267J23 E 60 12183937 12374586 12p13.2 BCL2L14, LRP6 
RP11-757G14 E 60 12374587 12516582 12p13.2 LOH12CR3  
RP11-180M15 
E 
60 12724970 12880857 12p13.2-12p13.1 
CREBL2, GPR19, CDKN1B, 
APOLD1 
RP11-59H1 E 60 12880858 13000779 12p13.1 hsa-mir-613, DDX47 
RP11-392P7 E 60 13000780 13160327 12p13.1 GPRC5A/D, HEBP1, hsa-mir-614 
RP11-377D9 
E/
U 
60/feb 2009 13160328 13251317 12p13.1   
RP11-688K16 E 60 13251318 13363944 12p13.1 GSG1, EMP1 
RP11-161A14 
E/
U 
60/feb 2009 13363945 13539444 12p13.1 C12orf36 
RP11-4N23 E 60 13614529 13701029 12p13.1   
RP11-72J9 E 60 14245642 14339661 12p13.1   
RP11-515B12 E 60 14449642 14613718 12p13.1 ATF7IP 
RP11-233G1 
E 
60 14944108 15122278 12p12.3 
WBP11, C12orf60/69, ART4, 
MGP,  
ERP27, ARHGDIB 
RP11-365O10 E 37 15259830 15381854 12p12.3   
RP11-74N9 E 37 17093825 17169824 12p12.3   
RP11-633O13 
E/
U 
60/feb2009 17889133 18071123 12p12.3   
RP11-604C20 E 60 19830459 19957265 12p12.3   
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Clone name Br. Version no. Start breakpoint End breakpoint Chromosome position Genes 
RP11-405A12 E 41 19976170 20140548 12p12.2   
RP11-125O5 E 41 21153764 21303649 12p12.1 SLCO1B1 
RP11-12D15 E 41 22250546 22369579 12p12.1 ST8SIA1 
RP11-444N1 E 41 23483119 23668225 12p12.1 SOX5 
RP11-318G08 E 41 25394082 25557296 12p12.1 IFLTD1(part of ) 
RP11-396G11 E 45 35424632 35624246 21q22.12 AML1ba (part of) 
RP11-714H12 
E/
U 
60/Feb 
2009 
37040715/3703971
6 
37206890/3720789
0 
21q22.12  hsa-mir-802 
RP11-773I18 
E/
U 
60/Feb 
2009 
37255989/3725499
0 
37426099/3742709
9 
21q22.12 SETD4 
RP11-23N18 
E/
U 
60/Feb 
2009 
37651721/3765072
2 
37833845/3783484
5 
21q22.12- 21q22.13 MORC3, CHAF1B 
RP11-383L18 
E 
/U 
60/Feb 
2009 
38188159/3818716
0 
38389773/3839077
3 
21q22.13 HLCS 
RP11-777J19 
E 
/U 
60/Feb 
2009 
38720388/3871938
9 
38886895/3888789
5 
21q22.13 DYRK1A 
WI2-2188G13  U 39845 12039458 12076941 12p13.2 ETV6 exon 8 
WI2-3280E3 * U Feb-09 176833554 176876728 3q26.32 3' TBL1XR1 part 
RP11-499P15 E 71 176836521 176920665 3q26.32 TBL1XR1 
WI2-
3156C10* 
U Feb-09 176918625 176960907 3q26.32 
5'TBL1XR1 area 
WI2-2979I5* U Feb-09 176966617 177011487 3q26.32 
RP11-484E7 E 45 76248984 76475216 3p12.3 
TBL1XR1 Control 
Cep 3        Centromeric chromosome 3 
RP11-278J6 E 50 142640980 142798050 5q31.3 NR3C1 
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Clone name Br. Version no. Start breakpoint End breakpoint Chromosome position Genes 
RP11-49C20 E 45 40469944 40650640 5p13.1 NR3C1 Control 
RP11-76G10 E 50 149237494 149397852 4q31.23 
NR3C2 
RP11-186E11 E 50 149420652 149539282 4q31.24 
RP11-
655B23* 
E 68.37 149318833 149500077 4q31.23 5' NR3C2 part 
RP11-572O17 U Mar 2006 1595349 1784573 4p16.3 NR3C2 Control 
RP11-231E6 E 68.37 112099169 112225162 3q13.2 BTLA 
RP11-90K6 ¥ E 68.37 112021325 112051638 3q13.2 CD200 
RP11-54L6 E 68.37 18526330 18628552 3p24.3 BTLA control 
CTD-2251F23 U Feb-09 40329778 40452050 15q15.1 BMF 
Cep 15        
Centromeric chromosome 
15 
BMF Control 
RP11-149I2 E 71 21911259 22010413 9p21.3 CDKN2A 
WI2-3139G6  U Feb-09 36981616 37016002 9p13.2 PAX5 exon 2 
WI2-1118A2    U Feb-09 36937043 36977242 9p13.2 PAX5 exon 7 
CEP 9        Centromeric chromosome 9  PAX5,CDKN2A/B control 
WI2-1903N19  U Feb-09 11862785 11903576 12p13.2 ETV6 exon 2 
WI2-1132J19 U Feb-09 11811608 11848801 12p13.2 ETV6 exon 1 
RP11-24B21 E 71 92378756 92536690 12q21.33 BTG1 
Cep 12        
Centromeric chromosome 
12 
BTG1 Control 
Note: *: These specific probes were only utilised for discrepant cases and not in the initial screening, ¥: Withdrawn because of suboptimal signals. Br. Genome browser, U UCSC, E 
Ensembl.
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Appendix D. Cut off values of the FISH probes used in the whole PhD 
project.  
Probe set Gene Cut off value 
Mapping der(12)t(12;21) deletion  Multiple genes 5% 
RUNX1-ETV6 DC SF RUNX1, ETV6 6% 
ETV6 DC BA ETV6  4% 
RUNX1 DC BA RUNX1 4% 
CEP12-subtel 12p  NA 2% 
WI2-2188G13 (G248P86604D7)[ETV6 exon 8] 
/RP11-434C1 [5'ETV6] 
ETV6 exon 8 
4% 
WI2-2188G13 (G248P86604D7)[ETV6 exon 8] 
/RP11-396G11 [5'RUNX1] 
4% 
WI2-3280E3 (G248P89324C2)/CEP3 
TBL1XR1 
2% 
RP11-499B15/RP11-484E7 or CEP3 4% 
WI2-3156C10 (G248P8042B5)/CEP3 2% 
WI2-2979I5 (G248P88336E3)/CEP3 2% 
RP11-278J6/RP11-49C20 NR3C1 2% 
RP11-76G10/RP11-572O17 
NR3C2 
2% 
RP11-186E11/RP11-572O17 4% 
RP11-655B23/RP11-572O17 2% 
RP11-231E6/RP11-54L6 or CEP 3 BTLA 0% 
CTD-2251F23/Cep 15 BMF 2% 
RP11-24B21/CEP12 BTG1 2% 
RP11-149I2/CEP 9 CDKN2A/B 4% 
G248P800846D3/CEP9 PAX5 exon 2 2% 
G248P82998A1/CEP9 PAX5 exon 7 2% 
WI2-1903N19 (G248P86897G10)/CEP12 ETV6 exon 2 4% 
WI2-1132J19 (G248P84985E10 )/CEP12 ETV6 exon 1 2% 
Note: cut off value calculated as the mean false positive rate (MFPR) X 3 standard deviation.
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Appendix E.  Detailed FISH, MLPA and SNP6 results of patients with 
deleted and duplicated der(12)t(12;21).    
Group A 
Patient 
No. 
Investigations Results 
3052 TEL/AML1 NA  
ETV6 DC BA 1R 0G 1F [96%], 0R 0G 2F [4%] 
RUNX1 DC BA 1R 1G 1F [95%], 0R 0G 2F [4%] 
Mapping Deletion  
RP11-4N23 2R 1G 0F [89%], 2R 2G 0F [11%]  
RP11-365O10 2R 2G 0F [80%], 2R 1G 0F [4%] 
3053 TEL/AML1 NA  
 ETV6 DC BA 1R 0G 1F [98%] 
 RUNX1 DC BA 1R 1G 1F [91%], 0R 0G 2F [5%] 
 Mapping Deletion  
 RP11-633O13 2R 1G 0F [94%], 2R 2G 0F [6%] 
 RP11-604C20 1R 1G 1F [93%], 2R 2G 0F [7%] 
3135 TEL/AML1 1R 1G 1F [58%] 
 ETV6 DC BA 1R 0G 1F [90%], 0R 0G 2F [6%] 
 RUNX1 DC BA 1R 1G 1F [91%], 0R 0G 2F [4%] 
 Mapping Deletion  
 RP11-392P7 2R 1G 0F [90%], 2R 2G 0F [7%] 
 RP11-377D9 1R 1G 1F [89%], 2R 1G 1F [7%], 2R 2G 0F [4%] 
 RP11-396G11/RP11-
4N23/ 
RP11- 180M15 
1R 1F(green/gold) 1F (green/red) [93%], 2R 
2F(green/gold)[7%] 
3189 TEL/AML1 NA  
 ETV6 DC BA 1R 0G 1F [89%], 0R 0G 2F [9%] 
 RUNX1 DC BA 1R 1G 2F [85%], 0R 0G 2F [9%] 
 Mapping Deletion  
 RP11-233G1 3R 1G 0F [83%], 2R 2G 0F [17%] 
 RP11-365O10 2R 1G 1F [80%], 1R 1G 1F [5%],  2R 2G 0F [15%] 
3498 TEL/AML1 ES 2R 1G 1F [62%], 1R 1G 1F [23%] 
 ETV6 DC BA 1R 0G 1F [94%], 0R 0G 2F [5%] 
 RUNX1 DC BA 1R 1G 1F [81%], 0R 0G 2F [8%] 
 Mapping Deletion  
 RP11-444N1 2R 1G 0F [85%], 2R 2G 0F [15%] 
 RP11-318G08 1R 1G 1F [89%], 2R 2G 0F [11%] 
4192 TEL/AML1 NA  
 ETV6 DC BA 1R 0G 1F [94%], 0R 0G 2F [4%] 
 RUNX1 DC BA 1R 1G 2F [74%], 1R 1G 1F [19%], 0R 0G 2F [4%] 
 Mapping Deletion  
 RP11-12D15 3R 1G 0F [67%],  2R 1G 0F [24%], 2R 2G 0F [9%] 
 RP11-444N1 2R 1G 1F [62%], 1R 1G 1F [31%], 2R 2G 0F [7%] 
4287 TEL/AML1 NA  
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Group A 
Patient 
No. 
Investigations Results 
 ETV6 DC BA 1R 0G 1F [94%], 0R 0G 2F [3%] 
 RUNX1 DC BA 1R 1G 1F [86%], 0R 0G 2F [11%] 
 Mapping Deletion  
 RP11-688K16 2R 1G 0F [92%],  2R 2G 0F [8%] 
 RP11-161A14 1R 1G 1F [84%],  2R 2G 0F [16%] 
 RP11-396G11/RP11-
4N23/ 
RP11- 180M15 
1R 1F(green/gold) 1F (green/red) [92%], 2R 
2F(green/gold)[8%] 
4854 TEL/AML1 NA  
 ETV6 DC BA 1R 0G 1F [87%], 0R 0G 2F [9%] 
 RUNX1 DC BA 1R 1G 1F [86%], 0R 0G 2F [11%] 
 Mapping Deletion  
 RP11-688K16 2R 1G 0F [84%], 2R 2G 0F [16%] 
 RP11-161A14 1R 1G 1F [90%], 2R 2G 0F [10%] 
4947 TEL/AML1 NA  
 ETV6 DC BA 1R 0G 1F [89%], 2R 0G 1F [9%] 
 RUNX1 DC BA 1R 1G 2F [88%], 0R 0G 2F [6%] 
 Mapping Deletion  
 RP11-180M15 3R 1G 0F [84%], 2R 2G 0F [16%]  
 RP11-59H1 2R 1G 1F [87%], 2R 2G 0F [13%] 
4969 TEL/AML1 NA  
 ETV6 DC BA 2R 0G 1F [73%], 3R 0G 1F [12%], 4R 0G 1F [7%], 
0R 0G 2F [6%] 
 RUNX1 DC BA 1R 2G 1F [74%], 2R 2G 1F [20%] 
 Mapping Deletion  
 RP11-515B12 2R1G0F [89%], 2R2G0F [6%], 3R1G0F [5%] 
 RP11-233G1 1R1G1F [82%], 2R2G0F [10%], 2R1G1F [8%] 
 
Group B 
Patient 
No. 
Invesigations Results 
3990 TEL/AML1 NA  
 ETV6 DC BA 1R 0G 0F [72%], 0R 0G 2F [23%] 
 RUNX1 DC BA 1R 1G 1F [69%], 0R 0G 2F [27%] 
 Mapping Deletion  
 RP11-267J23 2R 0G 0F [90%], 2R 2G 0F [10%] 
 RP11-757G14 1R 0G 1F [68%], 2R 2G 0F [32%] 
4112 TEL/AML1 NA  
 ETV6 DC BA 1R 0G 0F [63%], 1R 0G 1F [23%], 0R 0G 2F [7%] 
 RUNX1 DC BA 1R 1G 1F [89%], 0R 0G 2F [5%] 
 Mapping Deletion  
 RP11-233G1 2R 1G 0F [57%], 2R 0G 0F [28%], 2R 2G 0F [15%] 
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Group B 
Patient 
No. 
Invesigations Results 
 RP11-365O10 2R 2G 0F [94%] 
4133 TEL/AML1 NA  
 ETV6 DC BA 1R 0G 0F [97%] 
 RUNX1 DC BA 1R 1G 1F [93%], 0R 0G 2F [6%] 
 Mapping Deletion  
 RP11-405A12 2R 1G 0F [94%], 2R 2G 0F [6%] 
 RP11-125O5 1R 1G 1F [90%], 2R 2G 0F [10%] 
4284 TEL/AML1 NA  
 ETV6 DC BA 1R 0G 1F [71%], 1R 1G 0F [9%], 0R 0G 2F [14%] 
 RUNX1 DC BA 1R 1G 1F [77%], 0R 0G 2F [21%] 
 Mapping Deletion  
 RP11-12D15 2R 1G 0F [95%], 2R 2G 0F [11%] 
 RP11-444N1 1R 1G 1F [86%], 2R 2G 0F [10%] 
4358 TEL/AML1 NA  
 ETV6 DC BA 1R 0G 1F [68%], 1R 1G 0F [9%], 0R 0G 2F [22%] 
 RUNX1 DC BA 1R 1G 1F [79%], 0R 0G 2F [16%] 
 Mapping Deletion  
 RP11-365O10 2R 1G 0F [89%], 2R 2G 0F [11%] 
 RP11-405A12 Failed 
3066 TEL/AML1 NA  
 ETV6 DC BA 1R 0G 0F [77%], 0R 0G 2F [17%] 
 RUNX1 DC BA 1R 1G 1F [75%], 0R 0G 2F [20%] 
 
Group C 
Patient 
No. 
Investigations Results 
3319 TEL/AML1 NA  
 ETV6 DC BA 1R 1G 0F [93%], 0R 0G 2F [4%] 
 RUNX1 DC BA 0R 1G 1F [93%], 0R 0G 2F [4%] 
 Mapping Deletion  
 RP11-714H12 1R 1G 0F [89%], 2R 2G 0F [11%] 
 RP11-773I18 2R 1G 0F [90%], 2R 2G 0F [10%] 
4692 TEL/AML1 NA  
 ETV6 DC BA 1R 1G 1F [75%], 1R 1G 0F [4%], 0R 0G 2F [17%] 
 RUNX1 DC BA 0R 1G 1F [82%], 0R 1G 2F [4%], 0R 0G 2F [10%] 
 Mapping Deletion  
 RP11-383L18 1R 2G 0F [83%], 2R 2G 0F [13%] 
 RP11-777J19 1R 1G 1F [79%], 2R 2G 0F [19%] 
4917 TEL/AML1 NA  
 ETV6 DC BA 1R 1G 1F [67%], 1R 1G 0F [29%] 
 RUNX1 DC BA 0R 1G 2F [91%], 0R 0G 2F [7%] 
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Group C 
Patient 
No. 
Investigations Results 
 Mapping Deletion  
 RP11- 396G11 2R 2G 0F [50%], 2R 1G 0F [20%], 1R 2G 0F [5%] 
 RP11-714H12 2R 1G 1F [50%], 2R 0G 1F [30%], 1R 1G 1F 
[11%], 2R 2G 0F [9%] 
Ψ 3277  TEL/AML1 NA  
 ETV6 DC BA 1R 1G 1F [30%], 0R 0G 2F [68%] 
 RUNX1 DC BA 0R 1G 1F [89%], 1R 1G 1F [4%], 0R 0G 2F [6%] 
 
Group D 
Patient 
No. 
Investigations Results 
3130 TEL/AML1 NA  
 ETV6 DC BA 1R 2G 0F [56%], 1R 1G 1F [34%], 1R 1G 0F [5%] 
 RUNX1 DC BA 2R 1G 1F [58%], 1R 1G 1F [37%], 0R 0G 2F [4%] 
 RP11-525I3/RP11-
396G11 DC SF 
1R 0G 2F [67%], 
1R 1G 1F [24%], 
 0R 0G 2F [9%], 
 1R 0G 1F [7%] 
 CEP12/Subtel12p 2R 1G 0F [69%], 2R 2G 0F [31%] 
3726 TEL/AML1 2R 1G 1F [73%] 
 ETV6 DC BA 1R 1G 1F [60%], 1R 2G 0F [26%], 0R 0G 2F [10%] 
 RUNX1 DC BA 1R 1G 1F [59%], 2R 1G 1F [29%], 0R 0G 2F [11%] 
 RP11-525I3/RP11-
396G11 DC SF 
1R 1G 1F [49%], 1R 0G 2F [30%], 2R 2G 0F [12%] 
 CEP12/Subtel12p 2R 1G 0F [79%], 2R  2G 0F [20%] 
4136 TEL/AML1 NA  
 ETV6 DC BA 1R 2G 0F [84%], 1R 1G 1F [7%], 0R 0G 2F [4%] 
 RUNX1 DC BA 2R 1G 1F [78%], 0R 0G 2F [13%] 
 RP11-525I3/RP11-
396G11 DC SF 
1R 0G 2F [61%], 2R 0G 2F [24%], 1R 1G 1F 
[19%], 0R 0G 2F [10%],  
2R  1G 1F [9%], 2R 2G 0F [12%] 
 CEP12/Subtel12p 2R 1G 0F [79%], 2R  2G 0F [20%] 
4281 TEL/AML1 NA 
 ETV6 DC BA 1R 2G 0F [92%], 0R 0G 2F [5%] 
 RUNX1 DC BA 2R 1G 1F [91%], 0R 0G 2F [5%] 
 RP11-525I3/RP11-
396G11 DC SF 
1R 0G 2F [43%], 2R 1G 1F [27%], 1R  1G 1F [7%], 
2R 2G 0F [19%] 
 CEP12/Subtel12p 2R 1G 0F [90%], 2R 2G 0F [8%] 
4560 TEL/AML1 NA 
 ETV6 DC BA 1R 2G 0F [63%], 1R 1G 1F [20%], 1R 1G 0F [14%] 
 RUNX1 DC BA 2R 1G 1F [60%], 1R 1G 1F [37%] 
 RP11-525I3/RP11- 1R 0G 2F [59%], 1R 1G 1F [26%], 0R  0G 2F [9%], 
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Group D 
Patient 
No. 
Investigations Results 
396G11 DC SF 1R  0G 1F [6%] 
 CEP12/Subtel12p 2R 1G 0F [51%], 2R 2G 0F [49%] 
4637 TEL/AML1 NA 
 ETV6 DC BA 1R 2G 0F [87%], 0R 0G 2F [11%] 
 RUNX1 DC BA 2R 1G 1F [95%], 0R 0G 2F [4%] 
 RP11-525I3/RP11-
396G11 DC SF 
1R 0G 2F [81%], 1R 1G 1F [7%], 0R 0G 2F [6%], 
2R 2G 0F [8%] 
 CEP12/Subtel12p 2R 1G 0F [88%], 2R 2G 0F [11%] 
4678 TEL/AML1 NA 
 ETV6 DC BA 1R 2G 0F [84%], 0R 0G 2F [11%] 
 RUNX1 DC BA 2R 1G 1F [92%], 0R 0G 2F [6%] 
 RP11-525I3/RP11-
396G11 DC SF 
1R 0G 2F [77%], 0R 0G 2F [11%], 1R 1G 1F [7%], 
2R 2G 0F [6%] 
 CEP12/Subtel12p 2R 1G 0F [82%], 2R 2G 0F [17%] 
3472 TEL/AML1 ES 3R 1G 1F [41%], 2R 1G 1F [30%], 2R 0G 1F 
[13%], 3R 2G 0F [10%] 
 ETV6 DC BA 1R 1G 1F [78%], 1R 2G 0F [16%], 0R 0G 2F [5%] 
 RUNX1 DC BA 1R 1G 2F [84%], 2R 1G 2F [11%] 
4040 TEL/AML1 NA 
 ETV6 DC BA 1R 1G 0F [54%], 1R 2G 0F [24%], 0R 0G 2F [21%] 
 RUNX1 DC BA 1R 1G 1F [65%], 2R 1G 1F [14%], 0R 0G 2F [20%] 
4934 TEL/AML1 NA 
 ETV6 DC BA 2R 2G 0F [65%], 2R 1G 0F [15%], 2R 1G 1F [6%], 
0R 0G 2F [4%] 
 RUNX1 DC BA 2R 2G 1F [83%], 1R 1G 1F [5%], 0R 0G 2F [5%] 
Note: Group A: deletion of  3’ETV6 sequences from der(12)t(12;21) plus intact non-rearranged  ETV6, 
Group B: deletion of  3’ETV6 sequences from der(12)t(12;21) plus deletion of non-rearranged ETV6, Group 
C: deletion of 5’RUNX1 sequences from der(12)t(12;21) and Group D: duplication of der(12)t(12;21) fusion 
gene, Ψ this patient showing discrepant FISH results which cannot be clarified due to unavailable material.
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Appendix F.  Detailed SNP6 data on deleted, duplicated 
der(12)t(12;21) and Down syndrome within ETV6 -RUNX1 patients.
  
Reg ID Abnormality Size 
(kb) 
GENES 
3135‡ loss (1)(19.45[q31.3]-19.47[q31.3]) 181 No genes 
 gain (4)(19.09[q35.2]-19.10[q35.2]) 111 Multiple genes  
 loss (7)(14.20[q34]-14.25[q34]) 397 Multiple genes 
 gain (8)(69.91[q13.2]-146.30[q24.3]) 58020 Multiple genes 
 loss (9)(14.66[p22.3]-24.18[p21.3]) 7854 Multiple genes 
 loss (10)(97.80[q24.1]-98.07[q24.1]) 264 Multiple genes 
 loss (11)(85.41[q14.1]-117.10[q23.3]) 26299 Multiple genes 
 loss (12)(12.02[p13.2]-13.18[p13.1]) 1004 Multiple genes 
 loss (12)(92.28[q21.33]-92.51[q21.33]) 232 3' BTG1  
3189‡ LOH (12)(12.04[p13.2]-15.11[p12.3]) 3068 Multiple genes 
 gain (21)(11.08[p11.1]-48.10[q22.3]) 36446 Multiple genes 
3428* loss (1)(19.08[q31.2]-19.14[q31.2]) 618 No genes 
 loss (3)(60.07[p14.2]-60.56[p14.2]) 493 FHIT 
 loss (4)(108.46[q25]-108.62[q25]) 169 PAPSS1 
    
 loss (5)(157.50[q33.3]-157.62[q33.3]) 121 No genes 
    
 loss (6)(24.99[p22.3]-29.48[p22.1]) 4490 Multiple genes 
 gain (6)(31.08[p21.33]-74.59[q13]) 43510 Multiple genes 
 loss (6)(78.73[q14.1]-170.98[q27]) 92250 Multiple genes 
 loss (7)(33.13[p14.3]-33.56[p14.3]) 427 RP9,BBS9 
    
 loss (10)(21.68[p12.31]- 22.27[p12.31]) 596 Multiple genes 
 loss (10)( 120.91[q26.11]-135.51[q26.3]) 14597 Multiple genes 
 loss (12)(20.45[p12.2]-20.73[p12.2]) 279 PDE3A 
 loss (12)(0.15[p13.33]-16.39[p12.3]) 16240 Multiple genes 
 loss (17)(73.90[q25.1]-74.42[q25.1]) 518 Multiple genes 
    
 loss (18)(70.00[q22.3]-78.02[q23]) 8015 Multiple genes 
    
 loss (19)(33.40[q13.11]-33.62[q13.11]) 221 GPATCH1,RHPN2, 
   C19orf40, CCDC123 
 loss (20)(10.42[p12.2]-10.52[p12.2]) 101 C20orf94 
 gain (21)(10.74[q11.2]-48.10[q22.3]) 32000 Multiple genes 
3472* loss (1)(90.10[p22.2]-90.25[p22.2]) 151 LRRC8C 
 loss (5)(16.96[q35.1]-18.05[q35.3]) 1090 Multiple genes 
    
 loss (9)(21.90[p21.3]-22.19[p21.3]) 289 C9orf53,CDKN2A/B 
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Reg ID Abnormality Size 
(kb) 
GENES 
    
 loss (12)(25.40[p12.1]-25.54[p12.1]) 133 5' KRAS 
 loss (12)(92.28[q21.33]-92.54[q21.33]) 258 BTG1 
 CNN LOH (18)(72.42[q22.3]-74.33[q23])  1910 Multiple genes 
 gain(X)(12.98[q26.1]-15.49[q28]) 2510 Multiple genes 
 gain(21)(10.74[q11.2]-48.10[q22.3]) 32960 Multiple genes 
3684* loss (9)(36.77[p13.2]-37.03[q13.2]) 260 PAX5  
 loss (11)(85.77[q14.2]-13.49[q25]) 49180 Multiple genes 
 loss (X)(91.16[q21.31]-91.29[q21.31]) 134 PCDH11X 
 gain(X)(12.31[q25]-15.52[q28]) 3210 Multiple genes 
 gain(21)(15.20[q11.2]-48.10[q22.3]) 32890 Multiple genes 
 CNN LOH (9)(11.10[p23]- [12.36[p23]) 1260 No genes 
3726¶ loss (4)(149.35[q31.23]-149.90[q31.23]) 558 NR3C2 
 loss (7)(142.10[q34]-142.47[q34]) 376 MTRNR2L6,PRSS1 
 gain (8)(64.33[q12.3]-146.30[q24.3]) 81970 Multiple genes 
 loss (9)(0.844[p24.3]-24.02[p21.3]) 23176 Multiple genes 
 gain (9)(136.72[q34.2]-136.91[q34.2]) 187 Multiple genes 
 LOH (11)(81.85[q14.1]-134.94[q25]) 53090 Multiple genes 
 loss (12)(0.87[p13.33]-9.36[p13.31]) 8490 PZP,A2M,C12ORF33, 
KLRG1 
 gain (12)(41.66[q12]-41.89[q12]) 225 PDZRN4 
 gain (21)(36.72[q22.12]-47.90[q22.3]) 11180 No genes 
 LOH (X)(100.34[q22.1]-154.15[q28]) 53810 Multiple genes 
4281¶Ψ loss (3)(176.91[q26.32]-177.17[q26.32]) 256 TBL1XR1 
 loss (4)(149.34[q31.23]-149.90[q31.23]) 563 NR3C2  
 loss (6)(6.83[p25.1]-7.10[p25.1]) 271 No genes 
 LOH (6)(81.56[q14.1]-170.98[q27]) 89 Multiple genes  
 loss (9)(18.33[p22.2]-22.46[p21.3]) 3882 Multiple genes  
 gain (11)(134.81[q25]-134.94[q25]) 137 No genes 
 LOH (12)(0.19[p13.33]-8.36[p13.31]) 8172 Multiple genes 
 loss (12)(8.59[p13.31]-12.02[p13.2]) 3415 Multiple genes 
 loss (14)(61.85[q23.1]-62.23[q23.2]) 381 PRKCH,HIF1A 
 gain (14)(69.61[q24.1]-71.57[q24.2]) 1830 Multiple genes 
 gain (21)(36.39[q22.12]-48.10[q22.3]) 11676 Multiple genes 
 LOH (X)(2.70[p22.33]-155.23[q28]) 87792 Multiple genes 
4969‡ loss (2)(22.19[q36.1]-22.21[q36.1]) 208 No genes 
 loss (3)(11.21[q13.2]-11.22[q13.2]) 156 BTLA/CD200 
 LOH (6)(90.35[q15]-170.98[q27]) 76969 Multiple genes  
 Loss (9)(0.21[p24.3]-26.08[p21.2]) 25465 Multiple genes 
 gain (12)(0.15[p13.33]-12.03[p13.2]) 11727 multiple genes 
 loss (12)(12.03[p13.2]-14.58[p13.1]) 2551 multiple genes 
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Reg ID Abnormality Size 
(kb) 
GENES 
 LOH (15)(41.38[q15.1]-41.50[q15.1]) 121 INO80,EXD1 
 gain (21)(10.74[p11.2]-36.42[q22.12]) 25477 Multiple genes 
 LOH (X)(27.04[p22.33]-87.88[q21.31]) 60840 Multiple genes 
9859Ψ Loss (1)(49.94[p33]-50.00[p33]) 53 AGBL4 
 Loss (1)(231.01[q42.2]-231.54[q42.2]) 525 Multiple genes 
 Loss (1)(37.63[p34.3]-37.69[p34.3]) 55 No genes 
 Gain (3)(126.72[q21.3]-126.94[q21.3]) 217 PLXNA1 
 Loss (3)(112.13[q13.2]-112.22[q13.2]) 88 BTLA 
 Loss (6)(143.19[q24.2]-143.25[q24.2]) 58 HIVEP2 
 Loss (7)(30.33[p14.3]-30.38[q14.3]) 48 ZNRF2 
 Loss (7)(50.36[p12.2]-50.47[p12.2]) 109 IKZF1 
 Gain (10)(131.50[q26.3]-131.55[q26.3]) 49 MGMT 
 Gain (11)(77.42[q14.1]-77.78[q14.1]) 361 RSF1, c11orf67, 
INTS4 
 Loss (12)(91.98[q21.33]-92.54[q21.33]) 554 3'BTG1 
 Loss (12)(11.73[p13.2]-11.79[p13.2]) 58 No genes 
 Loss (12)(65.58[q14.3]-65.61[q14.3]) 30 LEMD3 
 Loss (13)(60.55[q21.2]-60.59[q21.2]) 43 DIAPH3 
 Loss (15)(35.67[q14]-35.83[q14]) 167 ATPBD4 
 Gain (16)(8.13[p13.2]-8.16[q13.2]) 28 No genes 
 Loss (17)(36.95[q12]-36.99[q12]) 39 PIP4K2B, CWC25 
 Gain (21)(48.06[q22.3]-48.10[q22.3]) 37 PRMT2 
 Loss (21)(26.84[q21.3]-26.86[q21.3]) 22 No genes 
 Loss (X)(44.07[p11.3]-44.71[p11.3]) 641 EFHC2, FUNDC1 
21820* loss (9)(36.88[p13.2]-37.03[q13.2]) 153 PAX5 
 gain (21)(15.10[q11.2]-48.10[q22.3]) 37360 Multiple genes 
 CNN LOH (9)(20.18[p21.3]- [22.13[p21.3]) 1950 CDKN2A/B 
Note: patients with : ‡: deleted der(12)t(12;21), ¶: duplicated RUNX1-ETV6 fuson, *: Down syndrome , 
Ψ: positive control used for TBL1XR1 and BTG1, respectively. 
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Appendix G.  Detailed FISH results of additional cases with 
suggested MLPA ETV6 profile of deleted 3'ETV6 of der(12)t(12;21) 
and  duplicated RUNX1-ETV6 fusion gene.    
Deleted 3'ETV6 of der(12)t(12;21)  
Patient 
No. 
Investigations Results 
7613 
TEL/AML1  2R 1G 2F [41%] 
ETV6 DC BA 2R 0G 1F [52%], 0R 0G 2F [43%], 1R 0G 1F [5%] 
RUNX1 DC BA 0R 0G 2F [38%], 1R 2G 1F [33%], 1R 1G 1F [25%] 
Mapping Deletion 
RP11-515B12 2R 1G 0F [54%], 2R 2G 0F [24%], 2R 0G 0F [20%] 
RP11-365O10 1R 1G 1F [64%], 2R 2G 0F [32%] 
10398 
TEL/AML1 ES 2R 1G 1F [28%] 
ETV6 DC BA 0R 0G 2F [66%], 1R 0G 1F [26%], 0R 0G 1F [7%] 
RUNX1 DC BA 0R 0G 2F [57%], 1R 1G 1F [35%]                         
Mapping Deletion 
RP11-59H1 2R 2G 0F [72%], 2R 1G 0F [21%]        
RP11-4N23 NA 
22044 
TEL/AML1 DC DF 2R 1G 1F [69%] 
ETV6 DC BA 0R 0G 2F [46%], 1R 0G 1F [43%], 0R 0G 1F [7%] 
RUNX1 DC BA 1R 1G 2F [36%], 1R 1G 1F [30%], 0R 0G 2F [24%], 0R 1G 2F [6%] 
Mapping Deletion 
RP11-365O10 3R 1G 0F [70%], 2R 2G 0F [24%], 2R 1G 0F [6%] 
RP11-405A12 F 
22574 
TEL/AML1 ES 2R 1G 2F [61%] 
ETV6 DC BA 0R 0G 2F [47%], 2R 0G 1F [39%], 1R 0G 1F [8%] 
RUNX1 DC BA 1R 2G 1F [53%], 0R 0G 2F [29%], 1R 1G 1F [12%] 
Mapping Deletion 
RP11-405A12 2R 1G 0F [62%], 2R 2G 0F [36%] 
RP11-12D15 1R 1G 1F [70%], 2R 2G 0F [24%], 0R 1G 1F [6%] 
11052 
TEL/AML1 ES 2R 1G 1F [54%], 1R 1G 1F [21%] 
TEL(so)/AML1(sg) 
DC DF 1R 2G 1F [82%] 
ETV6 DC BA 1R 0G 1F [74%], 2R 0G 0F [15%], 0R 0G 2F [7%] 
RUNX1 DC BA 1R 1G 1F [81%], 1R 2G 1F [15%] 
Mapping Deletion 
RP11-757G14 2R 0G 0F [50%], 3R 0G 0F [18%], 2R 1G 0F [18%], 3R 1G 0F [9%], 1R 
1G 0F [5%]            
RP11-59H1 2R 2G 0F [78%], 3R 2G 0F [11%], 4R 2G 0F [7%] 
20755 
TEL/AML1 NA 
ETV6 DC BA 1R 0G 1F [79%], 0R 0G 2F [7%] 
RUNX1 DC BA 1R 1G 1F [79%], 0R 0G 2F [21%] 
Mapping Deletion 
RP11-59H1  2R 1G 0F [78%], 2R 2G 0F [18%] 
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RP11-4N23 F 
4894 
TEL/AML1 NA 
ETV6 DC BA 1R 1G 0F [96%] 
RUNX1 DC BA 1R 1G 2F [97%] 
12529 
TEL/AML1 ES 2R 0G 1F [61%] 
ETV6 DC BA 1R 1G 0F [69%], 0R 0G 2F [24%], 1R 1G 1F [7%] 
RUNX1 DC BA 1R 1G 1F [47%], 0R 0G 2F [33%], 1R 0G 1F [18%] 
21200 
TEL/AML1 DC DF 1R 1G 2F [95%] 
ETV6 DC BA 1R 1G 1F [48%], 1R 1G 0F [15%], 2R 1G 0F [13%], 0R 0G 2F [9%], 1R 
0G 2F [7%] 
RUNX1 DC BA 1R 2G 1F [60%], 1R 1G 1F [21%], 0R 0G 2F [6%] 
22324 
TEL/AML1 ES 4R 0G 2F [55%], 3R 0G 2F [17%] 
ETV6 DC BA 2R 1G 1F [60%], 1R 1G 1F [32%] 
RUNX1 DC BA F 
Deleted non-rearranged ETV6 
Patient 
No. 
Investigations Results 
3181 
TEL/AML1 Not done 
ETV6 DC BA 1R 1G 1F [90%] 
RUNX1 DC BA 1R 1G 1F [94%] 
Exon 8/RP11-
434C1 Failed 
Exon 8/RP11-
396G11 1R 1G 1F [52%], 1R 0G 1F [24%], 2R 2G 0F [12%], 2R 1G 1F [8%]               
Gain der(21)t(12;21) PLUS loss non-rearranged ETV6 
Patient 
No. 
Investigations Results 
3269 
TEL/AML1  Not done 
ETV6 DC BA 3R 1G 0F [36%], 2R 1G 1F [16%], 0R 0G 2F [38%] 
RUNX1 DC BA 1R 3G 1F [32%], 1R 2G 1F [18%], 0R 0G 2F [31%] 
3359 
TEL/AML1  Not done 
ETV6 DC BA 2R 1G 0F [93%] 
RUNX1 DC BA 1R 2G 1F [97%] 
3602 
TEL/AML1  Not done 
ETV6 DC BA 2R 1G 0F [55%] 
RUNX1 DC BA 1R 2G 1F [60%] 
4707 
TEL/AML1  Not done 
ETV6 DC BA 4R 2G 0F [53%], 2R 1G 0F [35%] 
RUNX1 DC BA 1R 2G 1F, 2R 2G 2F, 2R 4G 2F 
4758 
TEL/AML1  Not done 
ETV6 DC BA 2R 1G 0F [92%] 
RUNX1 DC BA 1R 2G 2F [80%], 1R 1G 2F [16%] 
11636 TEL/AML1 DC DF 0R 1G 3F 
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ETV6 DC BA 2R 1G 0F [90%], 1R 1G 0F [8%] 
RUNX1 DC BA Failed 
Gain der(21)t(12;21) PLUS loss non-rearranged ETV6 
Patient 
No. 
Investigations Results 
5859 
TEL/AML1 Not done 
ETV6 DC BA 1F 1R 1G [88%],  0R 0G 2F [11%]  
RUNX1 DC BA 1R 1G 2F[44%], 1R 0G 2F [18%], 0R 1G 2F [15%], 0R 0G 2F [11%] 
Exon 8/RP11-
396G11 
Failed 
11562 
TEL/AML1 ES 2R 1G 1F [25%] 
ETV6 DC BA 0R 0G 2F [54%], 0R 1G 1F [28%], 1R 1G 1F [19%] 
RUNX1 DC BA 0R 0G 2F [45%], 1R 0G 1F [29%], 1R 1G 1F [27%] 
Exon 8/RP11-
434C1 
Not done 
Exon 8/RP11-
396G11 
 2R 2G 0F [45%], 2R 1G 0F [49%] 
12290 
TEL/AML1 ES  2R 1G 2F [71%] 
ETV6 DC BA 2R 1G 1F [68%], 0R 0G 2F [24%], 1R 1G 1F [8%] 
RUNX1 DC BA 1R 2G 1F [56%], 0R 0G 2F [28%], 1R 1G 1F [8%] 
Exon 8/RP11-
396G11 
Failed 
Suggested duplicated RUNX1-ETV6 fusion gene 
Patient 
No. 
Invesigations Results 
3250 
TEL/AML1 NA 
ETV6 DC BA NA 
RUNX1 DC BA NA 
20164 
TEL/AML1 ES 2R 1G 1F [54%], 2R 0G 1F [17%], 1R 1G 1F [6%], 2R 2G 0F [21%] 
ETV6 DC BA 1R 1G 1F [29%], 2R 1G 0F [11%], 0R 0G 1F [5%], 0R 1G 2F [5%], 1R 
1G 0F [5%], 0R 0G 2F [41%] 
RUNX1 DC BA NA 
21741 
TEL/AML1 DC DF 3R 3G 2F [86%] 
ETV6 DC BA NA 
RUNX1 DC BA NA 
22264 
TEL/AML1 ES 3R 0G 1F [80%] 
ETV6 DC BA F 
RUNX1 DC BA F 
22289 
TEL/AML1 ES 2R 0G 1F [78%], 1R 0G 1F [8%], 2R 2G 0F [12%] 
ETV6 DC BA NA 
RUNX1 DC BA NA 
 Note: Group A: deletion of  3’ETV6 sequences from der(12)t(12;21) , Group B: Microdeletion of 
der(12)t(12;21), Group D: suggested unconfirmed duplication of der(12)t(12;21) fusion gene, NA: not 
done owing to lack of material, sg: spectrum green, so: spectrum orange. 
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Appendix H.  Detailed information of the target probe assays used in 
this part of study.   
 
probes locations Probe I.D Genomic 
position 
Amplicon 
length 
Cytoband  
TBL1XR1 5'TBL1XR1 Hs05887117_cn Chr.3:177096119 93 3q26.32 
 within 
intron 1 
Hs06694058_cn Chr.3:176844786 99 3q26.32 
NR3C1 within 
intron 4 
Hs06057433_cn  Chr.5:142715774 80  5q31.3 
NR3C2 5'NR3C2 Hs05970766_cn Chr.4:149490099 110 4q31.23 
 within 
intron 4 
Hs04830188_cn* Chr.4:149103738 109  4q31.23 
BTLA Within 
Intron 4 
Hs04722014_cn¥  Chr.3:112186825 86 3q13.2 
BMF Within 
Exon 4 
Hs02711690_cn Chr.15:40398104 
 
86 15q15.1 
Note: The genomic positions were based on NCBI build 37. *: This probe was withdrawn from the study 
(non- robust assay, in which the amplification plot was noisy), ¥:  showing lower efficiency than the 
remaining assays but within acceptable range. 
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Appendix I.  Algorithim used for evalution of individual cases in 
terms of q PCR and FISH results.      
Concordant TERT and 
RNaseP 
Confidance Z-score Evidence by 
FISH 
Status 
Yes >= 0.95 < 2.65 Yes Accept  
Yes >= 0.95 > 2.65 Yes Repeat 
Yes < 0.95  Any 
value 
Yes Repeat 
Yes >= 0.95 < 2.65 No Accept+Further 
FISH 
Yes >= 0.95 > 2.65 No Repeat+Further 
FISH 
Yes < 0.95 - > 
0.50 
Any 
value 
No Repeat+Further 
FISH 
Yes < 0.50 Any 
value 
No Reject 
No  >= 0.95 < 2.65 Yes Accept 
No  >= 0.95 > 2.65 Yes Repeat 
No  < 0.95  Any 
value 
Yes Repeat 
No  >= 0.95 < 2.65 No Accept+Further 
FISH 
No  >= 0.95 > 2.65 No Repeat+Further 
FISH 
No  < 0.95  < 2.65 No Repeat+Further 
FISH 
No  < 0.95  > 2.65 No Reject 
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Appendix J. Details clinical features of the relapse and the non-relapse cases studies in Chapter 5    
Reg.ID Time to 1st  
relapse/months€ 
Site at  
1st relapse 
% blasts  
at diagnosis 
% blasts  
at 1st relapse 
Outcome Material availability 
2712 21 BM 87 NA died 1.5 months 
after 2nd relapse  
Diag. DNA,Fixed cells 
Rel. Fixed cells 
2774 34 CNS 84 NA Complete 
remission after 
1st relapse 
Diag. DNA 
Rel. NA 
2850 34 BM+ CNS 70 NA Complete 
remission after 
1st relapse 
Diag. DNA, Fixed cells 
Rel. Fixed cells 
2897 n.a. n.a. 99 n.a. Complete 
remission 
DNA, Fixed cells 
3026 n.a. n.a. 91 n.a. Complete 
remission 
DNA, Fixed cells 
3098 9 BM 95 NA BMT after 1st 
relapse 
Diag. DNA 
Rel. NA 
3181* 74 BM 99 70 Complete 
remission after 
1st relapse 
Diag. DNA, Fixed cells 
Rel. DNA 
3359 39.5 BM 95 NA BMT after 1st 
relapse 
Diag. DNA 
Rel. NA 
3431 51 BM+ CNS 99 NA BMT after 1st 
relapse 
Diag. DNA 
Rel. Fixed cells 
3562 5.5 CNS 99 NA died after 1st 
relapse  
Diag. DNA, Fixed cells 
Rel. NA 
3588 42.5 BM 89 NA BMT after 1st Diag. DNA 
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Reg.ID Time to 1st  
relapse/months€ 
Site at  
1st relapse 
% blasts  
at diagnosis 
% blasts  
at 1st relapse 
Outcome Material availability 
relapse Rel. NA 
3700 46.5 BM+ CNS 88 NA BMT after 1st 
relapse 
Diag. DNA, Fixed cells 
Rel. Fixed cells 
3703* 49.5 BM+ CNS 99 NA BMT after 1st 
relapse 
Diag. DNA, Fixed cells 
Rel. Fixed cells 
3711 n.a. n.a. 79 n.a. Complete 
remission 
DNA, Fixed cells 
3761 n.a. n.a. 99 n.a. Complete 
remission 
DNA, Fixed cells 
3833 35.5 BM 100 NA BMT after 1st 
relapse 
Diag. DNA, Fixed cells 
Rel. NA 
4011 n.a. n.a. 98 n.a. Complete 
remission 
DNA, Fixed cells 
4036* 51.5 BM 100 95 BMT after 1st 
relapse 
Diag. DNA, Fixed cells 
Rel. DNA, Fixed cells 
4044 30 BM 96 NA BMT after 1st 
relapse 
Diag. DNA, Fixed cells 
Rel. NA 
4288 n.a. n.a. 49 n.a. Complete 
remission 
DNA, Fixed cells 
4439 n.a. n.a. 99 n.a. Complete 
remission 
DNA, Fixed cells 
4536 n.a. n.a. 98 n.a. Complete 
remission 
DNA, Fixed cells 
4569 n.a. n.a. 95 n.a. Complete 
remission 
DNA 
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Reg.ID Time to 1st  
relapse/months€ 
Site at  
1st relapse 
% blasts  
at diagnosis 
% blasts  
at 1st relapse 
Outcome Material availability 
4609 n.a. n.a. 97 n.a. Complete 
remission 
DNA, Fixed cells 
4902* 52 BM 99 NA BMT after 1st 
relapse 
Diag.  DNA, Fixed cells 
Rel.  DNA, Fixed cells 
4995 n.a. n.a. 91 n.a. Complete 
remission 
DNA, Fixed cells 
5062* 27 CNS 95 35 Died after 3 
years from 1st 
relapse 
Diag. DNA, Fixed cells 
Rel. NA 
5597* 24 CNS 95 0 BMT after 1st 
relapse 
Diag. DNA, Fixed cells 
Rel.  NA 
5647 n.a. n.a. 94 n.a. Complete 
remission 
DNA, Fixed cells 
5659 n.a. n.a. 96 n.a. Complete 
remission 
DNA, Fixed cells 
5721 n.a. n.a. NA n.a. NA DNA 
5807 n.a. n.a. NA n.a. NA DNA, Fixed cells 
5914 n.a. n.a. NA n.a. NA DNA, Fixed cells 
10875‡ 46 BM 95 NA Died after BMT Diag. DNA, Fixed cells 
Rel.   DNA, Fixed cells 
Note: * treated on ALLR3 at relapse, ‡ treated on UKALL2003 at presentation, ¥ percentages are relative to ETV6-RUNX1 positive cells, n.a. not applicable, NA not available, BM 
bone marrow, CNS central nervous system, BMT bone marrow transplantation,  € Early relapse: from diagnosis to <6 months from end of treatment, Late: >6 months from end of 
treatment.  
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Appendix K. Detailed copy number q PCR results of the positive controls used in screening of different gene deletions.   
   
Sample Name Target Reference CN Calculated CN Predicted Confidence |Z-Score| FISH 
L707¥ NR3C1 RNAase P 0.07 0   2R 0G 0F [93%], 2R 2G 0F [7%] 
 NR3C1 TERT 0.83 1    
REH* NR3C1 RNAase P 1.13 1 > 0.99 0.2 2R 2G 0F [100%] 
 NR3C1 TERT 0.99 1 > 0.99 0.7  
KG-1 5'NR3C2 RNase P 0.98 1 > 0.99 0.04 2R 1G 0F [96%], 3R 2G 0F [3%] 
KG1 5'NR3C2 TERT 0.73 1 > 0.99 0.04  
KASUMI BMF RNase P 1.2 1 > 0.99 1.05 2R 1G 0F [95%], 2R 2G 0F [3%] 
KASUMI BMF TERT 0.83 1 > 0.99 0  
4037 TBL1XR1 RNase P 0.82 1 > 0.99 0 1R 2G 0F [90%], 2R 2G 0F [9%] 
4037 TBL1XR1 TERT 1.09 1 > 0.99 0.08  
4281 5'TBL1XR1 RNase P 0.97 1 > 0.99 0.02 NA 
4281 5'TBL1XR1 TERT 1.01 1 > 0.99 0.37  
9859¥ BTLA RNase P 0.57 1 > 0.99 1.84  
9859 BTLA TERT 0.52 0    
Note: *: one of the green signals was diminished, NA: Not performed.  ¥:  these positive controls, with documented biallelic deletion either by FISH or SNP6, showed discrepant 
predicted copy number of 1 and 0 by q PCR but still both calculated copy number are almost similar approaching 0.
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Appendix L. FISH and q PCR data of the atypical cases studies in Chapter 6 
Reg.ID NR3C1 NR3C2 5'NR3C2 TBL1XR1 5'TBL1XR1 BTLA BMF Collective 
No. 
of CNA 
q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH(%)¥ q PCR FISH 
(%)¥ 
q PCR FISH(%)¥ q 
PCR 
FISH 
(%)¥ 
q 
PCR 
FISH 
(%)¥ 
Infant Group 
9381 N N NA N N NA N N N NA N N N N 0 
10267 N N NA N N NA N N N NA N N N N 0 
11638 N N NA N N NA N N N NA D 47 N N 1 
11783 N N NA N N NA N N N NA NA N NA N 0 
12018 N N NA N N NA N N N NA F N N N 0 
12358 N N NA N N NA N N N NA N N N N 0 
19851 N NA NA NA N NA N NA N NA N NA N NA 0 
20123 N N NA N D 28 N N N NA N N N N 1 
20215 N N NA N N NA N N N NA N N N N 0 
20768 N NA NA NA N NA N NA N NA N NA N NA 0 
Adult Group 
1780 N N NA N N NA N N N NA N N N N 0 
1927* U N NA N D NA D N U NA D N U N 0 
3367 N N NA N N NA N N N NA N N N N 0 
3936* N N NA N D NA N N D NA D N D N 0 
7597 N NA NA NA N NA N NA N NA D NA N NA 1 
10216* N N NA N D NA D N N NA D N N N 0 
22240 N NA NA NA N NA N NA N NA N NA N NA 0 
22264 N NA NA NA N NA N NA N NA N NA N NA 0 
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Reg.ID NR3C1  NR3C2  5'NR3C2  TBL1XR1  5'TBL1XR1  BTLA  BMF  Collective 
No. 
of CNA 
 q PCR FISH 
(%)¥ 
q PCR FISH 
(%)¥ 
q PCR FISH(%)¥ q PCR FISH 
(%)¥ 
q PCR FISH(%)¥ q 
PCR 
FISH 
(%)¥ 
q 
PCR 
FISH 
(%)¥ 
 
23013 N N NA N N NA N N N NA N N N N 0 
24247 U N NA N N NA NA N NA NA NA N NA N 0 
Down syndrome Group 
3418 N NA NA NA N NA N NA N NA U NA N NA 0 
4905 F NA NA NA F NA NA NA NA NA NA NA NA NA 0 
7038 D N NA NA U NA NA N NA NA NA NA NA NA 1 
8906 U NA NA NA N NA NA NA NA NA NA NA NA NA 0 
9879 N NA NA NA N NA N N N NA NA N NA N 0 
20383 N N NA N N NA N N N NA N N N N 0 
20410 N NA NA NA D NA N NA N NA N NA N NA 1 
20754 D NA NA NA U NA NA NA NA NA NA NA NA NA 1 
24347 N N NA N N NA N N N NA N N N N 0 
Note: * showing false positive q PCR results owing to the presence of either near tetraploid or near triploidy suggested by cytogenetics and FISH, NA: not performed, U: undetermined 
due to intradiscrepant copy number by q PCR, D: deleted, N: normal, F: failed, ¥: percentages calculated as relative to ETV6-RUNX1 positive cells.  
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Abnormalities of the der(12)t(12;21) in ETV6-RUNX1
Acute Lymphoblastic Leukemia
Halima Al-Shehhi, Zoe J. Konn,† Claire J. Schwab, Amy Erhorn, Kerry E. Barber,† Sarah L. Wright,†
Alem S. Gabriel, Christine J. Harrison, and Anthony V. Moorman*
Leukaemia Research Cytogenetics Group,Northern Institute for Cancer Research,Newcastle University,Newcastle-upon-Tyne,UK
ETV6-RUNX1 fusion [t(12;21)(p13;q22)] occurs in 25% of childhood B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) and is associated with a favorable outcome. Additional abnormalities involving der(21)t(12;21) and nonrearranged
chromosome 12 are well characterized but aberrations involving the der(12)t(12;21) have rarely been described. Herein,
we describe two novel abnormalities affecting the der(12)t(12;21): a deletion (20/247, 8%) and duplication (10/247, 4%).
All 30 patients were under 10 years of age, had a median white blood count of 12.4  109/L and 19.2  109/L, respec-
tively, with a good outcome. Deletions of der(12)t(12;21) on both sides of the breakpoint were confirmed and mapped:
centromeric (12p11.21-12p13.2) and telomeric (21q22.12-21q22.3). The size of these deletions extended from 0.4–13.4 to
0.8–2.5 Mb, respectively. The centromeric deletion encompassed the following genes: LRP6, BCL2L14, DUSP16, CREBL2, and
CDKN1B. We postulate that this deletion occurs at the same time as the translocation because it was present in all ETV6–
RUNX1-positive cells. A second abnormality representing duplication of the reciprocal RUNX1–ETV6 fusion gene was a
secondary event, which we hypothesize arose through mitotic recombination errors. This led to the formation of the
following chromosome: der(12)(21qter!21q22.12::12p13.2-12p12.3::12p12.3!12qter). Both abnormalities affect the recip-
rocal RUNX1–ETV6 fusion product which could either eliminate or amplify its expression and thus contribute to leukemo-
genesis. However, other consequences such as haploinsufficiency of tumor suppressor genes and amplification of
oncogenes could also be driving forces behind these aberrations. In conclusion, this study has defined novel abnormalities
in ETV6–RUNX1 BCP-ALL, which implicate new genes involved in leukemogenesis. VC 2012 Wiley Periodicals, Inc.
INTRODUCTION
The translocation, t(12;21)(p13;q22), which
generates the ETV6–RUNX1 fusion gene, is the
most common chromosomal abnormality in B-pre-
cursor childhood ALL (BCP-ALL). It is found in
25% cases, with a peak incidence between the
ages of 3–6 years (Golub et al., 1995; Romana
et al., 1995). Patients with ETV6–RUNX1 gener-
ally have a favorable outcome (Pui, 2004; Moor-
man et al., 2010). Although this translocation is
believed to constitute the first transforming event
arising in utero, alone it is unable to generate
overt disease (Greaves and Wiemels, 2003).
Therefore, additional secondary genetic events
are required for leukemogenesis. For instance,
deletion of the nonrearranged ETV6 allele has
been implicated as an important secondary event,
which occurs in up to 60% of cases (Attarbaschi
et al., 2004; Stams et al., 2006). Furthermore,
gain of chromosome 21 (þ21) and duplication of
the derivative chromosome 21 (þder(21)t(12;21))
are frequently observed in both presentation and
relapsed ETV6–RUNX1 BCP-ALL (Attarbaschi
et al., 2004; Alvarez et al., 2005; Martineau et al.,
2005; Stams et al., 2006; Forestier et al., 2007;
Tsuzuki et al., 2007). Recently, genome-wide
copy number alteration analyses of ETV6–RUNX1
BCP-ALL, using high-resolution single-nucleo-
tide polymorphism (SNP) arrays and comparative
genomic hybridization arrays, have revealed addi-
tional gene deletions targeting various pathways,
such as B-cell development and differentiation,
tumor suppression, cell-cycle control, apoptosis,
drug responsiveness, and nuclear hormone
response (Kuiper et al., 2007; Lilljebjorn et al.,
2007; Mullighan et al., 2007; Tsuzuki et al., 2007;
Additional Supporting Information may be found in the online
version of this article.
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Kawamata et al., 2008; Mullighan et al., 2008;
Parker et al., 2008; Lilljebjorn et al., 2010).
In a standard t(12;21) translocation, the recipro-
cal RUNX1–ETV6 gene fusion is formed on the
der(12)t(12;21). Expression of RUNX1–ETV6 is
found concomitantly with ETV6–RUNX1 in only
76% of t(12;21)-positive ALL cases (Stams et al.,
2005). The factors which govern the expression
of RUNX1–ETV6 and its effect on leukemogene-
sis are ill-defined. We screened 247 patients with
ETV6–RUNX1 using fluorescence in situ hybrid-
ization (FISH) probes covering both the ETV6
and the RUNX1 loci and observed a series of
novel abnormalities targeting der(12)t(12;21).
Further characterization of these abnormalities
revealed novel additional abnormalities in ETV6–
RUNX1 BCP-ALL, targeting the reciprocal
RUNX1–ETV6 fusion gene.
MATERIALS AND METHODS
Patients in this study were diagnosed with
ETV6–RUNX1 BCP-ALL by standard criteria and
were registered to the UK Medical Research
Council (MRC) treatment trial, ALL97 (Moor-
man et al., 2010). This trial included children
aged from 1 to 18 years. Approval from the local
ethical committee and written informed consent
from patients or guardians were obtained by par-
ticipating centers on entry to the clinical trial
(Moorman et al., 2010). This present study used
fixed cell suspensions and DNA from pretreat-
ment diagnostic bone marrow samples, which
were obtained from the member laboratories of
the United Kingdom Cancer Cytogenetics Group
(UKCCG). Karyotypes were collected and
reviewed centrally by the Leukaemia Research
Cytogenetics Group (Harrison et al., 2001). The
Clinical Trial Service Unit and Epidemiological
Studies Unit (CTSU, University of Oxford) sup-
plied patient details.
Fluorescence In Situ Hybridization
All patients in the study had been found to
harbor ETV6–RUNX1 fusion by FISH using a
TEL-AML1 probe (Abbott Diagnostics, Maiden-
head, UK) or by reverse transcriptase polymerase
chain reaction (Moorman et al., 2010). Initial
screening was performed using dual color (DC)
break-apart (BA) probes, targeting either the
ETV6 locus (DakoCytomation, Denmark) or the
RUNX1 locus (centromeric—RP11-272A03 and
telomeric—RP11-396G11, Sanger Institute, UK).
In a standard t(12;21) translocation, the ETV6 DC
BA probe has a signal pattern of one red, one
green, and one fusion (1R 1G 1F), indicating
the presence of der(21)t(12;21), der(12)t(12;21),
and normal chromosome 12, respectively. Simi-
larly, the expected signal pattern with the
RUNX1 DC BA probe is 1R 1G 1F, representing
der(12)t(12;21), der(21)t(12;21), and normal chro-
mosome 21, respectively. Deletion mapping was
performed using two different probe sets,
depending on the region of the deletion and
comprised differentially labeled target and anchor
probes (Supporting Information Table S1). The
anchor probe was either RP11-396G11 (labeled
red) or RP11-525I3 (labeled green) depending on
whether we were mapping deletion of chromo-
some 12 or chromosome 21 sequences, respec-
tively (Fig. 1). The target was considered to be
deleted if a signal pattern of either 2R 1G 0F or
1R 2G 0F was observed, respectively. Three-
color FISH was performed to confirm that the
deletion involved the der(12)t(12;21) rather than
the normal chromosome 12. The home-grown
probes comprised a control probe (RP11-396G11)
(labeled red), a known intact 30ETV6 probe
(RP11-4N23) (labeled green), and the target
probe (RP11-180M15) (labeled gold). In a stand-
ard translocation, a signal pattern of 1R 1F
(green-gold) 1F (green-red-gold) would be
observed, representing the normal chromosome
21, normal chromosome 12, and intact
der(12)t(12;21), respectively (Figs. 2E–2F). In
this test, the signal pattern of 1R 1F (green-gold)
1F (red-green) indicated the presence of a normal
chromosome 21, normal chromosome 12, and
deletion of the gold probe from the
der(12)t(12;21), respectively. To investigate the
origin of the extra der(12)t(12;21) signals
observed with the ETV6 DC BA and RUNX1 DC
BA probes, a home-grown DC single fusion (SF)
probe was designed. This probe comprised the
50RUNX1 probe (RP11-396G11) (labeled red) and
30ETV6 probe (RP11-525I3) (labeled green) (Figs.
3A–3B and Supporting Information Table S1).
The signal pattern, 1R 0G 2F, indicated an extra
fusion signal with associated loss of the green
signal, corresponding to the duplication of the re-
ciprocal chimeric gene RUNX1–ETV6 with loss of
30ETV6 sequences from the normal chromosome
12. A commercial probe set consisting of centro-
mere 12 (CEP 12, labeled red, Cytocell, Cam-
bridge, UK) and subtelomere 12p (subtel12p,
labeled green, Abbott Diagnostics, Maidenhead,
UK) was used to enumerate the chromosome 12
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centromeres and telomeres. For all FISH tests, a
minimum of 50–100 interphase cells were scored
and, with the exception of deletion mapping,
were independently checked. Individual probe-
specific cutoff levels were calculated using the
mean false-positive rate derived from five control
samples plus three times the standard deviation,
with the exception of probes for deletion map-
ping where a generic cutoff value of 4% was
used.
Multiplex Ligation-Dependent Probe Amplification
Genomic DNA from six diagnostic bone mar-
row samples (patients no. 3135, 3189, 4969, 3726,
4281, and 4637) was extracted using standard
procedures. In one case, the DNA was extracted
from the same fixed cell pellet as used for FISH;
this DNA was isolated using the Qiagen DNeasy
tissue and blood kit according to the manufac-
turer’s instructions. We have previously demon-
strated that these samples provide an effective
source of DNA for multiplex ligation-dependent
probe amplification (MLPA) when used in con-
junction with control DNA prepared in the same
manner (Schwab et al., 2010). Genomic DNA
from healthy donors was obtained for use as
control samples. DNA was analyzed using the
SALSA MLPA kit P335 (MRC Holland, Amster-
dam, The Netherlands) as described previously
(Schwab et al., 2010). This kit includes probes
for IKZF1 (eight probes), CDKN2A/B (three
probes), PAX5 (six probes), EBF1 (four probes),
ETV6 (six probes), BTG1 (four probes), RB1 (five
probes), and the PAR1 region: CRLF2, CSF2RA,
and IL3RA (one probe each). Data were analyzed
using GeneMarker V1.85 analysis software
(SoftGenetics).
Figure 1. Details of FISH mapping of der(12)t(12;21) deletions in 18 cases with ETV6–RUNX1 BCP-
ALL. Group A: deletion of 30ETV6 sequences from der(12)t(12;21) plus intact nonrearranged ETV6;
Group B: deletion of 30ETV6 sequences from der(12)t(12;21) plus deletion of nonrearranged ETV6;
Group C: deletion of 50RUNX1 sequences from der(12)t(12;21).
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SNP Arrays
DNA samples (patients no. 3135, 3189, 4969,
3726, and 4281) were hybridized to Affymetrix
Genome-Wide Human SNP Array 6.0 by AROS
Applied Biotechnology (Aarhus, Denmark)
according to the manufacturer’s instructions. Affy-
metrix CEL files were analyzed using Affymetrix
Genotyping Console software (version 4.0) for
initial quality control, followed by use of the
Affymetrix Birdseed algorithm (version 2.0) to
generate SNP genotype calls on all samples. All
samples passed the Affymetrix recommended
contrast quality control and SNP call rates thresh-
old. Copy number, allele ratio, and allele-specific
copy number data analysis were performed on
CEL files using Affymetrix Genotyping Console
software (version 4.1.1.834). To locate segments
with copy number changes, genomic segmentation
algorithm of Affymetrix Genotyping Console was
used.
RESULTS
A total of 247 ETV6–RUNX1 BCP-ALL cases
were screened using BA probes, targeting the
ETV6 and RUNX1 loci. Unexpected signal pat-
terns which indicated the involvement of
der(12)t(12;21) were observed. First, a group of
patients (16/247, 6%) showed a signal pattern of
either 1R 0G 1F (n ¼ 10, Group A) or 1R 0G 0F
(n ¼ 6, Group B) using the ETV6 DC BA probe,
indicating the deletion of 30ETV6 sequences from
the der(12)t(12;21) with or without intact nonrear-
ranged ETV6, respectively (Table 1, Fig. 1, and
Supporting Information Table 2). The RUNX1
DC BA probe uncovered another group of
patients (n ¼ 4, 2%, Group C), showing a dele-
tion of the 50RUNX1 sequences from the
der(12)t(12;21) as indicated by a signal pattern of
0R 1G 1F (Table 1, Fig. 1, and Supporting Infor-
mation Table 2). In all these patients, these
abnormal signal patterns were present in 100% of
fusion-positive cells, indicating that the deletion
occurred at the same time as the translocation
(Supporting Information Table 2). Overall, dele-
tions of the nonrearranged ETV6 allele were
observed among 165 (67%) successfully tested
cases. Deletions of der(12) were more common
among patients with an intact versus deleted non-
rearranged ETV6: 11/80 (14%) versus 9/165 (5%),
P ¼ 0.026. This cohort of 20 patients with a
deleted der(12) comprised 14 males and 6
females, who were all aged <10 years and had a
median white blood cell count (WCC) of 12.4 
109/L. All 20 patients remain in first complete
remission after a median follow-up time of 9.2
years.
Second, a group of 10 patients (4%, Group D)
showed abnormal signal patterns of 1R 2G 0F
and 2R 1G 1F using both ETV6 DC BA and
RUNX1 DC BA, respectively, which suggested a
duplication of the RUNX1–ETV6 fusion gene
(Table 2 and Supporting Information Table 2).
These signal patterns were often found in con-
junction with the standard abnormal signal pat-
tern (1R 1G 1F), indicating that this abnormality
represented a secondary event. This cohort of
patients comprised six females and four males,
who were all aged <10 years, had a median WCC
of 19.2  109/L, and were all in continuing com-
plete remission more than 8 years after diagnosis.
Figure 2. Three-color FISH confirmation of the origin of the
der(12)t(12;21) deletion. (A–C) Serial application of the green (A),
gold (B), and red (C) probes to a single metaphase from patient
3135, showing a signal pattern of 1R 1F(green-gold) 1F(green-red),
confirming that the gold (target) probe was deleted from the
der(12)t(12;21) rather than the nonrearranged chromosome 12. (D)
The same metaphase highlighting the normal nonrearranged chromo-
some 12 (green), normal chromosome 21 (yellow), and the
der(12)t(12;21) (red-blue); (E and F) Ideograms indicating the posi-
tions of the three probes in a normal and a standard t(12;21) cell,
respectively. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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Figure 3. Identification and proposed mechanism for the formation
of der(12)(21qterfi21q22.12::12p13.2-12p12.3::12p12.3fi12qter)
(A and B) Ideograms showing the positions of the probes used
in ETV6–RUNX1 DC SF probe in a normal and standard t(12;21)
cell, respectively; (C) An ideogram representing the proposed
mechanism behind the der(12)(21qter!21q22.12::12p13.2-12p12.3::
12p12.3!12qter) through mitotic recombination. (D and E) An inter-
phase and a metaphase cell, respectively, from patient 3726 hybridized
with the ETV6–RUNX1 DC SF probe. The signal pattern of 1R 0G
2F indicates the presence of a normal chromosome 21 (yellow),
and a der(12)(21qter!21q22.12::12p13.2-12p12.3::12p12.3!12qter)
(red-blue) which harbors a duplicated RUNX1–ETV6 fusion gene.
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
TABLE 1. Demographic and Genetic Characteristics of ETV6–RUNX1-positive BCP-ALL Patients With der(12)t(12;21) Deletion
Patient
number
Sex/age
(years) Karyotype
Range of
deletion (Mb)
Size of
deletion (Mb)a Other tests
Group A: Deletion of 30ETV6 sequences from der(12)t(12;21) plus intact nonrearranged ETV6
3052 F/2 Fail 12.02–max(15.26)b Undefined NA
3053 F/2 46,XX 12.02–19.83 7.81 NA
3135 M/9 46,XY,der(9)del(9)(p21)del(9)(q34),
del(11)(q13q23)t(12;21)
(p13;q22),der(20)t(8;20)(q13;p?)
12.02–13.16 1.14 Three-color FISH,
MLPA, SNP6
3189 F/1 46,XX 12.02–15.26 3.24 MLPA, SNP6
3498 M/5 Fail 12.02–25.39 13.37 NA
4192 F/3 47,XX,del(11)(q13),del(12)(p?),þ21 12.02–23.48 11.46 NA
4287 M/4 46,XY 12.02–13.36 1.34 Three-color FISH
4854 M/2 46,XY,add(2)(p11),del(12)(p11),22,þ2–3mars[cp] 12.02–13.36 1.34 NA
4947 M/3 48–50,XY,add(8)(p2?),þ10,t(12;15)(p1?;p1?),þ21[cp] 12.02–12.88 0.86 NA
4969 M/6 46,XY,del(9)(p2?),þ21 12.02–14.94 2.92 MLPA, SNP6
Group B: Deletion of 30ETV6 sequences from der(12)t(12;21) plus deletion of nonrearranged ETV6
3990 M/4 46,XY 12.02–12.37 0.35 NA
4112 M/8 46,XY,add(9)(p21),del(12)(p12) 12.02–15.26 3.24 NA
4133 M/2 46,XY 12.02–21.15 9.13 NA
4284 M/4 46,XY,del(12)(p1?) 12.02–22.25 10.23 NA
4358 M/2 46–47,XY,del(12)(p?)[cp] 12.02–23.36þb Undefined NA
3066 M/1 47,XY,þ10 NA NA NA
Group C: Deletion of 50RUNX1 sequences from der(12)t(12;21)
3319 F/8 45,X,-X 36.26–37.26 1.00 NA
4692 M/2 46,XY,add(16)(q22) 36.26–38.72 2.46 NA
4917 F/2 47,XX,þ21 36.26–37.04 0.78 NA
3277 M/5 46,XY,add(11)(p15),add(12)(p12),
del(12)(p12),del(21)(q21)
NA NA NA
Note: Groups A and B: Deletion starts at 12.02 Mb (within ETV6 intron 5); Group C: Deletion starts at 36.26 Mb (within RUNX1 intron 1); NA:
not performed owing to lack of material.
aSize determined using data from ENSEMBL version no.60
bA lack of material prevented the deletion being fully mapped.
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Characterization of the Deletion of
der(12)t(12;21)
A total of 18 out 20 patients with indirect evi-
dence for a deletion of der(12)t(12;21) were
selected on the basis of availability of material.
They were divided into three groups and investi-
gated separately according to the status of non-
rearranged ETV6 and whether the deleted
sequences affected the 30ETV6 or 50RUNX1 part
of the fusion gene. Groups A and B were both
characterized by loss of 30ETV6 and additional
chromosome 12 sequences centromeric of the
breakpoint with either an intact (n ¼ 10) or
deleted (n ¼ 5) nonrearranged ETV6, respec-
tively. Although the third group (C) (n ¼ 3) con-
sisted of patients with deletion of 50RUNX1 and
additional chromosome 21 sequences telomeric of
the breakpoint.
The FISH, MLPA, and SNP array data were
concordant for the presence of deletions on
der(12)t(12;21), which resulted in loss of 30ETV6
and contiguous centromeric sequences. FISH
probes mapping along 12p from 12p11.21-12p13.2
(Supporting Information Table 1) were serially
applied to all 15 samples to map the extent of
the deletion (Table 1 and Fig. 1). The deletion
was fully mapped in all cases except patients
3052 (Group A) and 4358 (Group B), where a
lack of material prevented completion of all
required tests. Among 13 deletions, fully mapped,
including three cases analyzed by SNP array
(3135, 3189, and 4969), the median size of the
deletion was 3.24 Mb with a range of 0.35–13.37
Mb. A common region of deletion (CRD),
defined by patient 3990 (Group B), was observed
spanning 0.35 Mb and comprising two genes:
LRP6 and BCL2L14. Although patients 3052
(Group A) and 4112 (Group B) showed evidence
of variant t(12;21) translocations involving an
additional chromosome, the FISH patterns were
consistent with a deletion of 30ETV6 from the
der(12)t(12;21) (Supporting Information Table 2).
Three-color FISH was attempted in four cases
(3135, 4287, 4854, and 4947). It was successful in
patients 3135 and 4287 (Group A), where it
showed a signal pattern of 1R 1F(green-gold)
1F(green-red), confirming that the target probe
was deleted from the der(12)t(12;21) rather than
from the nonrearranged chromosome 12 (Figs.
2A–2D and Supporting Information Table 2). In
addition, MLPA in three patients (3135, 3189,
and 4969) showed a monoallelic deletion of ETV6
exon 8 with retention of exons 1–5, a pattern
which is consistent with deletion from the
der(12)t(12;21) rather than the normal
chromosome.
The third group (C) comprised patients with
loss of 50RUNX1 and chromosome 21 sequences
from the der(12)t(12;21). FISH mapping of the
three patients using different deletion probe sets
along 21q from 21q22.12-21q22.3 (Supporting
Information Table 1) revealed deletions with a
median size of 1.00 Mb (range, 0.78–2.46 Mb)
(Table 1, Fig. 1, and Supporting Information
Table 2). No subsequent MLPA and SNP array
tests were possible owing to a lack of material.
The CRD defined by patient 4917 did not
include any known genes. Although patient 3319
showed evidence of a variant t(12;21) transloca-
tions involving an additional chromosome, the
FISH patterns were consistent with a deletion of
50RUNX1 from the der(12)t(12;21) (Supporting
Information Table 2).
Gain of RUNX1–ETV6 Fusion Gene on a
der(12)(21qter!21q22.12::12p13.2-
12p12.3::12p12.3!12qter)
FISH, MLPA, and SNP array findings con-
firmed our initial observation of the gain of the
RUNX1–ETV6 fusion gene of patients in Group
D (Table 2). FISH experiments performed on
seven patients, using the DC SF probe, con-
firmed two copies of the RUNX1–ETV6 fusion in
all cases in an average of 55% of ETV6–RUNX1-
positive cells (Table 2 and Fig. 3D). Metaphases
from patient 3726 showed that the two fusion
signals were on separate chromosomes (Fig. 3E).
Further FISH revealed the presence of only two
chromosomes 12 centromeres and the loss of one
12p subtelomeric region in all seven cases (Table
2 and Supporting Information Table S2). MLPA
in two cases (4281 and 4637) revealed a single
copy of ETV6 exons 1–5 but two copies of ETV6
exon 8, a pattern consistent with two copies of
the RUNX1–ETV6 fusion and no normal ETV6 al-
lele. Although a third patient (3726) did not show
the same copy number profile of ETV6 exons by
MLPA, FISH indicated that this abnormality was
present only in 18% cells which is below the
detection threshold of 30% for MLPA (Schwab
et al., 2010). In all three cases, MLPA revealed a
normal copy number for the BTG1 gene, consist-
ent with the FISH data and indicated that only
two chromosomes 12 were present. SNP array
analysis of two cases (4281 and 3726) revealed
the presence of two chromosomes 12 with
copy number neutral loss of heterozygosity
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(CNN-LOH), spanning a region of the short arm
of chromosome 12 12(12.02[p13.2]-19.87[p12.3]).
This abnormality was clearly evident in patient
4281 as it constituted the major clone, unlike
patient 3726, where it represented only a subpo-
pulation of cells. In addition, three copies of a
part of the long arm of chromosome 21
21(36.39[q22.12]!48.10[qter]) and one copy of
the subtelomeric region of 12p del(12)(0.19
[pter]!19.87[p12.3]) were detected.
Taken together, these data indicate the presence
of an extra RUNX1–ETV6 fusion gene which
could not have arisen from a simple gain of
der(12)t(12;21) and loss of the normal chromosome
12. Instead, these data pointed to a secondary event
which involved mitotic recombination between the
normal chromosome 12 and the der(12)t(12;21),
resulting in the formation of der(12)(21qter!
21q22.12::12p13.2-12p12.3::12p12.3!12qter) (Fig.
3C). This derived chromosome consisted of one
copy of the der(12)t(12;21) from the 21q telomere,
including the RUNX1–ETV6 fusion site, up to
12p12.3 and thereafter, material from the other
chromosome 12 that had not been involved in the
original t(12;21) translocation. The mitotic recombi-
nation point not only differed between the two
patients, but also the area of complex CNN-LOH
(Area C) observed in patient 4281 (Fig. 4)
suggested the presence of multiple independent
mitotic recombination events in the same patient.
Collectively, these rearrangements resulted in the
loss of the nonrearranged ETV6 allele with the
contiguous telomeric sequences, duplication of
the reciprocal RUNX1–ETV6 fusion gene, as well as
the CNN-LOH of a region on the short arm of
chromosome 12.
DISCUSSION
The ETV6–RUNX1 fusion gene alone is insuffi-
cient to initiate overt leukemia. Accordingly,
additional abnormalities are required to contrib-
ute to leukemogenesis. Here, we characterize two
novel abnormalities which target the RUNX1–
ETV6 fusion gene, either by deletion or by dupli-
cation, which were identified using FISH probes,
targeting the ETV6 and RUNX1 loci. (1) A
deleted der(12)t(12;21) was detected in 8%
ETV6–RUNX1-positive cases and (2) a complex
der(12) including a duplication of the RUNX1–
ETV6 fusion gene was identified in 4% ETV6–
RUNX1-positive cases. The demographic and
clinical features of these 30 patients were unre-
markable and none of these patients had relapsed
or died. However, it should be noted that only
13% of ETV6–RUNX1-positive patients treated on
ALL97 suffered a relapse (Moorman et al., 2010).
In this study, deletions involving chromosome
12 material from the der(12)t(12;21) were more
prevalent than deletion of chromosome 21 mate-
rial. Neither deletion has been reported previ-
ously. However, we and other researchers
referred to deletions of 50RUNX1 sequences while
using the commercial TEL-AML1 extra signal
Figure 4. SNP 6.0 profile for chromosome 12 from a patient with
der(12)(21qterfi21q22.12::12p13.2-12p12.3::12p12.3fi12qter). SNP array
analysis of patient 4281 showed four regions on chromosome 12: an
area of deletion (Area A) from the telomere to 12p12.3 (19.7 Mb) fol-
lowed by three regions with different patterns of heterozygosity: (B)
copy number neutral loss of heterozygosity (CNN-LOH)
(12)(12.02[p13.2]-19.87[p12.3]); (C) complex CNN-LOH (12)(19.87
[p12.3]-28.06[p11.22); (D) normal heterozygous chromosome
12(28.06[p11.22]-133.85[qter]). It is not possible to discern whether
areas B and C represent distinct or overlapping lesions. [Color figure
can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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probe, observing loss of the extra signal (Jabber
Al-Obaidi et al., 2002; Martineau et al., 2005;
Rothman et al., 2005; Konn et al., 2010). How-
ever, as this loss was almost always present in
subclones it is unlikely that there is much, if any,
overlap between the two groups. The failure of
the previous studies to identify this deletion is
probably owing to the fact that the majority of
commercially available probes do not include
probes that would localize to the der(12) in the
presence of a translocation. Interestingly,
genomic copy number profiling may erroneously
identify deletions of chromosome 12 sequences
from the der(12)t(12;21) as intragenic deletions of
the nonrearranged ETV6 allele which represent a
different entity.
These deletions join a list of submicroscopic
deletions that accompany primary chromosomal
rearrangements in leukemia including t(9;22)
(q34;q11), inv(16)(p13q22), t(8;21)(q22;q22), and
rearrangements of the MLL gene (Rothman et al.,
2005). For example, der(9)t(9;22) deletions,
involving either 50ABL1, 30BCR, or both, are
detected in 9–33% of CML patients with conse-
quent worse prognosis especially in those with
50ABL losses (Sinclair et al., 2000; Vaz de Campos
et al., 2007). Interestingly, the extent of deletion
of der(9)t(9;22) is comparable to our findings with
smaller 30BCR deletions (<0.5 Mb) than 50ABL-
deleted regions (mean size, 2.80 Mb) (Sinclair
et al., 2000; Storlazzi et al., 2002; Douet-Guilbert
et al., 2006). In addition, deletions of 50MYH11
(16p13) or 30CBFB are detected in 20% (Tirado
et al., 2010) and 8% (Kelly et al., 2005) of AML
with inv(16), respectively. Similarly, there are
deletions of the region 50RUNX1T1, representing
9% of t(8;21) with no occurrence of 30RUNX1
losses (Godon et al., 2002). Approximately, 20–
25% of MLL rearrangements are associated with
30MLL deletions (Konig et al., 2002). Little is
known about the time at which these deletions
arise and the mechanisms involved in their origin.
However, the nature of the sequences that flank
translocation breakpoint regions may play a role.
Nonrandom distribution of high-density flanking
Alu repeats, which are known to facilitate illegiti-
mate recombination, within the vicinity of dele-
tion breakpoints is considered to be one possible
mechanism giving rise to deletion (Kolomietz
et al., 2001, 2002). Unlike der(9)t(9;22) deletions,
the prognostic impact of the submicroscopic dele-
tions that accompany other rearrangements
remains to be determined. The molecular
mechanisms responsible for the poor prognosis
associated with der(9)t(9;22) deletions are obscure
although it has been proposed that the loss of
one or more tumor suppressor genes may induce
more aggressive disease through a secondary event
or haploinsufficiency. Furthermore, deletions may
result in genetic instability which predisposes to
subsequent additional genetic alterations or to
intronic deletions within BCR–ABL1 itself. How-
ever, no increase in the frequency of secondary
cytogenetic abnormalities during disease progres-
sion has been observed in patients with deletions
(Vaz de Campos et al., 2007).
We have hypothesized that der(12)t(12;21)
deletions, like der(9)t(9;22) deletions, occur at
the same time as the translocation and are a by-
product of the translocation event itself. This is
evidenced by the fact that the deletion is present
in 100% fusion-positive cells and that the boun-
daries of the deletion appear identical to the
translocation breakpoint. Hence, the deletion
must have occurred after the breakage of the
chromosomes and prior to the illegitimate fusion
of the chromosomes. Therefore, there is no selec-
tion pressure solely for the deletion. Hence, any
leukemic effect will not only be a bystander
effect but will also vary from patient to patient.
There are several candidate genes on 12p within
the CRD which may be acting as tumor suppres-
sor genes in this scenario, such as LRP6,
BCL2L14, DUSP16, CREBL2, and CDKN1B
(Kiyokawa et al., 1996; Guo et al., 2001; Masuda
et al., 2001). However, no somatic mutations or
altered expression has been reported for these
genes in BCP-ALL (Montpetit et al., 2004).
Deletion of chromosome 21 material from the
der(12) was rare and this CRD did not include
any known genes. The one consistent feature of
all der(12) deletions was loss of the reciprocal
fusion gene—RUNX1–ETV6. This fusion product
consists of the ETS domain from the ETV6
portion, whereas the RUNX1 portion does not
contain a functional domain. It has been sug-
gested that RUNX1–ETV6 is likely to have a
function in ETV6–RUNX1 ALL through the
action of this isolated ETS domain and it may
behave in a similar manner to wild-type ETV6
where the nonrearranged allele has been deleted
(Stams et al., 2005). Cases with der(12) deletions
will not be able to express the reciprocal fusion
product; hence, any functional consequence of
RUNX1–ETV6 would be abrogated in these cases.
Stams et al. (2005) have shown that 25% ETV6–
RUNX1-positive ALL do not express any
RUNX1–ETV6 mRNA. Der(12) deletions are one
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mechanism by which expression of RUNX1–ETV6
could be switched off.
Previous FISH studies based on observations
using the TEL-AML1 ES probes have suggested
that duplication of the reciprocal product is owing
to a simple gain of the der(12)t(12;21) or the
result of an independent translocation (Ma et al.,
2001; Jalali et al., 2003; Martineau et al., 2005;
Rothman et al., 2005). However, our investiga-
tions have shown that the resulting derived chro-
mosome 12 is more complex and results in
duplicated regions of 21q and 12p as well as
CNN-LOH of regions of 12p but not 12q as
would be assumed from gain of der(12)t(12;21)
and loss of the normal chromosome 12. It is
known that a proportion of ETV6–RUNX1 cases
exhibit high expression of the reciprocal product,
RUNX1–ETV6. Indeed, it has been shown to be
an independent prognostic factor which confers a
poor outcome (Stams et al., 2005). It is logical to
postulate that duplication of RUNX1–ETV6 may
lead to its overexpression. Unfortunately, we
were unable to confirm this hypothesis owing to a
lack of material. The difference in survival
between our patients, who had an excellent out-
come and those mentioned in the article by
Stams et al. (2005), is likely to be due to the
advances in treatment rather than evidence that
the two groups are distinct. Clearly, the der(12)
(21qter!21q22.12::12p13.2-12p12.3::12p12.3!
12qter) results in other events which may also be
contributing to leukemogenesis via the unmasking
of cancer driver mutations, either by the inactiva-
tion of tumor-suppressor genes or by the activation
of oncogenes. There are multiple genes encom-
passed within this region including LRP6,
BCL2L14, DUSP16, CREBL2, and CDKN1B. In
addition, the loss of nonrearranged ETV6 allele may
be one of the driving forces of the leukemogenic
process in this group of patients. Further functional
studies will be required to address these questions.
It is now well established that ETV6–RUNX1-
positive ALL harbors several additional abnor-
malities. In this study, we have characterized two
additional aberrations which, although indicated
previously, had not been fully characterized. Both
abnormalities affect the RUNX1–ETV6 fusion
product located on der(12)t(12;21), resulting ei-
ther in its deletion or in its duplication. Neither
abnormality was associated with a poor outcome
within this cohort. This is likely to be a reflection
of the highly efficient therapy that is available for
ETV6–RUNX1-positive patients, which has
resulted in a very low relapse rate (Moorman
et al., 2010), rather than an indication that the
abnormalities do not influence the development
of the disease. Generally, most research on chro-
mosomal translocations is focussed on the primary
product and ETV6–RUNX1 ALL is no exception
which explains the reason why these abnormal-
ities have remained uncharacterized until now.
However, evidence from the studies of the
t(4;11) translocation suggest that the reciprocal
product, AFF1-MLL, may play a more important
biological role than the previously imagined
(Kowarz et al., 2007). Our data suggest that the
same may be true for RUNX1–ETV6. Further
research into the functional consequences of
altered expression of RUNX1–ETV6 in patients
with ETV6–RUNX1 ALL will be required to
establish its role in leukemogenesis.
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Pediatric Acute Lymphoblastic Leukemia
In childhood B-cell precursor acute lymphoblastic leukemia, cytogenetics is important in diagnosis and as an indi-
cator of response to therapy, thus playing a key role in risk stratification of patients for treatment. Little is known
of the relationship between different cytogenetic subtypes in B-cell precursor acute lymphoblastic leukemia and the
recently reported copy number abnormalities affecting significant leukemia associated genes. In a consecutive series
of 1427 childhood B-cell precursor acute lymphoblastic leukemia patients, we have determined the incidence and
type of copy number abnormalities using multiplex ligation-dependent probe amplification. We have shown strong
links between certain deletions and cytogenetic subtypes, including the novel association between RB1 deletions
and intrachromosomal amplification of chromosome 21. In this study, we characterized the different copy number
abnormalities and show heterogeneity of PAX5 and IKZF1 deletions and the recurrent nature of RB1 deletions.
Whole gene losses are often indicative of larger deletions, visible by conventional cytogenetics. An increased num-
ber of copy number abnormalities is associated with NCI high risk, specifically deletions of IKZF1 and CDKN2A/B,
which occur more frequently among these patients. IKZF1 deletions and rearrangements of CRLF2 among patients
with undefined karyotypes may point to the poor risk BCR-ABL1-like group. In conclusion, this study has demon-
strated in a large representative cohort of children with B-cell precursor acute lymphoblastic leukemia that the pat-
tern of copy number abnormalities is highly variable according to the primary genetic abnormality.
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lymphoblastic leukemia: association with cytogenetics and 
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Introduction
The cytogenetics of B-cell precursor acute lymphoblastic
leukemia (BCP-ALL) is well documented, with specific chro-
mosomal abnormalities used in risk stratification of patients
for treatment.1,2 Genomic studies have shown that copy
number abnormalities (CNA) of genes involved in B-lympho-
cyte development and differentiation, cell cycle control and
those of significance in hematopoiesis are common in BCP-
ALL.3-5 Notable deletions include PAX5, IKZF1 (Ikaros),6-11 and
genes within the pseudoautosomal region (PAR1) of the sex
chromosomes, resulting in the P2RY8-CRLF2 gene fusion and
overexpression of CRLF2.12 Here there is particular interest in
IKZF1 and CRLF2 in relation to outcome and their role as
molecular targets for therapy. IKZF1 deletions have been
associated with a poor prognosis in BCP-ALL,6-10 while the
risk relating to CRLF2 has been variable and dependent on
other features.13-15 Nevertheless, thus far these diverse findings
have not led to any treatment changes. Studies have focused
on small or selected cohorts and analyses have often been car-
ried out independently from other genetic changes. Thus
their accurate incidence, relationship to each other, and the
major cytogenetic subgroups still have to be determined in
order to understand their true clinical relevance. 
Recently, we demonstrated that multiplex ligation-depen-
dent probe amplification (MLPA) provided an accurate and
reliable high throughput method to screen for CNA of the sig-
nificant genes in BCP-ALL.16 In this study, we screened a
cohort of 1427 childhood BCP-ALL patients from two consec-
utive treatment trials using the same MLPA approach. We
report the frequency and type of CNA involving these genes,
their associations with established chromosomal abnormali-
ties, and other clinical features.
Design and Methods
Patients in this study were diagnosed with BCP-ALL and registered
on UK treatment trials UKALL97/99 (April 1997-June 2002) for chil-
dren aged 1-18 years17 and UKALL2003 (October 2003-July 2011) for
children aged 1-25 years.18 Clinical details were provided by the
Clinical Trial Service Unit (CTSU), Oxford, UK. All participating cen-
ters obtained local ethical committee approval and written informed
consent from patients, parents or guardians in accordance with the
Declaration of Helsinki. Risk was assessed using National Cancer
Institution (NCI) criteria.  
Patients were classified into eight cytogenetic subgroups according
to the presence of the following chromosomal abnormalities: 1)
t(12;21)(p13;q22)/ETV6-RUNX1 fusion; 2) high hyperdiploidy (51-65
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chromosomes); 3) translocations involving  11q23/MLL rearrange-
ments;  4) t(9;22)(q34;q11)/BCR-ABL1 fusion; 5) intrachromosomal
amplification of chromosome 21 (iAMP21);19 6)
t(1;19)(q23;p13)/TCF3-PBX1; 7) other abnormal (absence of abnor-
malities in subgroups 1-7 above); and 8) normal karyotype.
Patients were classified into good, intermediate, and poor cytoge-
netic risk groups according to previously published data.20 
DNA obtained from the presentation bone marrow sample was
used to determine the copy number of IKZF1, CDKN2A/B, PAX5,
EBF1, ETV6, BTG1, RB1, and genes within PAR1: CRLF2, CSF2RA,
IL3RA, using the SALSA MLPA kit P335 IKZF1 (MRC Holland,
The Netherlands), as previously described.16 In those patients
entered on UKALL2003, deletions of IKZF1 and RB1 were con-
firmed and further characterized by the P202 IKZF1 and the P047
RB1 SALSA MLPA kits, respectively. 
Deletions of genes within the PAR1 region identified by MLPA
were confirmed as P2RY8-CRLF2 or unbalanced IGH@-CRLF2
translocations by interphase fluorescence in situ hybridization
(FISH) as previously reported.12 
Statistical analysis was carried out using Intercooled STATA v.
12.0 (StataCorp, USA), particularly Wilcoxon Rank Sum for non-
parametric assays and χ2 for comparison of categorical variables.
Results
CNA among the entire cohort 
In total, 1427 patients were included in this study. There
was no difference between these patients and other trial
participants with respect to sex, age, central nervous sys-
tem (CNS) disease or NCI risk group. Tested patients were
more likely to have a white blood cell (WBC) count over
10 x 109/L reflecting the increased possibility of surplus
available material (Online Supplementary Table S1).  
Incidences of CNA for genes tested by MLPA are given
in Table 1. Overall, 59% of patients showed an abnormal-
ity of at least one of these genes: 433 (30%) patients had
one, 254 (18%) had two, 131 (9%) had three and 28 (2%)
had four or more deletions. Overall, deletions of
CDKN2A/B and ETV6 were the most frequent, while
EBF1 deletions were rare. Patients classified as NCI high
risk were significantly more likely to have a greater num-
ber of deletions compared to those classified as NCI stan-
dard risk (P<0.001) (Figure 1).
Table 1 shows the distribution of abnormalities in rela-
tion to demographic and clinical features. The cohort com-
prised 665 (46%) females and 762 (54%) males. There was
no shift in the gender balance within each subgroup
according to the defined CNA. The median age of the
cohort was five years (range 1-23) with 24% of patients
being 10 years or older. Patients with IKZF1 and
CDKN2A/B deletions were significantly older. The medi-
an age for IKZF1 and CDKN2A/B deletions was seven
years (P <0.0001) and six years (P <0.0001), respectively,
with 39% and 33%, respectively, of deletions occurring in
patients aged 10 years old or older. The incidence of these
deletions increased with age (Table 1), a trend that contin-
ued into adulthood as shown by the incorporation of
MLPA data from the UK adult ALL treatment trial,
UKALLXII21 (Figure 2). There was a peak in incidence of
ETV6 deletions in children aged 2-4 years (data not shown),
explained by their strong association with ETV6-RUNX1,
which has a peak incidence in this age group.22 There was
no significant change in incidence linked to age for dele-
C.J. Schwab et al.
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Table 1. Association of copy number abnormalities with demographics and WCC.
Cohort Genes with CNA/chromosomal region
IKZF1 PAX5 RB1 CDKN2A/B ETV6 EBF1 BTG1 PAR11
N. of cases 1427 196 14% 272 19% 92 6% 395 28% 312 22% 30 2% 89 6% 63 4%
Age (years)
Median 5 7* 5 7 6* 4 6 6 5
1-4 704 55 8% 135 19% 30 4% 152 22% 168 24% 10 1% 35 5% 29 4%
5-9 386 64 17% 66 17% 33 9% 115 30% 82 21% 14 4% 29 8% 26 7%
10-14 240 54 23% 53 22% 23 10% 93 39% 40 17% 6 3% 19 8% 5 2%
15-24 97 23 24% 18 19% 6 6% 35 36% 22 23% 6 7% 3 3%
Gender M:F 
(ratio) 762:665 105:91 146:126 50:42 214: 181 160:152 15:15 46:43 28:35
(1.15) (1.15) (1.15) (1.19) (1.18) (1.05) (1.0) (1.07) (0.8)
WCC (x109/L )
Median 11.8 21.6* 21.3* 11.7 21.1* 13.1 13.9 14.8 22
<10 633 65 10% 97 15% 36 6% 131 21% 130 21% 12 2% 37 6% 22 3%
10-49.9 527 69 13% 92 17% 42 8% 150 28% 118 22% 9 2% 32 6% 26 5%
≥50 267 62 23% 83 31% 14 5% 114 43% 64 24% 9 3% 20 7% 15 6%
CNA: copy number abnormalities; 1this group includes P2RY8-CRLF2 and unbalanced IGH@-CRLF2 translocations; *P<0.0001.
Figure 1. Bar chart showing the percentage of patients within NCI
high and standard risk groups with increasing numbers of CNA.
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tions of the other genes tested, including ETV6 deletions
in ETV6-RUNX1 negative patients.
The median WBC count of the cohort was 11.8 x 109/L
with 44% of patients having a count of less than 10 x
109/L. Patients with IKZF1, PAX5 or CDKN2A/B deletions
were more likely to have a WCC of over 50 x 109/L (each
P<0.001) (Table 1). The association of these genes to age
and WBC count meant that there was a significantly high-
er incidence of patients with IKZF1, PAX5 and/or
CDKN2A/B deletions classified as NCI high risk compared
to other patients (each P<0.001) (Table 2). 
The frequency of each cytogenetic subgroup among
1351 patients with a successful cytogenetic result is
shown in Table 3. Patients with ETV6-RUNX1, high
hyperdiploidy and those classified as ‘other abnormal’
comprised the most common subgroups at incidences of
28%, 30% and 24%, respectively. Patients positive for
ETV6-RUNX1 showed the highest number of CNA over-
all, followed by those in the other abnormal group. In con-
trast, CNA occurred at a lower than expected level in high
hyperdiploid patients. The incidence of CNA was also
low in the subgroup with MLL rearrangements and higher
in the other poor-risk subgroups: BCR-ABL1 positive and
iAMP21. The increasing numbers of CNA in each cytoge-
netic group are shown in Figure 3, while the incidences
and distribution of the individual CNA within each cyto-
genetic group are shown in Figure 4.
Among ETV6-RUNX1 positive patients, in addition to a
high incidence of wild-type ETV6 deletions, CDKN2A/B
and PAX5 were each deleted in 22% of these patients,
while the incidence of IKZF1 deletions was low. Although
BTG1 deletions were rare throughout the cohort (n=87,
Gene deletions in childhood BCP-ALL
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Figure 2. Graphs showing the proportion of cases with IKZF1 and
CDKN2A/B deletions according to age among BCR-ABL1 negative
patients. As it is known that there is a strong association between
IKZF1 deletions and BCR-ABL1 positive ALL7 and that the incidence
of BCR-ABL1 positive ALL increases with age22, childhood BCR-ABL1
positive patients were excluded from this age association analysis
of IKZF1 and CDKN2A/B for direct comparison with the MLPA test-
ed adult BCR-ABL1 negative series21.
Table 2. Association of Copy Number Abnormalities with NCI and Cytogenetic Risk Group.
Cohort Genes with CNA
IKZF1 PAX5 RB1 CDKN2A/B ETV6 EBF1 BTG1 PAR11
N. of cases 1351 177 13% 255 19% 89 7% 371 27% 301 22% 27 2% 87 6% 56 4%
NCI Risk Group
Standard 838 62% 71 8% 124 15% 53 6% 171 20% 191 23% 18 2% 51 6% 39 5%
High 513 38% 106 21% 131 26% 36 7% 200 39% 110 21% 9 2% 36 7% 17 3%
Cyto Risk Group
Good 787 58% 46 6% 101 13% 39 5% 153 19% 231 29% 14 2% 59 7% 10 1%
Intermediate 441 33% 96 22% 121 27% 23 5% 173 39% 57 13% 7 <1% 21 5% 32 7%
Poor 123 9% 35 28% 32 26% 27 22% 45 37% 13 11% 6 5% 7 6% 14 11%
Cyto, cytogenetics; 1this group includes P2RY8-CRLF2 and unbalanced IGH@-CRLF2 translocations.
Table 3.  Incidences of CNA according to cytogenetic subgroups.
Cytogenetic Cases in IKZF1 PAX5 RB1 CDKN2A/B ETV6 EBF1 BTG1 PAR11 Total 
subgroup each group CNA
N. %2 N. %3 N. %3 N. %3 N. %3 N. %3 N. %3 N. %3 N. %3 N. %4
Total 13515 177 13% 255 19% 89 7% 371 27% 301 22% 27 2% 87 6% 56 4% 1334
ETV6-RUNX1 379 28% 11* 3% 83 22% 29 8% 84 22% 203* 54% 14 4% 57* 15% 3* <1% 484 6%
HeH 408 30% 35* 9% 18* 4% 10* 3% 65* 16% 28* 7% 0 2* <1% 7 2% 165 12%
MLL rearranged 28 2% 2 8% 2 8% 0 8 31% 1 4% 0 0 0 13 1%
BCR-ABL1 33 2% 21* 64% 15* 45% 3 9% 16‡ 48% 1 3% 2 6% 1 3% 1 3% 60 5%
iAMP21 33 2% 7 21% 4 12% 13* 39% 4 12% 7 21% 3 9% 1 3% 10* 30% 49 4%
t(1;19)/TCF3-PBX1 44 3% 3 7% 8 18% 7 16% 10 23% 2 5% 1 2% 0 1 2% 32 2%
Other abnormal 324 24% 77* 24% 115* 36% 23 7% 153* 47% 51 16% 5 2% 3 1% 33* 10% 460     34%
Normal 102 8% 20 20% 9 9% 4 4% 22 22% 8* 8% 1 <1% 6 6% 1 1% 71 5%
1This group includes P2RY8-CRLF2 and unbalanced IGH@-CRLF2 translocations; 2Calculated from total cohort with a successful cytogenetic result; 3Calculated as total number of patients in
this specific cytogenetic subgroup with this CNA; 4Calculated from total number of abnormalities, which is greater than the total number of patients; 5Patients with a successful cytogenetics
result only; *P<0.0001; ‡P=0.005.
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6%), they were frequently associated with ETV6-RUNX1
(15%) (P<0.0001). There was an association between
BCR-ABL1 and IKZF1 with 64% having a deletion of
IKZF1. Deletions of PAX5 and CDKN2A/B were also high
in this subgroup at incidences of 45% and 48%, respec-
tively. 
Among iAMP21 patients, RB1 deletions and P2RY8-
CRLF2 were observed at incidences (39% and 30%,
respectively) significantly higher than expected
(P<0.0001). They showed the second highest frequency of
ETV6 deletions. In the TCF3-PBX1 subgroup, there was a
high incidence of deletions of PAX5 and CDKN2A/B. In
the group classified as ‘other abnormal’, deletions of
CDKN2A/B, PAX5 and IKZF1, as well as P2RY8-CRLF2,
were seen at higher than expected frequencies.
C.J. Schwab et al.
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Figure 3. Bar chart showing the proportion of patients within each
cytogenetic subgroup with increasing numbers of CNA.
Figure 4. Circos plots
showing the relative
incidence and distri-
bution of CNA within
the overall cohort and
the individual cytoge-
netic groups. The pro-
portions of cases with
and without CNA are
indicated in black and
gray, respectively,
around the perimeter
and the ribbons repre-
senting the individual
CNA are color coded.
The width of the rib-
bons reflects the fre-
quency of each CNA.
100
90
80
70
60
50
40
30
20
10
0
Pe
rc
en
ta
ge
 o
f c
as
es
 (%
)
3+
2
1
None
heh 11q23 t(1;19) normal other t(12;21) t(9;22) iAMP21
Overall cohort
Normal karyotype
MLL rearranged iAMP21
With CNA
Without CNA
EBF1
IKZF1
ETV6
BTG1
RB1
PAR1
CDKN2A/B
PAX5
BCR-ABL1
Other abnormalityTCF3-PBX1
ETV6-RUNX1 High hyperdiploidy
©
 F
er
ra
ta
 S
to
rti
 F
ou
nd
at
io
n.
 
N
o 
co
m
m
er
ci
al
 u
se
 is
 a
llo
w
ed
Individual abnormalities
A range of interesting observations were made in rela-
tion to the individual abnormalities. IKZF1: deletions of
IKZF1 were present in 14% (n=196) of the cohort. The
size of the deletion varied between patients (Online
Supplementary Figure S1). The most frequent deletions
involved either the whole gene (n=60) or were restricted
to exons 4-7 (n=61).  Other deletions occurred at lower
frequencies: exons 2-3 (n=15), exons 2-7 (n=20), exons 4-8
(n=13), and miscellaneous deletions (n=27). Five patients
had biallelic deletions; each showed a different pattern of
loss, ranging from biallelic deletion of all exons to a subset
of exons. No significant association was seen between the
pattern of exon loss and cytogenetic subgroup, age or
WBC count. Although unlikely to be significant, the bial-
lelic deletions did not occur in association with any of the
major cytogenetic groups. Whole gene deletions were
associated with visible cytogenetic abnormalities of the
short arm of chromosome 7 in 36 of 60 cases including:
monosomy 7 (n=13), i(7)(q10) (n=7), dicentric chromo-
somes (dic) (n=6), balanced and unbalanced translocations
involving chromosome 7 (n=10). 
PAX5 and CDKN2A/B: a total of 272 (19%) patients
showed heterogeneous CNA of PAX5. The majority of
patients had deletions including exon 1 involving the
entire or part of the gene (n=141). The remaining patients
had partial deletions excluding exon 1 (n=121) or intra-
genic amplifications of exons 2 or 5 (n=10), as previously
illustrated.16 
Deletions of CDKN2A/B represented the most frequent
abnormality in the cohort (n=395), of which 143 showed
visible cytogenetic abnormalities of the short arm of chro-
mosome 9 (9p), 212 showed no 9p abnormality, while 40
failed cytogenetic analysis. Among those cases with a vis-
ible 9p abnormality, 103 showed concurrent CNA of
PAX5. A further 59 patients with CNA of both genes had
no visible 9p abnormality (n=41) or failed cytogenetic
results (n=18). The types of cytogenetic abnormalities
involving chromosome 9 associated with these CNA are
shown in Online Supplementary Table S2. Dicentric chro-
mosomes involving chromosome 9 were shown in 43
patients: dic(7;9) (n=7), dic(9;12) (n=16) and dic(9;20)
(n=20). Interestingly, they showed heterogeneous exon
loss from PAX5, ranging from the entire gene to loss of the
telomeric exons (not including exon 1) and they variably
included deletions of CDKN2A/B.
ETV6: ETV6 was frequently deleted throughout the
entire cohort (n=312). As expected, ETV6 deletions were
frequent among ETV6-RUNX1 positive patients (n=203).
FISH results were available on 186 of these ETV6-RUNX1
positive cases. In 154 (83%), the results by FISH and
MLPA were concordant. Among the remaining 32 cases,
deletions were found by MLPA but not FISH, indicating
the presence of focal deletions below the resolution of
FISH. Conversely, 40 cases with ETV6-RUNX1 showed an
ETV6 deletion by FISH only. These either represented
small populations of cells containing the deletions (<25%
of nuclei) below the level at which MLPA would be
expected to detect loss, or deletion of the wild-type ETV6
allele with an associated gain of the derivative chromo-
some 21, thus producing a normal copy number for the
ETV6 exons covered by the MLPA probes. These observa-
tions highlight the previously described advantages and
disadvantages of these two techniques.16 
In total, 109 ETV6-RUNX1 negative cases showed loss
of ETV6; among 86 of these cases with FISH results avail-
able, 52 showed loss of the entire ETV6 by both FISH and
MLPA, while 34 cases showed small intragenic deletions
by MLPA which were below the resolution of FISH. 
RB1: deletions of RB1 were present in 92 cases. These
were of two types: 1) loss of the entire gene (n=60); 2)
focal deletions, including exons 19-26 (n=28) (probes for
these exons are included in the MLPA kit). An additional 4
cases had biallelic deletions of exons 19-26 as well as
monoallelic loss of the remainder of the gene. Further
studies using the P047-RB1 MLPA kit on 65 cases con-
firmed whole gene loss in 40 cases tested. These studies
indicated that the deletions extended into the adjacent
genes: ITM2B and RCBTB2 in all 40 cases, including DLEU
in 38 of them. The relative location of these genes is
shown in Online Supplementary Figure S2A. These results
showed that RB1 loss in these patients is part of a larger
deletion targeting several genes.  
Further characterization of those cases with focal dele-
tions, using the P047-RB1 MLPA kit with a higher probe
density, showed the precise location of the deletion break-
point to be between exons 17 and 18 in 19 of 21 cases test-
ed, while in the 2 remaining cases the breakpoints were
located between exons 16 and 17 and exons 18 and 19. In
8 of 21 cases with this focal deletion, the 5’ breakpoint
included deletion of the RCBTB2 gene. The 4 patients
with both deletions showed different patterns of exon
loss: 2 showed monoallelic loss of ITM2B, RCBTB2 and
DLEU. The other 2 showed normal copy number for
ITM2B and DLEU with the biallelic loss extending to
RCBTB2 in one case and monoallelic loss of this gene in
the other. These results are illustrated in Online
Supplementary Figure S2B.
From cytogenetic analysis, 52 cases in the entire cohort
showed 13q abnormalities although only 52% (n=27) of
these were associated with an RB1 deletion. 
CRLF2 gene rearrangements: deletions within PAR1 were
detected by MLPA in 4% (n=63) of the cohort, of which
54 cases had fixed cells available for FISH investigations.
The P2RY8-CRLF2 fusion was confirmed by FISH in 49
cases, while the remaining 5 cases were found to be
IGH@-CRLF2 translocations with associated deletion
within the PAR1 region. FISH testing for the presence of
IGH@ rearrangements had been carried out on 57%
(n=807) of the entire cohort. Twelve cases, with a normal
result by MLPA, were shown to have balanced IGH@-
CRLF2 translocations by FISH. Collectively, these patients
were described as CRLF2 rearranged, accounting for 5.3%
of the cohort.
P2RY8-CRLF2 was most common among the iAMP21
subgroup (30%) and patients classified as ‘other abnormal’
(10%). Although P2RY8-CRLF2 was rare in association
with other cytogenetic subtypes, it was found in all sub-
types in this series except the MLL rearranged group. The
positive cases included 3 ETV6-RUNX1 positive patients
and one each of TCF3-PBX1 and BCR-ABL1. 
Among these patients with CRLF2 rearrangements,
48% also showed loss of IKZF1. However, IKZF1 dele-
tions were more significantly associated with IGH@-
CRLF2 than P2RY8-CRLF2, occurring in 82% and 37%,
respectively (P=0.001).  IGH@-CRLF2 patients were more
likely to be classified as NCI high risk than P2RY8-CRLF2
(65% and 29%, respectively, P=0.008). However, this
result did not translate into a correlation between IKZF1
deletion status and risk among CRLF2 rearranged patients,
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as 56% of high risk and 42% of standard risk CRLF2
rearranged patients also had IKZF1 deletions (P=0.22).  
Discussion
In this study, we present the findings from a detailed ret-
rospective analysis of CNA in significant genes involved in
B-cell development, cell cycle control and hematopoiesis
among a large consecutive series of pediatric BCP-ALL
patients treated on UK ALL treatment trials. Although
59% of patients showed an abnormality of at least one of
these genes, 41% showed none. The number of CNA
occurring simultaneously in the same patient was low.
Thus, these observations, in association with cytogenetic
data, confirm that the genomic profiles of childhood BCP-
ALL are not generally complex. Although the involvement
of other genes not covered by the MLPA kit cannot be
ruled out, data from SNP arrays have shown the incidence
of other recurrent sub-microscopic abnormalities to be
infrequent.3-5 From MLPA studies, it is not possible to gain
information on the temporal order in which these events
arose in terms of karyotypic evolution or identify which
abnormalities were the potential ‘drivers’ of leukemogen-
esis. However, it was possible to examine associations
between these abnormalities and demographic and clini-
cal features, as well as with cytogenetics. 
In relation to the individual abnormalities, IKZF1
showed heterogeneity in the size of the deletion, as previ-
ously demonstrated.3 The majority of patients either
showed deletion of the entire gene, often seen as a visible
cytogenetic change involving 7p, or restricted to exons 4-
7. A range of other deletion types were also observed of
which a small number were biallelic. No significant asso-
ciation was found between the pattern of exon loss and
cytogenetic subtype. IKZF1 is transcribed in several iso-
forms as a result of alternative splicing, essentially altering
the expression of exons 3 to 5 that encode the N-terminal
DNA-binding domain. Deletions of exons 4-7 result in
expression of a dominant negative IKZF1 isoform, Ik6,
that lacks the N-terminal DNA binding zinc finger and
shows oncogenic activity.11,23 Deletion of exon 2, which
harbors the translational start site, will inhibit protein
translation. Loss of exon 8 will have an effect on dimeriza-
tion of IKZF1. Thus, deletions involving these exons are
likely to have the same impact as whole gene deletions.
Loss of the non-coding exon 1 only is likely to be of no sig-
nificance. Accurate characterization of these heteroge-
neous deletions of IKZF1 is important before we can begin
to understand their prognostic relevance.
The extent of PAX5 deletions was variable, ranging from
whole gene loss to loss of the telomeric exons, confirming
previous SNP data3 and our earlier observations based on
FISH.24 Those with deletions of the entire or part of the
gene including exon 1 are predicted to result in reduced
PAX5 expression. Those with partial deletions not involv-
ing exon 1 are predicted to express a mutant allele.25 Ten
patients showed intragenic amplifications of exons 2 or 5.
These amplifications have been previously reported as a
rare occurrence and are similarly predicted to express
mutant alleles.25 In a number of cases, PAX5 deletions
occurred as the result of dicentric chromosomes involving
chromosome 9. Interestingly, among those cases with
dic(9;12), 4 were associated with ETV6-RUNX1 fusion,
while the remaining 5 were classified as ‘other abnormal’.
Although the number of cases was small, there was a dis-
tinct pattern of exon loss between the two groups of
dic(9;12) cases. The other abnormal cases showed loss of
ETV6 exons 1-2 and PAX5 exons 5-10. This finding was
consistent with previously published data in which this
abnormality was associated with expression of an ETV6-
PAX5 fusion protein.26 The dicentric chromosomes associ-
ated with ETV6-RUNX1 showed larger deletions of ETV6
and loss of the entire PAX5, indicating that these dic(9;12)
translocations do not result in ETV6-PAX5 fusion. 
Deletions of CDKN2A/B represented the most frequent
abnormality in the cohort, which were often associated
with visible abnormalities of 9p and concurrent loss of
PAX5.  Interestingly, 8 of the 10 cases showing intragenic
amplification of PAX5 also showed deletion of
CDKN2A/B. 
RB1 deletions were homogeneous compared to other
deletions, being restricted to two types: 1) those including
the entire gene, as well as the adjacent genes: ITM2B,
RCBTB2 and DLEU; and 2) focal deletions including exons
18-26 in all but one case. They were occasionally biallelic
with different sized deletions on the two alleles. Some of
the larger deletions were visible at the cytogenetic level.
Deletions of 13q have been associated with increased risk
of relapse.20 However, this study showed that only approx-
imately 50% of visible 13q abnormalities were associated
with an RB1 deletion, indicating that in at least some of
these cases RB1 is not the target of the deletion. RB1 dele-
tions of exons 18-27 have been previously reported in lym-
phoma.27 The molecular consequence of this recurring dele-
tion is still not well understood. Expression of a truncated
protein with altered function or deletion of LPAR6/P2RY5,
located within RB1, may be one of the consequences.
With the exception of patients with MLL rearrange-
ments, the presence of CRLF2-P2RY8 has now been
reported in association with all cytogenetic subtypes. In
this study, we identified a small number of cases among
patients with ETV6-RUNX1, TCF3-PBX1 and BCR-ABL1;
the latter two have not been previously reported. We
showed CRLF2 rearrangements to be present in 5.3% of
the cohort. Several groups have reported a strong associa-
tion between CRLF2 overexpression and IKZF1 alter-
ations.13,14,28-30 Although this study is restricted to the detec-
tion of CRLF2 rearrangements, with the exception of rare
mutations of the gene,31 without measure of expression,
we confirmed this association. We also confirmed that
IGH@-CRLF2 occurred at a higher incidence in NCI high-
risk patients, while P2RY8-CRLF2was seen at a higher fre-
quency in NCI standard risk. 
We have previously reported the high incidence of
P2RY8-CRLF2 among iAMP21 patients.32 We confirmed
an increased incidence of ETV6 deletions as previously
reported;33 however, the frequent occurrence of RB1 dele-
tions in these patients is shown here for the first time. 
There was some correlation between the distribution of
CNA and patient age. Patients with IKZF1 and
CDKN2A/B deletions were older and their incidence
increased with age. Patients with IKZF1, PAX5 and
CDKN2A/B deletions had significantly higher WBC count
than patients with the other CNA. These associations
with older age and higher WBC count explain why these
deletions occur at a higher frequency in the NCI high-risk
group, that is defined by age and WBC count. Previous
studies have been inconclusive as to the prognostic rele-
vance of CDKN2A/B in both childhood and adult ALL.34
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The association with NCI risk defined here, coupled with
observations that patients with CDKN2A/B deletions have
a shorter time to relapse than other relapsed patients,35,36
suggests that further studies are warranted in order to clar-
ify the prognostic relevance of CDKN2A/B deletions.
The frequency of each cytogenetic subgroup among this
patient cohort was the same as that previously reported
by us for a single UK childhood ALL treatment trial,
ALL97/99.15,20 We showed that the incidence of CNA var-
ied according to cytogenetic subtype, although the num-
ber did not correlate with the cytogenetic risk. For exam-
ple, the good-risk cytogenetic groups (ETV6-RUNX1 and
high hyperdiploidy) as well as the poor risk (BCR-ABL1
and MLL rearranged) showed a high and low number of
CNA, respectively. 
The high number of CNA in the ETV6-RUNX1 positive
group suggests that CNA rather than point mutations may
be the drivers of leukemia in this subgroup, as other stud-
ies have shown ETV6-RUNX1 positive leukemia to harbor
a modest number of point mutations.37 Interestingly,
although BTG1 deletions were rare, they were most often
associated with ETV6-RUNX1, as previously reported.38
As BTG1 has been reported to be associated with gluco-
cortoid receptor autoinduction,39 these patients require fol-
low up to determine whether these deletions affect their
overall survival. 
The lower than expected level of deletions in high
hyperdiploid patients is unlikely to be an artefact of ana-
lyzing CNA in the context of ploidy change, as neither the
genes tested nor the reference probes in the MLPA kit are
located on chromosomes commonly gained in high hyper-
diploidy. Point mutations have been found at an increased
level in this subgroup, indicating that disease progression
in high hyperdiploid patients may be driven by mutations
rather than deletions, at least among the genes tested.40
Although the incidence of CNA was also low in patients
in the poor-risk subgroup with MLL rearrangements, this
finding might be expected from the known potency of this
abnormality as a driver of leukemogenesis.41 From these
observations, it is evident that future studies assessing the
prognostic value of these CNA must include cytogenetic
data in order to gain a clear picture of their association
with outcome.
As previously shown, there was a strong association
between BCR-ABL1 fusion and IKZF1 deletions.7
Deletions of PAX5 and CDKN2A/B were also high in the
BCR-ABL1 positive group. In the group classified as ‘other
abnormal’, deletions of CDKN2A/B, PAX5 and IKZF1
were also frequent. The striking similarity in CNA profiles
between these two groups is clearly shown in Figure 4.
The poor-risk group described as BCR-ABL1-like,6,41
defined as sharing the same gene expression profile as well
as the same poor risk as BCR-ABL1 positive patients, is
most likely to be found among those patients with ‘other
abnormal’ karyotypes as no distinctive karyotypic features
have yet been described to define them. Thus the occur-
rence of deletions of CDKN2A/B, PAX5 and IKZF1, as well
as deregulated CRLF2, among patients in this ‘other abnor-
mal’ group may provide a pointer to the BCR-ABL1-like
subgroup, as indicated by others.42
This study represents the largest trial-based screen for
abnormalities in selected genes of significance in the
development of BCP-ALL. It has confirmed findings of
previous studies of associations between copy number
abnormalities and particular cytogenetic subgroups.  It has
shown the heterogeneous nature of deletions such as
PAX5 and IKZF1 and the recurrent nature of RB1 dele-
tions. The association of IKZF1 and CDKN2A/B deletions
with NCI high risk is of interest, and within the ‘other
abnormal’ cytogenetic group, the presence of these dele-
tions and/or rearrangements of CRLF2 may point to the
poor-risk BCR-ABL1 like group. 
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